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Circulating	   endothelial	   progenitor	   cells	   may	   be	   important	   in	   the	   pathogenesis	   of	   idiopathic	  
pulmonary	  arterial	  hypertension	   (IPAH)	  and	  give	   rise	   to	  endothelial	   colony-­‐forming	   cells	   (ECFCs)	   in	  
culture.	   These	   cells	   represent	   an	   accessible	   surrogate	   population	   to	   investigate	   endothelial	  
dysfunction	  in	  IPAH.	  
Peripheral	  blood	  mononuclear	  cells	  were	  cultured	   from	  healthy	  volunteers	   (n=25,	  72%	  female;	  age	  
range	  23-­‐57	  yr)	  and	  IPAH	  patients	  (n=30,	  60%	  female;	  age	  range	  22-­‐56	  yr).	  	  Older	  IPAH	  patients	  (n=6,	  
50%	  female;	  age	  range	  62-­‐82	  yr)	  were	  also	  sampled.	  	  Distinct	  colonies	  appeared	  after	  13-­‐35	  days	  and	  
exhibited	  a	  typical	  cobblestone	  morphology.	  The	  average	  frequency	  of	  colonies	  and	  clonal	  growth	  of	  
isolated	  cells	  was	  similar	   in	  healthy	  volunteers	  and	   IPAH	  patients.	  Age-­‐dependent	  differences	  were	  
observed	  however	  in	  the	  number	  and	  frequency	  of	  colonies,	  which	  declines	  with	  age	  in	  the	  control	  
but	   not	   in	   IPAH	   subjects.	   The	   endothelial	   phenotype	   was	   confirmed	   by	   immunostaining	   and	   flow	  
cytometry,	   exhibiting	   endothelial	   and	   progenitor	   markers,	   but	   not	   hematopoietic	   markers.	  
Endothelial	  cell	  functions,	  including	  proliferation,	  angiogenesis,	  migration	  and	  responses	  to	  apoptotic	  
stimuli,	  were	   compared	   in	   cells	   between	  passages	   4	   to	   7.	   IPAH	   cells	   showed	  enhanced	   angiogenic	  
capacity	   (tube	   formation	   on	   Matrigel),	   significantly	   less	   apoptosis	   (lower	   caspase-­‐3/7	   activity)	   in	  
response	  to	  serum	  and	  growth	   factor	  deprivation,	  and	   impaired	  migratory	  capacity	  compared	  with	  
control	   ECFCs.	   Dysfunctional	   transforming	   growth	   factor	   (TGF)-­‐β	   and	   bone	  morphogenetic	   protein	  
receptor	  expression	  and	  signalling	  are	  implicated	  in	  IPAH	  and	  were	  assessed	  by	  RT-­‐PCR	  and	  western	  
blotting.	  IPAH	  and	  control	  ECFCs	  differed	  in	  their	  TGF-­‐β	  type	  I	  (ALK5)	  receptor	  expression/signalling	  
and	  in	  the	  expression	  of	  other	  regulatory	  proteins	  (e.g.	  chloride-­‐like	  intracellular	  channel-­‐4).	  
Blood-­‐derived	  ECFCs	  display	  an	  endothelial	  lineage	  similar	  to	  that	  of	  mature	  endothelial	  cells.	  ECFCs	  
from	   IPAH	  patients	  have	  a	  distinct	   functional	   phenotype	  and	  exhibit	   differences	   in	   TGF-­‐β	   receptor	  
superfamily	   expression/signalling,	   which	   may	   contribute	   to	   endothelial	   dysfunction	   and	   vascular	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SUMMARY	  OF	  THESIS	  STRUCTURE	  
	  
Chapter	   1	   contains	  an	  overall	   introduction	  to	   the	  thesis,	  which	  concludes	  with	   the	  hypothesis	   and	  
objectives.	  	  
	  
Chapter	  2	  contains	  detailed	  methodologies	  with	  material	  sources	  covering	  the	  studies	  described	  in	  
Chapters	  3-­‐7.	  	  
	  
Chapter	   3	   focuses	  on	  comparing	   the	  appearance	  of	  blood-­‐derived	  endothelial	   colony-­‐forming	  cells	  
(ECFCs),	   which	   shows	   that	   IPAH	   patients	   possess	   different	   ECFC	   colony	   forming	   properties	  
compared	   to	   healthy	   volunteers.	   ECFCs	   phenotypes	   were	   confirmed	   by	   analysis	   of	   phenotypic	  
expression	   and	   functional	   characteristics,	   and	   samples	   were	   then	   selected	   based	   on	   functional	  
criteria	  for	  use	  as	  endothelial	  cell	  models	  for	  IPAH	  in	  further	  investigations	  in	  chapters	  4	  –	  7.	  	  
	  
Chapter	   4	   explores	   the	   functional	   characteristics	   of	   ECFCs	   from	   IPAH	   patients,	   with	   evidences	   to	  
indicate	  that	  the	  ECFCs	   from	   IPAH	  patients	  exhibit	  endothelial	  dysfunctions	   including	   resistant	   to	  
apoptosis,	  enhanced	  angiogenesis,	  impaired	  migration	  and	  disrupted	  barrier	  functions.	  These	  lead	  
to	  investigation	  of	  molecular	  mechanisms	  underlying	  these	  dysfunctions	  in	  chapters	  6	  –	  7.	  
	  
Chapter	  5	  investigates	  the	  transforming	  growth	  factor-­‐β	  (TGF-­‐β)	  signalling	  receptors	  expression,	  and	  
identifies	   downregulated	   ALK5	   expression	   and	   impaired	   TGF-­‐β1	   activation	   of	   ALK5/Smad2	  
signalling	  in	  ECFCs	  from	  IPAH	  patients.	  	  
	  
Chapter	   6	   investigates	   further	   the	   TGF-­‐β	   signalling	   regulations	   of	   ECFCs	   functions,	   and	   establishes	  
the	   mechanism	   underlying	   the	   apoptosis-­‐resistant	   dysfunctions	   in	   ECFCs	   from	   IPAH	   patients,	  
primarily	  due	  to	  the	  possible	  imbalance	  between	  ALK1	  and	  ALK5	  activations	  in	  IPAH	  cells.	  	  
	  
Chapter	   7	   further	   explores	   the	   credibility	   of	   ECFCs	   as	   endothelial	   cellular	   models	   for	   IPAH.	   Two	  
other	   novel	   mechanisms	   proposed	   to	   underlie	   endothelial	   pathogenesis	   in	   IPAH	   are	   investigated,	  
through	  which	  the	  possible	  regulation	  of	  other	  dysfunctions	  such	  as	  dysregulated	  angiogenesis	  and	  
disrupted	  barrier	  functions	  in	  IPAH	  cells	  are	  established.	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Chapter	  1	  –	  Introduction	  
	  
1.1	   The	  pulmonary	  vasculature	  –	  Structure,	  function	  and	  development	  
Anatomically,	   the	   human	   pulmonary	   circulation	   can	   be	   divided	   into	   distinct	   segments.	   The	  
pulmonary	   trunk	   ascends	   from	   the	   right	   ventricle	   and	   branches	   into	   the	   right	   and	   left	   main	  
pulmonary	  arteries.	  These	  arteries	  divide	  into	  lobar	  pulmonary	  arteries	  which	  supply	  individual	  lobes	  
of	   the	   lung	  and	  sub-­‐divide	  distally	   into	  muscular	   resistance	  pulmonary	  arteries,	  arterioles,	  capillary	  
bed	  and	  pulmonary	  veins	  (Harris	  and	  Heath,	  1986).	  	  Throughout	  the	  course	  of	  the	  pulmonary	  arterial	  
tree,	   the	  vessel	   size	  and	   structure	   change	  according	   to	   their	   function,	   comprising	  elastic,	  muscular	  
and	  non-­‐muscular	  vessels	   (Wagenvoort	  and	  Wagenvoort,	  1979).	  The	  walls	  of	   the	  pulmonary	  artery	  
are	   composed	   of	   three	   layers	   –	   the	   tunica	   intima,	   the	   tunica	  media,	   and	   the	   tunica	   adventitia.	   In	  
elastic	   and	  muscular	   arteries	   the	   tunica	   intima	   forms	   the	   innermost	   layer	   and	   comprises	   a	   single	  
layer	  of	  endothelial	   cells	   (ECs)	  and	  associated	  connective	   tissue	   lying	  on	  an	   internal	  elastic	   lamina.	  
The	  tunica	  media	  forms	  the	  middle	  layer	  of	  the	  vessel	  wall	  and	  comprises	  circumferentially-­‐arranged	  
pulmonary	  artery	  smooth	  muscle	  cells	  (PASMCs)	  and	  elastic	  laminae	  enclosed	  by	  an	  external	  elastic	  
lamina.	  The	  tunica	  adventitia	  is	  the	  outermost	  layer	  and	  is	  primarily	  composed	  of	  connective	  tissue	  
and	  matrix	  secreting	  fibroblasts	  that	  serves	  to	  anchor	  the	  vessels	  in	  place.	  Non-­‐muscular	  vessels	  are	  
made	  up	  of	  a	   single	   layer	  of	  ECs	   lying	  on	  an	   internal	  elastic	   lamina	   (Wagenvoort	  and	  Wagenvoort,	  
1979).	  	  
The	   large	  proximal	  vessels	   (pulmonary	   trunk,	  main	  arteries	  and	   lobar	  branches)	  are	  predominantly	  
elastic	   in	   nature,	   consistent	   with	   their	   function	   as	   conduit	   and	   blood	   storage	   vessels	   following	  
ventricular	  systole.	  Muscular	  pulmonary	  arteries	  continue	  imperceptibly	  from	  the	  elastic	  arteries	  and	  
continue	   distally	   down	   to	   arteries	   500-­‐1000	   µm	   in	   diameter	   (Brenner,	   1935;	   Wagenvoort	   and	  
Wagenvoort,	   1979).	   Within	   the	   lung,	   branches	   of	   muscular	   pulmonary	   arteries	   run	   parallel	   to	  
accompanying	  airways.	  The	  concentric	  arrangement	  of	  the	  smooth	  muscle	  and	  ability	  to	  contract	  is	  
consistent	  with	  their	  role	  in	  the	  control	  of	  vascular	  resistance.	  Pulmonary	  arterioles	  are	  the	  terminal	  
branches	   of	   the	   arterial	   tree	   and	   are	   also	   associated	   with	   the	   control	   of	   pulmonary	   vascular	  
resistance.	  These	  pre-­‐capillary	  vessels	  are	  approximately	  70	  µm	  in	  diameter	  and	  consist	  of	  a	  tube	  of	  
endothelium	   surrounded	   by	   a	   spiral	   of	   elastic	   fibril,	   which	   is	   contiguous	   with	   the	   internal	   elastic	  
lamina	  and,	  at	  their	  origin,	  may	  have	  a	  cuff	  of	  PASMCs	  or	  pericytes	  (Brenner,	  1935).	  The	  pulmonary	  
capillary	   bed,	   with	   its	   single	   cell	   lining,	   is	   the	   site	   of	   gaseous	   exchange	   and	   forms	   an	   extensive,	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interdigitating	   network	   within	   the	   alveolar	   walls.	   The	   pulmonary	   veins	   lie	   in	   the	   interlobular	  
connective	   tissue	   septae	   and	   receive	   blood	   from	   the	   capillary	   bed,	   serving	   as	   a	   conduit	   to	   return	  
oxygenated	  blood	  to	  the	  left	  side	  of	  the	  heart	  (Wagenvoort	  and	  Wagenvoort,	  1979).	  
The	  development	  of	  the	  pulmonary	  circulation	  begins	   in	  the	  first	  4-­‐16	  weeks	  of	  gestation,	  with	  the	  
formation	  of	  a	  recognisable	  blood	  gas	  barrier	  by	  24	  weeks	  of	  gestation	  (Hislop,	  2005).	  The	  pulmonary	  
arteries	  and	  veins	  are	   independently	  derived	  and	   initially	   form	  de	  novo	  as	  endothelial	   tubes	   in	   the	  
mesechyme	  adjacent	  to	  airways	  by	  a	  process	  of	  vasculogenesis	   (Hall	  et	  al.,	  2000;	  Hall	  et	  al.,	  2002).	  
The	  endothelial	  tubes	  combine	  to	  form	  the	  pulmonary	  circulation,	  which	  develops	  in	  synchrony	  with	  
the	  airways	  of	  the	  lung	  and	  results	  in	  an	  increase	  in	  surface	  area	  of	  alveoli	  and	  its	  capillary	  supply	  by	  
a	   process	   of	   angiogenesis	   (Hislop,	   2002;	   Parera	   et	   al.,	   2005).	   Growth	   factors	   such	   as	   vascular	  
endothelial	   growth	   factor	   (VEGF),	   angiopoietin,	   fibroblast	   growth	   factor	   (FGF)	   are	   important	   in	  
stimulating	   and	   stabilising	   the	   growth	   of	   the	   new	   endothelium	   in	   a	   bed	   of	   extracellular	   matrix	  
(Hislop,	  2005).	  Large	  vessels	  are	  supported	  by	  the	  development	  of	  several	  layers	  of	  smooth	  muscle,	  
separated	  by	  collagen	  that	  provides	  rigidity,	  and	  elastin	  that	  provides	  the	  vessels	  with	  distensibility	  
(Hislop	  and	  Pierce,	  2000).	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1.2	   Pulmonary	  hypertension	  
1.2.1	   Definition	  and	  Classification	  
The	  healthy	  adult	  pulmonary	  circulation	  is	  a	  distensible,	  high-­‐capacity	  and	  low-­‐pressure	  system	  with	  
relatively	   thin-­‐walled	   blood	   vessels	   compared	   to	   the	   systemic	   circulation	   (Naeije	   and	   Rondelet,	  
2004).	   The	   normal	   mean	   pulmonary	   artery	   pressure	   (mPAP)	   is	   approximately	   15	   mmHg	   at	   rest.	  
Pulmonary	   hypertension	   (PH)	   is	   a	   progressive	   and	   intractable	   disease	   of	   diverse	   origins	   that	   is	  
clinically	  defined	  as	  an	  elevation	  of	  mean	  PAP	  above	  25	  mm	  Hg	  at	  rest	  (Badesch	  et	  al.,	  2009).	  	  PAP	  is	  
a	  product	  of	  cardiac	  output	  (CO)	  and	  pulmonary	  vascular	  resistance	  (PVR).	  A	  sustained	  elevation	   in	  
PVR	  has	  a	  harmful	  effect	  on	   the	  heart	  as	   the	   right	  heart	   is	   subjected	   to	  an	   increased	  work	   load	   in	  
order	  to	  overcome	  the	  downstream	  resistance.	  This	   leads	  to	  right	  ventricular	  (RV)	  hypertrophy	  and	  
eventual	  right	  heart	  failure,	  a	  common	  cause	  of	  death	  in	  patients	  with	  PH.	  PH	  has	  been	  classified	  into	  
five	   main	   groups,	   according	   to	   pathological,	   physiological	   and	   therapeutic	   characteristics.	   The	  
current	   classification	  was	   adopted	   at	   the	   4th	  World	   symposium	  on	  PH	  held	   in	   2008	   at	  Dana	  Point,	  













Clinical	  Classification	  of	  Pulmonary	  Hypertension	  
1. Pulmonary	  arterial	  hypertension	  (PAH)	  
1.1. Idiopathic	  PAH	  
1.2. Heritable	  
1.2.1. BMPR2	  
1.2.2. ALK-­‐1,	  endoglin	  (with	  or	  without	  hereditary	  hemorragic	  telangiectasia)	  
1.2.3. Unknown	  
1.3. Drug-­‐	  and	  toxin-­‐induced	  
1.4. Associated	  with	  
1.4.1. Connective	  tissue	  diseases	  
1.4.2. HIV	  infection	  
1.4.3. Portal	  hypertension	  
1.4.4. Congenital	  heart	  diseases	  
1.4.5. Schistosomiasis	  
1.4.6. Chronic	  haemolytic	  anemia	  
1.5. Persistent	  pulmonary	  hypertension	  of	  the	  newborn	  
1' Pulmonary	  veno-­‐occlusive	  disease	  (PVOD)	  and/or	  pulmonary	  capillary	  hemangiomatosis	  (PCH)	  
2. Pulmonary	  hypertension	  owing	  to	  left	  heart	  disease	  
2.1. Systolic	  dysfunction	  
2.2. Diastolic	  dysfunction	  
2.3. Valvular	  disease	  
3. Pulmonary	  hypertension	  owing	  to	  lung	  disease	  and/or	  hypoxia	  
3.1. Chronic	  obstructive	  pulmonary	  disease	  
3.2. Interstitial	  lung	  disease	  
3.3. Other	  pulmonary	  diseases	  with	  mixed	  restrictive	  and	  obstructive	  pattern	  
3.4. Sleep-­‐disordered	  breathing	  
3.5. Alveolar	  hypoventilation	  disorders	  
3.6. Chronic	  exposure	  to	  high	  altitude	  
3.7. Developmental	  abnormalilites	  
4. Chronic	  thromboembolic	  pulmonary	  hypertension	  (CTEPH)	  
5. Pulmonary	  hypertension	  with	  unclear	  multifactorial	  mechanisms	  
5.1. Hematologic	  disorders:	  myeloproliferative	  disorders,	  splenectomy	  
5.2. Systemic	  disorders:	  sarcoidosis,	  pulmonary	  Langerhans	  cell	  histiocytosis:	  
lymphangloleiomyomatosis,	  neurofibromatosis,	  vasculitis	  
5.3. Metabolic	  disorders:	  glycogen	  storage	  disease,	  Gaucher	  disease,	  thyroid	  disorders	  
5.4. Others:	  tumoral	  obstruction,	  fibrosing	  mediastinitis,	  chronic	  renal	  failure	  on	  dialysis	  
Table	  1.1	  Updated	  clinical	  classification	  of	  pulmonary	  hypertension	  (Dana	  Point,	  2008).	  ALK1,	  
activin	  receptor-­‐like	  kinase	  type	  1;	  BMPR2,	  bone	  morphogenetic	  protein	  receptor	  type	  2;	  HIV,	  




1.2.2	   Pulmonary	  arterial	  hypertension	  (PAH)	  
Pulmonary	  arterial	  hypertension	  (PAH)	  represents	  the	  first	  main	  group	  of	  PH	  and	   is	   further	  divided	  
into	  5	  sub-­‐categories	  (Table	  1.1).	  These	  comprise:	  idiopathic	  PAH	  (IPAH)	  –	  formerly	  known	  as	  primary	  
PH	  –	  for	  PAH	  with	  no	  identified	  cause	  or	  family	  history;	  heritable	  PAH	  (HPAH)	  –	  formerly	  known	  as	  
familial	  PAH	  –	  when	  occurs	  in	  a	  familial	  context;	  drug-­‐	  and	  toxin-­‐induced	  PAH;	  PAH	  associated	  with	  
various	   other	   diseases;	   and	   persistent	   pulmonary	   hypertension	   of	   the	   newborn.	   	   The	   definitive	  
diagnosis	   of	   PAH	   is	   dependent	   on	   demonstrating	   presence	   of	   pre-­‐capillary	   PH	   at	   cardiac	  
catheterisation,	  with	   raised	  mPAP	   (>25	  mmHg)	   and	  normal	   capillary	  wedge	  pressure	   (≤15	  mmHg),	  
and	  associates	  with	  substantial	  mortality	  and	  morbidity.	  	  	  
PAH	   is	   a	   rare	   disease	   that	   affects	   less	   than	   5/100,000	   in	   Europe	   and	   has	   a	   prevalence	   of	   15-­‐50	  
patients/million	  of	  the	  population	  (Humbert	  et	  al.,	  2006;	  Peacock	  et	  al.,	  2007;	  NAPH,	  2011)	  (National	  
Audit	   for	  Pulmonary	  Hypertension,	  2011).	  The	  prognosis	  of	  PAH	  remains	  poor,	  being	  a	  progressive	  
disease	   with	   high	   mortality	   rate.	   	   The	   estimated	   median	   survival	   time	   for	   untreated	   IPAH	   was	  
historically	  2.8	  years,	  with	  1-­‐	  and	  3-­‐year	  survival	  rates	  of	  68%	  and	  48%	  respectively	  in	  a	  cohort	  of	  194	  
patients	  with	  primary	  PH	  from	  32	  centres	  in	  the	  USA	  (D'Alonzo	  et	  al.,	  1991).	  Despite	  the	  advances	  in	  
understanding	  and	  improved	  treatment	  options	  for	  PAH	  in	  recent	  years	  had	  improved	  the	  prognosis	  
to	  a	  certain	  degree,	  a	  recent	  multi-­‐centres	  report	   revealed	  1-­‐	  and	  3-­‐year	  survival	   rates	  of	  83%	  and	  
58%	   respectively	   in	   PAH	   populations	   largely	   composed	   of	   IPAH	   (Humbert	   et	   al.,	   2010a).	   For	   end-­‐
stage	  PAH	  patients	  who	  failed	  to	  respond	  to	  the	  current	  therapeutics	  and	  interventions,	  there	  is	  no	  
choice	  but	  to	  consider	  cardiopulmonary	  transplantation	  as	  the	  final	  option	  (Keogh	  et	  al.,	  2009).	  
While	   a	  normal	   level	   of	   the	   cardiac	   stress-­‐marker	  brain	  natriuretic	  peptide	   (BNP)	  or	   its	  N-­‐terminal	  
peptide	   (NT-­‐proBNP)	  may	   help	   rule	   out	   PH,	   there	   is	   no	   blood	   biomarker	   that	   is	   diagnostic	   of	   the	  
condition.	  Risk	   stratification	  can	   inform	  not	   just	  prognosis	  but	  may	  help	  optimisation	  of	   treatment	  
and	  the	  achievement	  of	  specific	  goals	  aimed	  at	   improving	   longer-­‐term	  survival.	  Multicentre	  patient	  
registries	  –	  National	  Institutes	  of	  Health	  (NIH),	  French	  PAH	  registry	  and	  US-­‐based	  Registry	  to	  Evaluate	  
Early	   and	   Long-­‐term	  Pulmonary	  Arterial	  Hypertension	  Disease	  Management	   (REVEAL)	   –	  have	  been	  
very	  useful	   in	   identifying	   independent	   factors	   that	  are	  associated	  with	  prognosis	  of	  PAH,	   including	  
age,	   sex,	   disease	   aetiology,	   World	   Health	   Organization	   (WHO)	   functional	   class,	   6	   minute	   walk	  
distance	  (6MWD),	  and	  haemodynamic	  parameters	  (D'Alonzo	  et	  al.,	  1991;	  Rich	  et	  al.,	  2000;	  Benza	  et	  
al.,	  2010;	  Humbert	  et	  al.,	  2010a).	  The	  WHO	  functional	  classification	  classifies	  PAH	  patients	  according	  
to	  their	  physical	  capability	  and	  usually	  correlates	  with	  poor	  survival	   rate	  (McLaughlin	  et	  al.,	  2009b;	  
Humbert	  et	  al.,	  2010a)	   (Table	  1.2).	  Measurements	  of	  circulating	  BNP	  and	  NT-­‐proBNP	   levels	   remain	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the	  most	  commonly	  used	  blood	  biomarkers	  for	  stratifying	  PH	  patients	  and	  are	  recommended	  in	  the	  
European	  guidelines	  for	  the	  diagnosis	  and	  treatment	  of	  PH	  (Galie	  et	  al.,	  2009b).	  
	  
World	  Health	  Organisation	  Functional	  Classification	  of	  PH	  patients	  
I	   Patients	  with	  PH	  in	  whom	  there	  is	  no	  limitation	  of	  usual	  physical	  activity;	  ordinary	  physical	  
activity	  does	  not	  cause	  increased	  dyspnea,	  fatigue,	  chest	  pain,	  or	  presyncope.	  
II	   Patients	  with	  PH	  who	  have	  mild	  limitation	  of	  physical	  activity.	  There	  is	  no	  discomfort	  at	  rest,	  
but	  normal	  physical	  activity	  causes	  increased	  dyspnea,	  fatigue,	  chest	  pain,	  or	  presyncope.	  
III	   Patients	  with	  PH	  who	  have	  a	  marked	  limitation	  of	  physical	  activity.	  There	  is	  no	  discomfort	  at	  
rest,	  but	  less	  than	  ordinary	  activity	  causes	  increased	  dyspnea,	  fatigue,	  chest	  pain,	  or	  
presyncope.	  
IV	   Patients	  with	  PH	  who	  are	  unable	  to	  perform	  any	  physical	  activity	  at	  rest	  and	  who	  may	  have	  
signs	  of	  right	  ventricular	  failure.	  Dyspnea	  and/or	  fatigue	  may	  be	  present	  at	  rest,	  and	  
symptoms	  are	  increased	  by	  almost	  any	  physical	  activity.	  
Table	  1.2.	  World	  Health	  Organisation	  classification	  of	  functional	  status	  of	  patients	  with	  PH.	  
Adapted	  from	  (McGoon	  et	  al.,	  2004).	  
	  
PAH	   is	   characterised	   by	   increased	   PVR,	   mediated	   by	   vasoconstriction,	   endothelial	   dysfunction,	  
vascular	  remodelling,	  inflammation	  and	  thrombosis	  (Archer	  et	  al.,	  2010;	  Schermuly	  et	  al.,	  2011),	  and	  
these	  are	  discussed	  in	  further	  details	  in	  the	  following	  sections.	  
	  
1.2.3	   Pulmonary	  vasoconstriction	  
The	  increased	  vasoconstriction	  of	  the	  pulmonary	  arteries	  in	  patients	  with	  PAH	  reflects	  the	  abnormal	  
regulation	  of	  vessel	  tone.	  The	  endothelium	  plays	  an	  essential	  role	   in	  regulating	  pulmonary	  vascular	  
homeostasis	  and	  is	  the	  main	  source	  of	  vasodilators,	  such	  as	  prostacyclin	  (Christman	  et	  al.,	  1992)	  and	  
nitric	  oxide,	  and	  the	  potent	  vasoconstrictors	  thromboxane	  A2	  (Christman	  et	  al.,	  1992),	  endothelin-­‐1	  
and	  serotonin	  (5-­‐hydroxytryptamine)	  (Schermuly	  et	  al.,	  2011).	  	  
Prostacyclin	   (PGI2)	   is	   a	   potent	   vasodilator	   that	   also	   has	   inhibitory	   effects	   on	   platelet	   aggregation,	  
inflammation	  and	  vascular	  smooth	  muscle	  proliferation,	  all	  of	  which	  have	  been	  implicated	  in	  PAH.	  	  It	  
is	  synthesised	  in	  ECs	  from	  prostaglandin	  H2	  by	  PGI2	  synthase	  and	  acts	  by	  stimulating	  the	  production	  
of	   cyclic	   adenosine	  monophosphate	   (Clapp	   et	   al.,	   2002).	   PGI2	   synthase	   expression	   is	   lower	   in	   the	  
pulmonary	   arteries	   of	   patients	  with	  PAH	   (Tuder	   et	   al.,	   1999)	   and	   circulating	   levels	   of	   PGI2	  are	   also	  
reduced,	  while	  levels	  of	  the	  vasoconstrictor	  thromboxane	  A2	  are	  raised	  (Christman	  et	  al.,	  1992).	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Nitric	   oxide	   (NO)	   is	   a	   potent	   vasodilator	   and	   its	   activity	   is	   mediated	   via	   cyclic	   guanosine	  
monophosphate	   (cGMP).	   The	   metabolism	   of	   cGMP	   is	   dependent	   on	   the	   activation	   of	  
phosphodiesterases,	  in	  particular	  phosphodiesterase	  type	  5	  (PDE5)	  (Corbin	  and	  Francis,	  1999).	  PDE5	  
is	  the	  most	  abundantly	  expressed	  isoform	  within	  the	  pulmonary	  circulation	  (Hanson	  et	  al.,	  1998)	  and	  
levels	  are	  raised	   in	  the	   lungs	  and	  right	  ventricle	  of	  PAH	  patients	  (Murray	  et	  al.,	  2002;	  Corbin	  et	  al.,	  
2005;	   Wharton	   et	   al.,	   2005).	   Reduced	   bioavailability	   of	   NO	   may	   reflect	   lower	   expression	   of	  
endothelial	   NO	   synthase	   (eNOS)	   in	   the	   lung	   microvasculature	   (Giaid	   and	   Saleh,	   1995)	   and/or	  
increased	  levels	  of	  the	  endogenous	  eNOS	  inhibitor	  asymmetric	  dimethylarginine	  (ADMA).	  This	  in	  turn	  
may	  be	  due	  to	  reduced	  expression	  of	  the	  enzymes	  –	  dimethylarginine	  dimethylaminohydrolase-­‐I	  and	  
-­‐II	  (DDAH-­‐I	  and	  DDAH-­‐II)	  –	  responsible	  for	  the	  degradation	  of	  ADMA	  (Pullamsetti	  et	  al.,	  2005).	  
Endothelin-­‐1	  (ET-­‐1)	  is	  a	  21	  amino	  acid	  peptide	  and	  potent	  endothelium-­‐derived	  vasoconstrictor	  and	  
SMC	  mitogen,	  which	   is	  thought	  to	  have	  an	   important	  pathogenic	  role	   in	  PAH	  (Giaid	  et	  al.,	  1993).	   It	  
acts	  via	  two	  receptors	  (ETA	  and	  ETB)	  in	  the	  pulmonary	  vasculature,	  ETA	  receptors	  being	  predominately	  
expressed	  by	  PASMCs	  while	  ETB	  receptors	  are	  mainly	  localised	  to	  the	  endothelium	  but	  also	  expressed	  
by	  PASMCs	  in	  more	  distal	  regions	  of	  the	  arterial	  tree	  (Davie	  et	  al.,	  2002).	  Binding	  of	  ET-­‐1	  to	  receptors	  
on	   PASMCs	   induces	   vasoconstriction	   and	   proliferation	   whereas	   binding	   to	   ETB	   receptors	   on	  
endothelial	   cells	   causes	   vasodilation	   via	   PGI2	   and	   NO	   production	   and	   mediates	   clearance	   of	   ET-­‐1	  
(Hirata	  et	  al.,	  1993;	  Seo	  et	  al.,	  1994;	  Shao	  et	  al.,	  2011).	  The	  ETB-­‐mediated	  vasodilatation	  effect	  has	  
also	  recently	  been	  shown	  to	  be	  reduced	  in	  animal	  models	  of	  PH,	  possibly	  due	  to	  increased	  ET-­‐1	  and	  
aldosterone	   production	   and	   subsequent	   rise	   in	   reactive	   oxygen	   species	   (ROS)	   that	   inhibit	   ETB-­‐
dependent	  NO	  production	  (Maron	  et	  al.,	  2012).	  	  
5-­‐hydroxytryptamine	  (5-­‐HT)	  levels	  are	  also	  raised	  in	  PAH	  (Herve	  et	  al.,	  1995)	  and	  the	  occurrence	  of	  
PH	   in	   patients	   using	   anorexic	   agents	   has	   indicated	   a	   role	   for	   5-­‐HT	   in	   the	   pathogenesis	   of	   PAH	  
(Abenhaim	   et	   al.,	   1996).	   The	   analysis	   of	   lung	   tissues	   from	   patients	   undergoing	   transplantation	  
demonstrated	   increased	   expression	   of	   the	   5-­‐HT	   transporter	   (5-­‐HTT),	   as	   well	   as	   enhanced	  
proliferative	   response	   of	   isolated	   PASMCs	   to	   5-­‐HT	   (Eddahibi	   et	   al.,	   2001;	   Marcos	   et	   al.,	   2004).	  	  
Inhibitors	  of	  5-­‐HTT	  reverse	  PH	   in	  monocrotaline	   (MCT)-­‐induced	  PH	   in	  rats	   (Guignabert	  et	  al.,	  2005)	  
and	   mice	   treated	   with	   targeted	   5-­‐HTT	   gene	   disruption	   or	   selective	   serotonin	   reuptake	   inhibitors	  
develop	   less	  severe	  hypoxic	  PH	  than	  wild-­‐type	  controls	   (Eddahibi	  et	  al.,	  2000;	  Marcos	  et	  al.,	  2003).	  
But	  the	  benefits	  of	  this	  for	  patients	  with	  PAH	  are	  debatable	  (Kawut	  et	  al.,	  2006;	  Dhalla	  et	  al.,	  2012)	  
and	  alternative	   strategies	   that	   target	   specific	  5-­‐HT	   receptors	  may	  be	  preferable	   (Dumitrascu	  et	  al.,	  
2011).	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The	  pathological	  pulmonary	  vasomotor	  tone	  in	  PAH	  has	  also	  been	  attributed	  to	  other	  abnormalities,	  
including	   those	   in	   K+	   and	   Ca2+	   channels	   (Yuan	   et	   al.,	   1998;	   Yu	   et	   al.,	   2004;	   Burg	   et	   al.,	   2008)	   and	  
RhoA/Rho	  kinase	  (ROCK)	  signaling	  (Oka	  et	  al.,	  2007;	  Mouchaers	  et	  al.,	  2010).	  However,	  like	  the	  5-­‐HT	  
pathway,	  these	  are	  still	  emerging	  targets	  for	  the	  treatment	  of	  PAH	  (as	  discussed	  in	  section	  1.4).	  	  
	  
1.2.4	   Endothelial	  dysfunction	  in	  PAH	  
Pulmonary	  endothelial	  damage	  is	  widely	  considered	  to	  be	  an	  early	  event	  in	  the	  development	  of	  PAH	  
and	  a	  critical	  step	  leading	  to	  adverse	  structural	  changes	  (remodelling)	  in	  the	  vascular	  wall.	  In	  addition	  
to	   affect	   the	   production	   of	   vasodilators	   and	   vasoconstrictors,	   endothelial	   dysfunction	   has	   other	  
important	  consequences	  in	  the	  pulmonary	  vasculature	  (Budhiraja	  et	  al.,	  2004;	  Humbert	  et	  al.,	  2004).	  
Most	  endothelial	  vasoactive	  mediators	  affect	  the	  growth	  of	  SMCs	  and	  the	   imbalance	  may	  promote	  
structural	   changes.	   For	   example,	   pulmonary	  microvascular	   ECs	   (PMVECs)	   from	   patients	   with	   IPAH	  
exhibit	   excessive	   production	   of	   ET-­‐1	   and	   5-­‐HT,	   which	   can	   act	   as	   paracrine	   factors	   stimulating	  
proliferation	  of	  PASMCs	  (Eddahibi	  et	  al.,	  2006).	  Injury	  to	  the	  endothelium	  and	  loss	  of	  barrier	  function	  
also	   allows	   access	   to	   circulating	   factors	   that	   activate	   growth	   factor	   pathways	   and	   endogenous	  
elastases,	  leading	  to	  cell	  proliferation	  and	  remodelling	  in	  the	  underlying	  medial	  and	  adventitial	  layers	  
(Budhiraja	   et	   al.,	   2004;	   Humbert	   et	   al.,	   2004;	   Morrell	   et	   al.,	   2009).	   Enhanced	   production	   of	  
chemokines	   such	   as	   monocyte	   chemotactic	   protein-­‐1	   (MCP-­‐1)	   can	   promote	   the	   recruitment	   of	  
circulating	  inflammatory	  cells	  (Sanchez	  et	  al.,	  2007).	  Another	  important	  function	  of	  the	  endothelium	  
is	   the	   elaboration	   of	   factors	   (e.g.	   heparin	   sulphates,	   thrombomodulin,	   plasminogen	   activator	  
inhibitors	   and	   von	   Willebrand	   factor)	   involved	   in	   the	   maintenance	   of	   normal	   coagulation.	  
Dysfunction	   of	   the	   endothelium	   is	   likely	   to	   contribute	   to	   thrombotic	   process,	   which	   is	   a	   common	  
feature	  of	  PAH,	  as	  discussed	  in	  section	  1.2.7.	  	  
A	  paradigm	  of	  PAH	  has	  gained	  acceptance	  in	  which	  endothelial	  apoptosis	   is	  considered	  to	  be	  a	  key	  
factor	   (Sakao	   et	   al.,	   2005;	   Michelakis,	   2006).	   An	   inherited	   or	   acquired	   insult	   leads	   to	   the	   initial	  
apoptosis	   of	   PAECs	   and	   subsequent	   appearance	   of	   apoptosis-­‐resistant	   ECs,	   which	  may	   proliferate	  
and	  give	  rise	  to	  the	  disorganised	  angiogenesis	  found	  in	  the	  plexiform	  lesions	  of	  advanced	  PAH	  (Yi	  et	  
al.,	   2000).	   These	   lesions	   possess	   phenotypically	   distinct	   ECs	   that	   express	  markers	   of	   angiogenesis,	  
such	  as	  vascular	  endothelial	  growth	  factor	  (VEGF),	  VEGF	  receptor	  2	  (VEGFR2)	  and	  hypoxia	  inducible	  
factor	  subunits	  α	  and	  β	  (Cool	  et	  al.,	  1999;	  Geiger	  et	  al.,	  2000;	  Tuder	  et	  al.,	  2001).	  CD44	  expression	  in	  
plexiform	  lesions	  from	  IPAH	  patients	  has	  also	  been	  linked	  to	  increased	  adhesion	  and	  infiltration	  of	  T-­‐
cells	   (Ohta-­‐Ogo	   et	   al.,	   2012).	   These	   lesions	   could	   lead	   to	   enormous	   pulmonary	   vascular	   luminal	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obliteration.	  Endothelial	  dysfunction	  is	  now	  considered	  a	  hallmark	  of	  PAH	  (Budhiraja	  et	  al.,	  2004)	  and	  
the	  restoration	  of	  endothelial	  function	  is	  a	  common	  goal	  of	  available	  treatments.	  
	  
1.2.5	   Pulmonary	  vascular	  remodelling	  in	  PAH	  
Vascular	  remodelling	  usually	  involves	  all	  three	  layers	  of	  the	  vessel	  wall	  and	  severely	  reduces	  the	  area	  
of	   the	   lumen	   (Tuder	   et	   al.,	   2009)	   as	  well	   as	   the	   compliance	   of	   larger	   proximal	   pulmonary	   arteries	  
(Fourie	  et	  al.,	  1992).	  Despite	  differences	  in	  the	  cause	  of	  progression	  in	  PAH	  patients	  with	  idiopathic	  
and	  other	  forms	  of	  the	  disease,	  the	  structural	  abnormalities	  found	  in	  the	  pulmonary	  vasculature	  are	  
remarkably	  similar	  (Strange	  et	  al.,	  2002).	  Structural	  changes	  occur	  in	  all	  three	  layers	  of	  the	  vessel	  wall	  
and	   involve	   the	   proliferation	   or	   infiltration	   of	   ECs,	   SMCs,	   fibroblasts,	   platelets,	   inflammatory	   cells,	  
and	  progenitor	  cells,	  as	  well	  as	  ECM	  components	  such	  as	  collagen,	  elastin	  and	  fibronectin	  (Tuder	  et	  
al.,	  2009).	  Remodelling	  is	  observed	  in	  large	  elastic	  pulmonary	  arteries	  as	  well	  as	  the	  smaller	  muscular	  
arteries.	  There	  is	  also	  distal	  muscularisation	  of	  normally	  non-­‐muscular	  vessels,	  with	  differentiation	  of	  
pericytes	   into	   SMCs	   and	  medial	   thickening	   due	   to	   SMC	  hyperplasia	   and	   hypertrophy	   (Rabinovitch,	  
2008).	   Occlusive	   lesions	   are	   often	   observed,	   with	   inward	   neointimal	   proliferation	   of	   SMCs	   and	  
myofibroblasts	   that	   are	   embedded	   in	   a	   mucopolysaccharide	   matrix	   resulting	   from	   an	   imbalance	  
between	   matrix	   metalloproteinases	   (MMPs)	   and	   tissue	   inhibitors	   of	   metalloproteinases	   (TIMPs)	  
(Lepetit	   et	   al.,	   2005).	   Plexiform	   lesions	   are	   a	   feature	   of	   severe	   end-­‐stage	   disease	   and	   thought	   to	  
represent	   disorganised	   angiogenesis,	   with	   the	   clonal	   expansion	   of	   apoptosis-­‐resistant	   ECs	   in	   IPAH	  
patients	  (Lee	  et	  al.,	  1998).	  The	  vasculopathy	  in	  PAH	  leads	  to	  occlusion	  of	  the	  pulmonary	  artery	  lumen	  
and	   obliteration	   of	   pulmonary	   vessels,	   thus	   the	   focus	   for	   therapy	   has	   now	  been	   directed	   towards	  
preventing	  and	  reversing	  excessive	  vascular	  cell	  growth	  (see	  section	  1.4).	  
	  
1.2.6	   Immune	  and	  inflammatory	  cell	  involvement	  
The	  relationship	  between	  inflammation	  and	  pulmonary	  vascular	  remodelling	  is	  well	  recognised,	  PAH	  
being	  associated	  with	  a	  variety	  of	  connective	  tissue	  diseases	  as	  well	  as	  viral	  and	  parasitic	  infections.	  
Increasing	   evidence	   indicates	   that	   inflammatory	   and/or	   immune	   processes	   are	   important	   both	   in	  
PAH	   patients	   and	   experimental	   models	   of	   the	   disease	   (Hassoun	   et	   al.,	   2009).	   Several	   histological	  
studies	   have	   described	   inflammatory	   cell	   infiltrates,	   composed	   of	   mast	   cells,	   monocytes,	  
macrophages,	  dendritic	  cells	  and	  T	  lymphocytes,	   in	  perivascular	  regions	  as	  well	  as	  plexiform	  lesions	  
in	  PAH	  (Tuder	  et	  al.,	  1994;	  Mitani	  et	  al.,	  1999;	  Perros	  et	  al.,	  2007).	  Most	  animal	  models	  of	  PH	  also	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exhibit	   a	   perivascular	   infiltration	   of	   inflammatory	   cells	   associated	   with	   remodelled	   vessels	   (as	  
reviewed	   by	   (Price	   et	   al.,	   2012)).	   Furthermore,	   Tuder	   and	   co-­‐workers	   have	   now	   examined	   a	   large	  
series	  of	   lungs	  explanted	   from	  PAH	  patients	   (n=62)	  and	   found	  significant	  correlations	  between	   the	  
degree	  of	  perivascular	   inflammation	  and	   intima	  plus	  media	   remodeling,	   as	  well	   as	  with	  adventitial	  
thickness	   (Stacher	   et	   al.,	   2012).	   The	   accumulation/infiltration	  of	   immunostained	   inflammatory	   and	  
immune	  cells	  has	  also	  recently	  been	  described	  in	  lungs	  from	  IPAH	  patients,	  associated	  with	  vascular	  
lesions	   and	   distributed	   in	   the	   adventitial	   layer	   of	   pulmonary	   arteries	   20-­‐50µm,	   51—150µm	   and	  	  
>150µm	   in	   diameter	   (Savai	   et	   al.,	   2012).	   These	   included	   mast	   cells,	   macrophages	   (CD68+),	  
monocytes/macrophages	  (CD4+),	  dendritic	  cells	  (CD209+),	  T	  cells	  (CD3+),	  cytoxic	  (CD8+)	  and	  T	  helper	  
cells	   (CD4+)	   and	   B	   cells	   (CD20+).	   In	   contrast,	   regulatory	   T	   (Treg)	   cells	   (FoxP3+)	   were	   found	   to	   be	  
depleted	  in	  the	  IPAH	  pulmonary	  vasculature.	  This	  observation	  is	  interesting	  as	  it	  parallels	  the	  results	  
of	   animal	   studies	   implicating	   T-­‐cell	   deficiency	   and	   reduced	   Treg	   activity	   in	   the	   development	   of	  
pulmonary	  hypertension	  (Taraseviciene-­‐Stewart	  et	  al.,	  2007;	  Tamosiuniene	  et	  al.,	  2011).	  	  
Cytokines	   and	   chemokines	   are	   important	   mediators	   of	   inflammation	   and	   substantial	   evidence	  
indicates	  they	  have	  a	  role	   in	  PAH.	  Circulating	  cytokines	  such	  as	  tumour	  necrosis	   factor	  (TNF)-­‐α	  and	  
interleukin	   (IL)-­‐1β,	   IL-­‐2,	   IL-­‐6,	   IL-­‐8,	   IL-­‐10,	   and	   IL-­‐12	   are	   raised	   in	   PAH	   and	   may	   predict	   survival	  
(Humbert	  et	  al.,	  1995;	  Soon	  et	  al.,	  2010).	  Levels	  of	  chemokines	  such	  as	  MCP-­‐1,	  chemokine	  ligand	  5	  
(CCL-­‐5;	  also	  known	  as	  RANTES	  -­‐	  Regulated	  upon	  Activation,	  Normally	  T	  cell	  Expressed	  and	  Secreted)	  
and	   fractalkine	   (CX3CL1)	  are	  also	  elevated	   in	  PAH	   (Balabanian	  et	  al.,	  2002;	  Dorfmuller	  et	  al.,	  2002;	  
Itoh	  et	  al.,	  2006;	  Sanchez	  et	  al.,	  2007).	  C-­‐reactive	  protein,	  a	  circulating	  marker	  of	   inflammation	  and	  
tissue	  damage,	  is	  also	  increased	  in	  patients	  with	  PAH	  and	  correlates	  with	  adverse	  outcomes	  (Quarck	  
et	   al.,	   2009).	   Studies	   in	   experimental	   models	   support	   the	   role	   of	   cytokines/chemokines	   in	   the	  
pathogenesis	   of	   PAH.	   For	   example,	   the	   injection	   or	   over	   expression	   of	   IL-­‐6	   has	   been	   shown	   to	  
promote	  the	  development	  of	  pulmonary	  hypertension	  whereas	  mice	  deficient	  in	  IL-­‐6	  were	  protected	  
(Miyata	  et	  al.,	  1995;	  Savale	  et	  al.,	  2009;	  Steiner	  et	  al.,	  2009).	  An	  interaction	  has	  also	  been	  found	  with	  
BMPR2	  signalling	  and	  increased	  IL-­‐6	  levels	  can	  suppress	  BMPR2	  expression	  (Brock	  et	  al.,	  2009).	  Anti-­‐
inflammatory	  treatments	  targeting	  IL-­‐1,	  MCP-­‐1	  and	  activation	  of	  nuclear	  factor	  activated	  T	  cells	  and	  
the	   use	   of	   glucocorticoids	   has	   also	   been	   shown	   to	   prevent	   the	   development	   of	   experimental	  
pulmonary	  hypertension	   (Voelkel	  et	  al.,	  1994;	   Ikeda	  et	  al.,	  2002;	  Suzuki	  et	  al.,	  2006;	  Bonnet	  et	  al.,	  




1.2.7	   Thrombosis	  
In	  situ	  thrombosis	  is	  a	  common	  feature	  of	  PAH	  (Fuster	  et	  al.,	  1984)	  and	  at	  least	  some	  patients	  with	  
IPAH	  exhibit	  a	  hypercoagulable	  phenotype	  (Tournier	  et	  al.,	  2010).	  Endothelial	  dysfunction	  is	  likely	  to	  
be	  an	  important	  cause,	  providing	  a	  pro-­‐	  rather	  than	  anti-­‐thrombotic	  environment,	  and	  the	  induction	  
of	   tissue	   factor	   is	   a	   prominent	   feature	   of	   the	   pulmonary	   vasculature	   in	   IPAH	   patients	   as	   well	   as	  
experimental	  models	  of	  pulmonary	  hypertension	  (White	  et	  al.,	  2007).	  Increased	  circulating	  levels	  of	  
fibrinopeptide	   A	   (a	   marker	   of	   fibrin	   generation),	   plasminogen	   activator	   inhibitor	   1	   and	   von	  
Willebrand	   factor	   (vWF),	   as	   well	   as	   reduced	   thrombomodulin,	   have	   led	   to	   the	   suggestion	   that	  
abnormalities	   of	   blood	   coagulation,	   anti-­‐thrombotic	   factors	   and	   fibrinolysis	   contribute	   to	   a	   pro-­‐
thrombotic	  state	  in	  PAH	  (Johnson	  et	  al.,	  2006).	   	  Platelet	  aggregation	  might	  be	  increased	  due	  to	  the	  
imbalance	   in	   the	   production	   of	   pro-­‐aggregatory	   (thromboxane	   A2)	   and	   anti-­‐aggregatory	   (NO	   and	  
PGI2)	   factors	   in	   patients	   with	   PAH	   (Schermuly	   et	   al.,	   2011).	   Increased	   platelet	   and	   leukocyte	  
activation	   has	   been	   described	   in	   MCT-­‐induced	   pulmonary	   hypertension	   (Hu	   et	   al.,	   2010).	  
Anticoagulants	  such	  as	  warfarin	  are	  commonly	  prescribed	  for	  patients	  with	  PAH	  (see	  1.3	  below)	  and	  
anticoagulants	   such	   as	   aspirin	   and	   Factor	   Xa	   inhibitor	   rivaroxaban	   have	   also	   been	   reported	   to	  
prevent	  MCT-­‐induced	  pulmonary	  hypertension	  (Delbeck	  et	  al.,	  2011;	  Shen	  et	  al.,	  2011).	  	  
	  
1.2.8	   Genetic	  mutation	  	  
It	  has	  been	  suggested	  that	  the	  development	  of	  PAH	  requires	  a	  permissive	  genotype,	  vulnerable	  cell	  
phenotype	   (EC,	   SMC	   or	   both)	   and	   an	   additional	   exogenous	   trigger	   or	   “second	   hit”,	   the	   latter	  
accounting	   for	   reduced	   penetrance	   in	   families	  with	   PAH.	   The	   discovery	   of	   heterozygous	   germ-­‐line	  
mutations	   in	  BMPR2,	   a	   constitutively	   active	   serine/threonine	  kinase	  belonging	   to	   the	   transforming	  
growth	  factor	  β	  (TGF-­‐β)	  receptors	  superfamily,	  represents	  an	  important	  milestone	  in	  understanding	  
the	  pathogenesis	  of	  PAH.	  BMPR2	  mutations	  are	  detected	  in	  about	  70%	  of	  families	  with	  HPAH	  (Lane	  
et	   al.,	   2000;	  Aldred	  et	   al.,	   2006;	  Cogan	  et	   al.,	   2006),	   and	  approximately	  10	   -­‐	   40%	  of	   IPAH	  patients	  
(Thomson	   et	   al.,	   2000;	  Machado	   et	   al.,	   2006).	   Patients	   with	   BMPR2	   mutations	   present	   with	   PAH	  
about	   10	   years	   earlier	   than	   those	   without	   mutations,	   and	   are	   more	   severely	   haemodynamically	  
compromised	  (Sztrymf	  et	  al.,	  2008),	  and	  less	  likely	  to	  respond	  to	  vasodilator	  therapy	  (Rosenzweig	  et	  
al.,	  2008).	  Nevertheless,	  disease	  penetrance	  in	  individuals	  with	  BMPR2	  mutation	  is	  only	  about	  20%,	  
and	  small	  animal	  models	  of	  heterozygous	  deletions	  of	  BMPR2	  fail	  to	  show	  a	  PAH	  phenotype	  (Long	  et	  
al.,	  2006),	  suggesting	  that	  another	  genetic	  and/or	  environmental	  factor	   is	  necessary	  to	  develop	  the	  
phenotype.	  Studying	  “second	  hits”	  in	  cultured	  cells	  may	  further	  our	  understanding	  of	  the	  differences	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between	  pulmonary	  ECs	  in	  patients	  with	  PAH	  and	  healthy	  controls.	  Examples	  of	  potential	  additional	  
hits	  include	  inflammatory	  insults	  and	  increased	  activity	  of	  vasoconstrictors	  such	  as	  5-­‐HT	  (Long	  et	  al.,	  
2006).	  	  
More	  than	  298	  mutations	  identified	  in	  BMPR2	  in	  PAH	  patients	  to	  date	  (Machado	  et	  al.,	  2009).	  Many	  
of	   the	   mutations	   (~70%)	   are	   either	   nonsense	   or	   frameshift	   mutations	   and	   are	   likely	   to	   result	   in	  
degradation	  of	  the	  transcripts	  by	  nonsense-­‐mediated	  mRNA	  decay	  and	  a	  state	  of	  haplo-­‐insufficiency	  
arises	   as	   only	   the	   non-­‐mutant	   allele	   encodes	   protein	   production.	   About	   30%	  of	  mutations	   lead	   to	  
missense	   mutations	   in	   highly	   conserved	   cysteine	   residues	   in	   functional	   domains	   of	   the	   receptor.	  
Some	   interrupt	   receptor	   trafficking	   to	   the	   cell	   surface	   (Rudarakanchana	   et	   al.,	   2002)	   and	  may	   be	  
rescued	   with	   chemical	   chaperones	   (Sobolewski	   et	   al.,	   2008).	   In	   contrast,	   non-­‐cysteine	   mutations	  
within	   the	   kinase	   domain	   reach	   the	   cell	   surface	   but	   display	   dysfunctional	   downstream	   signalling.	  
Mutations	   also	   occur	   in	   the	   long	   cytoplasmic	   tail	   of	   BMPR2.	   There	   is	   a	   general	   reduction	   in	   the	  
capacity	   for	   Smad	   activation	   (phosphorylation)	   and	   reduced	   transcription	   of	   target	   genes	   in	   cells	  
harbouring	  BMPR2	  mutations	  (Yang	  et	  al.,	  2005).	  
Rarely,	   mutations	   in	   activin	   receptor-­‐like	   kinase	   type	   1	   (ALK-­‐1),	   another	   member	   of	   the	   TGF-­‐β	  
superfamily,	   have	   been	   linked	   with	   the	   development	   of	   severe	   PAH	   in	   families	   with	   hereditary	  
hemorrhagic	   telangiectasia	   (HHT)	   (Trembath	   et	   al.,	   2001).	   More	   recently,	   mutation	   in	   SMAD1,	  
SMAD4	   and	   SMAD9	   (gene	   symbol	   for	   SMAD8),	   the	   downstream	   target	   of	   receptors	   in	   TGF-­‐β	  
superfamily,	  were	  also	  discovered	   in	  HPAH	  patients	   (Shintani	  et	  al.,	   2009;	  Nasim	  et	  al.,	   2011),	   and	  
mutation	  in	  TGF-­‐β	  type	  I	  receptor	  ALK-­‐6	  was	  also	  discovered	  in	  children	  with	  IPAH	  who	  are	  without	  
mutation	  in	  BMPR2,	  ALK-­‐1	  and	  SMAD9	  (Chida	  et	  al.,	  2012).	  The	  mechanism	  of	  the	  dysfunctional	  BMP	  
and	   TGF-­‐β	   signalling	   in	   relation	   to	   the	   pathogenesis	   of	   PAH	   will	   be	   discussed	   in	   more	   details	   in	  
section	  1.7.5.	  Other	  genetic	  mutations,	  including	  a	  polymorphic	  variant	  of	  5-­‐HTT	  gene	  promoter	  have	  
been	  associated	  with	  5-­‐HTT	  over-­‐expression	  and	  increased	  5-­‐HT	  transport	  (Eddahibi	  et	  al.,	  2001).	  In	  
addition,	  a	  frameshift	  mutation	  in	  caveolin-­‐1	  (CAV1)	  (Austin	  et	  al.,	  2012)	  has	  been	  found	  in	  IPAH	  and	  
HPAH	  patients	  with	  no	  identified	  mutation	  in	  the	  TGF-­‐β	  superfamily	  members	  (Maloney	  et	  al.,	  2012).	  
However,	   these	   represent	   infrequent	   causes	   of	   the	   disease,	   and	   some	   of	   these	   mutations	   need	  





1.3	   Current	  drug	  treatments	  for	  PAH	  
Most	  patients	  with	  PAH	  receive	  so-­‐called	   ‘background’	  or	   ‘conventional’	   therapies,	  which	  comprise	  
anticoagulants,	   diuretics,	   inotropic	   agents	   and	   oxygen	   supplementation.	   Anticoagulants	   such	   as	  
warfarin	  might	  provide	  survival	  advantage	  and	  improve	  quality	  of	  life,	  but	  its	  contribution	  is	  difficult	  
to	   be	   estimated	   and	   is	   based	   on	   retrospective	   analysis	   (Fuster	   et	   al.,	   1984;	   Frank	   et	   al.,	   1997).	  
Analysis	  of	  clinical	   trials	   in	  PAH	  has	  shown	  that	  a	  majority	  of	  patients	  are	   taking	  diuretics	  and	  may	  
offer	   symptomatic	   benefit	   by	   reducing	   volume	   overload	   and	   RV	   wall	   stress	   (Galie	   et	   al.,	   2009b).	  
Inotropic	  agents	  such	  as	  digoxin	  may	  also	  provide	  some	  benefit	  in	  patients	  with	  RV	  dysfunction	  due	  
to	   pulmonary	   hypertension	   (Rich	   et	   al.,	   1998),	   though	   its	   long-­‐term	   effects	   have	   not	   been	  
systemically	  examined.	  	  	  
Acute	  vasodilator	   testing	   is	   recommended	   for	  all	  patients	  with	  PAH	   in	  order	   to	   identify	   those	  with	  
pulmonary	   vasoreactivity,	   defined	   as	   a	   reduction	   in	   mPAP	   of	   at	   least	   ≥	   10mm	   Hg	   to	   an	   absolute	  
mPAP	   <35-­‐40mm	   Hg	   with	   either	   no	   change	   or	   an	   increase	   in	   cardiac	   output	   (McLaughlin	   et	   al.,	  
2009a).	   A	   small	   proportion	   (<10%)	   of	   patients	   exhibit	   pulmonary	   vasoreactivity	   when	   tested	   with	  
short-­‐acting	  vasodilators	   (e.g.	   adenosine	  or	   inhaled	  nitric	  oxide).	   Importantly,	   they	   respond	   to	  oral	  
calcium-­‐channel	   blockers	   such	   as	   nifedipine	   and	   diltiazem	   and	   show	  marked	   improvements	   in	   the	  
quality	  of	   life	   and	   survival	   (Rich	  et	   al.,	   1992;	   Sitbon	  et	   al.,	   2005a).	  However,	   approximately	  half	   of	  
these	   patients	   experience	   reduced	   benefit	   over	   time	   and	   required	   alternative	   PAH-­‐targeted	  
therapies.	  	  
Until	   the	   1990s	   the	   only	   therapies	   available	   for	   PAH	   were	   those	   described	   above.	   With	   greater	  
understanding	   of	   the	   pathophysiological	   mechanisms	   involved,	   in	   particular	   abnormalities	   in	   the	  
endothelial	  prostacyclin,	  endothelin	  and	  nitric	  oxide	  pathways,	  a	  number	  of	  PAH-­‐specific	  vasodilator	  
therapies	   have	   been	   developed	   that	   target	   one	   of	   these	   three	   major	   pathways.	   These	   comprise	  
prostanoids,	   endothelin	   receptor	   antagonists	   and	   phosphodiesterase	   type	   5	   (PDE5)	   inhibitors	   and	  
the	   results	   of	  meta-­‐analysis	   suggests	   that	   their	   introduction	   has	   led	   to	   significant	   improvement	   in	  
patient’s	   symptomatic	   status	   and	   clinical	   end-­‐points,	   including	   exercise	   capacity,	   WHO	   functional	  





1.3.1	   Prostanoids	  
Intravenous	  PGI2	  (epoprostenol)	  was	  the	  first	  targeted	  therapy	  for	  PAH	  and	  long-­‐term	  use	  improves	  
pulmonary	  haemodynamics	   and	  quality	   of	   life,	   delays	   lung	   transplantation	   and	   is	   the	  only	   therapy	  
that	  has	  prospectively	  been	  shown	  to	  enhance	  survival	  (Rubin	  et	  al.,	  1990;	  Barst	  et	  al.,	  1996;	  Shapiro	  
et	  al.,	  1997;	  McLaughlin	  et	  al.,	  2002;	  Sitbon	  et	  al.,	  2002).	  However,	  it	  has	  a	  short	  half	   life	  (<	  5	  min),	  
and	   its	   intravenous	   administration	   via	   indwelling	   catheter	   and	   an	   infusion	   pump	   is	   complex	   and	  
requires	   frequent	   monitoring.	   In	   common	   with	   all	   prostanoids,	   epoprostenol	   may	   cause	   adverse	  
effects	  such	  as	  headache,	  flushing,	  jaw	  pain	  and	  gastrointestinal	  upset,	  but	  most	  problems	  arise	  from	  
the	  route	  of	  delivery	  (Agarwal	  and	  Gomberg-­‐Maitland,	  2011).	  Other	  prostanoid	  analogues	  have	  since	  
been	  developed	  and	   licensed	   that	  offer	   greater	   stability,	   longer	  half-­‐life	   and	  alternatives	   routes	  of	  
administration.	  These	  include	  a	  novel	  formulation	  of	  epoprostenol	  (veletri®)	  that	   is	  stable	  for	  up	  to	  
24	  h	  and	   the	  PGI2	  analogue	   treprostinil,	  which	  can	  be	  administered	  by	   intravenous,	   subcutaneous,	  
inhaled	  or	  oral	  routes	  (Barst	  et	  al.,	  1996;	  Simonneau	  et	  al.,	  2002;	  Channick	  et	  al.,	  2006;	  McLaughlin	  et	  
al.,	   2010).	   Iloprost	   is	   a	   stable	  PGI2	   analogue	  developed	   for	   intravenous	   and	   inhaled	  administration	  
and	  was	   approved	   in	   2004	   (Higenbottam	   et	   al.,	   1998;	  Olschewski	   et	   al.,	   2002;	  Opitz	   et	   al.,	   2005).	  
Beraprost	   is	   an	   orally	   active	   prostanoid	   that	   exhibits	  modest	   efficacy	   in	   PAH	  patients	   (Galie	   et	   al.,	  
2002;	  Barst	  et	  al.,	  2003).	  Data	  on	  the	  oral	   form	  of	   treprostinil	  has	  been	  mixed	  as	   it	  did	  not	  display	  
significant	   benefit	   when	   examined	   in	   combination	   with	   PDE-­‐5	   inhibitors	   or	   endothelin	   receptor	  
antagonists	   (Tapson	   et	   al.,	   2012a;	   Tapson	   et	   al.,	   2012b)	   but	   did	   display	   efficacy	   in	   PAH	   patients	  
receiving	  it	  as	  a	  monotherapy	  (Rubin	  et	  al.,	  2011).	  
	  
1.3.2	   Endothelin	  receptor	  antagonists	  
Bosentan	  is	  an	  irreversible	  dual	  ETA/ETB	  antagonist	  that	  was	  approved	  in	  Europe	  in	  2002	  on	  the	  basis	  
of	  the	  BREATHE-­‐1	  trial	  (Channick	  et	  al.,	  2001;	  Rubin	  et	  al.,	  2002).	  Subsequent	  studies	  indicated	  that	  
long-­‐term	   treatment	  was	   associated	  with	   sustained	   improvements	   in	   exercise	   capacity,	   functional	  
class	   and	   pulmonary	   haemodynamics	   and	   possibly	   survival	   (McLaughlin	   et	   al.,	   2005;	   Sitbon	   et	   al.,	  
2005b).	   Bosentan	   also	   conferred	   haemodynamic	   improvements	   and	   delayed	   time	   to	   clinical	  
worsening	   in	   patients	   with	  mildly	   symptomatic	   PAH	   (Galie	   et	   al.,	   2008b)	   and	  may	   be	   effective	   in	  
slowing	  disease	  progression	  in	  children	  with	  PAH	  (Hislop	  et	  al.,	  2011).	  	  
The	   selective	  ETA	   antagonists	   sitaxentan	  and	  ambrisentan	  were	   subsequently	   licensed	   in	  2006	  and	  
2008	  after	  showing	  favourable	  results	   in	  clinical	  trials	  (Barst	  et	  al.,	  2004;	  Barst	  et	  al.,	  2006;	  Galie	  et	  
al.,	   2008a;	   Oudiz	   et	   al.,	   2009).	   However,	   sitaxentan	   was	   withdrawn	   worldwide	   in	   2010	   after	   a	  
	  36	  
number	  of	  deaths	  attributed	  to	  liver	  failure	  were	  reported	  (Lavelle	  et	  al.,	  2009;	  Lee	  et	  al.,	  2011).	   In	  
the	   absence	   of	   head-­‐to-­‐head,	   adequately	   powered,	   randomised	   controlled	   trials,	   it	   is	   difficult	   to	  
judge	  whether	   selective	   ETA	   antagonism,	  which	   spares	   endothelial	   ETB	   receptors	   and	   theoretically	  
preserves	  ET-­‐1-­‐mediated	  vasodilatory	  and	  anti-­‐mitogenic	  activity,	  offers	  advantages	  in	  efficacy	  over	  
combined	  ETA	  and	  ETB	  antagonism,	  but	   their	  effects	  are	   similar	   in	  magnitude	   (Rhodes	  et	  al.,	   2009;	  
O'Callaghan	   et	   al.,	   2011).	   Ambriesentan	   has	   however	   displayed	   less	   hepatotoxicity	   than	   bosentan,	  
providing	   an	   alternative	   for	   patients	   that	   develop	   acute	   liver	   damage	   with	   other	   antagonists	  
(McGoon	  et	  al.,	  2009).	  Macitentan,	  a	  novel	  and	  highly	  potent	  dual	  ETA/ETB	  antagonist,	  has	  recently	  
completed	   a	   phase	   III	   placebo-­‐controlled	   (SERAPHIN)	   trial,	   which	   showed	   favourable	   results	   with	  
reduced	  risk	  of	  a	  morbidity/mortality	  event	  by	  30%	  (3	  mg	  dose)	  to	  45%	  (10	  mg	  dose)	  compared	  with	  
those	  who	  received	  placebo	  and	  was	  well	  tolerated	  (Rubin	  et	  al.,	  2012).	  
	  
1.3.3	   Phosphodiesterase	  type	  5	  inhibitors	  
The	   NO-­‐cGMP	   signalling	   pathway	   has	   become	   an	   important	   therapeutic	   target	   in	   PAH,	   with	  
phosphodiesterase	  type	  5	   (PDE5)	  inhibitors	  exerting	  anti-­‐proliferative	  as	  well	  as	  vasodilatory	  effects	  
on	  PASMCs	  (Wharton	  et	  al.,	  2005).	  Sildenafil	  was	  the	  first	  PDE-­‐5	  inhibitor	  approved	  as	  a	  PAH	  therapy,	  
based	  on	  the	  SUPER-­‐1	  trial	  (Galie	  et	  al.,	  2005).	  There	  are	  uncertainties	  however	  concerning	  its	  impact	  
at	   approved	   doses	   on	   haemodynamics	   and	   long-­‐term	   survival	   (Agarwal	   and	   Gomberg-­‐Maitland,	  
2011)	  and	  in	  Europe	  it	  is	  only	  approved	  as	  a	  monotherapy	  for	  PAH	  patients	  with	  functional	  class	  II-­‐III	  
symptoms	  (Figure	  1.1).	  Two	  other	  PDE5	  inhibitors,	  tadalafil	  and	  vardenafil,	  have	  also	  been	  examined	  
as	  treatments	  (Galie	  et	  al.,	  2009a;	  Jing	  et	  al.,	  2011)	  and	  tadalafil	  received	  approval	  for	  use	  in	  patients	  
with	  PAH	  in	  2009.	  	  
	  
1.3.4	   Combination	  treatment	  
Meta-­‐analysis	   of	   randomised	   controlled	   trials	   in	   PAH	   suggests	   an	   improvement	   of	   survival	   in	   the	  
patients	   treated	   with	   the	   targeted	   therapies	   (Galie	   et	   al.,	   2009c)	   and	   consensus	   evidence-­‐based	  
treatment	  algorithms	  have	  been	  developed	   (Figure	  1.1).	  Continued	  disease	  progression	   in	  PAH	  has	  
led	  however	  to	  consideration	  of	  the	  need	  for	  early	  aggressive	  intervention	  and	  combination	  therapy	  
in	   patients	  who	   fail	   to	   show	   improvement	   or	   deteriorate	  with	  monotherapy	   (Galie	   et	   al.,	   2009b).	  	  
Several	   studies	   support	   the	   efficacy	   of	   combination	   treatment	   but	   the	   long-­‐term	   clinical	   benefits	  
remain	  unclear	  (Barst	  et	  al.,	  2009).	  In	  this	  regard,	  ongoing	  trials	  such	  as	  AMBITION	  (ClinicalTrials.gov	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Identifier	   NCT01178073),	   COMPASS-­‐2	   (ClinicalTrials.gov	   Identifier	   NCT00303459)	   and	   A1481243	  
(ClinicalTrials.gov	   Identifier	   NCT00323297)	   should	   provide	   additional	   data	   on	   how	   combination	  
therapy	  and	  goal-­‐oriented	  treatment	  strategies	  affect	  outcome	  in	  PAH.	  
While	   the	  present	   therapies	   represent	  a	   significant	  advance	  many	  PAH	  patients	  do	  not	   respond	   to	  
the	  current	  vasodilator	  treatments	  and	  responsiveness	  declines	  as	  the	  disease	  progresses.	  The	  one	  
year	  incident	  mortality	  rate	  remains	  high	  (12-­‐15%)	  for	  many	  patients	  with	  PAH	  (Humbert	  et	  al.,	  2006;	  
Thenappan	  et	  al.,	  2007)	  and	  contemporary	  registry	  data	  in	  France	  and	  the	  USA	  indicate	  that	  longer	  






Figure	  1.1.	  Treatment	  algorithm	  for	  pulmonary	  arterial	  hypertension.	  *Licensed	  indications	  for	  
individual	   agents	   with	   respect	   to	   functional	   class	   vary	   between	   countries.	   ERA:	   endothelin	  
receptor	  antagonists;	  Inh:	  inhaled;	  IV:	  intravenous;	  PAH:	  pulmonary	  arterial	  hypertension;	  PDE-­‐5-­‐
I:	  phosphodiesterase	   type	  5	   inhibitors;	   SC:	   subcuntaneous;	  WHO-­‐FC:	  World	  Health	  Organisation	  
functional	  class.	  (Modified	  from	  O’Callaghan	  et	  al.	  2011a)	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1.4	   Emerging	  therapeutics	  for	  PAH	  
1.4.1	   Emerging	  drug	  treatments	  for	  PAH	  
There	  is	  an	  unmet	  need	  for	  drugs	  that	  can	  reverse	  pulmonary	  vascular	  remodelling,	  improve	  survival	  
and	   inhibit	   disease	   progression	   in	   patients	   with	   PAH.	   This	   includes	   agents	   that	   can	   stop	   cell	  
proliferation,	  inhibit	  cell	  migration	  and	  matrix	  deposition	  or	  promote	  apoptosis,	  as	  recently	  reviewed	  
(Archer	   et	   al.,	   2010;	   Agarwal	   and	   Gomberg-­‐Maitland,	   2011;	   McLaughlin,	   2011;	   Schermuly	   et	   al.,	  
2011).	   In	   fact,	   there	  are	  now	  more	  than	  30	  drugs	  at	  different	  stages	  of	  development	  and	  although	  
some	   represent	   variations/extensions	   of	   current	   therapies,	   the	   majority	   are	   novel	   ‘first-­‐in-­‐class’	  
drugs.	   They	   include	   growth	   factor	   receptor	   tyrosine	   kinase	   inhibitors	   (imatinib,	   nilotinib	   and	  
sorafenib)	   (Moreno-­‐Vinasco	   et	   al.,	   2008;	   Ghofrani	   et	   al.,	   2010b;	   Gomberg-­‐Maitland	   et	   al.,	   2010;	  
Hoeper	   et	   al.,	   2011;	   Chaumais	   et	   al.,	   2012;	   Hoeper	   et	   al.,	   2012);	   drugs	   that	   target	   changes	   in	  
mitochondrial	   and	   metabolic	   function	   (e.g.	   dichloroacetate,	   a	   pyruvate	   dehydrogenase	   kinase	  
inhibitor,	  and	  peroxisome	  proliferator-­‐activator	  receptor	  agonists)	  (Michelakis	  et	  al.,	  2002;	  McMurtry	  
et	   al.,	   2004;	   Guignabert	   et	   al.,	   2009);	   soluble	   guanylate	   cyclise	   stimulators	   and	   activators	   (e.g.	  
riociguat)	  (Ghofrani	  et	  al.,	  2010a);	  agents	  that	  enhance	  coupling	  of	  eNOS	  (e.g.	  cicletanine)	  (Waxman	  
et	   al.,	   2008);	   prostacylin	   receptor	   agonists	   (e.g.	   selexipag)	   (Simonneau	   et	   al.,	   2012);	   vasoactive	  
intestinal	   peptide	   (Petkov	   et	   al.,	   2003;	   Leuchte	   et	   al.,	   2008);	   adrenomedullin	   (Harada-­‐Shiba	   et	   al.,	  
2009);	   apelin	   (Alastalo	   et	   al.,	   2011);	   serotonin	   inhibitors	   (e.g.	   terguride)	   (Ghofrani	   et	   al.,	   2012);	  
inhibitors	  of	  Rho	  kinase	  signalling	  (Fujita	  et	  al.,	  2010);	  protease	  and	  elastase	  inhibitors;	  the	  oral	  late	  
sodium	  current	  inhibitor	  ranolazine	  (Liles	  et	  al.,	  2011);	  and	  drugs	  that	  affect	  epigenetic	  targets	  such	  
as	   histone	   deacetylase	   (HDAC)	   activity	   (Zhao	   et	   al.,	   2012).	   Studies	   with	   tyrosine	   kinase	   inhibitors	  
(imatinib,	   nilotinib),	   soluble	   guanylate	   cyclise	   stimulator	   (riociguat),	   serotonin	   5-­‐HT2A	   and	   5-­‐HT2B	  
receptor	   antagonist	   (terguride)	   and	   orally	   available	   prostacyclin	   receptor	   agonist	   (selexipag)	   are	  
among	   the	   most	   advanced,	   having	   displayed	   encouraging	   results	   in	   animal	   models	   and	   reached	  
phase	   II-­‐III	  human	  trials	   (Schermuly	  et	  al.,	  2011).	  Not	  all	  drugs	  prove	  to	  be	  successful	  however	  and	  
several	  have	  been	  withdrawn	  following	  human	  trials,	  recent	  examples	  being	  cicletanine	  and	  imatinib.	  	  
	  
1.4.2	   Gene-­‐	  and	  microRNA-­‐based	  therapies	  for	  PAH	  
Recent	   studies	   in	   experimental	   animal	   models	   have	   demonstrated	   the	   potential	   of	   gene-­‐	   and	  
microRNA-­‐based	  therapies	   in	  PAH.	  Deficiencies	   in	  BMPR2	  expression	  and	  signalling	   in	  PAH	  patients	  
and	   animal	   models	   makes	   this	   an	   obvious	   potential	   target,	   although	   an	   initial	   attempt	   to	   over	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express	  BMPR2	  was	  not	  successful	  in	  inhibiting	  MCT-­‐induced	  pulmonary	  hypertension	  (McMurtry	  et	  
al.	  2007).	   In	   contrast,	  Reynolds	  and	  co-­‐workers	  used	  an	  adenoviral	  BMPR2	   gene	  delivery	  vector	   to	  
target	  the	  endothelium	  in	  the	  pulmonary	  hypertensive	  rat	  lung,	  restoring	  BMPR2	  levels,	  diminishing	  
up-­‐regulation	  of	  TGF-­‐β	  signalling,	  improving	  pulmonary	  haemodynamics	  and	  reducing	  cardiovascular	  
remodelling	  (Reynolds	  et	  al.,	  2007;	  Reynolds	  et	  al.,	  2012).	  As	  most	  BMPR2	  mutations	  are	  thought	  to	  
lead	   to	  haploinsuffiency,	   alternative	  approaches	   that	   increase	  BMPR2	  mRNA	  or	  protein	  expression	  
might	   also	   be	   successful.	   For	   example,	   it	  may	   be	   possible	   to	   rescue	   the	   failure	   of	   BMPR2	   protein	  
trafficking	  in	  PAH	  (Sobolewski	  et	  al.,	  2008)	  and	  inhibit	  the	  removal	  and	  degradation	  of	  the	  receptor	  
from	  the	  cell	  surface	  (Durrington	  et	  al.,	  2010).	  
It	  is	  now	  recognised	  that	  non-­‐protein	  coding	  microRNA	  (miRNA	  or	  miR)	  sequences	  have	  a	  critical	  role	  
in	   regulating	   gene	   expression	   in	   the	   cardiovascular	   system	   (Small	   and	   Olson,	   2011)	   and	   aberrant	  
miRNA	  expression	  has	  been	   implicated	   in	   the	  pathogenesis	  of	   cardiovascular	  diseases	   such	  as	  PAH	  
(McDonald	   et	   al.,	   2012).	   In	   particular,	   two	   miRNAs	   (miR-­‐17	   and	   miR-­‐20a)	   have	   been	   found	   to	  
regulate	   BMPR2	   expression	   and	   specific	   inhibitors	   (so-­‐called	   ‘antagomirs’)	   used	   to	   block	   these	  
miRNAs	  in	  experimental	  animals	  (Brock	  et	  al.,	  2012;	  Pullamsetti	  et	  al.,	  2012).	  Injection	  of	  antigomirs	  
directed	  against	  miR-­‐17	  or	  miR-­‐20a	  was	   found	   to	   improve	  pulmonary	  haemodynamics	   and	   reduce	  
cardiovascular	  remodelling	  in	  hypoxia-­‐	  and	  MCT-­‐induced	  pulmonary	  hypertension.	  	  	  
	  
1.4.3	   Cell-­‐based	  therapies	  for	  PAH	  
Cell-­‐based	   therapies	   represent	   another	   approach	   for	   the	   treatment	   of	   pulmonary	   diseases.	   This	  
strategy	   involves	   the	  use	  of	   stem	  or	  progenitor	  cells,	  which	  may	  be	  manipulated	   to	   inhibit	  disease	  
progression	  or	  initiate	  repair	  and	  regeneration.	  This	  is	  further	  discussed	  in	  section	  1.6.4.	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1.5	   Endothelial	  progenitor	  cells	  (EPCs)	  
1.5.1	   Definition	  
The	   endothelium	   is	   considered	   to	   be	   central	   in	   maintaining	   vascular	   homeostasis	   and	   in	   the	  
pathogenesis	   of	   vascular	   diseases	   such	   as	   PAH	   (Hirschi	   et	   al.,	   2008).	   New	   blood	   vessel	   formation	  
occurs	   via	   three	  main	  processes:	   vasculogenesis,	   angiogenesis,	   or	   arteriogenesis.	   Vasculogenesis	   is	  
the	   de	   novo	   formation	   of	   vascular	   structures,	   begins	   with	   local	   differentiation	   of	   mesodermal	  
precursors-­‐derived	  cluster	  of	  hematopoetic	  stem	  cells	  at	  the	  centre	  and	  angioblasts	  at	  the	  periphery	  
that	  differentiate	   into	   ECs	   that	   coalesce	   into	   a	  primitive	  network,	   and	   is	   historically	   thought	   to	  be	  
exclusively	   a	   phenomenum	   of	   embryonic	   development	   (Risau	   and	   Flamme,	   1995).	   Angiogenesis	  
comprises	  several	  morphogenic	  events	   that	   involve	  sprouting,	  branching,	   lumen	  formation,	  making	  
new	   connections	   (anastomose)	   and	   rearrangements,	   a	   process	   that	   involves	   cell	   migration,	  
proliferation	   and	   tubulogenesis.	   These	   result	   in	   a	   new	   vascular	   network	   from	   the	   endothelium	   of	  
pre-­‐existing	   vessels	   that	   can	   be	   regulated	   by	   proteases,	   growth	   factors	   and	   micro-­‐environmental	  
cues	  (Risau,	  1997).	  Arterogenesis	  involves	  the	  specific	  remodelling	  of	  existing	  endothelial	  capillaries	  
for	   greater	   size,	   elasticity,	   and	   reactivity	   by	   recruitment	   of	   and	   encompassed	   by	   SMCs	   and	   other	  
mesenchymal	  cells	  that	  secrete	  specific	  ECM	  components	  (Carmeliet	  and	  Jain,	  2011).	  	  
It	  has	  been	  known	  for	  several	  decades	  that	  circulating	  ECs	  exist	  and	  have	  some	  level	  of	  proliferative	  
potential,	   as	   shown	   by	   the	   ability	   of	   EC	   monolayers	   to	   form	   on	   Dacron	   grafts	   in	   animal	   models	  
(Stump	  et	  al.,	   1963;	  Gonzalez	  et	  al.,	   1969).	  However,	  a	  paradigm	  shift	  occurred	  when	  a	   circulating	  
population	  of	  CD34+	  or	  VEGFR2+	  progenitor	  cells	  was	  identified	  in	  adult	  human	  peripheral	  blood,	  with	  
the	   ability	   to	   differentiate	   into	   ECs	   in	   vitro	   and	   participate	   in	   postnatal	   vasculogenesis	   in	   vivo	  
(Asahara	   et	   al.,	   1997;	   Shi	   et	   al.,	   1998).	   These	   so-­‐call	   endothelial	   progenitor	   cells	   (EPCs)	   have	   since	  
been	   recognised	   as	   a	   normal	   component	   of	   the	   blood	   and	   the	   term	   has	   been	   widely	   applied	   to	  
describe	   a	   heterogeneous	   group	   of	   cells	   that	   have	   the	   potential	   to	   form	   mature	   ECs	   and/or	  
participate	  in	  angiogenesis.	  Typically,	  they	  were	  thought	  to	  arise	  from	  mesodermal	  stem	  cells	  or	  so-­‐
called	   haemangioblasts	   (common	   progenitor	   of	   hematopoietic	   cells	   and	   ECs)	   in	   the	   bone	  marrow	  
(BM)	   and	   home	   to	   sites	   of	   ischemia	   or	   endothelial	   injury,	   contributing	   to	   neovascularisation	   and	  
tissue	   repair	   (Hristov	   et	   al.,	   2003;	   Hristov	   and	   Weber,	   2004;	   Liew	   et	   al.,	   2006)	   (see	   Figure	   1.2).	  
Numerous	  studies	  have	  since	  attempted	  to	  define	  the	  circulating	  levels	  of	  EPCs	  in	  a	  variety	  of	  clinical	  
disorders,	  but	  true	  circulating	  EPCs	  appear	  to	  be	  present	  in	  very	  low	  numbers	  and	  in	  order	  to	  study	  




Figure	   1.2.	   Putative	   origin	   and	   differentiation	   of	   endothelial	   progenitor	   cells	   (EPCs)	   and	   their	  
relation	   to	   cells	   expressing	   CD45.	   The	   figure	   displays	   the	   possible	   origin	   and	   differentiation	   of	  
EPCs	   and	   the	   interaction	   between	   the	   pro-­‐angiogenic	   “early”	   EPCs	   and	   ECFCs	   in	   promoting	  
angiogenesis	   and	   vasculogenesis.	   BM,	   bone	   marrow;	   ECs,	   endothelial	   cells;	   ECFCs,	   endothelial	  
colony-­‐forming	  cells;	  HSCs,	  hematopoietic	  stem	  cells.	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1.5.2	   Identification	  and	  growth	  of	  EPCs	  in	  vitro	  
Despite	   enormous	   interest	   in	   EPCs	   and	   their	   role	   in	   cardiovascular	   disease,	   there	   is	   a	   lack	   of	  
consensus	  regarding	  their	  phenotype.	   In	   fact,	  a	  variety	  of	  cells	   types	  have	  been	  described	  as	  being	  
EPCs,	   leading	   to	   considerable	   confusion	   in	   nomenclature	   (Hirschi	   et	   al.,	   2008;	   Timmermans	   et	   al.,	  
2009).	  Essentially	  two	  methods	  have	  been	  used	  to	  assess	  EPCs:	  flow	  cytometry	  and	  cell	  culture.	  
	  
Identification	  by	  flow	  cytometry	  
Many	   research	   groups	   have	   attempted	   to	   identify	   circulating	   EPCs,	   using	   flow	   cytometry	   to	  
demonstrate	   surface	   proteins.	   This	   included	   different	   combinations	   of	   the	   three	   most	   commonly	  
used	  markers	  –	  CD34	  (hematopoietic	  stem	  cell	  –	  HSC	  –	  marker),	  CD133	  (immature	  hematopoietic	  cell	  
marker),	  and	  VEGFR2	  (KDR	   in	  human,	  Flk-­‐1	   in	  mice)	  –	  with	  or	  without	  other	  markers	  such	  as	  CD31	  
and	   Tie2	   (comprehensively	   reviewed	   by	   Timmermans	   et	   al.	   2009).	   Various	   studies	   have	   reported	  
statistically	  significant	  correlations	  between	  circulating	  putative	  EPCs	  and	  disease	  state,	  but	  relatively	  
few	   also	   sought	   to	   establish	   the	   functional	   properties	   of	   these	   cells.	   A	   specific	   subset	   of	   CD34+	  
(CD34+VEGFR2+CD133+)	   mononuclear	   cells	   (MNCs)	   was	   widely	   considered	   to	   represent	   EPCs	   and	  
were	  isolated	  from	  human	  BM,	  umbilical	  cord	  blood	  (UCB)	  and	  granulocyte-­‐colony	  stimulating	  factor	  
(G-­‐CSF)-­‐mobilised	  adult	  peripheral	  blood.	  However,	   they	   failed	   to	  establish	  EC	  colonies	  or	  Matrigel	  
tubular	   networks	   in	   vitro,	  expressed	   the	   pan-­‐leukocyte	  marker	   CD45	   and	   displayed	   hematopoietic	  
progenitor	   cell	   (HPC)	   properties	   in	   hematopoiesis	   assays	   (Case	   et	   al.,	   2007;	   Timmermans	   et	   al.,	  
2007).	  In	  fact,	  CD14+,	  CD34+/CD45+,	  CD45+	  or	  CD133+	  selected	  MNCs	  do	  not	  give	  rise	  to	  EPC	  colonies	  
with	  typical	  cobble-­‐stone	  morphology.	  Conversely,	  cells	  with	  this	  capacity	  lack	  the	  monocytic	  (CD14-­‐)	  
and	  haematopoietic	  (CD45-­‐)	  markers	  (Gulati	  et	  al.,	  2003;	  Case	  et	  al.,	  2007;	  Timmermans	  et	  al.,	  2007).	  
This	  led	  to	  doubt	  about	  the	  validity	  of	  using	  surface	  marker	  combinations	  involving	  CD34+	  subsets	  to	  
identify	   circulating	   EPCs.	   Flow	   cytometry	   is	   currently	   limited	   by	   the	   lack	   of	   specific	   cell	   surface	  
markers	  and	  standardised	  methodology	  for	  identifying	  EPCs	  (see	  also	  section	  1.5.5).	  	  
	  
Identification	  by	  cell	  culture	  
Cell	  culture	  methods	  enable	  the	  isolation	  and	  expansion	  of	  cells	  for	  analysis	  in	  vitro	  and	  in	  vivo.	  Two	  
major	  cell	  sub-­‐populations	  have	  been	  identified	  in	  human	  MNCs	  cultures	  derived	  from	  UCB	  and	  adult	  
peripheral	   blood	   (Figure	   1.3).	   These	   comprise	   (i)	   so-­‐called	   “early”	   EPCs	   (also	   known	   as	   early	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outgrowth	   EPCs,	   colony-­‐forming	   unit-­‐endothelial	   cells	   (CFU-­‐EC),	   colony-­‐forming	   unit-­‐Hill	   (CFU-­‐Hill),	  
circulating	  angiogenic	  cells)	   that	  display	  a	  mixed	  endothelial/monocytic/haematopoietic	  phenotype	  
(Asahara	  et	  al.,	  1997;	  Shi	  et	  al.,	  1998;	  Peichev	  et	  al.,	  2000;	  Romagnani	  et	  al.,	  2005;	  Diller	  et	  al.,	  2008;	  
Sieveking	   et	   al.,	   2008),	   and	   (ii)	   proliferative	   “late”	   EPCs	   	   (also	   known	   as	   late	   outgrowth	   EPCs,	  
endothelial	   colony-­‐forming	   cells	   (ECFCs),	   blood	   outgrowth	   endothelial	   cells,	   endothelial	   outgrowth	  
cells,	   endothelial	   progenitor-­‐derived	   cells)	   that	   display	   typical	   endothelial	   morphology	   and	  
characteristics	  and	  possesses	  an	  endothelial	  progenitor	  lineage	  (Lin	  et	  al.,	  2000;	  Ingram	  et	  al.,	  2004;	  
Yoder	  et	  al.,	  2007;	  Sieveking	  et	  al.,	  2008).	  “Early”	  EPCs	  are	  identified	  after	  the	  short	  term	  (4	  -­‐	  7	  days)	  
in	   culture	  of	   peripheral	   blood	  MNCs	   (PBMNCs)	  on	   fibronectin-­‐	   or	   collagen-­‐coated	  plates.	   They	   are	  
typically	  spindle-­‐shaped	  and	  have	  the	  capacity	  to	  form	  colonies	  (so-­‐called	  CFU-­‐ECs	  or	  CFU-­‐Hill)	  when	  
cultured	  in	  EndoCult™	  medium.	  	  In	  contrast,	  “late”	  EPCs	  represent	  rare	  precursors	  (~	  one	  cell	  in	  20ml	  
blood),	   they	   are	   generally	   identified	   only	   ~14	   days	   after	   culturing	   PBMNCs,	   and	   give	   rise	   to	   a	  
circumscribed	   colony	   of	   cells	   with	   a	   cobblestone	   morphology	   akin	   to	   the	   appearance	   of	   primary	  
endothelial	  cells	  in	  culture	  (Lin	  et	  al.,	  2000;	  Ingram	  et	  al.,	  2004;	  Yoder	  et	  al.,	  2007).	  These	  cells	  were	  
first	   identified	   as	   blood	   outgrowth	   endothelial	   cells	   (BOECs)	   or	   endothelial	   outgrowth	   cells	   (EOCs)	  
(Lin	  et	  al.,	  2000),	  but	  are	  now	  commonly	  referred	  to	  as	  endothelial	  colony-­‐forming	  cells	  (ECFCs)	  after	  
Yoder	  and	  colleague	  refined	   the	  culture	   technique	  and	  demonstrated	   their	  ability	   to	   form	  colonies	  
from	  a	  single	  cell	  (Ingram	  et	  al.,	  2004;	  Yoder	  et	  al.,	  2007).	  Throughout	  this	  thesis,	  I	  will	  use	  the	  term	  
ECFCs.	  A	  diagrammatic	  summary	  of	  the	  common	  culture	  methods	  and	  cultured	  “EPCs”	  is	  provided	  in	  




Figure	  1.3.	  An	  overview	  of	  the	  most	  common	  methods	  used	  to	  isolate	  EPCs	  from	  peripheral	  blood	  
mononuclear	  cells	  (PB-­‐MNCs).	  	  Method	  A	  -­‐	  Culture	  of	  colony-­‐forming	  unit-­‐endothelial	  cells	  (CFU-­‐EC,	  
also	  known	  as	  CFU-­‐Hill)	  includes	  a	  5	  day	  process	  where	  non-­‐adherent	  MNCs	  are	  recultured	  and	  give	  
rise	   to	   the	  colony.	  Metod	  B	  –	  Culture	  of	  circulating	  angiogenic	  cells	   (CAC).	   Includes	  adherent	  cells	  
after	  4	  to	  7	  days	  of	  culture,	  which	  do	  not	  typically	  display	  colony	  formation.	  Method	  C	  –	  Culture	  of	  
endothelial	  colony-­‐forming	  cells	  (ECFCs),	  derived	  from	  adherent	  MNCs	  cultured	  for	  7	  days	  (for	  MNCs	  
derived	   from	   cord	   blood),	   or	   13	   –	   28	   days	   (for	   MNCs	   derived	   from	   peripheral	   blood).	   Colonies	  




1.5.3	   Hematopoietic	  cells/CFU-­‐EC	  characteristics	  
Both	  “early”	  and	  “late”	  populations	  of	  EPCs	  are	  positive	  for	  endothelial	  surface	  markers	  (e.g.	  CD31,	  
CD105,	  VE-­‐cadherin,	  eNOS	  and	  VEGFR2)	  and	  the	  intracellular	  protein	  markers	  (eNOS	  and	  vWF).	  They	  
can	   also	   express	   the	  mesoderm	   progeny	  marker	  mucosialin	   (CD34),	   type	   I	   scavenger	   receptor	   (as	  
demonstrated	   by	   uptake	   of	   acetylated	   low	   density	   lipoprotein;	   acLDL)	   and	   bind	  Ulex	   europeasus	  
agglutinin-­‐1	  (UEA-­‐1)	  lectin	  (Hirschi	  et	  al.,	  2008).	  “Early”	  EPCs	  can	  be	  distinguished	  by	  their	  ability	  to	  
form	  colonies	  in	  culture	  using	  in	  vitro	  colony-­‐forming	  assays,	  hence	  they	  are	  also	  known	  as	  “CFU-­‐EC”	  
or	  “CFU-­‐Hill”	  (Hill	  et	  al.,	  2003).	  However,	  this	  capacity	  has	  been	  shown	  to	  be	  heavily	  dependent	  on	  T	  
cells	  (particularly	  activated	  T	  cells)	  that	  produces	  cytokines	  and	  MMP-­‐9,	  questioning	  the	  use	  of	  CFU-­‐
EC	  assay	  as	  a	  means	  of	  identifying	  EPCs	  (Rohde	  et	  al.,	  2006;	  Hur	  et	  al.,	  2007;	  van	  Beem	  et	  al.,	  2008).	  
In	   addition,	   these	   cells	   are	   heterogeneous	   and	   comprise	   predominantly	   hematopoietic	   cells	   of	  
myeloid	   lineage	   that	   display	   hematopoietic	   (CD133+),	   pan-­‐leukocyte	   (CD45+)	   and	  
monocyte/macrophage	   (CD14+;	   CD11c+;	   CD163+)	   surface	   markers	   –	   which	   are	   not	   expressed	   by	  
mature	   ECs	   –	   and	   possess	   the	   monocyte/macrophage	   characteristics	   phagocytosis,	   and	   form	  
hematopoietic	  colonies	   in	  hematopoiesis	  assays	  (Rehman	  et	  al.,	  2003;	  Rohde	  et	  al.,	  2006;	  Zhang	  et	  
al.,	   2006;	   Case	   et	   al.,	   2007;	   Prater	   et	   al.,	   2007;	   Yoder	   et	   al.,	   2007;	  Medina	   et	   al.,	   2010).	   Although	  
these	   cells	   also	   take-­‐up	   acLDL	   and	   bind	   UEA-­‐1	   lectin	   (historically	   considered	   to	   be	   endothelial	  
properties),	  it	  is	  now	  known	  that	  monocytes	  and	  macrophages	  also	  take	  up	  ac-­‐LDL	  and	  UEA-­‐1	  lectin	  
binds	  to	  epithelial	  cells	  and	  a	  variety	  of	  other	  cell	  types	  (Hirschi	  et	  al.,	  2008).	  CFU-­‐ECs,	  but	  not	  ECFCs,	  
can	  also	  harbour	  mutations	  present	  in	  patients	  with	  myeloproliferative	  disorders,	  indicating	  the	  CFU-­‐
ECs	   belong	   to	   the	   hematopoetic	   lineage	   (Piaggio	   et	   al.,	   2009).	   Moreover,	   CFU-­‐ECs	   lack	   the	  
proliferative	   capacity	   of	   true	   progenitors	   and	   do	   not	   independently	   form	   de	   novo	   capillary-­‐like	  
structures	   in	   vitro	   (Hur	   et	   al.,	   2004;	   Sieveking	   et	   al.,	   2008)	   or	   contribute	   directly	   to	   neovessel	  
formation	  via	  in	  vivo	  (Yoon	  et	  al.,	  2005;	  Cho	  et	  al.,	  2007;	  Yoder	  et	  al.,	  2007).	  Nonetheless,	  they	  may	  
contribute	   indirectly	   in	   a	   paracrine	   fashion	   by	   secreting	   angiogenic	   substances	   such	   as	   VEGF,	  
hepatocyte	  growth	   factor	   (HGF),	   IL-­‐8,	  G-­‐CSF	  and	  granulocyte-­‐macrophage	  colony-­‐stimulating	   factor	  
(GM-­‐CSF)	  (Rehman	  et	  al.,	  2003;	  Hur	  et	  al.,	  2004)	  that	  promote	  vascular	  repair	  by	  resident	  ECs	  in	  vivo	  
(Yoon	   et	   al.,	   2005;	   Cho	   et	   al.,	   2007;	   Yoder	   et	   al.,	   2007)	   and	   the	   incorporation	   of	   ECFCs	   in	   tubular	  
networks	   in	   vitro	   (Rehman	   et	   al.,	   2003;	   Yoon	   et	   al.,	   2005;	   Cho	   et	   al.,	   2007;	   Yoder	   et	   al.,	   2007;	  
Sieveking	   et	   al.,	   2008).	   Criticism	   of	   the	   culture	   method	   has	   also	   been	   raised	   due	   to	   prominent	  
contamination	  by	  platelets	  and	  the	  indiscriminate	  transfer	  of	  platelet	  plasma	  membrane	  proteins	  to	  
adherent	  cells	  attached	  to	  the	  culture	  matrix	  (Prokopi	  et	  al.,	  2009).	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1.5.4	   Endothelial	  colony-­‐forming	  cells	  (ECFCs)	  
ECFCs	   display	   properties	   of	   true	   EPCs,	   having	   the	   ability	   to	   independently	   form	   de	   novo	   tubular	  
networks	  in	  vitro	  (Hur	  et	  al.,	  2004;	  Case	  et	  al.,	  2007;	  Sieveking	  et	  al.,	  2008);	  structurally	  contribute	  to	  
neovessels	   and	   inosculate	  with	  nearby	   vessels	   in	   subcutaneous	  gels	   implanted	   in	   immunodeficient	  
mice	   (Shepherd	   et	   al.,	   2006a;	   Melero-­‐Martin	   et	   al.,	   2007;	   Yoder	   et	   al.,	   2007);	   and	   exhibit	   high	  
clonogenic	   and	   proliferative	   potential	   (Hur	   et	   al.,	   2004;	   Ingram	   et	   al.,	   2004;	   Yoder	   et	   al.,	   2007).	  
Typical	   EC	   characteristics	   were	   also	   demonstrated	   through	   up-­‐regulation	   of	   activated	   EC	   marker	  
VCAM-­‐1	  upon	  TNF-­‐α	  and	  IL-­‐1	  stimulation	  (Ingram	  et	  al.,	  2004).	  In	  addition,	  ECFCs	  do	  not	  express	  pan-­‐
leukocyte	  marker	  CD45,	  monocytic/macrophage	  markers	  CD14	  or	  CD115	  and	  do	  not	  ingest	  bacteria	  
or	  give	  rise	  to	  HPCs	  colonies	  (Case	  et	  al.,	  2007;	  Yoder	  et	  al.,	  2007).	  Secretion	  of	  high	  level	  of	  MMP-­‐2,	  
but	   low	   level	  of	  MMP-­‐9,	  and	   selective	  expression	  of	  BMP-­‐2	  and	  BMP-­‐4	   in	  ECFCs	  also	  distinguishes	  
them	  from	  early	  EPCs,	  these	  features	  being	  considered	  to	  be	  important	  for	  their	  differentiation	  and	  
regulation	   in	  angiogenesis	   (Yoon	  et	  al.,	  2005;	  Smadja	  et	  al.,	  2008).	  Other	  factors	  may	   influence	  the	  
survival	   and	   proliferation	   of	   ECFCs.	   For	   example,	   activation	   of	   the	   thrombin	   receptor	   protease-­‐
activated	   receptor	   1	   promotes	   proliferation,	   migration,	   differentiation	   and	   IL-­‐8	   synthesis	   in	   these	  
cells,	   leading	   to	   a	   pro-­‐angiogenic	   effect	   in	   vitro	   (Smadja	   et	   al.,	   2005;	   Smadja	   et	   al.,	   2009a).	   The	  

















“Early”	  EPCs	  	  	  
Also	  known	  as	  CFU-­‐EC,	  CFU-­‐
Hill,	  circulating	  angiogenic	  
cells	  &	  hematopoietic	  
progenitor	  cells	  
	  
“Late”	  EPCs	  or	  ECFCs	  
Also	  known	  as	  blood	  
outgrowth	  endothelial	  cells,	  
endothelial	  outgrowth	  cells	  &	  
endothelial	  progenitor-­‐	  
derived	  cells	  
Origin	   CD45+	  hematopoietic	  lineage	  
cells	  (CD34+	  CD45+/CD133+	  
CD45+,	  CD34-­‐	  CD45+	  CD14+	  
CD45+)	  
CD45-­‐CD133-­‐CD34+	  cells/	  
CD34+	  CD146+	  CD31+	  CD105+	  	  
CD45-­‐	  cells,	  from	  bone	  
marrow	  or	  the	  vascular	  wall	  
Appearance	   Round	  to	  spindle	  shape	  
appearance	  
Typical	  polygonal	  cells	  in	  a	  
confluent	  cobblestone	  
monolayer	  
Endothelial	  population	   Heterogeneous	   Homogenous	  
Functional	  properties:	   	   	  
Clonal	  proliferative	  status	   Low	   High	  
Replating	  ability	   -­‐	   +	  
In	  vitro	  tube	  formation	   -­‐	   +	  
De	  novo	  vessel	  formation	  in	  vivo	   -­‐	   +	  
NO	  generation	   Low	   High	  
Homing	  to	  ischemic	  sites	  in	  vivo	   +	   +	  
Proangiogenic	  factors	  release	   High	   Low	  
Paracrine	  augmentation	  of	  
angiogenesis	  
+	   +/-­‐	  
Hematopoeitic	  	  
colony-­‐forming	  potential	  
+	   -­‐	  
Phagocytosis	  	   +	   -­‐	  
MMPs	  release	   High	  MMP9	  release	   High	  MMP2	  release	  
	   	   	  
Phenotype:	   	   	  
Endothelial	  markers	  expression	   CD31+,	  Flk-­‐1+,	  Tie-­‐2+,	  
VEGFR2+,	  Also	  VE-­‐cadherin+,	  
CD105+,	  vWF+,	  eNOS+	  
CD31+,	  Flk-­‐1+,	  Tie-­‐2+,	  
VEGFR2+,	  VE-­‐cadherin+	  




CD14+/-­‐,	  CD45+/-­‐,	  CD11c+,	  
CD163+,	  CD115+	  
None	  
Progenitor	  markers	  expression	   CD34+/-­‐,	  CD133+	   CD34+/-­‐,	  CD133-­‐,	  c-­‐kit+/-­‐	  
acLDL	  uptake	   +	   +	  
UEA-­‐1	  lectin	  binding	   +	   +	  
BMP-­‐2	  &	  BMP-­‐4	   -­‐	   +	  
Table	  1.3.	  Characteristics	  of	  the	  two	  main	  “EPC”	  populations	  in	  culture.	  	  Represents	  a	  summary	  of	  
the	   literature	   cited	   in	   this	   chapter.	   	   (+)	   adherent	   cells	   that	   display	   a	   function/expression;	   (-­‐)	   cells	  
that	  do	  not	  display	  a	  function/expression	  ;	  (+/-­‐)	  the	  literature	  provides	  conflicting	  evidence.	  MMP,	  
matrix	   metalloproteinase;	   NO,	   	   nitric	   oxide;	   eNOS,	   endothelial	   NO	   synthase;	   VEGFR2	   ,	   vascular	  
endothelial	   growth	   factor	   receptor	   2;	   vWF,	   von	  Willebrand	   factor;	   acLDL,	   acetylated	   low	   density	  
lipoprotein;	  UEA-­‐1,	  Ulex	  europeasus	  agglutinin-­‐1;	  BMP,	  bone	  morphogentic	  protein.	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Despite	   their	   detailed	   characterisation,	   it	   is	   still	   unknown	   whether	   (i)	   ECFCs	   expanded	   ex	   vivo	  
represent	   the	   differentiated	   progeny	   of	   an	   undifferentiated	   precursor	   cell	   in	   vivo;	   (ii)	   ECFCs	   are	  
unipotent	  or	  possess	  mutli-­‐potent	   stem	  cell	   potential;	   and	   (iii)	   if	   ECFCs	   are	   fully	  differentiated	  ECs	  
with	  high	  proliferative	  potential.	  Earlier	  studies	   indicated	  that	  ECFCs	  displayed	  greater	  proliferative	  
potential,	  angiogenic	  cytokine	  release	  and	  stress	  resistance	  compared	  with	  HUVECs	  and	  other	  types	  
of	  EC	  (Bompais	  et	  al.,	  2004;	  He	  et	  al.,	  2004).	  However,	  some	  of	  these	  studies	  compared	  UCB-­‐derived	  
ECFCs	  that	  are	  known	  to	  have	  enhanced	  clonogenic	  and	  proliferative	  potential	  (Ingram	  et	  al.,	  2004)	  
and	  contradicting	  results	  have	  been	  reported	  elsewhere	  (Ingram	  et	  al.,	  2007).	  In	  fact,	  only	  one	  study	  
to	  date	  has	  reported	  increased	   in	  vitro	  and	   in	  vivo	  vessel	  forming	  ability	  in	  UCB-­‐ECFCs	  compared	  to	  
HUVECs	   (Nagano	  et	   al.,	   2007).	   Like	  ECFCs,	  mature	  ECs	  also	  have	   the	  ability	   to	   independently	   form	  
tubular	  networks	  in	  Matrigel	  implants	  (Melero-­‐Martin	  et	  al.,	  2007;	  Yoder	  et	  al.,	  2007).	  More	  detailed	  
molecular	   analysis	   of	   ECFCs	   has	   also	   served	   to	   emphasise	   their	   endothelial	   nature,	   possessing	   a	  
transcriptome,	   proteome	   ultrastructure	   that	   closely	   resembles	   those	   of	   mature	   (human	   dermal	  
microvascular)	  ECs	  (Medina	  et	  al.,	  2010).	  Despite	  exhibiting	  features	  consistent	  with	  an	  endothelial	  
lineage,	   ECFCs	   may	   also	   express	   specific	   proteins	   (Medina	   et	   al.,	   2010)	   and	   possess	   functional	  
characteristics	  that	  distinguish	  them	  from	  mature	  ECs.	  For	  example,	  ECFCs	  are	  reported	  to	  be	  more	  
proliferative	  and	  resistant	  to	  serum-­‐deprivation	  than	  mature	  ECs	  and	  may	  also	  differ	  in	  their	  in	  vivo	  
vasculogenic	  potential	  (Hur	  et	  al.,	  2004;	  Finkenzeller	  et	  al.,	  2009).	  ECFCs	  seem	  to	  possess	  higher	  rate	  
of	   spreading	   and	   higher	   expression	   of	   α5β1	  when	   compared	   to	   human	   aortic	   ECs	   (Stroncek	   et	   al.,	  
2009).	   Furthermore,	   ECFCs	   and	   mature	   ECs	   in	   culture	   have	   recently	   been	   shown	   to	   vary	   in	   their	  
response	  to	  hypoxia	  and	  deposition	  of	  extracellular	  matrix	  (Kusuma	  et	  al.,	  2012).	  	  
	  
1.5.5	   Origin	  of	  ECFCs	  
The	   origin	   of	   ECFCs	   remains	   elusive.	   Although	   proliferative	   ECFCs	   have	   been	   demonstrated	   to	  
originate	  from	  BM	  in	  human	  BM	  transplants	  (Lin	  et	  al.,	  2000),	  human	  UCB	  and	  adult	  peripheral	  blood	  
(Ingram	  et	  al.,	  2004),	  a	  similar	  hierarchy	  of	  ECFCs	  have	  also	  been	  identified	  among	  ECs	  isolated	  from	  
the	   human	   umbilical	   vein,	   aorta	   (Ingram	   et	   al.,	   2005;	   Zhang	   et	   al.,	   2009)	   and	   pulmonary	   artery	  
(Duong	   et	   al.,	   2011),	   as	   well	   as	   rat	   PMVECs	   and	   rat	   PAECs	   (Alvarez	   et	   al.,	   2008).	   Thus,	   the	  
endothelium	  of	  the	  mature	  vessel	  wall	  contains	  ECs	  with	  a	  robust	  proliferative	  potential	  and	  maybe	  
the	  origin	  of	  ECFCs.	   Indeed,	  a	   recent	  study	  has	  challenged	   the	  concept	  of	  a	  BM-­‐derived	  circulating	  
precursor	  for	  ECs,	  demonstrating	  that	  ECFCs	  from	  CD34+/CD133-­‐/CD146+	  PBMNCs	  are	  similar,	   if	  not	  
identical,	   to	   mature	   ECs	   and	   contribute	   to	   de	   novo	   vessel	   formation	   whereas	   BM-­‐derived	   cells	  
isolated	  under	  the	  same	  conditions	  do	  not	  (Tura	  et	  al.,	  2012).	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However,	  no	  markers	  yet	  to	  date	  can	  convincingly	  discriminate	  ECFCs	  against	  mature	  ECs,	  impeding	  
its	  progress	  as	  a	  therapeutic	  agent	  for	  cardiovascular	  disorders.	   Indeed,	  a	  common	  origin	  has	  been	  
suggested	  for	  both	  the	  hematopoietic	  pro-­‐angiogenic	  cells	  and	  ECFCs,	  as	  both	  cell	  populations	  share	  
similar	  endothelial	   surface	  antigens	   (e.g.	  CD31,	  VEGFR2)	  and	  can	  both	  be	  derived	   from	  CD34+	  cells	  
(Asahara	   et	   al.,	   1997;	   Bompais	   et	   al.,	   2004).	   They	   could	   be	   derived	   from	   the	   so-­‐called	  
hemangioblasts,	   a	   bipotent	   mesodermal	   stem	   cell	   that	   can	   differentiate	   into	   both	   hematopoietic	  
cells	  and	  ECs	   (Timmermans	  et	  al.,	  2009)	   (see	  Figure	  1.3).	  Although	  CD133,	  an	   immature	  progenitor	  
cell	  marker,	  is	  not	  present	  in	  both	  ECFCs	  and	  mature	  ECs,	  CD133	  expression	  can	  be	  detected	  earlier	  
at	  day	  14	  of	  culture	  in	  ECFCs	  derived	  from	  UCB-­‐CD34+	  cells	  and	  decrease	  gradually	  during	  maturation	  
(low	  expression	  at	  day	  28	  and	  undetectable	  at	  day	  40),	  while	  endothelial	  markers	  (CD144,	  KDR,	  Tie-­‐1)	  
gradually	   increases,	  suggesting	  possible	  CD133+	  expression	   in	  the	   immature	  phase	  of	  ECFCs	   in	  vivo	  
that	  might	  have	  been	  lost	  upon	  long	  term	  ex	  vivo	  expansion	  (Bompais	  et	  al.,	  2004).	  	  
Recent	   advances	   in	   flow	   cytometry	   instrumentation	   and	   analytical	   software	   have	   allowed	   the	  
development	  of	   polychromatic	   flow	   cytometry	   that	  may	  permit	   the	   identification	  of	   putative	   EPCs	  
and	   can	   distinguish	   pro-­‐angiogenic	   “early”	   EPCs	   with	   hematopoietic	   lineage	   form	   and	   circulating	  
ECFCs	  (Estes	  et	  al.,	  2010a;	  Estes	  et	  al.,	  2010b).	  Using	  this	  advanced	  technique,	  a	  rare	  subset	  of	  UCB	  
MNCs	   was	   identified	   (CD34+CD146+CD31+CD105+CD45-­‐)	   that	   contained	   both	   highly	   proliferative	  
ECFCs,	  which	  gave	  rise	  to	  ECFC	  but	  not	  HPC	  colonies,	  and	  circulating	  ECs	  with	  little	  or	  no	  clonogenic	  
potential	   (Mund	  et	  al.,	  2012).	   In	   the	   future,	   the	   identification	  of	  ECFCs	  may	  also	  be	  aided	  by	  novel	  
peptide	  ligands	  that	  specifically	  bind	  to	  these	  cells	  (Veleva	  et	  al.,	  2007).	  Nevertheless,	  blood-­‐derived	  
ECFCs	  closely	  resemble	  ECs	  of	   the	  vascular	  wall	  and	  represent	  a	  potentially	   important	  non-­‐invasive	  
means	   of	   obtaining	   patient-­‐specific	   ECs	   for	   functional	   and	   biochemical	   investigation	   (Fadini	   and	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1.6	   Role	  of	  progenitor	  cells	  in	  PAH	  
1.6.1	   Involvement	  of	  progenitor	  cells	  in	  pulmonary	  vascular	  remodelling	  in	  PAH	  
Several	   investigations	   have	   described	   mobilisation	   of	   BM-­‐derived	   MNCs	   and	   recruitment	   of	  
endogenous	   cells	   in	   the	   lung	   and	   pulmonary	   vasculature	   in	   experimental	   hypoxia-­‐induced	   PH	   and	  
pneumonectomy-­‐induced	  PH,	  but	  it	  is	  unclear	  whether	  this	  represents	  a	  protective	  process	  (Satoh	  et	  
al.,	   2006)	   or	   their	   involvement	   in	   the	   disease	   progression,	   advancing	   neointimal	   formation,	  
adventitial	   thickening,	   perivascular	   fibrosis,	   and	   myofibroblast	   accumulation	   (Davie	   et	   al.,	   2004;	  
Hayashida	  et	  al.,	  2005;	  Satoh	  et	  al.,	  2006;	  Sahara	  et	  al.,	  2007;	  Satoh	  et	  al.,	  2009;	  Angelini	  et	  al.,	  2011;	  
Liang	  et	  al.,	  2011).	  	  
The	  transmembrane	  tyrosine	  kinase	  receptor	  for	  stem	  cell	  factor,	  c-­‐kit,	  is	  considered	  to	  be	  a	  marker	  
for	   BM-­‐derived	  HSCs,	   although	   it	   is	   not	   exclusive	   to	   these	   cells	   (Lerner	   et	   al.,	   1991;	  Ogawa	   et	   al.,	  
1991).	   Putative	   BM	   progenitor	   cells	   expressing	   c-­‐kit,	   CD45	   and	   CD133	   have	   been	   found	   to	  
accumulate	  among	  ECs	   in	   the	  expanded	  vasa	  vasorum	  of	  pulmonary	  arteries	   in	  chronically	  hypoxic	  
bovine	  models	  of	  PH	  (Davie	  et	  al.,	  2004;	  Frid	  et	  al.,	  2009).	  An	  accumulation	  of	  similar	  cells	  has	  been	  
observed	  in	  lung	  tissues	  from	  PAH	  patients	  and	  circulating	  soluble	  c-­‐kit	  is	  increased	  in	  IPAH,	  but	  it	  is	  
unclear	  whether	  these	  cells	  are	  derived	  locally	  or	  from	  the	  circulation	  (Toshner	  et	  al.,	  2009;	  Montani	  
et	  al.,	  2011).	  Nevertheless,	  increased	  stromal	  cell-­‐derived	  factor-­‐1α	  (SDF-­‐1α)	  and	  its	  respective	  C-­‐X-­‐C	  
chemokine	  receptor	  type	  4	  (CXCR4)	  were	  also	  found	  in	  ECs	  within	  occlusive	  lesions	  in	  the	  IPAH	  lung	  
(Toshner	   et	   al.,	   2009;	  Montani	   et	   al.,	   2011).	   This	   is	   considered	   to	  be	   a	  major	   homing	  pathway	   for	  
progenitor	   and	   inflammatory	   cells	   and	   could	   be	   modulated	   by	   c-­‐kit	   activity	   (Phillips	   et	   al.,	   2004;	  
Satoh	  et	  al.,	  2009;	  Young	  et	  al.,	  2009;	  Cheng	  et	  al.,	  2010;	  Sharma	  et	  al.,	  2011).	  	  Conflicting	  arguments	  
exist	   for	   using	   this	   pathway	   as	   a	   therapeutic	   target,	   as	   its	   inhibition	   has	   been	   associated	   with	   a	  
reduction	   in	  BM-­‐derived	   cell	   recruitment	   and	   reduced	  pulmonary	   vascular	   remodelling	   in	  hypoxia-­‐
induced	   PH	   (Satoh	   et	   al.,	   2009;	   Young	   et	   al.,	   2009;	   Yu	   and	   Hales,	   2011),	   while	   it	   has	   also	   been	  
reported	  to	  augment	  cell	  recruitment	  and	  neovascularisation	  in	  another	  study	  (Jujo	  et	  al.,	  2010).	   In	  
addition	  to	  PAH,	  putative	  EPCs	  are	  postulated	  to	  contribute	  to	  neointimal	  proliferation	  and	  vascular	  
remodelling	  in	  patients	  with	  CTEPH	  (Yao	  et	  al.,	  2009b).	  	  
	  
1.6.2	   Circulating	  progenitors	  in	  PAH	  
The	  number	  of	  circulating	  “EPCs”	  and	  activity	  of	  cultured	  cells	  isolated	  from	  peripheral	  blood	  may	  be	  
affected	   in	   various	   pulmonary	   conditions	   (Weiss,	   2008).	   An	   increase	   in	   circulating	   progenitors	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(defined	   by	   Flk-­‐1+/CD133+,	   CD45+/VEGFR2+,	   CD45+/VEGFR2+/c-­‐kit+	   and	   CXCR4+/VEGFR2+/c-­‐kit+	   cells)	  
has	  been	  observed	  in	  hypoxia-­‐induced	  PH	  in	  mice	  (Satoh	  et	  al.,	  2006;	  Marsboom	  et	  al.,	  2008;	  Satoh	  
et	   al.,	   2009),	  whereas	  CD133+/VEGFR2+	   cells	  were	  depleted	   in	   a	   canine	  model	   of	  MCT-­‐induced	  PH	  
(Xia	   et	   al.,	   2009b).	   Conflicting	   data	   has	   also	   been	   obtained	   when	   putative	   circulating	   progenitors	  
were	  assessed	  in	  human	  PAH.	  A	  number	  of	  studies	  have	  described	  a	  reduction	  in	  circulating	  “early”	  
EPCs	  in	  PAH	  patients	  (including	  patients	  with	  IPAH,	  HPAH	  and	  PAH	  associated	  with	  connective	  tissue	  
disease,	   congenital	   heart	   disease,	   or	   sickle	   cell	   disease),	   when	   compared	   with	   healthy	   controls	  
(Fadini	   et	   al.,	   2007;	   Diller	   et	   al.,	   2008;	   Junhui	   et	   al.,	   2008;	   Anjum	   et	   al.,	   2012),	  while	   others	   have	  
reported	   an	   increase	   in	   circulating	   angiogenic	   cells	   in	   patients	   with	   PAH	   (Asosingh	   et	   al.,	   2008;	  
Toshner	  et	  al.,	   2009;	   Farha	  et	  al.,	   2011;	  Hansmann	  et	  al.,	   2011;	  Montani	  et	   al.,	   2011)	  or	   found	  no	  
difference	  (Smadja	  et	  al.,	  2009b)	  (see	  Table	  1.4	  for	  a	  summary).	  These	  discrepancies	  may	  be	  due	  to	  
variation	   in	   the	   methodology	   and	   protein	   markers	   employed	   to	   identify	   and	   quantify	   putative	  
progenitor	  cells,	  differences	  in	  flow	  cytometry,	  experimental	  design	  and	  cell	  preparation	  techniques,	  
and	  differences	  in	  the	  stage	  of	  disease	  and	  therapy	  prior	  to	  blood	  sampling.	  It	  might	  be	  argued	  that	  a	  
reduction	   in	  circulating	  progenitor	  cells	   reflects	  a	  depletion	  of	  BM	  pool	  due	  to	  ongoing	  endothelial	  
damage	   and	   EPC	   recruitment	   (Fadini	   et	   al.,	   2007),	   while	   increased	   circulating	   progenitors	   might	  
represent	  participation	  in	  the	  proliferative	  vascular	  remodelling	  in	  PAH.	  It	  remains	  difficult	  to	  identify	  
and	  quantify	  EPCs	  without	  specific	  cells	  markers,	  and	  advancement	  in	  flow	  cytometry	  might	  help	  to	  
elucidate	  these	  specific	  markers	   in	  future	  (discussed	  in	  section	  1.5.5).	  The	  recent	  development	  of	  a	  
microfluidic	  chip	  that	  measures	  circulating	  progenitor	  in	  only	  200	  µl	  of	  human	  blood	  may	  enable	  the	  
development	  of	  bedside	  screening	  and	  monitoring	  of	  patients	  in	  the	  future	  (Hansmann	  et	  al.,	  2011).	  	  
A	  number	  of	   studies	  have	   shown	   that	   the	  number	  of	  CFU-­‐ECs	  and	  CD14	  monocytes	  are	   related	   to	  
cardiovascular	  risk	  (Hill	  et	  al.,	  2003)	  and	  implicated	   in	  the	  genesis	  of	  vascular	  pathology	   in	  diseases	  
such	   as	   diabetes	   (Loomans	   et	   al.,	   2004),	   COPD	   (Palange	   et	   al.,	   2006),	   congenital	   heart	   failure	  
(Valgimigli	  et	  al.,	  2004)	  and	  rheumatoid	  arthritis	  (Grisar	  et	  al.,	  2005).	  In	  addition	  to	  alterations	  in	  the	  
number	  of	  circulating	  cells,	  the	   in	  vitro	  colony	  forming	  ability	  of	  the	  CFU-­‐ECs	  was	  also	  altered,	  with	  
increased	  CFU-­‐ECs	  or	  “early”	  adherent	  cells	  detected	  in	  IPAH	  patients	  (Asosingh	  et	  al.,	  2008;	  Toshner	  
et	  al.,	  2009;	  Farha	  et	  al.,	  2011).	  All	  the	  studies	  have	  pointed	  to	  a	  dysfunctional	  phenotype,	  cells	  from	  
IPAH	  patients	  exhibiting	  distinct	  dysfunctional	  responses	  to	  apoptotic	  stimuli	  and	  TGF-­‐β1	  or	  BMPs,	  an	  
impaired	   ability	   to	   incorporate	   in	   tubular	   networks,	   as	   well	   as	   reduced	  migration,	   adherence	   and	  
production	  of	  angiogenic	  factors	  (Teichert-­‐Kuliszewska	  et	  al.,	  2006;	  Asosingh	  et	  al.,	  2008;	  Diller	  et	  al.,	  
2008).	   A	   Janus	   faced	   paradigm	   has	   emerged,	   where	   EPCs	   recruited	   from	   the	   bone	   marrow	   or	  
resident	  in	  the	  vessel	  wall,	  either	  proliferate	  to	  repair	  the	  damaged	  endothelium	  or	  contribute	  in	  the	  
vascular	  remodelling	  and	  progression	  of	  pulmonary	  vasculopathy	  (Figure	  1.4).	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Author	   Year	   Type	  of	  PH	   N	   EPCs	  definition	  for	  quantification	   Difference	  
vs	  controls	  






JunHui	  et	  al.	   2008	   IPAH	   20	   CD133+/KDR+	   ê~30%	  



























Asosingh	  et	  al.	   2008	   IPAH	   10	   CD34+/CD133+	   é~3.0x	  
Toshner	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  al.	  
(2	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Smadja	  et	  al.	   2009	   APAH	  (CHD)	   26	   CD34+/CD133+	   ns	  








































































Table	  1.4.	   Summary	  of	  human	  studies	   investigating	  number	  of	  endothelial	  progenitor	   cells	   (EPCs)	   in	  
patients	  with	   pulmonary	   hypertension.	  PAH,	   pulmonary	   arterial	   hypertension;	  APAH,	   PAH	  associated	  
with	  other	  diseases;	  EMS,	  Eisenmenger’s	  syndrome;	  CHD,	  congenital	  heart	  disease;	  IPAH,	  idiopathic	  PAH;	  
HPAH,	  heritable	  PAH;	  IPF,	   idiopathic	  pulmonary	  fibrosis;	  CTD,	  connective	  tissue	  disease;	  SCD,	  sickle	  cell	  




Figure	   1.4.	   The	   EPC	   paradox	   in	   pulmonary	   hypertension	   –	   pulmonary	   vascular	   repair	   and/or	  
contribution	   to	   disease	   progression	   development.	   Endothelial	   insults	   might	   (i)	   stimulate	   local	  
EPCs	  in	  the	  pulmonary	  vessel	  wall	  to	  proliferate	  and	  contribute	  to	  vascular	  repair,	  or	  (ii)	  induce	  the	  
mobilisation	  and	  homing	  of	  bone	  marrow-­‐derived	  cells	  to	  the	  site	  of	  injury.	  Conversely,	  excessive	  
proliferation	   and	   accumulation	   of	   EPCs	   might	   promote	   vascular	   remodelling	   and	   lead	   to	   the	  
formation	   of	   plexiform	   lesions	   in	   PAH.	   CXCR4,	   C-­‐X-­‐C	   chemokine	   receptor	   type	   4;	   G-­‐CSF,	  
granulocyte-­‐colony	   stimulating	   factor;	   SDF-­‐1α,	   stromal	   cell-­‐derived	   factor-­‐1α;	   VEGF,	   vascular	  
endothelial	  growth	  factor.	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1.6.3	   ECFCs	  in	  cardiovascular	  disorders	  and	  PAH	  
Relatively	  few	  studies	  have	  examined	  ECFCs	  in	  patients	  with	  cardiovascular	  diseases.	  ECFC	  frequency	  
have	   been	   used	   as	   biomarkers,	   demonstrating	   differences	   in	   the	   number	   of	   ECFCs	   derived	   in	   a	  
variety	   of	   disease	   states,	   with	   higher	   ECFC	   frequency	   found	   in	   patients	   with	   age-­‐related	   macular	  
degeneration	   (Thill	   et	   al.,	   2008),	   acute	  myocardial	   infarction	   (Massa	  et	   al.,	   2009;	  Meneveau	  et	   al.,	  
2011),	  coronary	  artery	  disease	  (CAD)	  (Guven	  et	  al.,	  2006),	  myeloproliferative	  disorders	  (Della	  Porta	  
et	  al.,	  2008;	  Otten	  et	  al.,	  2008;	  Rosti	  et	  al.,	  2010),	   rheumatoid	  arthritis	   (Jodon	  de	  Villeroche	  et	  al.,	  
2010)	   and	   proliferative	   diabetic	   retinopathy	   (Tan	   et	   al.,	   2010),	   while	   lower	   number	   of	   ECFCs	   are	  
found	   in	   patients	  with	   chronic	   kidney	   disease	   (Krenning	   et	   al.,	   2009)	   and	   type	   2	   diabetes	  mellitus	  
(Ingram	  et	   al.,	   2008;	   Leicht	   et	   al.,	   2011).	   Contradictory	   results	   exist	   in	   relation	   to	  pre-­‐term	   infants	  
(Javed	   et	   al.,	   2008;	   Baker	   et	   al.,	   2009;	   Borghesi	   et	   al.,	   2009;	   Ligi	   et	   al.,	   2011).	   ECFCs	   derived	   from	  
peripheral	   blood	   also	   represent	   an	   attractive	   source	   of	   cells	   for	   protein	   expression	   and	   functional	  
studies	  in	  vitro.	  Importantly,	  differences	  in	  growth	  and/or	  functional	  characteristics	  were	  maintained	  
during	  subsequent	  cell	  culture.	   Increased	  angiogenic	  potentials	   for	  example	  have	  been	  observed	   in	  
ECFCs	  from	  patients	  with	  macular	  degeneration	  (Thill	  et	  al.,	  2008)	  and	  von	  Willebrand	  disease	  (Starke	  
et	  al.,	  2011),	  while	   impaired	  angiogenesis	  and	  endothelial	   functions	  were	  found	  in	  ECFCs	  from	  pre-­‐
term	  infants	  (Fujinaga	  et	  al.,	  2009;	  Ligi	  et	  al.,	  2011),	  patients	  with	  diabetes	  (Ingram	  et	  al.,	  2008;	  Tan	  
et	   al.,	   2010),	   CAD	   (Wang	   et	   al.,	   2011)	   and	  HHT	   (Fernandez	   et	   al.,	   2005).	  More	   importantly,	   ECFCs	  
have	   been	   used	   as	   surrogate	   endothelial	   cells	   to	   investigate	   novel	   mechanisms	   in	   disease	  
pathogenesis	   (Fernandez	   et	   al.,	   2005;	   Fernandez	   et	   al.,	   2007;	   Avouac	   et	   al.,	   2008;	   Fujinaga	   et	   al.,	  
2009;	  Enenstein	  et	  al.,	  2010;	  Ligi	  et	  al.,	  2011;	  Starke	  et	  al.,	  2011).	  
Heterogeneity	  of	  ECs	  along	  vessel	  walls	  with	  varying	  proliferative	  potential	  was	  first	  described	  more	  
than	   three	   decades	   ago	   (Schwartz	   and	   Benditt,	   1976).	   In	   fact,	   ECFCs	   exhibit	   a	   hierarchy	   of	  
proliferative	  potential	  in	  the	  rat	  pulmonary	  circulation,	  cells	  with	  higher	  proliferative	  potential	  (HPP-­‐
ECFCs),	  higher	   telomerase	  activity,	  barrier	  properties	  and	  robust	  de	  novo	  vessel-­‐forming	  properties	  
being	   found	   in	   PMVECs	   than	   PAECs	   (Alvarez	   et	   al.,	   2008).	   A	   subset	   of	   highly	   proliferative	   resident	  
progenitor	   cells	   can	  also	  be	   found	   in	  murine	  PMVECs	   (Schniedermann	  et	   al.,	   2010).	  More	   recently	  
ECFCs	  were	  also	  isolated	  from	  human	  pulmonary	  artery	  endothelium	  (Asosingh	  et	  al.,	  2008;	  Duong	  et	  
al.,	  2011).	  Interestingly,	  using	  a	  single	  cell	  colony	  assay,	  HPP-­‐ECFCs	  were	  not	  found	  in	  rat	  kidney	  ECs	  
(Basile	   et	   al.,	   2012),	   raising	   the	   possibility	   that	   ECFCs	  may	   be	   tissue-­‐specific	   and	   reflect	   higher	   EC	  
turnover	  in	  the	  pulmonary	  circulation.	  However,	  little	  is	  known	  about	  the	  phenotype	  and	  functional	  
activity	  of	  ECFCs	  isolated	  from	  patients	  with	  PAH.	  There	  have	  been	  only	  three	  reports	  to	  date	  and	  in	  
the	  first	  Asosingh	  et	  al.	  observed	  no	  difference	  in	  number	  of	  ECFC	  colonies	  isolated	  from	  the	  PAECs	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of	   IPAH	   patients	   (Asosingh	   et	   al.,	   2008).	   Subsequently,	   the	   same	   group	   have	   published	   some	  
evidence	  indicating	  that	  ECFCs	  derived	  from	  PAECs	  of	  IPAH	  patients	  may	  be	  more	  proliferative	  than	  
those	  obtained	  from	  control	  subjects	  (Duong	  et	  al.,	  2011).	  A	  separate	  group	  found	  that	  ECFCs	  from	  
three	  PAH	  patients	  with	  BMPR2	  mutations	  displayed	  a	  hyperproliferative	  phenotype	  and	  an	  impaired	  
ability	  to	  form	  vascular	  networks	  in	  vitro	  (Toshner	  et	  al.,	  2009).	  However,	  BMPR2	  mutants	  constitute	  
a	  minor	   proportion	   of	   the	   IPAH	   population,	   and	   studying	   IPAH	   patients	   in	   general	  may	   provide	   a	  
more	  comprehensive	  understanding	  of	  the	  ECFC	  phenotype	  in	  this	  disease.	  	  
	  
1.6.4	   Therapeutic	  potential	  of	  progenitor	  cells	  in	  PAH	  
Endothelial	   injury	   and	   apoptosis	   is	   thought	   to	   have	   a	   significant	   role	   in	   the	   pathogenesis	   of	   PAH,	  
raising	  the	  possibility	  that	  novel	  treatments	  targeting	  vessel	  repair	  and	  regeneration	  of	  the	  vascular	  
endothelium	   might	   have	   therapeutic	   potential	   in	   PAH.	   Pre-­‐clinical	   studies	   have	   provided	   some	  
evidences	   supporting	   the	   potential	   for	   cell-­‐based	   therapies	   in	   preventing	   or	   even	   reversing	  
experimental	  PH,	  using	  BM-­‐derived	  cells	  and	  MNCs	  following	  short-­‐term	  culture.	  These	  studies	  have	  
described	   improvements	   in	   pulmonary	   hemodynamic	   parameters,	   right	   ventricular	   and	  pulmonary	  
remodelling	  as	  well	   as	   survival	  benefits	   in	   rats	   treated	  with	  MCT	   (see	  Table	  1.5).	  However,	   the	   rat	  
model	   of	  MCT	   is	   characterised	   by	   a	   dramatic	   perivascular	   accumulation	   of	   inflammatory	   cells	   and	  
endothelial	  damage,	  and	  does	  not	  represent	  all	  the	  histopathological	  changes	  associated	  with	  human	  
PAH,	  such	  as	  occlusive	  intimal	  lesions	  (Stenmark	  et	  al.,	  2009).	  It	  is	  also	  important	  to	  note	  that	  the	  rat	  
MCT	  model	  seems	  to	  be	  curable	  by	  almost	  every	  intervention	  tried,	  probably	  due	  to	  its	  acute	  nature,	  
and	   is	   therefore	  quite	  unlike	  patients	  with	  PAH.	  Conversely,	   it	  was	   recently	   reported	   that	   injecting	  
human	   early	   EPCs	   into	   MCT	   model	   in	   the	   rat	   did	   not	   confer	   to	   any	   clinical	   or	   histological	  
improvements	  or	  survival	  benefits	   (Mirsky	  et	  al.,	  2011).	  These	  discrepancies	  between	  studies	  could	  
be	  due	  to	  differences	  in	  (i)	  the	  severity	  of	  the	  model	  (MCT	  dosage),	  (ii)	  number	  of	  cells	  administered,	  
(iii)	  difference	  in	  time	  of	  administration,	  (iv)	  route	  of	  administration,	  (v)	  the	  timing	  when	  end-­‐points	  
were	   assessed.	  Moreover,	   BM-­‐derived	   progenitors	   are	   generally	   ineffective	   in	   hypoxia-­‐induced	   PH	  
(Raoul	  et	  al.,	  2007;	  Marsboom	  et	  al.,	  2008).	  Some	  studies	  have	  also	  reported	  that	  the	  injected	  BM-­‐
derived	  progenitor	  cells	  incorporated	  with	  pulmonary	  vessels	  in	  MCT-­‐treated	  rats	  (Zhao	  et	  al.,	  2005;	  
Spees	   et	   al.,	   2008),	   while	   others	   have	   found	   little	   evidence	   for	   a	   substantial	   incoporation	   of	  
progenitor	  cells	  in	  the	  pulmonary	  arteries	  (Sahara	  et	  al.,	  2007;	  Mirsky	  et	  al.,	  2011).	  	  
Some	   investigators	   have	   found	   that	   survival	   and	   the	   restoration	   of	   pulmonary	  microcirculation	   in	  
MCT-­‐treated	   animals	   was	   markedly	   enhanced	   when	   progenitor	   cells	   were	   used	   to	   transfer	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angiogenic	  genes	  such	  as	  eNOS	  (Zhao	  et	  al.,	  2005).	  Moreover,	  established	  hypoxia-­‐induced	  PH	  can	  be	  
reversed	   by	  MSCs	   expressing	   heme	  oxygenase-­‐1,	   but	   not	   by	   early	   EPCs	   (Liang	   et	   al.,	   2011).	  Other	  
studies	  have	  also	   reported	   improvements	   in	  pulmonary	  haemodynamics,	  using	  SMCs	  or	   fibroblasts	  
as	  vehicles	  to	  transfer	  angiogenic	  genes	  (Table	  1.5).	  These	  promising	  preclinical	  findings	  have	  led	  to	  
an	   early-­‐phase	   clinical	   study	   -­‐	   The	   Pulmonary	   Hypertension	   And	   Cell	   Therapy	   (PHACet)	  
(ClinicalTrials.gov	  Identifier:	  NCT00469027),	  to	  assess	  the	  tolerability	  of	  eNOS-­‐enhanced	  autologous	  
early	   EPCs	   delivered	   into	   the	   pulmonary	   circulation	   of	   patients	   with	   severe	   IPAH	   refractory	   to	   all	  
available	   therapies.	   Further	   support	   for	   the	   therapeutic	   potential	   of	   cell-­‐based	   therapy	   has	   been	  
provided	   by	   two	   small	   pilot	   studies	   from	  a	   research	   group,	   indicating	   that	   intravenous	   infusion	   of	  
cultured	   autologous	  MNCs	   is	   accompanied	   after	   12	  weeks	   by	   an	   augmented	   six-­‐minute	  walk	   test	  
distance	  and	  improvement	  in	  pulmonary	  vascular	  hemodynamics	  in	  IPAH	  patients	  (Wang	  et	  al.,	  2007;	  
Zhu	  et	  al.,	  2008).	   Injection	  of	  BM-­‐derived	  or	  peripheral	  blood-­‐derived	  progenitors	   into	  patients	  are	  
apparently	  safe,	  as	  they	  have	  been	  demonstrated	  in	  several	  larger	  clinical	  trials	  in	  patients	  with	  heart	  
disease	  such	  as	  acute	  myocardial	   infarction	  and	  coronary	  heart	  disease	   	   (reviewed	   in	  Smadja	  et	  al.	  
2007).	   Although	   apparently	   safe,	   further	   blinded	   and	   placebo	   controlled	   trials	   are	   required	   to	  
establish	   the	   potential	   of	  ex-­‐vivo	   cell-­‐based	   therapy	   in	   PAH	  using	   early	   outgrowth	   haematopoietic	  
cells.	  	  
ECFCs	  have	  been	  shown	  to	  provide	  better	  vascular	  protection	   in	   rabbit	  carotid	   injury	   (Gulati	  et	  al.,	  
2004)	  and	  improved	  symptoms	  in	  rat	  stroke	  model	  (Moubarik	  et	  al.,	  2011).	  The	  therapeutic	  potential	  
of	  proliferating	  ECFCs	  in	  PAH	  is	  however	  less	  clear.	  Ormiston	  and	  colleagues	  recently	  compared	  the	  
effects	  of	  administering	  “early”	  human	  EPCs	  and	  ECFCs	  in	  rats	  with	  MCT-­‐induced	  PH	  and	  found	  that	  
while	   the	   early	   cells	   attenuated	   PH	   through	   an	   immune-­‐dependent	  mechanism	   (possibly	   involving	  
stimulation	   of	   natural	   killer	   cells)	   the	   ECFC	   population	   was	   ineffective	   (Ormiston	   et	   al.,	   2010).	  
Nevertheless,	   ECFCs	   were	   recently	   shown	   to	   be	   an	   effective	   carrier	   of	   angiogenic	   genes	   such	   as	  
erythropoietin	   (EPO),	   conferring	   systemic	   release	   of	   EPO	   and	   the	   formation	   of	   functional	  
anastomoses	  in	  the	  vasculature	  of	  mice	  with	  radiation-­‐induced	  anemia	  (Lin	  et	  al.,	  2011).	  ECFCs	  have	  
also	  been	  engineered	  to	  carry	  PGI2	  synthase,	  leading	  to	  the	  substantial	  release	  of	  PGI2	  and	  improved	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(Nagaya	  et	  al.,	  
2003)	  
2003	   Rat	   MCT	   Human	  EPCs	  
(UVB)	  




2004	   Dog	   MCT	   Dogs	  EPCs	   14–18	   -­‐	   PAP	  ↓,	  PVR	  ↓,	  CO	  ↑	  
(Zhao	  et	  al.,	  
2005)	  
2005	   Rat	   MCT	   Rat	  EPCs	  (BM)	   7–10	   eNOS	   RVSP	  ↓,	  RV-­‐hypertrophy	  ↓,	  




2006	   Rat	   MCT	   Rat	  MSCs	  (BM)	   *P3-­‐5	   eNOS	   RVSP	  ↓,	  RV-­‐hypertrophy	  ↓,	  
survival	  ↑	  
(Sahara	  et	  al.,	  
2007)	  
2007	   Rat	   MCT	  +	  uP	   BM	  chimeric	  rats	   -­‐	   -­‐	   limited	  cell	  incorporation,	  
NS	  effects	  on	  PH	  
(Zhao	  et	  al.,	  
2007)	  
2007	   Rat	   L-­‐R-­‐shunt	   Human	  EPCs	  (PB)	   7	   CGRP	   PAP↓,	  PVR↓,	  survival↑,	  
remodelling↓	  
(Raoul	  et	  al.,	  
2007)	  








RVSP	  ↓,	  	  
RV-­‐hypertrophy	  ↓	  
RVSP	  -­‐,	  RV-­‐hypertrophy	  -­‐	  
(Spees	  et	  al.,	  
2008)	  
2008	   Rat	   MCT	   BM	  chimeric	  rats	   -­‐	   -­‐	   Incorporation	  of	  cells	  in	  lung	  
and	  heart	  tissue	  
(Yip	  et	  al.,	  
2008).	  




2008	   Mouse	   Hypoxia	   Mouse	  EPCs	   7	   -­‐	   RVSP	  -­‐,	  RV-­‐hypertrophy	  -­‐	  
(Yoshida	  et	  
al.,	  2009)	  
2009	   Mouse	   MCT	   Mouse	  MNCs	  
(BM)	  
-­‐	   -­‐	   RV-­‐hypertrophy	  ↓,	  
remodelling	  ↓,	  VEGF	  ↑	  	  
(Sun	  et	  al.,	  
2009a)	  
2009	   Rat	   MCT	   Rat	  EPCs	  (BM)	  +	  
cilostazol	  
21	   -­‐	   RVSP	  ↓,	  remodelling	  ↓	  
(Xia	  et	  al.,	  
2009a)	  
2009	   Rat	   MCT	   Human	  eEPCs	  
(PB)	  
7	   -­‐	   RVSP	  ↓,	  RV-­‐hypertrophy	  ↓,	  
remodelling	  ↓	  
(Umar	  et	  al.,	  
2009)	  
2009	   Rat	   MCT	   Rat	  MSCs	  (BM)	  +	  
MCT	  










RVSP	  ↓,	  RV-­‐hypertrophy	  ↓	  
RVSP	  -­‐,	  RV-­‐hypertrophy	  -­‐	  
(Mirsky	  et	  al.,	  
2011)	  
2011	   Rat	   MCT	   Human	  eEPCs	  
(PB)	  
7	   -­‐	   RVSP	  -­‐,	  RV-­‐hypertrophy	  -­‐,	  
remodelling	  -­‐,	  survival	  -­‐	  
(Sun	  et	  al.,	  
2011)	  
2011	   Rat	   MCT	   Rat	  EPCs	  (BM)	  	  
+/-­‐	  sildenafil	  
21	   -­‐	   RVSP	  ↓,	  RV-­‐hypertrophy	  ↓,	  
combination	  therapy	  
superior	  than	  monotherapy	  
(Liang	  et	  al.,	  
2011)	  	  
2011	   Mouse	   Hypoxia	   Mouse	  MSCs	  
(BM)	  
-­‐	   HO-­‐1	   RVSP	  ↓,	  RV-­‐hypertrophy	  ↓,	  
remodelling	  ↓	  
(Zhang	  et	  al.,	  
2012)	  
2012	   Mouse	   MCT	   Human	  MSCs	  
(BM)	  
hESC-­‐MSCs	  	  
-­‐	   -­‐	   RVSP	  ↓,	  RV-­‐hypertrophy	  ↓,	  
remodelling	  ↓,	  capillary	  
density	  ↑,	  hESC-­‐MSCs	  
superior	  than	  BM-­‐MSCs	  
(Jiang	  et	  al.,	  
2012)	  
2012	   Rat	   MCT	   Rat	  MSCs	  (BM)	   *P1-­‐3	   -­‐	   RVSP	  ↓,	  RV-­‐hypertrophy	  ↓,	  
remodelling	  ↓,	  survival	  ↑	  
(Luan	  et	  al.,	  
2012)	  
2012	   Dog	   MCT	   Dog	  BM	   -­‐	   -­‐	   PAP	  ↓,	  PVR	  ↓,	  CO	  ↑,	  RV-­‐
hypertrophy	  ↓,	  remodelling	  






	   	  
Table	  1.5	  (continued)	  
	  
Author(s)	   Year	   Species	   PH	  
model	  






(Wang	  et	  al.,	  
2007)	  




5	   -­‐	   PAP	  ↓,	  PVR	  ↓,	  CO	  ↑,	  
6MWD	  ↑	  
(Zhu	  et	  al.,	  
2008)	  




5	   -­‐	   PAP	  ↓,	  PVR	  ↓,	  CO	  ↑,	  	  
NYHA	  class	  ↓,	  6MWD	  ↑	  




-­‐	   eNOS	   Safety	  &	  dosing	  study,	  
ongoing	  
Non-­‐EPC/BM-­‐cell-­‐based	  therapy	  in	  animals	  
(Campbell	  et	  
al.,	  1999)	  
1999	   Rat	   MCT	   SMCs	   -­‐	   eNOS	   PAP	  ↓	  
(Campbell	  et	  
al.,	  2001)	  
2001	   Rat	   MCT	   SMCs	   -­‐	   VEGF	   RVSP	  ↓,	  RV-­‐hypertrophy	  
↓	  
(Zhao	  et	  al.,	  
2003)	  
2003	   Rat	   MCT	   SMCs	   -­‐	   Ang1	   RVSP	  ↓,	  RV-­‐hypertrophy	  
↓,	  survival↑	  
(Zhao	  et	  al.,	  
2006)	  
2006	   Rat	   MCT	   Fibroblasts	   -­‐	   eNOS	  
or	  
VEGF	  
RVSP	  ↓,	  RV-­‐hypertrophy	  




2011	   Rat	   MCT	   Human	  AFS	  or	  rat	  
SVC-­‐GFP	  
-­‐	   -­‐	   RV-­‐hypertrophy	  ↓,	  
remodelling	  ↓,	  	  BNP	  ↓,	  
inflammatory	  cytokines	  ↓	  
(Liu	  et	  al.,	  
2011)	  
2011	   Rat	   Shunt	   Rat	  ADSC	   *P2-­‐3	   -­‐	   PAP	  ↓,	  RV-­‐hypertrophy	  
↓,	  remodelling	  ↓,	  
capillary	  density	  ↑	  
	   	  
Table	   1.5.	   Summary	   of	   studies	   investigating	   the	   effect	   of	   infusion	   of	   native	   or	   genetically	   modified	  
progenitor	   cells	   in	   experimental	   models	   of	   PH	   and	   patients	   with	   severe	   PAH.	   ADSC,	   adipose-­‐derived	  
stromal	  cells;	  AFS,	  amniotic	  fluid	  stem	  cells;	  Ang1,	  angiopoietin	  1;	  AM,	  adrenomedullin;	  BM,	  bone	  marrow;	  
CGRP,	   calcitonin	   gene-­‐related	   peptide;	   CO,	   cardiac	   output;	   hESC,	   human	   embryonic	   stem	   cells;	   HO-­‐1,	  
hemo	  oxygenase-­‐1;	  L-­‐R	  shunt	  =	   left	  to	  right	  shunt;	  MCT,	  monocrotaline;	  MSCs,	  mesenchymal	  stem	  cells;	  
PAP,	   pulmonary	   arterial	   pressure;	   PVR,	   pulmonary	   vascular	   resistance;	   RV,	   right	   ventricle;	   RVSP,	   right	  
ventricular	  systolic	  pressure;	  SMCs,	  smooth	  muscle	  cells;	  SVC-­‐GFP,	  adipose	  tissue	  stromal	  vascular	  fraction	  
green	  fluorescence	  protein-­‐positive	  cell;	  uP,	  unilateral	  pneumonectomy;	  UVB,	  umbilical	  venous	  blood;	  *P,	  
passage;	  6MWD,	  6-­‐minuate	  walk	  distance;	  NYHA,	  New	  York	  Heart	  Association.	  Modified	  from	  Diller	  et	  al.	  
2010.	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1.7	   Transforming	  growth	  factor-­‐β	  (TGF-­‐β)	  signalling	  
1.7.1	   Ligands	  and	  receptors	  of	  the	  TGF-­‐β	  superfamily	  	  
TGF-­‐β	  was	  first	  discovered	  more	  than	  three	  decades	  ago	  as	  a	  secreted	  dimeric	  peptide	  (25	  kDa)	  that	  
could	   induce	  a	   reversible	   transformed	  phenotype	  of	   fibroblasts	   in	  a	  soft	  agar	  colony-­‐forming	  assay	  
(De	   Larco	  and	  Tadaro,	   1978;	  Moses	  et	   al.,	   1981;	  Roberts	   et	   al.,	   1981).	   Three	  different	  mammalian	  
homodimeric	  isoforms	  –	  TGF-­‐β1,	  TGF-­‐β2	  and	  TGF-­‐β3	  –	  	  were	  subsequently	  identified	  (Cheifetz	  et	  al.,	  
1987;	  Derynck	  et	  al.,	  1988;	  ten	  Dijke	  et	  al.,	  1988).	  More	  than	  30	  other	  proteins	  that	  are	  structurally	  
similar	  to	  TGF-­‐β	  and	  functionally	  use	  the	  same	  family	  of	  receptors	  and	  signalling	  intermediates	  were	  
since	  identified	  and	  makes	  up	  the	  large	  family	  of	  TGF-­‐β	  superfamily	  ligands,	  including	  TGF-­‐βs,	  BMPs,	  
growth	   and	   differentiation	   factors	   (GDFs),	   activins,	   inhibins,	   Müllerian	   inhibiting	   substance,	   nodal	  
and	  leftys	  (Mueller	  and	  Nickel,	  2012)	  (Figure	  1.5).	  The	  latent	  form	  of	  these	  secreted	  proteins	  all	  have	  
a	   similar	   structure:	   an	   amino-­‐terminal	   signal	   peptide,	   a	   larger	   precursor	   segment,	   and	   a	   25-­‐kDa	  
carboxyl-­‐terminal	   polypeptide	   that	   becomes	   the	   mature	   peptide	   following	   its	   release	   from	   the	  
precursor	   by	   proteolytic	   cleavage	   (Khalil,	   1999).	   The	   structural	   similarity	   of	   the	   carboxyl-­‐terminal	  
sequence	  defines	  this	  family	  of	  related	  proteins.	  	  
Members	   of	   the	   TGF-­‐β	   family	   elicit	   their	   biological	   actions	   by	   binding	   to	   a	   family	   of	   structurally	  
related	  cell-­‐surface	  transmembrane	  serine-­‐threonine	  kinases,	  which	  is	  known	  as	  the	  TGF-­‐β	  receptor	  
superfamily	  and	  consists	  of	  seven	  type	  I	  and	  five	  type	  II	  receptors	  (see	  Figure	  1.6).	  Each	  receptor	  has	  
a	   common	   structure,	   comprising	   a	   short	   extracellular	   cysteine-­‐rich	   domain	   that	   is	   subjected	   to	  N-­‐
linked	   glycosylation,	   a	   single	   transmembrane	   domain,	   and	   an	   intracellular	   serine/threonine	   kinase	  
domain	  (Wrana	  et	  al.,	  2008).	  The	  BMPR2	  receptor	  represents	  an	  exception	  to	  this	  common	  structure	  
as	   it	   contains	   a	   long	   extension	   downstream	  of	   the	   kinase	   domain,	  which	   is	   believed	   to	   serve	   as	   a	  
scaffold	  for	  signalling	  molecules	  to	  the	  receptor	  (Wrana	  et	  al.,	  2008).	  The	  main	  difference	  between	  
type	   I	   and	   type	   II	   receptors	   lies	   in	   a	   glycine-­‐serine-­‐rich	   sequence	   (the	   GS	   region)	   that	   is	   located	  
upstream	  of	   the	   intracellular	   kinase	   domain	   in	   all	   type	   I	   receptors	   (Derynck	   and	  Miyazono,	   2008).	  
Each	  member	  of	  the	  TGF-­‐β	  receptor	  family	  is	  thought	  to	  exist	  as	  a	  homodimer	  in	  the	  cell	  membrane,	  
which	  assemble	  into	  heterotetramers	  of	  type	  II	  and	  type	  I	  receptors	  upon	  ligand	  binding	  (Yamashita	  
et	   al.,	   1994).	   Ligand	   binding	   and	   signal	   transduction	   is	   also	   assisted	   by	   the	   type	   III	   receptors	  
betaglycan	  and	  endoglin	  (Wrana	  et	  al.,	  2008).	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Figure	  1.5.	  Phylogenetic	  tree	  of	  the	  TGF-­‐β	  protein	  family	   in	  humans.	  There	  are	  four	  subfamilies	  of	  
TGF-­‐β	  ligands	  (numbers	  to	  the	  right	  of	  the	  branches)	  comprising:	  BMP/GDF	  (1),	  activin/inhibin/nodal	  
(2),	   TGF-­‐β	   (3)	   and	  others	   (4).	   Type	   I	   and	   type	   II	   receptor	  usages	   for	   each	   ligand	  are	  deduced	   from	  
biophysical	   interaction	   or	   in	   vitro	   pulldown	   and	   crosslinking	   analyses.	   Light-­‐blue	   shaded	   boxes	  
emphasise	  SMAD	  1/5/8,	  whereas	  light-­‐red	  shaded	  boxes	  highlight	  SMAD	  2/3	  downstream	  signalling.	  	  
Figure	   modified	   from	   Mueller	   &	   Nickel	   2012,	   updated	   with	   findings	   from	   (Scharpfenecker	   et	   al.,	  












	   	  
Figure	   1.6.	   The	   interactions	   of	   the	   TGF-­‐β	   receptor	   superfamily.	   Type	   I	   (red	   or	   blue)	   and	   type	   II	  
receptor	  (yellow)	  subtypes	  are	  indicated	  by	  the	  coloured	  nodes.	  Alternative	  terms	  in	  parentheses	  are	  
also	  widely	   used	   for	   type	   I	   receptors.	   The	   functional	   clustering	   of	   the	   type	   I	   receptors	   into	   either	  
TGF-­‐β-­‐like/activin-­‐like	   (light	   red	   box)	   or	   BMP-­‐like	   (light	   blue	   box)	   is	   indicated,	   while	   ligands	   that	  
induce	  formation	  of	  complexes	  between	  type	  I	  and	  type	  II	  receptors	  are	  indicated	  as	  coloured	  lines	  
(red	   for	  TGF-­‐β-­‐like	   ligands	  and	  blue	   for	  BMP-­‐like	   ligands).	  Figure	  modified	   from	  Wrana	  et	  al.	  2008,	  
“The	  TGF-­‐β	  Family”,	  p.153.	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1.7.2	   TGF-­‐β	  and	  BMP	  signalling	  pathways	  	  
The	  TGF-­‐β	  superfamily	  of	  ligands	  and	  serine-­‐threonine	  kinase	  receptors	  represents	  a	  unique	  ligand-­‐
receptor	   system	   (Wrana	   et	   al.,	   2008).	   Multiple	   ligands	   are	   able	   to	   interact	   with	   selected	  
combinations	  of	  type	  I	  and	  type	  II	  receptors	  (see	  Figures	  1.5	  and	  1.6	  for	  diagrammatic	  summaries	  of	  
the	   ligand	  and	   receptor	   combinations).	   Typically,	   the	   signalling	   cascade	   is	   initiated	  when	  an	   active	  
TGF-­‐β	   ligand	   binds	   to	   the	   type	   II	   receptor	   homodimer,	   subsequently	   forming	   a	   heterotetramer	  
complex	  with	   the	  type	   I	   receptor.	  However,	   the	  order	  of	  binding	   is	   reversed	   for	  some	  members	  of	  
the	  BMP	  family,	  as	  BMP	   ligands	  contain	   independent	   type	   II	  and	  type	   I	  binding	  sites	   (Sebald	  et	  al.,	  
2004;	  Miyazono	  et	  al.,	  2005).	   Ligands	   that	   initiate	  TGF-­‐β	   signalling	   transcriptional	   responses	   in	  ECs	  
have	  been	  shown	  to	  engage	  the	  TGF-­‐βRII	   receptor	  together	  with	  either	  the	  ubiquitously	  expressed	  
type	   I	   receptor	   ALK5	   or	   the	   predominantly	   EC	   restricted	   type	   I	   receptor	   ALK1	   (Oh	   et	   al.,	   2000;	  
Goumans	  et	  al.,	  2002).	  Ligands	  that	  initiate	  BMP	  signalling	  transcriptional	  responses	  engage	  the	  type	  
II	  receptors	  BMPRII,	  activin	  receptor	  type	  IIA	  (ActRIIA)	  or	  activin	  receptor	  type	  IIB	  (ActRIIB),	  and	  the	  
type	   I	   receptors	   ALK1,	   ALK2,	   ALK3	   or	   ALK6	   (Cai	   et	   al.,	   2012).	   Formation	   of	   these	   ligand-­‐bound	  
heterotetrameric	  receptor	  complexes	  results	  in	  the	  type	  I	  receptor	  becoming	  phosphorylated	  in	  the	  
GS	  rich	  region	  and	  a	  conformational	  change	  that	  induces	  full	  receptor	  activation.	  This	  in	  turn	  permits	  
the	   binding	   of	   intracellular	   signalling	   receptor-­‐activated	   Smads	   (R-­‐Smads),	   which	   are	   directly	  
phosphorylated	  by	   the	   type	   I	   receptor	  at	   two	  serine	   residues	   in	   their	  carboxyl	   termini.	  ALK1/2/3/6	  
activation	   induces	   phosphorylation	   of	   R-­‐Smad1,	   5	   and	   8	   (pSmad1/5/8),	   while	   ALK5	   activation	  
mediates	   R-­‐Smad2	   and	   3	   phosphorylation	   (pSmad2/3).	   Activated	   R-­‐Smads	   form	   a	   heteromeric	  
complex	  with	  the	  common	  mediator	  Smad4,	  which	  then	  translocate	  to	  the	  nucleus	  to	  regulate	  the	  
transcription	  of	  specific	  target	  genes	  together	  with	  other	  transcriptional	  modulators	  (see	  Figure	  1.7	  
for	   a	   diagrammatic	   illustration	   of	   TGF-­‐β	   signalling	   in	   ECs)	   (Goumans	   et	   al.,	   2009).	   These	   complex	  
receptor	   interactions	   and	   intracellular	   pathways	   allow	   for	   fine-­‐tuning	   of	   TGF-­‐β/BMP	   signalling	   and	  
regulation	  of	  cellular	  function.	  In	  addition	  to	  canonical	  signalling	  via	  Smad	  activation,	  TGF-­‐β	  and	  BMP	  
ligands	  can	  also	  elicit	  responses	  through	  Smad-­‐independent	  (non-­‐canonical)	  pathways.	  These	  include	  
various	  MAP	   kinase	   pathways	   –	   p38,	   extracellular	   signal	   related	   kinase	   (ERK)	   and	   c-­‐jun	  N-­‐terminal	  
kinase	   (JNK),	   Rho	   GTPases	   and	   the	   phosphatidylinositol-­‐3-­‐kinase/Akt	   pathway	   (Zhang,	   2009).	  
Crosstalk	   between	   these	   different	   pathways	   is	   also	   considered	   to	   be	   important	   in	  maintaining	   EC	  
homeostasis	  (Kimura	  et	  al.,	  2000;	  Su	  et	  al.,	  2011).	  
TGF-­‐β	   signalling	   is	   further	   modulated	   by	   several	   accessory	   proteins.	   Access	   of	   ligands	   to	   TGF-­‐β	  
receptors	  is	  regulated	  by	  the	  transmembrane	  accessory	  type	  III	  homodimers	  betaglycan	  and	  endoglin	  
(ten	  Dijke	  and	  Arthur,	  2007).	  These	  proteins	  are	  structurally	  similar,	  possessing	  long	  extracellular	  and	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short	   intracellular	   serine/threonine	   rich	  domains,	  and	   lack	  a	   signalling	  enzymatic	  motif.	  Betaglycan	  
(also	  known	  as	  TGF-­‐βRIII)	  potentiates	  TGF-­‐β	  and	  BMP	  signalling	  by	  facilitating	  ligand	  binding	  to	  type	  II	  
receptors.	  Endoglin	  (also	  known	  as	  CD105)	  selectively	  facilitates	  binding	  of	  TGF-­‐βs,	  BMP9	  and	  BMP10	  
to	   type	   II	   receptor	   that	   form	  complexes	  with	  ALK1	  but	  not	  ALK5	   (Lee	  et	  al.,	  2008;	  Goumans	  et	  al.,	  
2009).	   Endoglin	  may	   also	   bind	   directly	   with	   BMP9	   and	   BMP10	   and	   thereby	   regulate	   EC	   functions	  
(Castonguay	  et	   al.,	   2011).	  Other	   accessory	  proteins,	   including	   Smad	  anchor	   for	   receptor	   activation	  
(SARA)	   and	   Disabled-­‐2	   (Dab-­‐2)	   also	  modulate	   TGF-­‐β	   signalling	   at	   the	   Smad	   level	   (Tsukazaki	   et	   al.,	  
1998;	   Hocevar	   et	   al.,	   2001).	   The	   inhibitory	   Smads	   (I-­‐Smads)	   –	   Smad6	   and	   Smad7	   –	   oppose	   TGF-­‐β	  
signalling	   by	   competing	   with	   R-­‐Smads	   for	   interaction	   with	   type	   I	   receptors	   (Hayashi	   et	   al.,	   1997;	  
Imamura	  et	  al.,	  1997;	  Nakao	  et	  al.,	  1997),	  recruiting	  the	  E3	  ubiquitin	  ligase	  Smad	  ubiquitin	  regulatory	  
factor	   (Smurf)	   to	   facilitate	  proteasomal	  degradation	  of	   the	  activated	   receptor	  complex	   (Ebisawa	  et	  
al.,	  2001),	  and	  by	  interacting	  directly	  with	  TGF-­‐β-­‐related	  transcription	  factors	  (Schilling	  et	  al.,	  2008).	  	  
TGF-­‐β1	  can	  demonstrate	  opposing	  actions	  depending	  on	  its	  concentration,	  for	  example	  inducing	  pro-­‐
angiogenic	  effects	  at	  low	  concentration	  and	  anti-­‐angiogenic	  effects	  at	  higher	  concentration	  (Pepper	  
et	   al.,	   1993).	   These	   paradoxical	   effects	   may	   be	   mediated	   by	   the	   activation	   of	   different	   TGF-­‐β	  
receptors.	   Subsequent	   studies	   revealed	   that,	   depending	  on	   its	   concentration,	   TGF-­‐β1	   is	   capable	  of	  
stimulating	   both	   ALK1/Smad1/5/8	   and	   ALK5/Smad2/3	   signalling	   pathways	   in	   mouse	   embryonic	  
endothelial	  cells	  (MEECs)	  (Goumans	  et	  al.,	  2002).	  Smad2	  phosphorylation	  occurs	  over	  a	  wide	  range	  
of	   TGF-­‐β	   concentrations	   and	   remains	   stable	   over	   time,	   whereas	   Smad1/5	   phosphorylation	   is	  
transient	   and	   only	   prominent	   at	   higher	   concentration.	   Furthermore,	   while	   ALK1	   and	   endoglin	  
activation	  of	  Smad1/5/8	  directly	  antagonised	  ALK5	  signalling	  at	  the	  transcriptional	   level	   (but	  not	  at	  
the	  Smad	  level),	  the	  presence	  of	  ALK5	  kinase	  activity	  was	  a	  requirement	  for	  efficient	  ALK1	  signalling,	  
as	  demonstrated	  by	  ALK5	  deficient	  MEECs	   (Goumans	  et	   al.,	   2003;	   Lebrin	  et	   al.,	   2004).	   In	   contrast,	  
Fernandez	   and	   colleagues	   showed	   that	   ALK1	   and	   endoglin	   activations	   are	   essential	   for	   ALK5	  
promoter	  activity	   in	  ECFCs	   (Fernandez	  et	  al.,	   2005).	  Cunha	  and	   colleagues	  also	   showed	   that	  BMP9	  
activation	  of	  ALK1	  had	  synergistic	  effects	  on	  TGF-­‐β/ALK5-­‐stimulated	  plasminogen	  activated	  inhibitor-­‐
1	   (PAI-­‐1)	   gene	   expression	   (Cunha	   et	   al.,	   2010).	   However,	   this	   crosstalk	   between	   ALK1	   and	   ALK5	  
signalling	   has	   been	   questioned,	   as	   non-­‐overlapping	   expression	   patterns	   of	  murine	   ALK1	   and	   ALK5	  
suggest	  that	  these	  receptors	  may	  signal	  independently	  of	  each	  other	  (Seki	  et	  al.,	  2006).	  Indeed,	  ALK1	  
signalling	  has	  been	  reported	  to	  occur	  independently	  of	  ALK5	  activity	  in	  both	  human	  and	  bovine	  aortic	  
ECs	   (Shao	   et	   al.,	   2009).	  Nevertheless,	   the	   interdependency	   between	   TGF-­‐β	   activation	   of	   ALK1	   and	  






Figure	  1.7.	  TGF-­‐β/BMP	  canonical	  signalling	  in	  endothelial	  cells.	  TGF-­‐β	  signalling	  occurs	  via	  TGF-­‐βRII	  
and	  both	  ALK1	  and	  ALK5	  type	  I	  receptors,	  whereas	  BMPs	  signal	  via	  three	  type	  II	  –	  BMPRII,	  ActRIIA	  and	  
ActRIIB	  –	  and	  four	  type	  I	  receptors	  –	  ALK1,	  ALK2,	  ALK3	  and	  ALK6.	  Accessory	  receptors	  betaglycan	  and	  
endoglin	   can	   facilitate	   TGF-­‐βRII/ALK5	   and	   TGF-­‐βRII/ALK1	   signalling	   respectively.	   The	   activated	  
receptor	   complexes	   bind	  with	   R-­‐Smads,	  which	   are	   directly	   phosphorylated	   by	   the	   type	   I	   receptors	  
(TGF-­‐β/ALK5	  activates	  Smad2/3,	  while	  TGF-­‐β/ALK1	  or	  BMP/ALKs	  activate	  Smad1/5/8).	  This	  results	  in	  
their	   release	   from	   the	   receptor	   complex	   and	   association	  with	   Smad4.	   The	   Smads	   complexes	   then	  
translocate	   to	   the	   nucleus	  where	   they	   regulate	   the	   transcription	   of	   specific	   target	   genes	   together	  
with	   other	   transcription	   factors	   (e.g.	   pSmad1/5/8	   stimulates	   transcription	   of	   inhibitor	   of	  
differentiation	   (ID)	  while	  pSmad2/3	  up	  regulates	  plasminogen	  activator	   inhibitor	   (PAI)-­‐1).	  Activated	  
ALK1/Smad1/5	  signalling	  might	  inhibit	  the	  transcriptions	  by	  ALK5/Smad2/3	  signalling	  (dotted	  line).	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1.7.3	   TGF-­‐β	  and	  BMP	  signalling	  in	  endothelial	  cells	  
TGF-­‐β	   signalling	   has	   important	   roles	   in	   vasculogenesis	   and	   angiogenesis	   during	   embryonic	  
development.	  Inactivation	  of	  different	  components	  of	  the	  TGF-­‐β	  signalling	  pathway,	  such	  as	  TGF-­‐β1	  
(Dickson	  et	  al.,	  1995),	  ALK1	  (Oh	  et	  al.,	  2000;	  Urness	  et	  al.,	  2000),	  ALK5	  (Larsson	  et	  al.,	  2001),	  TGF-­‐βRII	  
(Oshima	  et	  al.,	  1996),	  endoglin	  (Bourdeau	  et	  al.,	  1999;	  Li	  et	  al.,	  1999),	  Smad1	  (Lechleider	  et	  al.,	  2001)	  
and	  Smad5	  (Chang	  et	  al.,	  1999;	  Yang	  et	  al.,	  1999),	  are	  embryonically	  lethal	  due	  to	  abnormal	  yolk	  sac	  
vasculogenesis	  and/or	  angiogenesis.	  TGF-­‐β	  signalling	  is	  also	  essential	  for	  vascular	  homeostasis	  in	  the	  
adult	  (ten	  Dijke	  and	  Arthur,	  2007).	  	  
Substantial	   evidence	   indicates	   that	   TGF-­‐β1-­‐induced	   activation	   of	   ALK1	   and	   ALK5	   in	   ECs	   can	   elicit	  
paradoxical	  effects	  on	  proliferation,	  migration	  and	  angiogenesis	   (Goumans	  et	  al.,	  2002;	  Shao	  et	  al.,	  
2009).	  For	  example,	  some	  studies	  found	  that	  ALK1	  activation	  promoted	  proliferation,	  migration,	  tube	  
formation	  and	  sprouting	  of	  ECs	  (Goumans	  et	  al.,	  2002;	  Cunha	  et	  al.,	  2010;	  Mitchell	  et	  al.,	  2010),	  while	  
others	  have	  found	  the	  opposite	  (Lamouille	  et	  al.,	  2002;	  Koleva	  et	  al.,	  2006;	  David	  et	  al.,	  2007b;	  Shao	  
et	   al.,	   2009).	   Similar	   conflicting	   findings	   have	   also	   been	   described	   for	   ALK5	   signalling,	   with	   some	  
studies	   reporting	   that	   ALK5/Smad2	   activation	   inhibits	   migration,	   proliferation	   and	   in	   vitro	   tube	  
formation	   by	   ECs	   (Goumans	   et	   al.,	   2002;	   Lebrin	   et	   al.,	   2004;	   Froese	   et	   al.,	   2011)	   while	   others	  
demonstrated	   pro-­‐proliferative	   and	   pro-­‐angiogenic	   effects	   (Shao	   et	   al.,	   2009;	   Tian	   et	   al.,	   2012a).	  
Furthermore,	   most	   studies	   indicate	   that	   TGF-­‐β1	   has	   pro-­‐apoptotic	   effects	   on	   ECs,	   either	   alone	  
(Tsukada	   et	   al.,	   1995;	   Yan	   and	   Sage,	   1998;	   Pollman	   et	   al.,	   1999;	   Emmanuel	   et	   al.,	   2002)	   or	   in	  
combination	   with	   VEGF	   (Ferrari	   et	   al.,	   2006),	   but	   a	   few	   have	   also	   described	   pro-­‐survival	   (anti-­‐
apoptotic)	  effects	  (Mauro	  et	  al.,	  2001;	  Vinals	  and	  Pouyssegur,	  2001;	  Li	  et	  al.,	  2003).	  These	  opposing	  
results	  are	  thought	  to	  reflect	  the	  context-­‐specific	  nature	  of	  TGF-­‐β	  signalling,	  which	  is	  dependent	  on	  
factors	  such	  as	  ligand	  concentration,	  cell	  type,	  culture	  conditions	  and	  experimental	  design.	  
Pleotropic	  effects	  have	  also	  been	  observed	  following	  activation	  of	  ALK1	  signalling	  by	  BMP9.	  On	  one	  
hand,	  BMP9	  is	  considered	  to	  contribute	   in	  the	  quiescence	  of	  the	  endothelium,	  as	  demonstrated	  by	  
the	   inhibition	  of	  EC	  migration	  and	  proliferation	   in	  vitro	  and	   inhibition	  of	  angiogenesis	   in	   several	  ex	  
vivo	  models	   (David	  et	  al.,	  2007a;	  Scharpfenecker	  et	  al.,	  2007;	  David	  et	  al.,	  2008;	  Shao	  et	  al.,	  2009;	  
Larrivee	   et	   al.,	   2012;	   Yao	   et	   al.,	   2012).	   On	   the	   other,	   BMP9	   has	   also	   been	   found	   to	   induce	   pro-­‐
angiogenic	  responses	  in	  several	  models	  (Suzuki	  et	  al.,	  2010;	  Lee	  et	  al.,	  2012;	  Park	  et	  al.,	  2012).	  One	  
possible	  explanation	  is	  that	  BMP9	  may	  activate	  different	  Smad	  pathways	  through	  its	  interaction	  with	  
ActRIIA	  (Smad2)	  and	  BMPR2	  (Smad1/5/8)	  receptors	  (Upton	  et	  al.,	  2009).	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BMP2	   and	   BMP4	   have	   a	   similar	   structure	   and	   belong	   to	   the	   same	   sub-­‐class	   of	   BMP	   ligands.	   Both	  
promote	  EC	  proliferation,	  migration,	  tube	  formation	  and	  survival	  in	  vitro	  and	  tumour	  angiogenesis	  in	  
vivo	   (Langenfeld	  and	  Langenfeld,	  2004;	  Teichert-­‐Kuliszewska	  et	  al.,	  2006;	  Rothhammer	  et	  al.,	  2007;	  
Southwood	   et	   al.,	   2008;	   Alastalo	   et	   al.,	   2011;	   Gangopahyay	   et	   al.,	   2011;	   Cahill	   et	   al.,	   2012;	  
Finkenzeller	  et	  al.,	  2012;	  Yao	  et	  al.,	  2012).	  Furthermore,	  BMP2,	  BMP4	  and	  BMP7	  have	  been	  shown	  to	  
protect	   HPAECs	   against	   serum	   deprivation-­‐induced	   apoptosis	   (Teichert-­‐Kuliszewska	   et	   al.,	   2006;	  
Southwood	  et	  al.,	  2008),	  while	  BMP4	  induced	  apoptosis	  via	  the	  non-­‐canonical	  (JNK	  and	  p38	  MAPK)	  
pathways	   in	   HUVECs	   and	   rat	   aortic	   ECs	   (Tian	   et	   al.,	   2012b).	   BMP6	   also	   promotes	   proliferation,	  
migration	  and	  tube	  formation	  in	  ECs,	  possibly	  acting	  through	  the	  stimulation	  of	  ALK3/ALK6	  and	  ID1	  
expression	   (Valdimarsdottir	  et	  al.,	  2002).	  Collectively,	   these	  data	  point	   to	   the	  pleiotropic	  effects	  of	  
both	  BMP	  and	  TGF-­‐β	  signalling	  in	  ECs.	  
	  
1.7.4	   TGF-­‐β	  signalling	  in	  cardiovascular	  disorders	  
Several	  cardiovascular	  disorders	  have	  been	  linked	  to	  alterations	  in	  TGF-­‐β	  signalling.	  One	  of	  the	  most	  
studied	   is	   hereditary	   haemorrhagic	   telangiectasia	   (HHT),	  which	   is	   an	   autosomal	   dominant	   vascular	  
dysplasia,	   characterised	   by	   multisystemic	   mucocutaneous	   telangiectasia	   and	   arteriovenous	  
malformations	  (AVMs)	  in	  the	  brain,	  lungs,	  liver	  and	  gastrointestinal	  tract	  (Govani	  and	  Shovlin,	  2009).	  
Mutations	  in	  three	  genes	  are	  casually	  related	  to	  HHT,	  comprising	  endoglin	  (HHT1),	  ALK1	  (HHT2)	  and	  
Smad4	  (McAllister	  et	  al.,	  1994;	  Gallione	  et	  al.,	  2004).	  In	  fact,	  endothelial	  specific	  deletion	  of	  ALK1	  and	  
endoglin	  in	  mice	  leads	  to	  a	  phenotype	  resembling	  the	  clinical	  manifestation	  of	  HHT	  (Park	  et	  al.,	  2009;	  
Mahmoud	   et	   al.,	   2010).	   Furthermore,	   blood-­‐derived	   ECFCs	   from	   both	   HHT1	   and	   HHT2	   patients	  
display	   impaired	   migration,	   proliferation	   and	   tube	   formation	   in	   culture	   (Fernandez	   et	   al.,	   2005;	  
Fernandez	  et	  al.,	  2007).	  
Mutations	  in	  either	  ALK5	  or	  TGF-­‐βRII	  can	  lead	  to	  the	  autosomal	  dominant	  connective	  tissue	  disorder	  
Loeys-­‐Dietz	   syndrome	   (LDS)	   (Loeys	   et	   al.,	   2005)	   and	   mutations	   in	   Smad3	   and	   TGF-­‐β2	   have	   also	  
recently	   been	   reported	   in	   LDS	   (van	   de	   Laar	   et	   al.,	   2011;	   Lindsay	   et	   al.,	   2012).	   The	   syndrome	   is	  
characterised	   by	   arterial	   aneurysms	   and/or	   dissections,	   with	   craniofacial	   or	   cutaneous	  
manifestations	   (Loeys	   et	   al.	   2006).	   The	   molecular	   mechanism	   underlying	   the	   disease	   is	   poorly	  
understood.	   Despite	   the	   loss-­‐of-­‐function	   mutations	   in	   the	   TGF-­‐β	   receptors,	   it	   is	   associated	   with	  
increased	   TGF-­‐β	   signalling	   and	   increased	   expression	   of	   TGF-­‐β1	   and	   TGF-­‐β2	   in	   affected	   tissues	  
(Lindsay	  et	  al.,	  2012).	  The	  clinical	  features	  of	  LDS	  are	  similar	  to	  Marfan	  syndrome,	  which	  is	  another	  
autosomal	  dominant	  connective	  tissue	  disorder	  that	   is	  associated	  with	  high	  circulating	  TGF-­‐β	   levels	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(Matt	  et	  al.,	  2009).	  This	  probably	  reflects	  either	  a	   loss-­‐of-­‐function	  mutation	   in	   fibrillin-­‐1,	   leading	  to	  
diminished	  sequestration	  of	  latent	  TGF-­‐β	  in	  the	  ECM	  and	  increased	  TGF-­‐β	  activation	  (Neptune	  et	  al.,	  
2003).	  Marfan	   syndrome	   is	   also	   associated	  with	  mutation	   in	   the	   TGF-­‐βRII	   locus	   (Mizuguchi	   et	   al.,	  
2004).	  Overall,	   these	   findings	  serve	   to	  underline	   the	   importance	  of	  maintaining	  a	  balance	   in	  TGF-­‐β	  
signalling	  for	  vascular	  homeostasis.	  	  
	  
1.7.5	   TGF-­‐β	  signalling	  in	  pulmonary	  arterial	  hypertension	  
Accumulating	   evidence	   shows	   that	   abnormalities	   in	   TGF-­‐β	   signalling	   have	   a	   critical	   role	   in	   PAH.	  
Heterozygous	   mutations	   in	   BMPR2	   and	   more	   rarely	   the	   genes	   encoding	   ALK1,	   ALK6,	   endoglin	   or	  
Smad1,	   Smad4	   and	   Smad8	   are	   associated	   with	   PAH	   (as	   discussed	   in	   Chapter	   1.2.4).	   Histological	  
observations	   indicate	   that	  expression	  of	  BMPR2	   (Atkinson	  et	  al.,	   2002),	  ALK3	   (Du	  et	  al.,	   2003)	  and	  
pSmad1	   (Yang	   et	   al.,	   2005)	   is	   reduced	   in	   the	   pulmonary	   endothelium	   of	   IPAH	   lungs.	   Reduced	  
expression	  of	  BMP	  receptors	  (ALK1,	  ALK3,	  ALK6,	  BMPR2),	  endoglin,	  and	  Smads,	  and	  decreased	  BMP	  
signalling	   (pSmad1	   and	   ID	   gene	   expression)	   has	   also	   been	   reported	   in	   rats	   with	  MCT-­‐induced	   PH	  
(Morty	   et	   al.,	   2007;	   Zakrzewicz	   et	   al.,	   2007;	   Long	   et	   al.,	   2009;	   Thomas	   et	   al.,	   2009),	   and	   reduced	  
BMPR2	  expression	  was	  described	  in	  rats	  with	  hypoxia-­‐induced	  PH	  (Takahashi	  et	  al.,	  2006).	  Attempts	  
have	  made	   to	   rectify	  deficiencies	   in	  gene	  expression	  and,	  while	  BMPR2	   gene	   therapy	   in	   the	  whole	  
lung	  was	   found	   to	  be	   ineffective	   in	  MCT-­‐induced	  PH	   (McMurtry	  et	   al.,	   2007),	   specifically	   targeting	  
BMPR2	   gene	   delivery	   to	   the	   pulmonary	   endothelium	   led	   to	   improvements	   in	   RV	   and	   pulmonary	  
vascular	   remodelling	   and	   pulmonary	   haemodynamics,	   both	   in	   hypoxia	   and	   MCT	   models	   of	   PH	  
(Reynolds	  et	  al.,	  2012).	  Heterozygous	  mutation,	  as	  well	  as	  conditional	  ablation	  or	  mutation	  of	  BMPR2	  
in	   the	   pulmonary	   endothelium	   predisposes	  mice	   to	   develop	   PH,	   as	   demonstrated	   by	   increases	   in	  
RVSP,	  RV	  hypertrophy	  and	   remodelling	  of	  pulmonary	   vessels	   (Song	  et	   al.,	   2005;	  Hong	  et	   al.,	   2008;	  
Majka	   et	   al.,	   2011).	   BMPR2	   deficient	   mice	   also	   exhibit	   an	   increased	   pulmonary	   vasoconstrictor	  
response	   (Long	   et	   al.,	   2006;	   Frank	   et	   al.,	   2008),	   disrupted	   pulmonary	   endothelial	   barrier	   function	  
(Burton	  et	  al.,	  2011),	  and	  heightened	  susceptibility	  to	  inflammation	  (Burton	  et	  al.,	  2011;	  Soon	  et	  al.,	  
2012).	  The	  observations	   that	  both	  ALK1	   and	  BMPR2	  mutations	   can	   lead	   to	  PAH	  argue	   in	   favour	  of	  
defective	   endothelial	   BMP9/BMPR2/ALK1	   signalling	   being	   critical	   in	   PAH	   (Upton	   et	   al.,	   2009).	   It	   is	  
significant	   therefore	   that	   the	   ALK1	   heterozygous	   mouse	   can	   develop	   PH,	   as	   characterised	   by	  
increased	   RVSP,	   vascular	   remodelling,	   reduced	   pulmonary	   vascular	   density	   and	   endothelial	  
dysfunction	   (Jerkic	   et	   al.,	   2011).	   Furthermore,	   this	   was	   associated	   with	   eNOS	   uncoupling	   and	  
increased	  production	  of	  ROS,	  and	  the	  development	  of	  PH	  being	  prevented	  by	   treatment	  with	  anti-­‐
oxidant.	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Histological	   examination	   of	   lung	   sections	   from	   IPAH	   patients	   has	   also	   provided	   evidence	   of	  
dysregulated	  TGF-­‐β	  signalling	  components,	  including	  ALK5,	  TGF-­‐βRII	  and	  Smads	  (Richter	  et	  al.,	  2004),	  
where	  were	  most	  apparent	  within	  plexiform	  lesions.	  These	  coincide	  with	  the	  somatic	  mutations	  and	  
decreased	  expression	  of	  TGF-­‐βRII	  found	  in	  the	  endothelial	  cells	  of	  plexiform	  lesions	  in	  IPAH	  patients	  
(Yeager	  et	  al.,	  2001).	  Studies	   in	  MCT-­‐treated	  rats	  have	  also	  provided	  evidence	  of	  reduced	  TGF-­‐βRII,	  
Smad3,	  and	  Smad4	  expression,	  diminished	  TGF-­‐β/ALK5	  signalling	  (pSmad2)	  and	  dysfunctional	  TGF-­‐β1	  
responses	   in	   cultured	   PASMCs	   (Zakrzewicz	   et	   al.,	   2007).	   Controversy	   exists	   however	   as	   other	   data	  
indicates	  that	  TGF-­‐β	  signalling	  is	  enhanced	  in	  PAH.	  Substantial	  expression	  of	  TGF-­‐β	  ligands	  was	  found	  
in	   the	   pulmonary	   arteries	   of	   patients	   with	   IPAH	   (Botney	   et	   al.,	   1994)	   as	   well	   as	   in	   the	   lungs	   and	  
pulmonary	  arteries	  in	  MCT	  (Arcot	  et	  al.,	  1993),	  chronic	  hypoxia	  (Jiang	  et	  al.,	  2007)	  and	  shunt	  model	  
(Mata-­‐Greenwood	  et	  al.,	  2003)	  of	  PH.	  PASMCs	  isolated	  from	  IPAH	  patients	  also	  display	  an	  abnormal	  
proliferative	  response	  to	  TGF-­‐β1,	  compared	  with	  an	  inhibitory	  response	  in	  PASMCs	  from	  control	  and	  
APAH	   patients	   (Morrell	   et	   al.,	   2001).	  Moreover,	   two	   studies	   described	   increased	   TGF-­‐β1,	   TGF-­‐βRII	  
and	  pSmad3	  expression	  in	  pulmonary	  arterial	  wall	  of	  rats	  with	  MCT-­‐induced	  PH	  (Zaiman	  et	  al.,	  2008;	  
Long	  et	  al.,	  2009),	  but	  not	   in	  rats	  exposed	  to	  chronic	  hypoxia	  (Long	  et	  al.,	  2009).	   Importantly,	  ALK5	  
and	   TGF-­‐β	   ligands	   inhibitions	   have	   been	   found	   to	   prevent	   the	   development	   of	   PH	   and	   partially	  
reverse	   established	   PH	   in	  MCT	   treated	   rats	   (Zaiman	   et	   al.,	   2008;	   Long	   et	   al.,	   2009;	   Thomas	   et	   al.,	  
2009;	  Megalou	  et	  al.,	  2010),	  suggesting	  that	  ALK5/TGF-­‐β	  signalling	  could	  be	  important	  at	  least	  in	  the	  
initiation	  of	  experimental	  PH.	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1.8	   Dysfunctional	  phenotype	  of	  endothelial	  cells	  isolated	  from	  the	  lungs	  of	  
IPAH	  patients	  
A	   hallmark	   of	   established	   end-­‐stage	   IPAH	   is	   the	   existence	   of	   angioproliferative	   plexiform	   lesions	  
within	  the	  pulmonary	  arteries	  (Cool	  et	  al.,	  1999;	  Tuder	  et	  al.,	  2001)	  and	  a	  model	  of	  PAH	  has	  emerged	  
where	   initial	  endothelial	  apoptosis	   is	   considered	   to	  be	  a	  key	   factor	   (Sakao	  et	  al.,	  2005;	  Michelakis,	  
2006).	   Central	   to	   this	   is	   the	   proposition	   that	   an	   inherited	   or	   acquired	   insult	   leads	   to	   apoptosis	   of	  
PAECs	  and	  loss	  of	  small	  capillaries.	  Increased	  flow	  and	  shear	  stress	  in	  the	  remaining	  vessels	  results	  in	  
the	  emergence	  of	  apoptosis-­‐resistant	  ECs	  that	  proliferate	  and	  give	  rise	  to	  plexogenic	  lesions	  (Sakao	  
et	   al.,	   2005).	   At	   the	   same	   time,	   a	   loss	   of	   PAECs	   would	   allow	   the	   ingress	   for	   growth	   factors	   and	  
proliferation	  of	  exposed	  PASMCs.	  	  Studies	  on	  pulmonary	  ECs	  isolated	  from	  the	  lungs	  of	  IPAH	  patients	  
provide	   support	   for	   this	  model,	  as	   they	  display	  a	  hyperproliferative,	  apoptosis-­‐resistant	  phenotype	  
compared	   to	   control	   pulmonary	   ECs	   (Masri	   et	   al.,	   2007;	   Tu	   et	   al.,	   2011).	   The	   hyperproliferative	  
potential	   may	   reflect	   increased	   activation	   of	   Janus	   kinase/signal	   transducer	   and	   activator	   of	  
transcription	  3	   (STAT3)	  and	  ERK1/2,	  while	   their	  apoptosis-­‐resistant	  phenotype	  was	  associated	  with	  
increased	  expression	  of	  anti-­‐apoptotic	  factors	  such	  as	  B-­‐cell	   lymphoma	  (BCL)2,	  BCL	  extra	  long	  (BCL-­‐
xL),	   and	  myeloid	   leukemia	   cell	   differentiation	   protein	   (Mcl-­‐1)	   (Masri	   et	   al.,	   2007;	   Tu	   et	   al.,	   2011).	  
Furthermore,	  pulmonary	  ECs	  from	  IPAH	  patients	  have	  been	  found	  to	  produce	  greater	  amounts	  of	  5-­‐
HT,	   ET-­‐1,	   MCP-­‐1	   and	   FGF-­‐2,	   stimulating	   the	   proliferation	   of	   PASMCs	   (Dewachter	   et	   al.,	   2006;	  
Eddahibi	  et	  al.,	  2006;	  Sanchez	  et	  al.,	  2007;	  Izikki	  et	  al.,	  2009).	  The	  overproduction	  of	  FGF-­‐2	  might	  also	  
act	  in	  an	  autocrine	  manner	  to	  increase	  proliferation	  and	  reduce	  sensitivity	  to	  apoptosis	  in	  pulmonary	  
ECs	  (Tu	  et	  al.,	  2011).	  	  
The	  utility	  of	  pulmonary	  ECs,	   isolated	  ex	  vivo	   from	  patients	  with	  PAH,	   is	   further	  exemplified	  by	  the	  
discovery	  of	  metabolic	  abnormalities,	  which	  are	  similar	  to	  those	  of	  cancer	  cells	  and	  characterised	  by	  
reduced	  mitochondria	  and	  oxygen	  consumption,	   increased	  glycolytic	   rate	   (the	  Warburg	  effect)	  and	  
an	  altered	  hypoxia	  sensing	  mechanism	  (Xu	  et	  al.,	  2007;	  Fijalkowska	  et	  al.,	  2010).	  In	  addition,	  the	  over	  
production	   of	   hypoxia	   inducible	   factors	   by	   PAECs	   from	   PAH	   patients	   has	   been	   linked	   to	   intrinsic	  
myeloid	  abnormalities	  and	  the	  recruitment	  of	  progenitor	  cells	  to	  their	  lungs	  (Farha	  et	  al.,	  2011).	  The	  
inflammatory	   manifestation	   of	   IPAH	   has	   also	   been	   demonstrated	   by	   the	   increased	   secretion	   of	  
inflammatory	  modulators	  and	  cytokines	  such	  as	  leptin	  (Huertas	  et	  al.,	  2012),	  IL-­‐15	  (Masri	  et	  al.,	  2007)	  
and	  MCP-­‐1	  (Sanchez	  et	  al.,	  2007)	  by	  pulmonary	  ECs	  from	  IPAH	  patients.	  Most	  importantly,	  these	  cells	  
have	  been	  used	   to	   identify	  and	  explore	  novel	  pathogenic	  mechanisms,	   such	  as	  dysregulated	  FGF-­‐2	  
and	  apelin	  expression,	  leading	  to	  further	  studies	  in	  pre-­‐clinical	  models	  and	  patients	  with	  IPAH	  (Izikki	  
et	  al.,	  2009;	  Alastalo	  et	  al.,	  2011).	  Other	  studies	  have	  led	  to	  the	  recent	   identification	  of	  pathogenic	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roles	  for	  p130Cas	  and	  adenomatous	  polyposis	  coli	  in	  IPAH	  (de	  Jesus	  Perez	  et	  al.,	  2012;	  Tu	  et	  al.,	  2012).	  
Moreover,	  isolated	  pulmonary	  ECs	  have	  also	  been	  used	  to	  study	  disease	  mechanisms	  associated	  with	  
mutations	   in	  BMPR2	  and	  SMAD9,	   leading	  to	  the	  discovery	  of	  dysfunctional	  microRNA	  processing	   in	  
PAH	   (Drake	   et	   al.,	   2011),	   and	   cells	   from	   CTEPH	   patients	   have	   been	   shown	   to	   exhibit	   increased	  
adhesion	  and	  secretion	  of	  pro-­‐thrombotic	  factors	  such	  as	  ET-­‐1	  and	  vWF	  (Wynants	  et	  al.,	  2012).	  	  
These	  findings	  provide	  a	  powerful	  rationale	  for	  studying	  endothelial	  cells	  isolated	  from	  the	  lungs	  of	  
PAH	  patients,	  both	  to	  understand	  the	  pathogenesis	  of	   the	  disease	  and	  develop	  novel	   therapeutics.	  
The	   availability	   of	   suitable	   tissues	   is	   however	   very	   limited	   and	   a	   clear	   disadvantage	   of	   using	   cells	  
isolated	   from	   explanted	   lungs	   is	   that	   they	   are	   only	   representative	   of	   endothelial	   dysfunction	   in	  
patients	  with	  severe	  late-­‐stage	  disease	  who	  require	  transplantation.	  Blood-­‐derived	  ECFCs	  could	  offer	  
a	  valuable	  non-­‐invasive	  means	  of	  deriving	  endothelial	  cells	  from	  patients	  at	  various	  stages	  of	  disease	  
progression	  and	  treatment,	  which	  offer	  great	  potentials	  in	  further	  understanding	  the	  development	  of	  
IPAH.	  	  
This	  study	  intends	  to	  determine	  whether	  ECFCs	  derived	  from	  patients	  with	  IPAH	  can	  be	  distinguished	  
from	  those	  produced	  by	  healthy	  volunteers	  and	  thus	  provide	  an	   in	  vitro	  model	  that	  can	  be	  used	  to	  
explore	   the	   endothelial	   functions,	   secretion	   of	   vasoactive	   factors	   and	   expression	   of	   specific	   genes	  
that	   are	   selectively	   affected	   in	   the	  disease.	   This	  model	  may	  be	   important	   in	   assessing	   the	   relative	  
contribution	   of	   TGF-­‐β	   signalling	   in	   the	   disease	   phenotype	   and	   identifying	   novel	   mechanisms	  
underlying	  endothelial	  dysfunction.	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1.9	   Hypothesis	   	  
ECFCs	   isolated	   from	   adult	   peripheral	   blood	   possess	   a	   distinct	   cell	   phenotype	   and/or	   functional	  
characteristics	   that	   distinguish	   patients	   with	   IPAH	   from	   healthy	   controls	   and	   are	   independent	   of	  
known	   BMPR2	   mutations.	   As	   such,	   ECFCs	   may	   represent	   an	   effective	   cell	   type	   for	   studying	  
mechanisms	  underlying	  endothelial	  dysfunction	  in	  IPAH,	  testing	  drug	  responses	  and	  development	  of	  
novel	  therapies	  in	  vitro.	  	  
	  
1.10	   Objectives	  
1. Isolate	  and	  grow	  ECFCs	  to	  a	  consistent	  standard	  and	  compare	  the	  phenotype	  and	  clonogenic	  
potential	  of	  cells	  derived	  from	  well-­‐characterised	  patients	  with	  IPAH	  and	  healthy	  volunteers.	  
	  
2. To	  investigate	  the	  functional	  characteristics	  of	  ECFCs	  isolated	  from	  peripheral	  blood	  of	  IPAH	  
patients	  and	  determine	  whether	  they	  replicate	  the	  endothelial	  dysfunction	  observed	  in	  vivo	  
and	  differences	  found	  in	  endothelial	  cells	  isolated	  from	  the	  diseased	  pulmonary	  vasculature.	  
	  
3. To	  investigate	  the	  dysfunctional	  TGF-­‐β	  and	  BMP	  receptor	  expression	  and	  signalling	  in	  ECFCs	  
from	  IPAH	  patients.	  
	  
4. To	   determine	   whether	   the	   dysfunctional	   TGF-­‐β	   receptors	   expression/signalling	   and	  
expression	   of	   other	   regulatory	   proteins	   are	   responsible	   for	   the	   functional	   phenotypes	  
presented	  in	  ECFCs	  from	  IPAH	  patients.	  
	  
5. To	  determine	  whether	  blood-­‐derived	  ECFCs	  can	  be	  used	  to	  investigate	  other	  novel	  aspects	  of	  
signalling	  dysregulation	   that	  might	   contribute	   to	   the	  pathogenic	  dysfunction	  of	  endothelial	  
cells	  in	  IPAH	  patients.	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Chapter	  2	  –	  Materials	  and	  methods	  
	  
2.1	   Declaration	  of	  responsibilities	  
Blood	  samples	  were	  collected	  with	  the	  assistance	  of	  Dr	  Luke	  Howard	  and	  Dr	  Simon	  Gibbs,	  the	  nurses	  
in	  the	  National	  Pulmonary	  Hypertension	  Service	  and	  the	  staff	  of	  the	  Sir	  John	  McMichael	  Centre	  for	  
Clinical	  Research,	  Hammersmith	  Hospital,	  London,	  UK.	  
Data	   in	   most	   of	   the	   CLIC4	   experiments	   (Fig.	   7.1,	   7.2	   and	   7.5)	   were	   collected	   and	   analysed	   in	  
collaboration	  with	  Dr	  Vahitha	  Abdul-­‐Salam.	  Fig.	  4.8,	  7.3	  and	  data	  from	  the	  connexin	  43	  experiments	  
(Fig.	   7.6-­‐7.9)	   were	   collected	   and	   analysed	   in	   collaboration	   with	   Dr	   Hilda	   Tsang.	   Asymmetric	  
dimethylarginine	   (ADMA)	  measurement	   in	   Figure	  7.6C	  was	  performed	  by	  Mr	   Lucio	   Iannone.	  Other	  
data	  were	  collected,	  produced	  and	  analysed	  by	  myself.	  	  
	  
2.2	   Blood	  samples	  
This	   study	   was	   approved	   by	   the	   Charing	   Cross	   Hospital	   Research	   Ethics	   Committee	   (REC	   Ref	  
09/H0711/4)	  and	  all	  blood	  samples	  were	  obtained	  with	  written	  informed	  consent.	  Blood	  samples	  (up	  
to	  50ml)	  were	  drawn	  from	  the	  antecubital	  vein	  and	  collected	  in	  either	  Vacutainer™	  tubes	  containing	  
tripotassium	   ethylene	   diamine	   tetra-­‐acetic	   acid	   (K3	   EDTA,	   10ml,	   cat.	   no.	   368457,	   BD	   Diagnostics,	  
Oxford,	  UK)	   or	   cell	   preparation	   tubes	  with	   sodium	   citrate	   (Vacutainers	  CPT™,	   8ml,	   cat.	   no.362782,	  	  
BD	  Biosciences).	   The	  blood	  was	   kept	  at	   room	   temperature	  and	  mononuclear	   cells	   (MNCs)	   isolated	  
within	  1	  hour	  of	  collection.	  The	  diagnosis	  of	  IPAH	  was	  based	  on	  standard	  criteria	  with	  confirmation	  
by	  right	  heart	  catheterisation	  and	  exclusion	  of	  other	  forms	  of	  PH	  as	  per	  recent	  guidelines	  at	  diagnosis	  
(Galie	   et	   al.,	   2009b).	   MNCs	   were	   also	   isolated	   from	   healthy	   volunteers	   recruited	   within	   Imperial	  






2.3	   ECFC	  isolation	  and	  cell	  culture	  
The	  method	   used	  was	   adapted	   from	   a	   protocol	   originally	   published	   by	   Ingram	   and	   co-­‐workers	   in	  
2004	  (Ingram	  et	  al.,	  2004),	  which	  has	  since	  been	  more	  fully	  described	  (Mead	  et	  al.,	  2008)	  (see	  Section	  
2.4).	  Venous	  blood	  collected	  in	  EDTA	  vacutainers	  was	  diluted	  1:1	  with	  PBS-­‐FBS	  (phosphate	  buffered	  
saline,	  Ca2+	  and	  Mg2+ free	  (cat.	  no.	  14190,	  Gibco,	  Invitrogen,	  Paisley,	  UK)	  containing	  0.2%	  w/v	  EDTA	  
(cat.	   no.	   03664,	   Sigma-­‐Aldrich,	  Dorset,	  UK]	   and	  2%	   fetal	   bovine	   serum,	   FBS)	   and	   aliquots	   carefully	  
layered	   onto	   an	   equal	   volume	   (~15	   ml)	   of	   Ficoll	   (cat.	   no.	   17-­‐1440-­‐03,	   Ficoll-­‐Paque	   PLUS;	   GE	  
Healthcare,	   Amersham,	   Buckinghamshire,	   UK)	   in	   50	   ml	   centrifugation	   tubes.	   Tubes	   were	   spun	   at	  	  
740	  g	   for	  30	  min	  without	  brake	  at	  room	  temperature,	  and	  the	  separated	  MNC	   layer	  was	  aspirated	  
with	  a	  sterile	  Pasteur	  pipette	  (Fig.	  2.1).	  Blood	  in	  Vacutainer	  CPT	  tubes	  was	  separated	  according	  to	  the	  
manufacturer	  instructions.	  Isolated	  MNCs	  were	  washed	  3	  times	  in	  PBS	  containing	  2%	  FBS	  and	  0.05%	  
EDTA	   (PBS-­‐FBS),	   stained	   with	   Türk's	   solution	   (cat	   no.	   1092770500,	   Merck,	   Nottingham,	   UK)	   and	  
counted	  using	  a	  haemocytometer	  (Bright-­‐line	  Haemocytometer,	  cat	  no.	  #	  Z35,	  962-­‐9,	  Sigma-­‐Aldrich).	  	  
The	   cells	   were	   resuspended	   in	   complete	   endothelial	   growth	   medium-­‐2	   (EGM-­‐2),	   comprising	  
endothelial	   cell	   basal	   medium-­‐2	   (EBM-­‐2;	   cat.	   No.	   CC-­‐3156,	   Lonza	   Biologics,	   Slough,	   UK),	   EGM-­‐2	  
SingleQuot	  supplement	  (cat	  no.	  CC-­‐4176,	  but	  excluding	  the	  supplied	  FBS),	  20%	  HyClone	  FBS	  (cat	  no.	  
SH30070.03E,	   Thermo	   Scientific	   HyClone,	   Fisher	   Scientific	   UK	   Ltd,	   Leicestershire,	   UK)	   and	   1%	  
antibiotic/antimycotic	   solution	   (cat.	   no.	   15240-­‐062,	   Gibco,	   Invitrogen).	   The	   EGM-­‐2	   supplement	  
contains	   hydrocortisone,	   epidermal	   growth	   factor,	   VEGF,	   basic	   FGF,	   insulin-­‐like	   growth	   factor-­‐I,	  
ascorbic	   acid,	   heparin	   and	   gentamicin/amphotericin-­‐B.	   The	   MNCs	   were	   seeded	   (3	   to	   5	   x	   107	  
cells/well	  in	  4	  ml	  of	  medium)	  into	  6-­‐well	  plates	  pre-­‐coated	  with	  50	  µg/ml	  rat-­‐tail	  collagen	  type	  1	  (cat	  
no.	   354236,	   BD	  Biosciences).	   Rat-­‐tail	   collagen	   type	   1	  was	   prepared	  by	   diluting	  with	   sterile	   filtered	  
0.02N	   acetic	   acid.	   The	   cells	   were	   incubated	   in	   5%	   CO2,	   at	   37°C,	   in	   a	   humidified	   incubator.	   The	  
medium	  was	  replaced	  daily	  for	  the	  first	  week,	  by	  gently	  washing	  with	  2ml	  of	  medium	  (removing	  non-­‐
adherent	  cells)	  before	  replacing	  gently	  with	  4	  ml	  of	  fresh	  medium.	  The	  medium	  was	  replaced	  every	  2	  
days	  thereafter.	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The	   number	   of	   colonies	   that	   appeared	   11	   to	   35	   days	   after	   plating	   was	   recorded,	   the	   colonies	  
consisting	   of	   a	   well-­‐circumscribed	   cobblestone	   monolayer	   of	   endothelial	   colony-­‐forming	   cells	   or	  
ECFCs	   (also	  known	  as	   late-­‐outgrowth	  endothelial	  progenitor	  cells	  and	  blood	  outgrowth	  endothelial	  
cells).	  Individual	  colonies	  were	  harvested	  either	  from	  a	  whole	  well	  (when	  colonies	  grew	  really	  quick	  
to	   grow	   beyond	   the	   size	   of	   the	   cloning	   rings)	   or	   using	   a	   cloning	   cylinders	   attached	   with	   vacuum	  
grease	  (8	  mm	  or	  10	  mm	  in	  diameter;	  cat	  no.	  TR-­‐1004	  or	  TR-­‐1005,	  Millipore,	  Watford,	  UK)	  (Javed	  et	  
al.,	   2008;	  Mead	   et	   al.,	   2008).	   Cells	   were	  washed	  with	   Ca2+	   and	  Mg2+	   free	   PBS	   and	   detached	  with	  
warm	   0.05%	   Trypsin-­‐EDTA	   (cat	   no.	   25300-­‐054,	   Invitrogen).	   The	   total	   number	   and	   proportion	   of	  
viable	  cells	  was	  determined	  following	  staining	  with	  0.4%	  Trypan	  Blue	  solution	  (cat	  no.	  T8154,	  Sigma-­‐
Aldrich),	  using	  a	  haemocytometer.	  After	  re-­‐suspension	  in	  fresh	  EGM-­‐2	  medium	  containing	  20%	  FBS,	  
the	  cells	  were	  seeded	  (3000	  to	  5000	  cells/cm2)	  in	  culture	  vessels	  pre-­‐coated	  with	  1%	  gelatin	  (diluted	  
to	  1%	  with	  PBS	  from	  2%	  stock,	  cat	  no.	  G1393,	  Sigma-­‐Aldrich).	  The	  medium	  was	  replaced	  every	  2	  days	  
and	  sub-­‐confluent	  cells	  (i.e.	  ~70-­‐80%	  confluent)	  were	  serially	  propagated	  in	  T25,	  T75	  and	  T175	  flasks.	  
Frozen	  stocks	  of	  cells	  were	  prepared	  during	  early	  passages	  by	  suspending	  them	  (0.5x106	  cells/ml)	  in	  
freezing	  medium	   (95%	   FBS,	   5%	  dimethyl	   sulfoxide	   (DMSO),	   immediately	   transferring	   1	  ml	   aliquots	  
Figure	  2.1.	  Ficoll-­‐Paque	  separation	  of	  human	  peripheral	  blood	  mononuclear	  cells	  (MNCs).	  After	  
gradient	   centrifugation,	   4	   layers	   are	   formed	   according	   to	   their	   relative	   density.	   Heavier	   blood	  
components	  such	  as	  erythrocytes	  migrate	  to	  the	  bottom	  of	  the	  tube,	  while	  MNCs	   form	  a	  dense	  
“buffy”	  layer	  above	  the	  Ficoll-­‐Paque	  media.	  The	  MNC	  layer	  was	  carefully	  aspirated	  and	  washed	  to	  
remove	  contaminating	  Ficoll.	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into	  cryovials	  and	  leaving	  these	  overnight	  at	  -­‐80°C	  in	  a	  freezing	  container	  (cat	  no.	  5100-­‐0001,	  Thermo	  
Scientific	   Nalgene,	   Fisher).	   The	   cryovials	   were	   then	   transferred	   to	   the	   vapour	   phase	   of	   a	   liquid	  
nitrogen	  tank	  for	  longer	  term	  storage.	   
	  
2.4	   Modification	  of	  ECFC	  culture	  protocol	  
While	  establishing	  the	  culture	  protocol	  for	  deriving	  ECFCs	  from	  adult	  peripheral	  blood	  I	  examined	  a	  
number	  of	  steps	   that	  may	   influence	   the	  yield	  and	  growth	  of	   these	  cells	   (summarised	   in	  Table	  2.1).	  	  
(1)	   The	   vacutainer	   CPT	   tubes	   represent	   a	   convenient	   means	   of	   isolating	   MNCs	   but	   provided	  
significantly	   fewer	  MNCs	  than	  the	  Ficoll	  density	  centrifugation	  method	   (see	  Figure	  2.2).	   (2)	   I	   found	  
that	  it	  was	  also	  preferable	  to	  wash	  the	  MNCs	  in	  PBS-­‐FBS	  rather	  than	  EGM-­‐2	  medium,	  as	  this	  reduced	  
the	  incidence	  of	  cell	  clumping.	  (3)	  Previous	  attempts	  to	  derive	  ECFCs	  in	  the	  Department	  used	  serum	  
marketed	  for	  human	  endothelial	  cell	  culture	  and	  were	  unsuccessful.	  	  I	  found	  that	  the	  type/source	  of	  
FBS	  was	   a	   critical	   factor	   in	   ECFC	   isolation	   and	  propagation	  of	   ECFCs	   from	  adult	   human	  blood,	   and	  
have	  used	  defined	  FBS	   (HYC-­‐001-­‐330Y)	  and	   stem	  cell-­‐screened	  FBS	   (HYC-­‐	  001-­‐331G)	   from	  HyClone	  
throughout	   these	   studies.	   Initially	   I	   used	   20%	   FBS,	   as	   this	  was	   described	   in	   the	   original	   patent	   for	  
ECFC	   isolation	   (WO	   2005/078073	   A2),	   and,	   having	   established	   the	   protocol,	   subsequently	   isolated	  
and	   cultured	   all	   ECFC	   populations	   in	   the	   presence	   of	   20%	   FBS.	   This	   concentration	   has	   also	   been	  
adopted	  in	  a	  number	  of	  published	  studies	  (Guven	  et	  al.,	  2006;	  Asosingh	  et	  al.,	  2008;	  Moonen	  et	  al.,	  
2010).	   (4)	   As	   described	   in	   other	   studies	   (Ingram	   et	   al.,	   2004;	   Mead	   et	   al.,	   2008),	   I	   used	   rat	   tail	  
collagen	  Type	   I	   as	   the	   initial	   coating	  of	  plastic	  ware	  when	  plating	  MNCs.	  However,	   1%	  gelatin	  was	  
routinely	   used	   to	   coat	   plastics	   for	   endothelial	   cell	   culture	   and	   once	   the	   ECFC	   colonies	   were	  
established	   I	   found	   that	   they	   could	  be	  propagated	  equally	  well	  with	  1%	  gelatin	  or	   rat	   tail	   collagen	  
coating.	   Recent	   studies	  have	   also	  described	  using	  1%	  gelatin	   coating	   for	   the	  propagation	  of	   ECFCs	  
(Starke	   et	   al.,	   2011).	   (5)	   ECFCs	   were	   successfully	   isolated	   and	   propagated	   after	   passing	   all	   the	  
adherent	  cells	   in	   the	  well,	  not	   just	   those	   in	   the	   initial	  colony.	  Nonetheless,	   I	   routinely	  used	  cloning	  
rings,	   as	   described	   by	  Mead	   and	   colleagues	   (Mead	   et	   al.,	   2008),	   in	   an	   attempt	   to	   isolate	   clonally	  
proliferating	  cell	  populations	  and	  minimize	  contamination	  by	  other	  cell	  types.	  (6)	  During	  propagation	  
of	   ECFCs,	   the	   cells	   were	   routinely	   passaged	   at	   70	   -­‐	   80%	   sub-­‐confluence,	   as	   viability	   tended	   to	   be	  
compromised	  when	   cultured	   to	   a	   higher	   density	   and	  was	   found	   to	   be	   a	   critical	   factor	  when	  using	  
ECFCs	  in	  tube-­‐formation	  assays.	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   Methodology	   Tests	   Results	  
1.	  Vacutainer	  CPT	  tubes	  
as	  an	  alternative	  to	  
Ficoll	  density	  
centrifugation	  of	  MNCs	  
MNC	  yield	  per	  50ml	  of	  blood	   Vacutainer	  CPT	  tubes	  are	  convenient	  	  
but	  provided	  fewer	  MNCs	  (up	  to	  50%	  
less)	  than	  Ficoll	  density	  separation	  of	  
MNCs.	  
2.	  Washing	  MNCs	  
during	  isolation	  
MNC	  clumping	  when	  washed	  
with	  EGM-­‐2	  medium	  	  
Used	  PBS-­‐FBS	  to	  wash	  MNCs,	  thereby	  
avoiding	  problems	  with	  clumping.	  
3.	  Source/type	  of	  serum	   Defined	  FBS	  (HYC-­‐001-­‐330Y)	  
and	  stem	  cell-­‐screened	  FBS	  
(HYC-­‐	  001-­‐331G)	  from	  	  
HyClone,	  compared	  with	  other	  
commercial	  sources	  of	  FBS	  
Colonies	  were	  routinely	  obtained	  using	  
both	  defined	  and	  stem	  cell-­‐screened	  FBS	  
from	  Hyclone,	  but	  not	  with	  FBS	  from	  
other	  sources.	  
4.	  Coating	  of	  culture	  
vessels	  	  
Rat	  tail	  collagen	  type	  I	  versus	  
1%	  gelatin	  coating	  
Rat	  tail	  collagen	  type	  I	  was	  used	  to	  	  
establish	  ECFC	  colonies	  whereas	  1%	  
gelatin	  and	  rat	  tail	  collagen	  type	  I	  
provided	  equally	  effective	  coating	  
solutions	  for	  propagating	  established	  
ECFC	  	  cultures.	  
5.	  Isolating	  ECFC	  
colonies	  
Propagating	  the	  contents	  of	  a	  
whole	  well	  versus	  cells	  inside	  a	  
cloning	  ring	  
Both	  methods	  were	  used	  successfully	  to	  
obtain	  homogeneous	  and	  proliferative	  
ECFC	  cultures,	  but	  cloning	  rings	  routinely	  
used	  as	  they	  may	  help	  select	  clonally	  
proliferating	  cells	  and	  reduce	  
contamination	  by	  other	  cell	  types.	  	  
6.	  Degree	  of	  confluence	  
before	  passing	  cells	  
70-­‐80%	  versus	  90-­‐100%	  
confluence	  
Sub-­‐culturing	  ECFCs	  when	  ~70-­‐80%	  
confluent	  produced	  a	  higher	  yield	  of	  
cells	  and	  prolonged	  their	  growth.	  
Table	   2.1.	   Summary	   of	   modifications	   to	   the	   ECFC	   culture	   protocol.	   ECFC,	   endothelial-­‐colony	  
forming	  cells;	  EGM-­‐2,	  endothelial	  growth	  medium-­‐2;	  FBS,	  foetal	  bovine	  serum;	  PBS-­‐FBS;	  phosphate	  
buffered	  sulphate	  with	  2%	  FBS	  and	  0.05%	  EDTA;	  	  MNC,	  mononuclear	  cells.	  
	  
	  
An	  alternative	  method	  for	  deriving	  ECFCs	  from	  peripheral	  blood	  has	  been	  published	  which	  uses	  10%	  
pooled	   human	   platelet	   lysate	   instead	   of	   FBS	   (Reinisch	   et	   al.,	   2009).	   In	   addition	   to	   using	   culture	  
conditions	  free	  of	  animal	  proteins,	  this	  protocol	  also	  offers	  other	  potential	  advantages	  as	  it	  requires	  
smaller	  volumes	  of	  blood	  and	  does	  not	  require	  MNC	  isolation	  prior	  to	  plating	  of	  blood	  cells.	  I	  sought	  






2.5	   Culture	  of	  other	  cell	  types	  
Human	   umbilical	   vein	   endothelial	   cells	   (cat.	   no.	   CC-­‐2517,	   HUVECs,	   Lonza)	   and	   human	   pulmonary	  
artery	  endothelial	   cells	   (cat.	  no.	  CC-­‐2530,	  HPAECs,	  Lonza)	  were	  used	  as	  control	  mature	  endothelial	  
cells.	   Both	   cell	   types	   were	   cultured	   in	   EBM-­‐2	   medium	   supplemented	   with	   EGM-­‐2	   SingleQuots	  
(including	   the	   2%	   FBS	   provided)	   and	   1%	   antibiotic/antimycotic	   solution.	   Culture	   vessels	  were	   pre-­‐
coated	  with	  1%	  gelatin	  and	  cells	  used	  at	  passages	  3-­‐7.	  Human	  pulmonary	  artery	  smooth	  muscle	  cells	  
(cat	  no.	  CC-­‐2581,	  PASMCs,	  Lonza)	  were	  used	  as	  negative	  controls	  for	  some	  of	  the	  protein	  and	  mRNA	  
probed,	   and	   were	   cultured	   in	   SmBM	   Basal	   Medium	   (cat	   no.	   CC-­‐3181,	   Lonza)	   supplemented	   with	  
SmGM-­‐2	   SingleQuot	   (cat	   no.	   CC-­‐4149,	   Lonza)	   and	   1%	   antibiotic/antimycotic	   solution.	   Human	  
hepatocellular	  carcinoma	  (HepG2)	  cells	  (cat.	  no.	  HB-­‐8065,	  LGC	  Standards,	  Teddington,	  Middlesex	  UK)	  
were	  cultured	   in	  minimum	  essential	  medium	  (MEM,	  cat	  no.	  M4655,	  Sigma-­‐Aldrich)	  containing	  10%	  
FBS	   (cat	   no.	   10437-­‐028,	   Gibco,	   Invitrogen)	   and	   1%	   antibiotic/antiomycotic	   solution.	   All	   cells	   were	  
















Figure	  2.2.	  Number	  of	  mononuclear	  cells	  (MNCs)	  isolated	  using	  vacutainer	  CPT	  tubes	  and	  ficoll	  
separation.	  Graph	  shows	  the	  number	  of	  MNCs	  isolated	  from	  50	  ml	  of	  peripheral	  blood	  obtained	  
from	  four	  age-­‐	  and	  sex-­‐matched	  healthy	  volunteers.	  Total	  number	  of	  MNCs	  isolated	  by	  CPT	  tubes	  
is	  less	  than	  half	  that	  obtained	  by	  the	  ficoll	  separation	  method.	  Data	  presented	  as	  mean±SEM,	  and	  
compared	  using	  T-­‐test.	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2.6	   Population	  doubling	  time	  	  
From	  the	  2nd	  passage	  onwards,	  the	  cells	  were	  counted	  during	  passaging	  to	  calculate	  the	  population	  
doubling	   time	   (PDT).	   The	   number	   of	   population	   doublings	   (PDs)	   occurring	   between	   passages	   was	  
determined	  according	  to	   the	  equation:	  PD	  =	   log2	   (CH/CS),	  where	  CH	   is	   the	  number	  of	  viable	  cells	  at	  
harvest	  and	  CS	   is	  the	  number	  of	  cells	  seeded.	  The	  PDT	  was	  derived	  using	  the	  time	  interval	  between	  
cell	  seeding	  and	  harvest	  divided	  by	  the	  number	  of	  PDs,	  as	  previously	  described	  (Ingram	  et	  al.,	  2004).	  	  	  
	  
2.7	   Phenotyping	  of	  ECFCs	  
2.7.1	   Immunostaining	  and	  lectin	  binding	  
ECFCs	   (5000	   cells/cm2)	  were	   grown	   to	   confluency	  on	   sterile	   glass	   coverslips	   (12	  mm,	   cat.	   no.	   631-­‐
0666,	  VWR	   International,	  Leicestershire,	  UK),	  etched	  with	  hydrochloric	  acid	   (1N	  HCl)	  overnight	  and	  
coated	  with	  1%	  gelatin.	  Prior	   to	   immunostaining,	   the	  cells	  were	   fixed	   in	  4%	  w/v	  paraformaldehyde	  
(PFA)	   in	   PBS	   for	   20	  min	   at	   4°C.	   After	   washing	   twice	   in	   PBS,	   coverslips	   were	   immersed	   in	   3%	  w/v	  
bovine	  serum	  albumin	  (BSA;	  cat	  no.	  A9418,	  Sigma-­‐Aldrich)	  in	  Tris-­‐buffered	  saline	  (TBS;	  cat	  no.	  94158,	  
Sigma-­‐Aldrich)	   for	   30	   min	   at	   room	   temperature.	   Cells	   were	   then	   incubated	   for	   1	   h	   at	   room	  
temperature	  with	   either	  mouse	  monoclonal	   anti-­‐human	  CD31;	   (1:30	  dilution;	   clone	   JC70A,	   cat	   no.	  
M0823,	   Dako,	   Glostrup,	   Denmark),	   mouse	   monoclonal	   anti-­‐human	   CD144	   (VE-­‐Cadherin;	   1:100	  
dilution,	   cat	   no.	   sc-­‐9989,	   Santa	  Cruz,	   Insight	  Biotechnology,	  Middlesex,	  UK),	   rabbit	   polyclonal	   anti-­‐
human	  von	  Willebrand	  Factor	  (vWF;	  1:	  200	  dilution;	  cat	  no.	  A0082,	  Dako),	  or	  CD34	  (cat	  no.	  sc-­‐9095,	  
Santa	  Cruz).	  The	  coverslips	  were	  then	  washed	  again	  in	  TBS	  six	  times,	  and	  incubated	  for	  1	  h	  at	  room	  
temperature	   with	   Alexa-­‐488	   green-­‐conjugated	   goat	   anti-­‐rabbit	   (1:500	   dilution;	   cat	   no.	   A-­‐11034,	  
Invitrogen)	   or	   goat	   anti-­‐mouse	   IgG	   (1:500	   dilution;	   cat	   no.	   A-­‐21121,	   Invitrogen).	   Controls	   included	  
omission	  of	  the	  primary	  antisera.	  	  
Lectin	  binding,	  a	  well-­‐known	  characteristic	  of	  endothelial	  cells	  (Holthofer	  et	  al.,	  1982),	  was	  assessed	  
by	   incubating	   live	   cells	   on	   coverslips	   with	   fluorescein	   isothiocyanate	   (FITC)-­‐conjugated	   EC-­‐specific	  
Ulex	   europaeus	   agglutinin-­‐1	   (UEA-­‐1)	   lectin	   (1:30,	   cat	   no.	   L9006,	   Sigma-­‐Aldrich)	   or	   FITC-­‐conjugated	  
microvascular	   EC-­‐specific	  Griffonia	   Simplicifolia	   Lectin-­‐1	   (cat	   no.	   FL-­‐1201,	   Vector	   Laboratories	   Ltd,	  
Peterborough,	   UK)	   in	   complete	   EGM-­‐2	  medium	   for	   1	   h	   in	   a	   humidified	   incubator	   (5%	   CO2,	   37°C).	  
These	   coverslips	  were	   then	  washed	   in	  TBS,	   and	   fixed	   in	  4%	  w/v	  PFA	   in	  PBS	   for	  20	  min	  at	  4°C.	   	  All	  
coverslips	   were	   washed	   with	   TBS	   6	   times	   before	   being	  mounted	   in	   4',6-­‐diamidino-­‐2-­‐phenylindole	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(DAPI)-­‐containing	  Vectashield	  (cat	  no.	  H-­‐1200,	  Vector	  Laboratories	  Ltd)	  in	  order	  to	  counter-­‐stain	  the	  
nucleus	   and	   reduced	   loss	   of	   fluorescence	   during	   microscopic	   examination.	   Stained	   cells	   were	  
observed	  using	  confocal	  microscopy	  (TCS	  SP5,	  Leica	  Microsystems	  (UK)	  Ltd,	  Bucks,	  UK).	  	  
	  
2.7.2	   Flow	  cytometry	  
More	   than	   106	   ECFCs	   were	   detached	   with	   0.05%	   trypsin-­‐EDTA,	   resuspended	   in	   FACS	   buffer	   (PBS	  
containing	  2%	  FBS)	  and	  divided	  in	  100	  μl	  aliquots,	  containing	  at	  least	  1	  x	  105	  cells	  per	  tube.	  Cells	  were	  
then	  suspended	  in	  Fc	  receptor	  blocker	  (1:50	  dilution;	  cat	  no.	  130-­‐059-­‐901,	  Miltenyl	  Biotec,	  Bergisch	  
Gladbach,	  Germany)	  for	  5	  min	  in	  dark	  at	  room	  temperature,	  before	  being	  resuspended	  for	  30	  min	  at	  
4°C	  in	  the	  dark	  with	  antibodies	  against	  markers	  for	  endothelial	  cells,	  monocytes,	  hematopoetic	  stem	  
cells	   or	   progenitor	   cells	   (see	   Table	   2.2).	   Fluorochrome-­‐matched	   isotype	   controls	   (mouse	   IgG1κ	   –
FITC,-­‐PE	  and	  –APC	   isotypes;	  BD	  Pharmingen)	  were	  used	  at	   the	   same	  dilution	   factor	  as	   the	   staining	  
antibodies,	   as	  per	   the	  manufacturers	   recommendations.	   Cells	  were	   then	  washed	  with	   FACS	  buffer	  
twice	  with	  centrifuging	  at	  1000	  rpm	  for	  5	  min	  each,	  before	  resuspending	  in	  0.5	  ml	  of	  FACS	  buffer.	  All	  
flow	   cytometric	   analysis	   was	   performed	   using	   a	   three	   colour	   FACSCalibur	   flow	   cytometer	   and	  
acquired	   by	   CellQuest	   Pro	   software	   (both	   from	  BD	   Biosciences).	   A	   gate	  was	   set	   to	   acquire	   events	  
within	  the	  ECFC	  population	  on	  a	  forward	  and	  side	  scatter	  graph	  (Figure	  2.3).	  Optimal	  compensation	  
was	   set	   for	   green,	   red	   and	   far-­‐red	   fluorescence	   by	   running	   the	   FITC-­‐,	   PE-­‐	   and	   APC-­‐stained	   ECFCs.	  
Samples	  were	  run	  at	  high	  flow	  rate	  with	  an	  acquisition	  cut-­‐off	  of	  20,000	  to	  30,000	  gated	  events.	  Data	  
were	   analysed	   using	   FCS	   Express	   (De	  Novo	   Software,	   Los	   Angeles,	   CA,	  USA)	   and	   presented	   as	   the	  
number	  of	  antigen	  expressing	  (positive)	  cells,	  normalised	  by	  subtracting	  the	  amount	  of	  stained	  cells	  










Figure	   2.3.	   Gating	   strategy	   for	   flow	   cytometric	   analysis	   of	   ECFCs.	   Images	   on	   the	   left	   display	  a	  
forward/side	  scatter	  density	  plots	  of	  acquired	  events	   from	  a	  ECFCs	   from	  healthy	  control	   (upper	  
panel)	  and	  HUVECs	  (lower	  panel),	  with	  both	  showing	  similar	  pattern.	  The	  gated	  populations	  are	  
then	  displayed	  in	  the	  histograms	  (right	  panel)	  with	  the	  CD31	  staining	  (blue	  line)	  and	  its	  respective	  
isotype	   control	   (black	   line)	   displayed.	   The	   expression	   of	   the	   protein	   is	   calculated	   by	   the	   FCS	  
express	  software	  in	  subtracting	  the	  area	  covered	  by	  the	  isotype	  control	  from	  the	  area	  covered	  by	  



























APC	   Mouse	  mAb	   R&D	  Systems	  
#FAB357A	  
1:6.7	   Endothelial	  
CD14	  (Clone	  
MΦP9)	  
PE	   Mouse	  mAb	   BD	  
Pharmingen	  
#345785	  
1:6.7	   Monocyte	  
CD45	  (Clone	  
TU116)	  
PE	   Mouse	  mAb	   BD	  
Pharmingen	  
#557059	  
1:40	   Pan-­‐leukocyte	  
CD133	  (Clone	  
AC133)	  
PE	   Mouse	  mAb	   Miltenyi	  
#130-­‐080-­‐801	  




FITC	   Mouse	  mAb	   BD	  
Pharmingen	  
#555821	  
1:5	   Progenitor	  
CD117	  (c-­‐kit)	  
(Clone	  YB5.B8)	  







PE	   Rabbit	  pAb	   e-­‐Bioscience	  
#FAB170P	  
1:5	   Chemokine	  
receptor	  
	   	   	   	   	   	  
Table	   2.2.	   Antibodies	   used	   in	   flow	   cytometry	   for	   identification	   of	   ECFCs.	   APC,	   allophycocyanin;	  
CXCR4,	   C-­‐X-­‐C	   chemokine	   receptor	   type	   4;	   FITC,	   fluorescein	   isothiocyanate;	   HPCs,	   hematopoetic	  
progenitor	   cells;	   HSCs,	   hematopoetic	   stem	   cells;	   KDR,	   kinase	   insert	   domain	   receptor;	   PE,	  
phycoerythrin;	  PECAM-­‐1,	  platelet	  endothelial	  cell	  adhesion	  molecule;	  VEGFR2,	  vascular	  endothelial	  
growth	  factor	  receptor	  type	  2.	  
	  
	  
2.8	   Clonal	  growth	  of	  ECFCs	  
A	   key	   characteristic	   of	   progenitor	   cells	   is	   their	   ability	   to	   grow	   under	   limiting	   dilutions	   or	   clonal	  
conditions	  and	  is	  one	  of	  the	  defining	  features	  that	  distinguishes	  ECFCs	  (also	  known	  as	  late	  outgrowth	  
EPCs)	   from	  early	  outgrowth	  EPCs	  or	  haematopoietic	  cells	   (Ingram	  et	  al.,	  2004;	   Ingram	  et	  al.,	  2005).	  	  
Early	   passage	   (passage	   3)	   ECFCs,	   grown	   to	   ~80%	   confluence,	   were	   seeded	   at	   limiting	   dilution	  
(equivalent	  to	  one	  cell	  per	  well	  in	  200	  μl	  of	  ECFC	  culture	  medium)	  in	  96-­‐well	  plates	  pre-­‐coated	  with	  
rat-­‐tail	  collagen	  Type	  1	  (see	  Section	  2.3)	  and	  incubated	  in	  5%	  CO2,	  at	  37°C,	  in	  a	  humidified	  incubator.	  
The	  medium	  was	  replaced	  every	  4	  days.	  After	  14	  days,	  the	  cells	  were	  washed	  twice	  with	  warm	  PBS	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and	   stained	  with	   100	   μl/well	   (1:5000	   in	   serum-­‐free	   EBM-­‐2)	   of	   Calcein-­‐AM	   (cat	   no.	   C1359,	   Sigma-­‐
Aldrich)	  for	  30	  min	  at	  37°C,	  before	  being	  washed	  three	  times	  with	  PBS	  and	  examined	  by	  fluorescence	  
microscopy	  (Olympus	  IX70,	  Olympus,	  Essex,	  UK)	  within	  2	  h.	  Each	  well	  was	  examined	  for	  endothelial	  
colonies,	   the	   colonies	  being	   scored	  as	  having	  high	  proliferative	  potential	   (HPP;	  >2000	  cells/colony)	  
and	  low	  proliferative	  potential	  (LPP;	  50–2000	  cells/colony)	  or	  representing	  endothelial	  clusters	  (<50	  
cells)	  (Coldwell	  et	  al.,	  2011).	  Images	  were	  taken	  of	  colonies	  comprising	  more	  than	  50	  cells	  by	  the	  CCD	  
camera	  (F-­‐view	  II,	  Olympus)	  attached	  to	  the	  microscope	  with	  its	  respective	  image	  software	  (analySIS,	  
Olympus)	  and	  the	  number	  estimated	  using	  ImageJ	  software	  (NIH,	  http://rsbweb.nih.gov/ij/).	  
	  
2.9	   RNA	  extraction	  and	  cDNA	  synthesis	  
RNA	  was	  extracted	  using	  either	  Trizol	   (cat	  no.	  15596-­‐026,	   Invitrogen)	  or	  RNeasy	  kit	   (cat	  no.	  74104,	  
QIAGEN,	   Crawley,	   UK)	   according	   to	   manufacturers’	   instructions.	   To	   remove	   possible	   DNA	  
contamination,	   samples	   were	   treated	   with	   DNase	   I	   (Amplification	   grade;	   cat	   no.	   AMPD1,	   Sigma-­‐
Aldrich)	  and	  the	  amount	  of	  RNA	  was	  quantified	  by	  absorption	  at	  260	  nm	  using	  NanoDrop®	  (ND-­‐1000;	  
NanoDrop	   Technologies,	   Willington,	   DE,	   USA).	   First	   strand	   complementary	   DNA	   (cDNA)	   was	  
synthesised	  by	  reverse	  transcription	  (RT)-­‐	  polymerase	  chain	  reaction	  (PCR).	  2	  μg	  of	  RNA	  in	  up	  to	  10	  μl	  
diethylpyrocarbonate	   (DEPC)-­‐treated	   RNase/DNase-­‐free	   water	   (cat	   no.	   750024,	   Invitrogen)	   were	  
mixed	   with	   4	   µl	   5x	   cDNA	   synthesis	   buffer,	   1	   µl	   0.1M	   DTT,	   1	   µl	   RNaseOUT™,	   1	   µl	   ThermoScript™	  
reverse	   transcriptase	   with	   1	   µl	   of	   50	   ng/µl	   random	   hexamers,	   and	   2	   µl	   10	   mM	   dNTP	   mix	  
(ThermoScript™	  RT-­‐PCR	  System;	  cat.	  no.	  11146-­‐016,	  Invitrogen).	  The	  20	  µl	  mixture	  was	  then	  placed	  
into	   a	   thermal	   cycler	   (Peltier	   Thermal	   Cycler	   PTC-­‐200;	   MJ	   Research,	   Watertown,	   MI,	   USA)	   with	  
profiles	  as	  follows:	  25oC	  for	  10	  min,	  followed	  by	  50	  min	  at	  50oC,	  terminated	  at	  85oC	  for	  5	  min.	  1	  µl	  of	  
RNase-­‐H	  (ThermoScript™	  RT-­‐PCR	  System)	  was	  then	  added	  and	  the	  solutions	  were	   incubated	  for	  20	  
min	   at	   37oC	   to	   digest	   any	   remaining	   RNA.	   The	   samples	   were	   finally	   diluted	   in	   DEPC-­‐treated	  
RNase/DNase-­‐free	  water	  (100	  µl	  final	  volume)	  to	  create	  a	  20	  ng/µl	  cDNA	  solution.	  Controls	  included:	  
(1)	  omission	  of	  the	  RT	  step	  in	  addition	  to	  the	  use	  of	  DNase-­‐treated	  RNA	  and	  (2)	  the	  use	  of	  cDNA	  from	  





2.10	   Semi-­‐quantitative	  and	  quantitative	  RT-­‐PCR	  (qRT-­‐PCR)	  analysis	  
Appropriate	   PCR	   primers	   (Invitrogen)	   were	   designed	   using	   Primer-­‐Blast	  
(http://www.ncbi.nlm.nih.gov/tools/primer-­‐blast)	   unless	   otherwise	   stated,	   with	   the	   primers	  
amplifying	  a	  sequence	  that	  spanned	  two	  exons	  to	  avoid	  amplification	  of	  genomic	  DNA.	  Primers	   for	  
qRT-­‐PCR	  were	  either	  designed	  by	  Primer-­‐Blast	   and	  manufactured	  by	   Invitrogen	  or	  purchased	   from	  
QIAGEN.	  Primer	  sets	  used	  and	  their	  thermal	  profiles	  are	  shown	  in	  Table	  2.3	  for	  semi-­‐quantitative	  RT-­‐
PCR	  and	  in	  Table	  2.4	  for	  qRT-­‐PCR.	  	  
	  
2.10.1	   Semi-­‐quantitative	  RT-­‐PCR	  
Semi-­‐quantitative	   PCR	   was	   performed	   using	   40	   ng	   of	   cDNA	  mixed	   with	   1	   µM	   of	   forward	   (F)	   and	  
reverese	   (R)	   primers	   (Table	   2.3),	   10	   µl	   of	   PCR	  Master	  Mix	   (M750B,	   Promega,	   Southampton,	   UK),	  
together	   with	   RNase/DNase-­‐free	   water	   in	   a	   20	   µl	   reaction.	   The	   PCR	   amplification	   was	   performed	  
with	   the	   following	   thermal	   profile:	   94⁰C	   for	   2	  min	   for	   denaturation,	   then	  94⁰C	   for	   30	   s,	   annealing	  
temperature	   for	   1	   min,	   and	   72⁰C	   for	   1	   min	   (underlined	   repeated	   for	   each	   cycle),	   with	   a	   final	  
extension	  of	  72⁰C	  for	  10	  min.	  5	  µl	  of	  the	  PCR	  product	  was	  mixed	  with	  2	  µl	  of	  6x	  loading	  dye	  (cat	  no.	  
R0611,	  Fermentas,	  York,	  UK)	  and	  separated	  in	  a	  1%	  agarose	  Tris-­‐acetate-­‐EDTA	  (TAE)	  gel	  (both	  from	  
Sigma-­‐Aldrich)	  and	  stained	  with	  GelRedTM	  Nucleic	  Acid	  Gel	  Stain	  (in	  1:20,000	  dilution;	  cat	  no.	  41003,	  
Biotium,	  Hayward,	  CA,	  USA).	  GeneRuler™	  1kb	  Plus	  DNA	  Ladder	  (0.25	  μg;	  cat	  no.	  SM1331,	  Fermentas)	  
was	   run	   alongside	   the	   samples	   in	   TAE	   running	   buffer	   at	   10	   V/cm	   for	   20	   –	   50	  min,	   and	   visualised	  
under	  the	  UV	  light.	  The	  intensity	  of	  each	  band	  was	  quantified	  with	  ImageJ.	  To	  ensure	  PCR	  reactions	  
were	   not	   saturated	   or	   components	   exhausted,	   preliminary	   runs	   were	   conducted	   over	   a	   range	   of	  
different	   cycles,	   showing	   linear	   increases	   in	   reaction	   products,	   and	   the	   optimal	   cycle	   number	  
selected	  that	   lie	  within	  the	   linear	  phase	  (see	  Figure	  2.4A-­‐C	  and	  Table	  2.3).	  Control	  blanks	  were	  run	  
with	  the	  no-­‐RT	  template	  to	  ensure	  genomic	  DNA	  was	  not	  carried	  forward	  and	  being	  replicated	  in	  the	  
cDNA	   solution	   (Figure	   2.4D).	   Gene	   expressions	   were	   expressed	   as	   fold	   change	   relative	   to	   the	  
reference	   gene	   β2-­‐microglobulin.	   β2-­‐microglobulin	   was	   the	   chosen	   reference	   gene	   because	   its	  
expression	   was	   constant	   throughout	   all	   the	   ECFC	   samples	   with	   the	   equal	   initial	   amount	   of	   cDNA	  
(Figure	   2.4D).	   Conversely,	   β-­‐actin	  was	  not	   expressed	   equally	  with	   equal	   starting	   cDNA	  of	   different	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Figure	   2.4.	   	  Optimisation	   of	   the	   PCR	   cycles	   for	   semi-­‐quantitative	   analysis	   of	   gene	   expression.	  
cDNA	   reverse-­‐transcribed	   from	   RNA	  were	   run	   on	   a	   thermal	   cycler	   for	   an	   increasing	   number	   of	  
cycles	  for	  each	  sets	  of	  primers	  and	  the	  end-­‐products	  separated	  by	  1%	  agarose	  gel	  electropheresis.	  
As	  an	  example,	  the	  amplification	  of	  different	  cDNA	  samples	  are	  shown	  with	  primers	  for	   (A)	  ALK3	  
(37	  –	  40	  cycles),	  (B)	  ALK4	  (28	  –	  34	  cycles)	  and	  (C)	  TGF-­‐βRII	  (28	  –	  34	  cycles).	  Bands	  in	  both	  A	  and	  B	  
display	   amplification	   in	   the	   linear	   phase,	  while	   in	  C	   the	  products	  were	  nearly	   saturated	   after	   32	  
cycles.	  (D)	  A	  batch	  of	  different	  cDNA	  samples	  were	  amplified	  for	  26	  cycles	  (the	  optimised	  cycle	  no.)	  
with	   primers	   for	   the	   reference	   gene	   β2-­‐microglobulin	   (β2M)	   on	   the	   left	   image,	   with	   the	   cDNA	  
samples	  without	  the	  RT	  transcriptase	  during	  the	  cDNA	  production	  shown	  on	  the	  right.	  (E)	  A	  batch	  
of	  different	  cDNA	  samples	  were	  amplified	   for	  24	  cycles	  with	  primers	   for	  β-­‐actin.	  H,	  HPAECs;	  HG,	  
HepG2	  cells;	  RT,	  reverse	  transcriptase.	  	  	  	  ,	  number	  of	  base	  pairs	  (bp).	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2.10.2	   qRT-­‐PCR	   	  
qRT-­‐PCR	  was	  prepared	  with	  20	  ng	  of	  cDNA	   in	  a	  10	  µl	   reaction	  volume	  using	  5	  µl	  of	  Platinum	  SYBR	  
Green	  qPCR	  SuperMix-­‐UDG	  with	  0.2	  µl	  ROX	  reference	  dye	  (catalogue	  No.	  11733-­‐046;	  Invitrogen),	  0.5	  
µM	  of	  primers	  (Table	  2.4)	  and	  1.8	  µl	  DEPC	  water.	  qPCR	  was	  performed	  using	  a	  7500	  Fast	  Real-­‐Time	  
PCR	   System	   (catalogue	   No.	   4351106;	   Applied	   Biosystem,	   Paisley,	   UK)	   with	   the	   following	   thermal	  
profile:	  	  95⁰C	  for	  20	  s	  for	  denaturation,	  then	  95⁰C	  for	  3	  s	  and	  56°C	  for	  25	  s	  (underlined	  repeated	  for	  
each	  cycle,	  for	  45	  cycles),	  and	  the	  dissociation	  stage	  95⁰C	  for	  15	  s,	  56⁰C	  for	  1	  min	  and	  95⁰C	  for	  15	  s	  
for	  assessing	  the	  melting	  curves	  to	  check	  for	  possible	  primer-­‐dimer.	  The	  efficiency	  of	  each	  primer	  set	  
was	  confirmed	  to	  be	  above	  90%.	  The	  relative	  expression	  of	  target	  mRNAs	  was	  determined	  using	  the	  
standard	   curve	   method	   and	   was	   normalised	   by	   the	   normalisation	   factors	   calculated	   from	  
peptidylprolyl	   isomerase	   A	   (PPIA)	   and	   α-­‐tublin	   expression	   using	   the	   geNorm	   software	  
(http://medgen.ugent.be/~jvdesomp/genorm/).	   The	   standard	   curve	   method	   is	   depicted	   in	   Figure	  
2.5A.	   Standards	   were	   produced	   from	   serial	   dilutions	   of	   pooled	   samples	   and	   a	   standard	   curve	  
constructed	  from	  the	  cycle	  threshold	  (Ct)	  value	  (Figure	  2.5).	  This	  was	  then	  used	  to	  obtain	  the	  relative	  
quantity	   of	   cDNA	   (i.e.	  mRNA)	   for	   individual	   samples.	   The	   fewer	   the	   cycles	   required	   to	   surpass	   the	  
threshold,	  the	  more	  of	  the	  specific	  mRNA	  is	  present	  in	  the	  sample.	  The	  standard	  curve	  in	  Figure	  2.5	  
indicates	  the	  primer	  sets	  for	  α-­‐tubulin	  (Figure	  2.5A)	  and	  PPIA	  were	  highly	  efficient	  (Figure	  2.5B).	  The	  
close	  position	  of	   the	   amplification	   curves	   for	   each	   sample,	   using	  both	  α-­‐tubulin	   and	  PPIA	  primers,	  
indicates	  similar	  levels	  of	  expression	  (i.e.	  RNA)	  for	  both	  housekeeping	  genes	  in	  each	  of	  the	  samples,	  
making	  them	  both	  effective	  as	  reference	  genes.	  However,	  primers	   for	  Glyceraldehyde	  3-­‐phosphate	  
dehydrogenase	   (GAPDH)	   provided	   a	   poor	   standard	   fit	   in	   the	   same	   set	   of	   samples	   (Figure	   2.5B),	  













Forward	  primer	  sequence	  
(5’	  –	  3’)	  or	  Primer	  Cat.	  no.	  
Reverse	  primer	  sequence	  








205	   Gift	  from	  Dr	  Mahul-­‐
Mellier	  (Impeial	  
College	  London)	  
PPIA	   CTGCACTGCCAAGACTGA	   GCCATTCCTGGACCCAAA	   109	   (Stronach	  et	  al.,	  
2011)	  
α-­‐tubulin	   GCCAAGCGTGCCTTTGTTC	   CACACCAACCTCCTCATAAT
CC	  
114	   (Stronach	  et	  al.,	  
2011)	  





112	   (Upton	  et	  al.,	  2009)	  
ALK1	   QT00050351	   	   	   QuantiTect®	  Primer	  	  
ALK5	   QT00083412	   	   	   QuantiTect®	  Primer	  	  





114	   (Upton	  et	  al.,	  2009)	  
TGF-­‐βRII	   QT00014350	   	   	   QuantiTect®	  Primer	  	  
Endoglin	   QT00013335	   	   	   QuantiTect®	  Primer	  	  
CLIC4	   QT02312569	   	   	   QuantiTect®	  Primer	  	  
THBS1	   QT00028497	   	   	   QuantiTect®	  Primer	  	  
Survivin	   QT00081186	   	   	   QuantiTect®	  Primer	  	  
ARC	   QT00234794	   	   	   QuantiTect®	  
Primer	  	  
	   	   	   	   	  
Table	  2.4.	  Primer	  sequences	  or	  product	  details	  for	  quantitative	  RT-­‐PCR.	  QuantiTect®	  Primer	  are	  pre-­‐









2.11	   Western	  blotting	  
For	  protein	   extraction,	   cells	  were	  washed	   twice	  with	   ice-­‐cold	  PBS	   and	   incubated	   in	   radio-­‐immuno-­‐
precipitation	   assay	   (RIPA)	   buffer	   (180	   µl	   6-­‐cm	   dish;	   350	   µl	   in	   10-­‐cm	   dish;	   cat	   no.	   R0278,	   Sigma-­‐
Aldrich)	  with	  protease	   inhibitor	   (1:100	  with	  RIPA	  buffer;	  cat	  no.	  R8346,	  Sigma-­‐Aldrich)	  on	   ice	   for	  at	  
least	  15	  min,	  before	  being	  harvested	  using	  a	  cell	  scraper.	  Protein	  concentration	  was	  determined	  by	  
Bradford	   assay	   (Bio-­‐Rad,	   Hertfordshire,	   UK)	   according	   to	   manufacturer	   instruction.	   Additional	  
phosphatase	   inhibitors	   (10	  mM	   sodium	   fluoride	   and	   1	  mM	   sodium	  orthovanadate)	   (all	   ingredients	  
from	   Sigma-­‐Aldrich)	   were	   added	   into	   the	   lysis	   buffer	   when	   phosphorylated	   proteins	   were	   being	  
analysed.	  Equal	  amounts	  of	  protein	  were	  denatured	  in	  lithium	  dodecyl	  sulphate	  (LDS)	  loading	  buffer	  
and	  reducing	  agent	   (both	   from	   Invitrogen)	  by	  heating	  at	  70°C	   for	  10	  min	  and	  separated	  by	  sodium	  
dodecyl	   sulphate-­‐polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE;	   10%	   or	   4	   –	   12%	   NuPAGE®	   Novex	  	  
Bis-­‐Tris	  Mini	   Gel	   1.5	  mm;	   Invitrogen)	   at	   120V	   for	   2h.	   A	  mixture	   of	   5	   μl	   Novex®	   Sharp	   Pre-­‐stained	  
Protein	   Standard	   (cat	   no.	   LC5800,	   Invitrogen)	   and	   5	  μl	  MagicMark™	  XP	  Western	   Standard	   (cat	   no.	  
LC5602,	  Invitrogen)	  was	  also	  run	  on	  each	  gel	  to	  show	  migration	  of	  marker	  proteins	  for	  estimation	  of	  
protein	  molecular	  weights.	  Proteins	  were	  electrophonically	  transferred	  to	  nitrocellulose	  membranes	  
(Amersham	   Hybond™	   ECL™,	   0.2	   µm	   pore	   size;	   cat	   no.	   RPN30320,	   GE	   Healthcare)	   using	   the	   wet	  
transfer	   method	   (BioRad).	   Briefly,	   bis-­‐tris	   gel	   and	   nitrocellulose	   membrane	   were	   sandwiched	   in	  
between	  sponges	  and	  filter	  papers	  in	  a	  transfer	  cassette	  soaked	  with	  transfer	  buffer	  (20%	  methanol	  
(Sigma)	   in	   1x	   Tris-­‐glycine-­‐SDS	   (TGS)	   (cat	   no.	   161-­‐0772,	   BioRad)),	   and	  was	   placed	   in	   a	   transfer	   tank	  
(BioRad)	  filled	  with	  transfer	  buffer	  and	  run	  at	  80	  V	  for	  1	  h	  with	  an	  ice	  pack.	  	  
Successful	   protein	   transfer	  was	   confirmed	  with	   protein	   staining	   on	   the	  membrane	  with	   Ponceau	   S	  
(cat	  no.	  P7170,	  Sigma-­‐Aldrich).	  Membrane	  was	  then	  washed	  with	  TBS	  and	  blocked	  in	  TBS-­‐T	  (TBS	  with	  
ç 	  Figure	  2.5.	  qRT-­‐PCR	  analysis	  using	  standard	  curve	  method.	  (A)	  cDNA	  samples	  were	  subjected	  
to	   amplification	   over	   45	   cycles	   with	   SYBR	   green	   qPCR	  mix	   and	   primers	   for	   α-­‐tubulin,	   with	   the	  
fluorescence	   intensity	   captured	   by	   the	   qPCR	   machine	   in	   every	   cycle.	   The	   threshold	   line	   is	   set	  
within	   the	   linear	   kinetic	   phase	   of	   all	   the	   samples,	   with	   the	   cycle	   no.	   of	   each	   samples	   on	   the	  
threshold	  line	  called	  threshold	  cycle	  (Ct)	  deduced.	  (B)	  The	  same	  set	  of	  samples	  was	  amplified	  with	  
primers	  for	  PPIA	  and	  GAPDH.	  Both	  the	  α-­‐tubulin	  (A)	  and	  PPIA	  (B,	  upper	  panel)	  primer	  sets	  amplify	  
with	  high	  efficiency,	  indicated	  by	  the	  good	  fit	  of	  standard	  curve,	  while	  the	  primers	  for	  GAPDH	  do	  
not	  provide	  a	  linear	  relationship	  between	  the	  standards	  and	  the	  Ct	  values	  (B,	  lower	  panel).	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0.1%	  Tween-­‐20	  (cat	  no.	  94158,	  Sigma-­‐Aldrich)	  with	  5%	  w/v	  BSA	  and	  5%	  w/v	  non-­‐fat	  dry	  milk	  for	  1h	  
(all	   from	   Sigma-­‐Aldrich).	  Membranes	   were	   then	   either	   incubated	   for	   1	   h	   at	   room	   temperature	   or	  
overnight	   at	   4°C	  with	   primary	   antibodies	   in	   TBS-­‐T	   containing	   5%	  w/v	   BSA	   or	   5%	  w/v	   non-­‐fat	  milk.	  
After	  washing	   five	   times	  with	   TBS-­‐T,	   5	  min	   each,	  membranes	  were	   incubated	   for	   1	   -­‐	   2	   h	   at	   room	  
temperature	   with	   respective,	   species-­‐specific	   horseradish	   peroxidised	   (HRP)-­‐conjugated	   secondary	  
antibodies	   (HRP-­‐conjugated	  sheep	  anti-­‐mouse	   IgG,	  cat	  no.	  NA9310,	  GE	  Healthcare;	  HRP-­‐conjugated	  
goat	   anti-­‐rabbit	   IgG,	   cat	   no	  A0545,	   Sigma-­‐Aldrich),	  washed	   five	   times	  with	   TBS-­‐T	   and	   visualised	  by	  
chemiluminescence,	  using	  Novex®	  ECL	  chemiluminescent	  substract	  kit	  (cat	  no.	  WP20005,	  Invitrogen)	  
for	   strongly-­‐expressed	   protein	   bands	   or	   Luminata™	   Forte	   Western	   HRP	   substrate	   (cat	   no.	  
WBLUF0500,	  Millipore)	  for	  weakly-­‐expressed	  bands.	  Following	  exposure	  to	  radiography	  film	  (FujiFilm	  
X-­‐ray	   film;	   cat	   no.	   AUT-­‐300-­‐040D,	   Fisher),	   the	   membrane	   was	   reprobed	   for	   β-­‐actin	   expression	   to	  
confirm	  equal	  protein	  loadings	  without	  stripping	  (as	  the	  molecular	  weight	  of	  all	  the	  proteins	  probed	  
did	  not	  overlap	  with	  β-­‐actin).	  Semi-­‐quantitative	  analysis	  of	  protein	  expression	  was	  performed	  using	  
densitometric	   measurement	   by	   Quantity	   One	   software	   (BioRad)	   and	   proteins	   of	   interest	   were	  
normalised	  to	  the	  loading	  control	  protein	  β-­‐actin.	  The	  antibodies	  used	  for	  Western	  blotting	  and	  the	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  blot	  as	  
loading	  
control)	  
	   	   	   	   	   	  
Table	  2.5.	  Primary	  and	  secondary	  antibodies	  used	   in	  Western	  blotting.	  Secondary	  antibodies	  were	  
used	   for	   respective,	   species	   specific	   primary	   antibodies,	   and	   they	   included	   horseradish	   peroxidase	  
(HRP)-­‐conjugated	   goat	   anti-­‐rabbit	   IgG	   (Sigma-­‐Aldrich,	   Cat	   no.	   A0545),	   HRP-­‐conjugated	   sheep	   anti-­‐
mouse	  IgG	  (GE	  Healthcare,	  Cat	  no.	  NA9310)	  and	  HRP-­‐conjugated	  rabbit	  anti-­‐goat	  IgG	  (Sigma-­‐Aldrich,	  
Cat	  no.	  A5420).	  DDAH-­‐1,	  dimethylarginine	  dimethylaminohydrolase;	  HIF-­‐1α,	  hypoxia-­‐inducible	  factor	  
1-­‐α;	  mAb,	  monoclonal	  antibody;	  pAb,	  polyclonal	  antibody;	  PARP,	  polyadenosine	  diphosphate-­‐ribose	  
polymerase;	  pSmad1/5/8,	  phospho-­‐Smad1/5/8;	  pSmad2,	  phospho-­‐Smad2;	  RT,	  room	  temperature.	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2.12	   Endothelial	  functional	  assays	  
2.12.1	   Proliferation	  assays	  
In	  addition	  to	  determining	  the	  PDT	  from	  each	  ECFC	  line,	  cell	  proliferation	  was	  examined	  by	  counting	  
cells	   (as	   described	   above)	   and	   using	   a	   chemiluminecent	   5-­‐bromo-­‐2’-­‐deoxyuridine	   (BrdU)	  
incorporation	  assay	  to	  assess	  DNA	  synthesis.	  	  BrdU	  is	  a	  thymidine	  analogue	  that	  is	  incorporated	  into	  
newly	  synthesised	  DNA	  during	  the	  S	  phase	  of	   the	  cell	  cycle	  and	  correlates	  well	  with	  the	  traditional	  
[3H]-­‐thymidine	  incorporation	  assay	  (Waldman	  et	  al.,	  1991).	  
The	  BrdU	  assay	   (cat	  no.	  11669915001;	  Roche,	  West	  Sussex,	  UK)	  was	  optimised	  by	  comparing	  BrdU	  
incorporation	  in	  ECFCs	  plated	  at	  two	  different	  seeding	  densities	  (1500	  and	  3000	  cells	  per	  well	  in	  a	  flat	  
black-­‐walled	  96-­‐wells	  optical	  bottom	  plates	  (Fisher))	  at	  a	  final	  volume	  of	  100	  μl/well	  of	  EBM-­‐2	  (100	  
μl/well)	   containing	   5%	   FBS.	   After	   overnight	   incubation,	   the	   cells	   were	   washed	   twice	   with	   warm	  
sterile	  PBS	  and	  cultured	  in	  serum-­‐deprived	  EBM-­‐2	  medium	  for	  6	  h.	  The	  medium	  was	  then	  replaced	  
with	  EBM-­‐2	  containing	  either	  5%	  or	  10%	  FBS	  or	  EGM-­‐2	  containing	  20%	  FBS.	  After	  24	  h,	  10	  μl	  of	  BrdU	  
(according	  to	  manufacturers	  recommendation)	  was	  added	  to	  each	  well	  and	  the	  cells	  incubated	  for	  a	  
further	   24	   h.	   The	  medium	  was	   then	   removed	   and	   the	   cells	   immersed	   in	   fixation	   solution	   at	   room	  
temperature.	  Cells	  were	  incubated	  in	  secondary	  antibody	  (anti-­‐BrdU	  conjugated	  with	  peroxidise,	  100	  
μl/well)	   for	   90	  min	   at	   room	   temperature,	   before	  being	  washed	  3x	   (5	  min	  each)	  with	  PBS.	  A	  blank	  
control	   (no	   cells)	   and	  background	   control	   (BrdU	   staining	  omitted)	  was	   included	   in	   all	   experiments.	  	  
The	   optical	   bottom	   of	   the	   plate	   was	   then	   covered	   with	   a	   black	   adhesive	   foil	   (PerkinElmer,	  
Beaconsfield,	  Bucks,	  UK)	  and	  luminescent	  substrate	  solution	  added	  (100	  μl/well),	  incubated	  for	  3	  min	  
on	   a	   shaker	   at	   room	   temperature	   and	   luminescence	   measured	   using	   a	   GloMax	   microplate	  
luminometer	   (GloMax®-­‐Multi	   Microplate	   Multimode	   Reader,	   Promega).	   BrdU	   incorporation	   was	  
presented	  as	  raw	  light	  units/s	  (rlu/s)	  following	  subtraction	  of	  blank	  values.	  The	  values	  obtained	  in	  the	  
background	  control	  did	  not	  exceed	  2%	  of	  the	  respective	  value	  in	  the	  presence	  of	  BrdU.	  
The	   incorporation	  of	  BrdU	  was	  more	   than	  doubled	  when	  ECFCs	  were	   seeded	  at	   3000	   versus	  1500	  
cells/well	   and	   cultured	   in	   EBM-­‐2	   containing	   5%	   FBS	   (Figure	   2.6).	   The	  presence	  of	   10%	   FBS	   further	  
increased	   BrdU	   incorporation.	  Maximum	   stimulation	  was	   observed	   in	   the	   presence	   of	   EGM-­‐2	   and	  
20%	  FBS,	  but	  exhibited	  a	  ceiling	  effect	  as	  cultures	  seeded	  at	  3000	  cells/well	  were	  confluent	  after	  3	  
days	  (Figure	  2.6).	  A	  seeding	  density	  of	  1500	  cells/well	  and	  cultures	  in	  EBM-­‐2	  (5%	  FBS)	  or	  EGM-­‐2	  (20%	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Figure	   2.6.	   Optimisation	   of	   BrdU	   assay.	   Sub-­‐confluent	   ECFCs,	   derived	   from	   healthy	   volunteers	  
(n=2),	  were	  seeded	   in	  triplicate	  at	  1500	  or	  3000	  cells	  per	  well	   in	  96-­‐wells	  plates	  and	  cultured	   in	  
EBM-­‐2	  containing	  5%	  or	  10%	  FBS,	  or	  EGM-­‐2	  containing	  20%	  FBS	  for	  48h.	  Statistics	  shown	  are	  from	  
two-­‐way	   ANOVA	   with	   Bonferroni	   post-­‐hoc	   analysis,	   with	   data	   presented	   as	   mean±SEM	   of	  
triplicate	  measurements.	   *,	  P	   <	  0.05,	  compared	  with	  cells	   cultured	   in	   EBM-­‐2	   and	  5%	  FBS.	   #,	  P	   <	  
0.05,	   compared	  with	  cells	   cultured	   in	  EBM-­‐2	  and	  10%	  FBS.	  λ,	  P	  <	  0.05,	  λλ,	  P	  <	  0.01,	   comparison	  
between	  indicated	  groups.	  	  
	  
	  96	  
2.12.2	   Apoptosis	  assay	   	  
A	  well-­‐established	  model	   of	   serum	  deprivation-­‐induced	   endothelial	   apoptosis	   (Karsan	   et	   al.,	   1997;	  
Gerber	  et	  al.,	  1998)	  was	  used	   to	  examine	   the	  sensitivity	  of	   cells	   to	  apoptosis.	   Sub-­‐confluent	  ECFCs	  
and	  HPAECs	  (passage	  4	  to	  7)	  were	  seeded	  (7000	  cells/well)	  in	  their	  respective	  complete	  medium	  (100	  
μl/well),	   in	   1%	   gelatin-­‐coated,	   white/clear	   bottom	   96-­‐well	   plates	   (cat	   no.	   PMX-­‐096-­‐125S,	   Thermo	  
Scientific	   Nunc,	   Fisher).	   After	   24h,	   the	   cells	   were	   washed	   twice	   with	   warm	   PBS,	   before	   being	  
incubated	  in	  control	  medium	  (EGM-­‐2	  with	  2%	  FBS)	  or	  serum-­‐deprived	  EBM-­‐2	  for	  a	  further	  24	  –	  48	  h.	  
Staurosporine	   (cat	   no.	   S4400,	   Sigma-­‐Aldrich),	   a	   potent	   apoptotic	   inducer,	   was	   used	   as	   a	   positive	  
control.	   Apoptosis	   was	   assessed	   in	   duplicate	   using	   a	   Caspase-­‐Glo®-­‐3/7	   assay	   (cat	   no.	   G8091,	  
Promega),	   with	   minor	   modification	   from	   the	   manufacturer’s	   protocol.	   Two	   dilutions	   of	   the	  
luminogenic	  substrate	  were	  tested,	  corresponding	  to	  a	  1:1	   (100	  μl,	   the	  suggested	  dilution)	  and	  1:2	  
(50	  μl)	  mixture	  with	  the	  medium,	  10	  min	  after	  the	  cell	  had	  acclimatised	  to	  room	  temperature.	  The	  
plates	  were	  gently	  agitated	  on	  a	  plate	  shaker	  (300	  –	  500	  rpm	  for	  30	  s)	  and	  luminescence	  measured	  at	  
15	  min	  intervals	  for	  2	  h,	  at	  constant	  room	  temperature,	  using	  a	  microplate	  luminometer	  (GloMax®-­‐
Multi	  Microplate	  Multimode	  Reader,	  Promega).	  The	  blank	  value	  was	  subtracted	  from	  the	  measured	  
rlu/s	  for	  each	  sample	  and	  the	  optimal	  incubation	  period	  (highest	  normalised	  values;	  typically	  45	  min	  
to	   60	  min,	   see	   Figure	   2.7A)	   determined.	   Substrate:medium	   ratios	   of	   1:2	   and	   1:1	   provided	   similar	  
proportional	   difference	   in	   rlu/s	   in	   the	   positive	   controls	   compared	   to	   the	   negative	   controls	   (Figure	  












































































































Figure	  2.7.	  Modification	  and	  validation	  of	  Caspase-­‐Glo	  3/7	  assay	  protocol.	   (A)	  Caspase-­‐Glo	  3/7	  
assay	  substrate	  was	  added	  in	  a	  ratio	  of	  1:2	  to	  ECFCs	  from	  a	  healthy	  volunteer	  up	  to	  180	  min.	   (B)	  
Measurements	   taken	   after	   60	   min	   to	   compare	   the	   sensitivity	   of	   the	   assay	   with	   using	  
substrate:medium	  ratios	  of	  1:1	  and	  1:2.	  (C)	  Values	  normalised	  against	  control	  conditions,	  showing	  
that	   the	   effects	   of	   staurosporine	   (10	   nM)	   and	   serum	   deprivation	   are	   equally	   well	   detected	   by	  
substrate:medium	  ratios	  of	  1:2	  and	  1:1.	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2.12.3	   Matrigel	  tube	  formation	  assay	  
The	   ability	   of	   ECFCs	   to	   form	   capillary-­‐like	   tubes,	   both	   in	   vitro	   and	   in	   vivo,	   is	   another	   critical	  
characteristic	   that	   distinguishes	   ECFCs	   from	   early	   (haematopoietic)	   progenitor	   cells	   (Ingram	   et	   al.,	  
2004;	  Timmermans	  et	  al.,	  2007;	  Sieveking	  et	  al.,	  2008).	  The	  angiogenic	  capacity	  of	  cultured	  cells	  was	  
studied	   using	   the	   Matrigel	   tube	   formation	   assay.	   Matrigel	   is	   a	   solubilised	   basement	   membrane	  
preparation	  that	   is	   rich	   in	  extracellular	  matrix	  proteins	  extracted	  from	  the	  Engelbreth-­‐Holm-­‐Swarm	  
mouse	   sarcoma	   cells	   and	   is	   commonly	   used	   in	   assessing	   the	   in	   vitro	   angiogenic	   capacity	   of	  
endothelial	   cells	   (Arnaoutova	   and	   Kleinman,	   2010).	   Endothelial	   cell	   tube	   formation	   on	   Matrigel	  
involves	  attachment,	  differentiation,	  migration	  and	  alignment	  of	  cells,	  but	  not	  proliferation	  (Kubota	  
et	  al.,	  1988;	  Grove	  et	  al.,	  2002).	  	  
ECFCs	   were	   maintained	   either	   in	   complete	   EGM-­‐2	   medium	   or	   subjected	   to	   serum-­‐free	   EBM-­‐2	  
medium	   for	   24	   h	   before	   use.	   Growth	   factor	   reduced	   (GFR)	   Matrigel	   (BD	   Matrigel	   Basement	  
Membrane	   Matrix	   Growth	   Factor	   Reduced,	   Cat	   no.	   354230,	   BD	   Biosciecnes)	   was	   thawed	   on	   ice	  
overnight,	  and	  30	  μl/well	  was	  added	  into	  cooled	  sterile	  transparent	  96-­‐well	  plate	  on	  ice	  with	  cooled	  
sterile	  tip	  and	  incubated	  at	  37°C	  for	  30	  min	  to	  solidify.	  Cells,	  at	  less	  than	  70	  -­‐	  80%	  confluence	  were	  
detached	   with	   0.05%	   Trypsin-­‐EDTA,	   resuspended	   in	   EBM-­‐2	   (serum-­‐deprived)	   and	   seeded	   at	   7000	  
cells/well	  in	  triplicate	  onto	  Matrigel.	  Plates	  were	  then	  incubated	  in	  the	  humidified	  incubator	  (5%	  CO2	  
at	   37°C)	   for	   16	   h,	   prior	   to	   fixation	   in	   4%	   formaldehyde	   (Sigma-­‐Aldrich)	   in	   PBS	   and	   microscopic	  
examination.	  In	  each	  well,	  two	  phase-­‐contrast	  images,	  one	  from	  each	  side	  of	  the	  well,	  were	  captured.	  
Total	  tube	  length	  in	  each	  image	  was	  determined	  using	  ImageJ	  software.	  Matrigel	  enriched	  with	  high	  
protein	   concentration	   and	   standard	   growth	   factor	   (HC-­‐Matrigel,	   BD	   Matrigel	   Matrix	   High	  
Concentration,	   cat	   no.	   354248,	   BD	   Bioscience)	   was	   also	   used	   with	   cells	   incubating	   with	   EBM-­‐2	  
containing	  1%	  FBS	   in	  order	   to	   test	   the	  consistency	  of	   the	  angiogenic	  capacity	  of	  ECFCs	   in	  different	  
conditions.	   It	   is	   important	   to	   use	   sub-­‐confluent	   ECFCs	   for	   seeding	   on	  Matrigel,	   as	   confluent	   cells	  





2.12.4	   Wound	  healing	  assay	  
A	  so-­‐called	  wound	  healing	  assay	  was	  used	  to	  assess	  the	  migratory	  properties	  of	  cultured	  endothelial	  
cells	   (Liang	  et	  al.,	  2007).	  Sub-­‐confluent	  ECFCs	  or	  HPAECs	  were	  seeded	  on	   to	  1%	  gelatin-­‐coated	  24-­‐
wells	  plate	  at	  a	  density	  of	  54,000/well	  (equivalent	  to	  30,000/cm2)	  in	  triplicate,	  and	  allowed	  to	  form	  a	  
confluent	  monolayer,	  which	  typically	  took	  2	  days.	  A	  horizontal	   line	  was	  drawn	  across	  the	  centre	  on	  
the	  bottom	  of	  each	  well	  as	  a	  marker,	  and	  a	  single	  vertical	  scratch	  was	  applied	  to	  each	  well	  using	  a	  
sterile	  200	  μl	  pipette	  tip.	  Cells	  were	  then	  washed	  twice	  with	  warm	  sterile	  PBS	  and	  rocked	  gently	  to	  
smoothen	   the	   edges	   of	   the	   wound,	   and	   500	   μl	   of	   EBM-­‐2	   containing	   1%	   or	   5%	   FBS,	   or	   EGM-­‐2	  
containing	  20%	  FBS,	  was	  added	  in	  each	  well.	  Images	  were	  captured	  at	  baseline	  (0	  h)	  and	  at	  6	  h,	  18	  h	  
and	  24	  h	  intervals	  thereafter	  at	  the	  same	  position	  just	  above	  or	  below	  the	  marked	  line.	  The	  area	  of	  
the	  wound	  was	  measured	  using	   ImageJ	  software,	  and	  data	  presented	  as	  percentage	  of	   the	  area	  of	  
the	  wound	  recovery	  from	  0	  h.	  	  
Figure	   2.8.	   Effect	   of	   ECFC	   confluency	   on	   Matrigel	   tube	   formation.	   Examples	   of	   ECFCs	   from	   a	  
healthy	   control	   and	   an	   IPAH	  patient	   that	  were	   cultured	   until	   ~70%	   or	   ~100%	   confluent	   before	  
seeding	  on	  Matrigel	  for	  16	  h.	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The	  wound	  healing	  assay	   represents	   restitution	  or	   chemokinesis	   (as	  occurs	  during	   the	  closure	  of	  a	  
cell	  monolayer)	  and	   is	  distinct	   from	  chemotaxis	   (movement	  of	  cells	  along	  a	  chemical	  gradient),	   the	  
other	  form	  of	  migration	  that	  is	  commonly	  measured	  in	  Boyden	  chamber	  experiments.	  The	  two	  forms	  
of	  migration	  may	   also	   require	   different	   signalling	   pathways	   (Yamaoka	   et	   al.,	   2011;	   Costello	   et	   al.,	  
2012).	   The	   advantage	   of	   the	  wound	   healing	   assay	   is	   that	   it	   is	   simple	   and	   economical	   to	   perform,	  
although	  the	  scratches	  can	  be	  difficult	  to	  standardise	  and	  may	  damage	  the	  underlying	  extracellular	  
matrix	   as	   well	   as	   cells	   at	   the	   edge	   of	   the	   scratch,	   possibly	   releasing	   unidentified	   factors	   into	   the	  
media.	  	  
	  
2.12.5	   Measurement	  of	  intercellular	  gap	  junctional	  communication	  
The	  cells	  were	   labelled	  with	  acetomethoxy	  derivate	  of	  calcein	  green	  (calcein	  AM;	  Molecular	  Probe)	  
and	   the	   dynamics	   of	   cell-­‐to-­‐cell	   communication	   was	   assessed	   by	   Fluorescence	   Recovery	   After	  
Photobleaching	   (FRAP)	   (modified	   from	   (Nickel	  et	  al.,	   2006)).	  Confluent	   cells	   grown	  on	  black-­‐walled	  
96-­‐well	  optical	  bottom	  plates	  were	  incubated	  with	  calcein	  AM	  (0.5	  µM,	  30	  min)	  and	  washed	  3	  times	  
in	  sterile	  PBS.	  After	  the	  last	  wash,	  PBS	  was	  replaced	  by	  fresh	  culture	  medium	  and	  plates	  were	  placed	  
on	   a	   heated	   stage	   of	   a	   confocal	   laser	   scanning	   microscope	   (Leica	   TCS	   SP5)	   in	   an	   atmosphere	  
containing	  5%	  CO2.	  	  A	  small	  area	  of	  about	  200	  µm2	  of	  calcein-­‐labelled	  cell	  monolayer	  was	  bleached	  at	  
maximum	  laser	  power	  for	  60	  s.	  Recovery	  of	  fluorescence	  in	  the	  bleached	  area	  was	  monitored	  for	  4	  
minutes	  at	  intervals	  of	  10	  s.	  An	  area	  of	  388	  µm2	  was	  recorded	  for	  pre-­‐bleach	  and	  post-­‐bleach	  scans	  
at	   low	   laser	  power.	  Analysis	  was	  carried	  out	  using	  the	  Leica	  LAS-­‐AF	  Lite	  2.0	  software.	  Fluorescence	  
intensity	  in	  three	  selected	  regions	  of	  interest	  (ROIs)	  was	  expressed	  as	  a	  function	  of	  time.	  ROIs	  in	  the	  
unbleached	   region	   served	   as	   control	   for	   an	   overall	   decrease	   in	   fluorescence	   attributable	   to	  
successive	  scanning.	  The	  relative	  fluorescence	  recovery	  at	  time	  t	  was	  displayed	  as	  the	  percentage	  of	  
pre-­‐bleach	  levels	  (PR(t)):	  	  
PR(t)	  =	  ([(It	  –	  Io)	  +	  (Ipre	  –	  Icontrol)]	  /	  Ipre)	  *	  100	  	  
Where	  Ipre,	  Io,	  and	  It	  were	  the	  measured	  fluorescence	  intensities	  of	  the	  ROI	  before	  (pre-­‐bleach),	  at	  the	  
first	   post-­‐bleach	   scan,	   and	   at	   the	   time	   t	   after	   the	   first	   scan,	   respectively.	   Icontrol	   was	   measured	   in	  
unbleached	  cells	  and	  the	  fluorescence	  recovery	  was	  corrected	  for	  the	  overall	  bleaching	  (Ipre	  –	  Icontrol)	  
attributable	  to	  successive	  scanning.	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2.12.6	   In	  vitro	  assessment	  of	  endothelial	  cell	  permeability	  
Cells	   were	   plated	   in	   Transwell-­‐Clear	   chambers	   (1-­‐µm	   pore	   size,	   12-­‐mm	   diameter;	   Costar	   Corning,	  
Costar,	   High	   Wycombe,	   United	   Kingdom)	   at	   cell	   density	   of	   1	   x	   104	   cells/well,	   and	   grown	   till	  
confluence.	  FITC-­‐dextran	  (MW	  42,000,	  1	  g/L,	  Sigma)	  was	  added	  to	  the	  upper	  chamber	  of	  Transwell	  
dishes,	   and	   samples	   were	   taken	   from	   the	   lower	   compartment	   after	   1	   h	   incubation,	   as	   previously	  
described	  (Wojciak-­‐Stothard	  et	  al.,	  2001;	  Wojciak-­‐Stothard	  et	  al.,	  2005).	  The	  amount	  of	  FITC-­‐dextran	  
was	  determined	  with	  the	  GloMax	  Multi+	  plate	  reader	  (Promega),	  using	  an	  excitation	  wavelength	  of	  
490	  nm	  and	  emission	  at	  510	  –	  570	  nm.	  	  
 
2.13	   Manipulation	  of	  gene	  expression	  and	  activity	  in	  cultured	  cells	  
2.13.1	   Small	  interference	  RNA	  (siRNA)	  transfection	  
siRNA	  transfection	   in	  HPAECs	  and	  ECFCs	  was	  performed	  according	  to	  the	  manufacturers	  guidelines	  
for	  transfecting	  HUVECs.	  Cells	  were	  seeded	  in	  6-­‐well	  plates	  (200,000	  cells	  per	  well)	  in	  2	  ml	  of	  growth	  
medium	  without	   antibiotics	   per	  well,	   so	   cells	   should	   be	   about	   85	   –	   95%	   confluent	   at	   the	   time	   of	  
transfection.	  The	  following	  day,	  375	  pmol	  of	  siRNA	  duplexes	  (20	  µM)	  (i.e.	  18.75	  µl)	  were	  diluted	  and	  
mixed	  gently	  with	  181.25	  µl	  Opti-­‐MEM	  reduced	  serum	  medium	  (cat	  no.	  31985-­‐062,	   Invitrogen)	  per	  
transfection	  sample.	  siRNA	  specific	   for	  target	  genes	  or	  a	  scrambled	  sequence	  of	  similar	  GC	  content	  
(catalogue	   No.	   12935-­‐200;	   Invitrogen)	   were	   used.	   In	   a	   separate	   RNase-­‐free	   tube,	   10	   µl	   of	  
Oligofectamine	   (cat	   no.	   12252-­‐011,	   Invitrogen)	  was	  mixed	   gently	   with	   40	   µl	   OptiMEM.	   To	   reduce	  
well-­‐to-­‐well	   variability	   when	   transfecting	   multiple	   wells,	   all	   reagent	   volumes	   were	   proportionally	  
scaled	   up	   in	   a	   RNase-­‐free	   tube	   as	  mastermix.	   Both	  mixtures	   were	   incubated	   for	   15	  min	   at	   room	  
temperature,	   and	  were	   then	  mixed	   together	   gently	   and	   incubated	   for	   a	   further	   15	  min	   period	   at	  
room	   temperature	   to	   allow	   siRNA-­‐Oligofectamine	   complexes	   to	   form.	   While	   complexes	   were	  
forming,	  growth	  medium	  from	  the	  cultured	  cells	  were	  removed	  and	  washed	  once	  with	  2	  ml	  per	  well	  
of	  pre-­‐warmed	  Opti-­‐MEM,	  and	  added	  1	  ml	  of	  Opti-­‐MEM	  to	  each	  well.	  After	  the	  15	  min	  incubation,	  
mixed	   the	  complexes	  gently	  and	  added	  250	  µl	  of	   the	  complexes	  dropwise	   to	   the	  cells	   in	  each	  well	  
(total	  volume	  per	  well	  =	  1.25	  ml)	  and	  incubated	  in	  a	  37°C	  in	  a	  humidified	  CO2	  incubator	  for	  5	  h.	  625	  
µl	  of	  EGM-­‐2	   (without	   the	  antibiotic/antimycotic)	   containing	  3X	   the	  normal	   concentration	  of	   serum	  
were	  added	  to	  each	  well	  without	  removing	  the	  transfection	  mixture.	  The	  cells	  were	  then	  incubated	  
in	  the	   incubator	  for	  24	  h	  before	  changing	  for	  fresh	  complete	  culture	  medium.	  The	  efficiency	  of	  the	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knockdown	  was	  determined	  2	  and	  3	  days	  after	  transfection	  by	  measuring	  protein	  and	  mRNA	  levels	  in	  
cell	  extracts,	  using	  Western	  blotting	  and	  RT-­‐PCR	  respectively.	  
	  
2.13.2	   Adenoviral	  transfection	  
The	  recombinant	  adenoviruses	  were	  constructed	  using	  the	  Ad-­‐Easy-­‐1	  system,	  where	  the	  adenoviral	  
construct	   is	   generated	   in	   bacteria	   BJ-­‐5183	   cells.	   These	   recombinant	   adenoviral	   vectors	   were	  
linearized	  with	  PacI	  and	  used	  to	  infect	  911	  cells.	  All	  adenoviruses	  were	  amplified	  in	  HEK293	  cells	  and	  
subsequently	   purified	   on	   2	   sequential	   cesium	   chloride	   gradients	   and	   then	   passed	   through	   PD10	  
column	   (GE	   Healthcare)	   to	   reduce	   the	   salt	   concentration.	   To	   establish	   numbers	   of	   active	   viral	  
particles,	  adenoviral	  titre	  was	  measured	  in	  plaque	  assay.	  	  
For	  manipulation	  of	  gene	  expression,	  cells	  were	  plated	  overnight	  and	  were	  washed	  twice	  with	   low	  
serum	  (0.5%)	  EGM-­‐2	  before	  adding	  adenovirus	  with	  the	  recombinant	  constructs.	  After	  incubation	  for	  
4	  h,	  cells	  were	  washed	  twice	  with	  culture	  medium	  and	  maintained	  in	  humidified	  incubator	  for	  48	  h	  
before	   assays.	   The	   efficiency	   of	   the	   overexpression	   or	   knockdown	   was	   determined	   by	   measuring	  
protein	  in	  cell	  extracts	  using	  Western	  blotting.	  
	  
2.14	   Additional	  reagents	  	  
Recombinant	  human	  BMP4	  carrier	  free	  (cat	  no.	  310-­‐BP-­‐010/CF;	  R	  &	  D	  Systems,	  Abingdon,	  Oxford,	  UK)	  
reconstituted	   in	   sterile	   PBS;	   recombinant	   human	   BMP9	   CF	   (cat	   no.	   3209-­‐BP/CF,	   R	   &	   D	   Systems)	  
reconstituted	   in	  sterile	  PBS;	   recombinant	  human	  TGF-­‐β1	  CF	   (cat	  no.	  240-­‐B-­‐002/CF,	  R	  &	  D	  Systems)	  
reconstituted	  in	  filtered	  sterile	  4	  mM	  HCl	  containing	  0.1%	  BSA;	  recombinant	  human	  ALK1-­‐Fc	  chimera	  
(cat	   no.	   370-­‐AL,	   R	   &	   D	   Systems)	   reconstituted	   in	   sterile	   PBS;	   SB	   431542	   hydrate	   (cat.	   no.	   S4317,	  
Sigma-­‐Aldrich),	   a	   selective	   ALK5	   inhibitor,	   reconstituted	   in	   sterile	   DMSO;	   SD208	   (cat.	   no.	   S7071,	  
Sigma-­‐Aldrich),	   a	   selective	   ALK5	   inhibitor,	   reconstituted	   in	   sterile	   DMSO;	   SU1498	   (cat	   no.	   572888,	  
Merck)	  a	   reversible	  VEGFR2	   inhibitor,	   reconstituted	   in	   sterile	  DMSO;	   staurosporine	   (cat	  no.	   S4400,	  
Sigma-­‐Aldrich),	   an	   apoptosis	   inducer,	   was	   reconstituted	   in	   sterile	   DMSO;	   5-­‐nitro-­‐2-­‐(3-­‐
phenylpropylamino)-­‐benzoate	  (NPPB)	  (Sigma-­‐Aldrich,	  Cat	  no.	  N4779)	  reconstituted	  in	  DMSO;	  ADMA	  
was	  reconstituted	  in	  sterile	  water	  (cat	  no.	  311203,	  Calbiochem,	  Millipore);	  L-­‐257	  was	  reconstituted	  in	  
nuclease-­‐free	  water	  (a	  kind	  gift	  from	  Dr	  James	  Leiper,	  MRC	  Clinical	  Sciences	  Centre,	  Imperial	  College	  
London);	  Gap26	   (VCYDKSFPISHVR)	   corresponding	   to	   residue	  63-­‐75 of	   the	   first	   extracellular	   loop	  of	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Cx43	  was	  custom	  synthesised	  (Peptide	  Protein	  Research	  Ltd,	  Hampshire,	  UK)	  and	  was	  reconstituted	  
in	   nuclease-­‐free	   water;	   rotigaptide	   was	   reconstituted	   in	   nuclease-­‐free	   water	   (a	   kind	   gift	   from	   Dr	  
Ninian	  Lang,	  University	  of	  Edinburgh).	  
During	   experiments	  with	   inhibitors	   for	  ALK5	   (SB431542	  or	   SD208),	   VEGFR2	   (SU1498),	   CLIC	   (NPPB),	  
DDAHI	  (L-­‐257)	  or	  Cx43	  (Gap26)	  were	  added	  30	  min	  before	  proceeding	  to	  assays	  with	  treatments	  with	  
agonists.	   ALK1	   binding	   sites	   of	   the	   agonists	   in	   the	   treatment	  medium	   and	   any	   additional	   cytokine	  
treatments	  were	  blocked	  using	  recombinant	  human	  ALK1-­‐Fc	  chimera	  for	  30	  min	  in	  prior	  to	  treating	  
cells.	  	  
	  
2.15	   Data	  presentation	  and	  statistical	  analysis	  
Results	  are	  presented	  in	  scatter	  plots	  or	  bar	  charts	  where	  appropriate,	  and	  horizontal	  lines	  indicated	  
means	  with	  standard	  error	  of	  the	  mean	  (SEM),	  while	  ‘n’	  refers	  to	  the	  number	  of	  ECFCs	  samples	  per	  
group.	  
All	  numerical	  data	  are	  tested	  for	  normal	  distribution	  using	  D’Agostino	  &	  Pearson	  omnibus	  normality	  
test.	  Data	  were	  analysed	  by	  unpaired	  t-­‐test	  (for	  normally	  distributed	  data)	  or	  Mann-­‐Whitney	  test	  (for	  
non-­‐normally	   distributed	   data)	   for	   two	   sample	   groups.	   One-­‐way	   ANOVA	   was	   applied	   for	   data	   of	  
more	  than	  2	  sample	  groups,	  or	  one-­‐way	  repeated	  measures	  ANOVA	  for	  data	  of	   the	  same	  group	   in	  
multiple	  experimental	  conditions,	  with	  Bonferroni	  post-­‐hoc	  analysis	  performed	  if	  P	  <	  0.05.	  Two-­‐way	  
repeated	   measures	   ANOVA	   was	   applied	   for	   comparing	   data	   of	   multiple	   groups	   with	   multiple	  
experimental	   conditions,	   with	   Bonferroni	   post-­‐hoc	   analysis	   performed	   if	   P	   <	   0.05.	   Statistical	  
significance	   was	   regarded	   as	   P	   <	   0.05	   for	   all	   presented	   data.	   All	   graphs	   and	   calculations	   were	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Chapter	  3	  -­‐	  Blood-­‐derived	  endothelial	  cell	  forming	  colonies	  in	  IPAH	  
	  
3.1	   Introduction	  
Circulating	   endothelial	   colony	   forming	   cells	   (ECFCs)	   are	   considered	   to	   be	   true	   EPCs,	   due	   to	   their	  
ability	  to	  independently	  form	  tube-­‐like	  networks	   in	  vitro	  and	  contribute	  structurally	  to	  angiogenesis	  
in	   vivo,	   as	  well	   as	   exhibit	   high	   clonogenic	   and	   proliferative	   potential.	   The	   frequency	   of	   circulating	  
ECFCs	   has	   also	   been	   considered	   a	   potential	   biomarker	   in	   a	   number	   of	   cardiovascular	   diseases	   (as	  
summarised	  in	  Section	  1.6.3),	  but	  relatively	  very	  little	  is	  known	  about	  ECFCs	  in	  PAH.	  In	  an	  early	  study	  
by	  Asosingh	  and	  colleagues,	  no	  difference	  was	  observed	  in	  the	  number	  of	  ECFCs	  derived	  from	  IPAH	  
patients	   and	   healthy	   volunteers	   (Asosingh	   et	   al.,	   2008).	   Conversely,	   the	   same	   research	   group	   has	  
recently	  reported	  using	  a	  single	  cell	  clonogenic	  assay	  to	   identify	  ECFCs	  among	  PAECs	  cultured	  from	  
pulmonary	  arteries	   in	  explanted	   lung	   tissues	  and	   suggested	   that	   those	  derived	   from	   IPAH	  patients	  
were	   more	   proliferative	   than	   the	   cells	   obtained	   from	   healthy	   controls	   (Duong	   et	   al.,	   2011).	  
Nevertheless,	  it	  is	  unclear	  whether	  the	  number	  of	  circulating	  ECFCs	  and/or	  the	  in	  vitro	  characteristics	  
of	  their	  progeny	  differs	  in	  IPAH	  patients	  and	  correlates	  with	  disease	  progression.	  	  
Endothelial	  dysfunction	  is	  typically	  thought	  to	  play	  critical	  role	  in	  the	  pathogenesis	  of	  IPAH	  (Budhiraja	  
et	   al.,	   2004),	   but	   studies	   of	   endothelial	   dysfunction	   at	   the	   cellular	   level	   have	   been	   limited	   by	   the	  
difficulty	  in	  obtaining	  pulmonary	  ECs	  from	  patients.	  ECs	  may	  be	  examined	  in	  biopsy	  samples	  (Fadini	  
and	   Avogaro,	   2010),	   but	   open	   lung	   biopsy	   is	   invasive,	   associated	   with	   significant	   morbidity	   and	  
mortality	  and	  rarely	  performed	  in	  PAH	  (Nicod	  and	  Moser,	  1989).	  Another	  way	  to	  obtain	  pulmonary	  
vascular	   ECs	   is	   through	   the	   isolation	   and	   ex	   vivo	   expansion	   of	   cells	   from	   the	   explanted	   lungs	   of	  
patients	   undergoing	   pulmonary/cardio-­‐pulmonary	   transplantation.	   However,	   these	   operations	   are	  
increasingly	  uncommon	  in	  PAH	  and	  the	  cells	  obtained	  at	  end-­‐stage	  disease	  may	  provide	  little	  insight	  
into	   the	  mechanisms	   that	   initiate	  endothelial	  dysfunction	  and	  vascular	   remodelling	   in	  PAH.	  A	  non-­‐
invasive	  method	  of	  isolating	  ECs	  could	  therefore	  be	  immensely	  useful.	  In	  fact,	  the	  ex	  vivo	  expansion	  
of	  blood-­‐derived	  ECFCs	  has	  been	  used	  as	   a	   source	  of	   surrogate	  ECs	   in	  HPAH	  patients	  with	  BMPR2	  
mutations	  (Toshner	  et	  al.,	  2009)	  as	  well	  as	  a	  variety	  of	  other	  diseases,	  including	  HHT	  (Fernandez	  et	  al.,	  
2005),	  systemic	  sclerosis	  (Avouac	  et	  al.,	  2008),	  von	  Willebrand	  disease	  (Starke	  et	  al.,	  2011),	  macular	  
degeneration	  (Thill	  et	  al.,	  2008),	  diabetes	  (Ingram	  et	  al.,	  2008;	  Tan	  et	  al.,	  2010)	  and	  coronary	  artery	  
diseases	  (Wang	  et	  al.,	  2011).	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I	  hypothesised	  that	  the	  frequency	  of	  circulating	  ECFCs	  might	  be	  higher	  in	  IPAH	  patients	  and	  correlate	  
with	  the	  severity	  of	  the	  disease.	  The	  aims	  of	  this	  chapter	  are	  to:	  
1. Establish	   a	  working	   protocol	   to	   isolate	   and	   grow	  ECFCs	   from	   the	  peripheral	   blood	  of	   IPAH	  
patients	  and	  healthy	  volunteers.	  
2. Investigate	   whether	   there	   is	   a	   relationship	   between	   the	   frequency	   of	   ECFCs	   and	   patient	  
demographics	  or	  clinical	  parameters	  in	  IPAH	  patients.	  	  	  
3. Confirm	  the	  endothelial	  phenotype	  of	  blood-­‐derived	  ECFCs	  and	  identify	  cell	  populations	  that	  
can	  be	  expanded	  for	  functional/mechanistic	  investigations.	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3.2	   Methods	  
See	  Chapter	  2	  for	  detailed	  materials	  and	  protocol.	  
25	  healthy	  volunteers,	  36	   IPAH	  patients	  and	  2	  HPAH	  patients	   consented	   to	  provide	  blood	   samples	  
(Table	   3.1).	   The	   IPAH	   cohort	   included	   6	   patients	  who	  were	  more	   than	   60	   years	   of	   age,	   forming	   a	  
distinct	  group	  of	  older	  patients.	  MNCs	  were	  isolated	  from	  ~50	  ml	  of	  peripheral	  blood,	  counted	  using	  
a	  haemocytometer	  and	  cultured	  in	  EGM-­‐2	  with	  20%	  FBS	  for	  up	  to	  35	  days,	  as	  described	  in	  section	  2.3.	  
Colonies	  of	  ECFCs	  were	  identified	  as	  a	  well-­‐circumscribed	  monolayer	  of	  cobblestone-­‐appearing	  cells,	  
and	   were	   recorded	   as	   they	   appeared,	   with	   the	   total	   number	   and	   frequency	   of	   colonies	   being	  
determined	  for	  each	  subject.	  	  
The	   colonies	   were	   expanded	   (see	   section	   2.3),	   with	   cells	   re-­‐seeded	   at	   a	   density	   of	   3000-­‐5000	  
cells/cm2)	   on	   each	   passage,	   and	   the	   population	   doubling	   time	   (PDT)	   calculated.	   ECFC	   populations	  
were	   carefully	   phenotyped,	   by	   immunostaining	   and	   flow	   cytometry	   (see	   sections	   2.7.1-­‐2.7.2)	   and	  
were	  subjected	  to	  serial	  passaging	  (i.e.	  continual	  growth).	  Only	  cells	  that	  grew	  beyond	  passage	  8	  and	  
exhibited	  stable	  PDTs	  were	  used	  for	  further	  experiments,	  these	  being	  conducted	  with	  cells	  between	  
passages	   3-­‐8.	   The	   ECFC	   phenotype	  was	   also	   demonstrated	   by	   their	   ability	   to	   grow	   under	   limiting	  
dilutions	  (equivalent	  to	  one	  cell	  per	  well	  in	  a	  96-­‐wells	  plate),	  this	  being	  considered	  a	  defining	  feature	  










	   Control	  (n=25)	   IPAH	  (n=30)	   IPAH	  (n=6)	   HPAH	  (n	  =	  2)	  
Gender	  (male/female)	   7/18	   12/18	   4/2	   0/2	  
Age	  (years)	   27.0	  (33.0	  to	  
57.0)	  
38.5	  (22.0	  to	  
56.0)	  
69.5	  (62.0	  to	  
82.0)	  
36	  (35.0	  to	  37.0)	  
Time	  from	  diagnosis	  
(months)	  
-­‐	   48.0	  (0.5	  to	  
122.0)	  
21	  (0.1	  to	  61.0)	   36.6	  (0.2	  to	  
73.0)	  
mPAP*	  (mm	  Hg)	   -­‐	   56.0	  (39.0	  to	  
79.0)	  
49.5	  (36.0	  to	  
68.0)	  
79.0	  (79.0)	  
PVR*	  (dynes.s.cm5)	   -­‐	   865.0	  (364.0	  to	  
1730.0)	  
737.5	  (270.0	  to	  
905.0)	  
2510	  (2510)	  
CI*	  (l/min/m2)	   -­‐	   2.22	  (1.25	  to	  
4.10)	  
2.54	  (1.96	  to	  
3.86)	  
1.15	  (1.15)	  
6MWDΨ	  (m)	   -­‐	   396.0	  (0	  to	  
570.0)	  
274.5	  (120.0	  to	  
420.0)	  
N/A	  
WHO	  classΨ	   	  I	   -­‐	   3	   0	   0	  
	   II	   -­‐	   10	   0	   1	  
	   III	   -­‐	   13	   6	   0	  
	   IV	   -­‐	   4	   0	   1	  
Warfarin	   -­‐	   26	   5	   0	  
	   	   	   	   	  
PAH	  therapies	   	   	   	   	  
Naïve	   -­‐	   1	   1	   1	  
Calcium	  channel	  blocker	   -­‐	   3	   0	   0	  
ERA	   -­‐	   16	   4	   1	  
PDE5	  inhibitor	   -­‐	   25	   2	   1	  
Prostanoid	   -­‐	   10	   0	   0	  
	   	   	   	   	  
Other	  therapies	   	   	   	   	  
Statin	   -­‐	   4	   1	   0	  
	  
Table	  3.1.	   	  Demographics	  and	  clinical	   information.	  Data	  presented	  as	  median	  (range).	  6MWD,	  6	  
minute	   walk	   distance;	   CI,	   cardiac	   index;	   ERA,	   endothelin	   receptor	   antagonist;	   mPAP,	   mean	  
pulmonary	  arterial	  pressure;	  PDE5,	  phosphodiesterase	  type	  5;	  PVR,	  pulmonary	  vascular	  resistance.	  
*,	  obtained	  at	  baseline	  cardiac	  catheter;	  Ψ,	  concurrent	  with	  blood	  sample	  collection.	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3.3	   Results	  
3.3.1	   Establishing	  ECFC	  culture	  	  
ECFCs	   grew	   as	  well-­‐circumscribed	   colonies	   of	   cobblestone-­‐shaped	   cells	   (Figure	   3.1A	  &	   B)	   and	   this	  
typical	   endothelial-­‐like	  morphology	  was	  maintained	   during	   serial	   passages	   (Figure	   3.1C	  &	  D),	   until	  
they	   became	   senescent	   (Figure	   3.1E).	   Despite	   the	   use	   of	   cloning	   cylinders	   to	   isolate	   and	   pass	  
individual	   colonies,	   a	   distinct	   mesenchymal-­‐like	   phenotype	   occasionally	   (<4%	   of	   colonies)	  
predominated	   as	   the	   cultures	   were	   expanded	   (Figure	   3.1F).	   Others	   have	   noted	   a	   similar	  
phenomenon	   (Mead	   et	   al.,	   2008).	   These	   elongated,	   fibroblast-­‐like	   cells	   were	   highly	   proliferative	  
(PDTs	  from	  two	  samples	  at	  P2	  are	  0.71	  and	  1.06	  days).	  
	  
	  
Figure	  3.1.	  Morphology	  of	  ECFCs.	  Representative	  phase	  contrast	  photomicrographs	  of	  ECFCs	  from	  
healthy	   volunteers	   (A,	   D	   &	   E)	   and	   IPAH	   patients	   (B	   &	   C).	   (A)	   A	   well-­‐circumscribed	   colony	   of	  
cobblestone-­‐shaped	   cell	   at	   day	   13,	   10X	   magnification.	   (B)	   An	   ECFC	   colony	   at	   day	   15,	   4X	  
magnification.	  (C)	  A	  confluent	  ECFC	  culture	  at	  passage	  1,	  10X	  magnification.	  (D)	  Subconfluent	  ECFCs	  
at	  passage	  4,	  20X	  magnification.	  (E)	  ECFCs	  showing	  a	  larger	  and	  irregularly	  shape	  as	  they	  approach	  
senescence	   at	   passage	   5,	   10X	   magnification.	   (F)	   A	   distinct	   population	   of	   fibroblast-­‐like	   cells	  
occasionally	  predominated	  following	  the	  expansion	  of	  a	  colony,	  10X	  magnification.	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Figure	  3.2	  outlines	   the	  ECFCs	  samples	   that	  were	  proceed	  to	  different	  stages	  of	  culture	  expansions,	  
which	  were	  used	  subsequently	  in	  flow	  cytometric	  analysis,	  PDT	  determination,	  and	  functional	  studies.	  






Figure	   3.2.	   Overview	   of	   success	   in	   establishing	   ECFC	   colonies	   and	   subsequent	   expansion	   in	  
culture.	  ECFCs	  at	  P3-­‐	  P6	  were	  used	  for	  flow	  cytometry	  and	  determination	  of	  population	  doubling	  
times.	  ECFCs	  that	  grew	  beyond	  P8	  (subject	  codes	  in	  blue)	  were	  used	  for	  functional	  studies.	  Subject	  




I	  also	  investigated	  an	  alternative	  method	  for	  deriving	  ECFCs	  from	  peripheral	  blood,	  which	  uses	  10%	  
pooled	   human	   platelet	   lysate	   instead	   of	   fetal	   bovine	   serum	   (Reinisch	   et	   al.,	   2009).	   This	   was	  
repeated	  using	  blood	   from	  six	  healthy	  volunteers	   (Healthy	  1,	  2,	  3,	  4,	  9,	  10),	   all	  of	  whom	  produced	  
ECFCs	  following	  the	  established	  protocol,	  and	  in	  two	  cases	  (Healthy	  9	  and	  10)	  the	  two	  methods	  were	  
performed	  concurrently.	  However,	  despite	  closely	  following	  the	  method	  of	  Reinisch	  and	  colleagues	  
and	   obtaining	   pooled	   human	   platelet	   lysate	   directly	   from	   this	   research	   group,	   no	   colonies	   were	  
observed	  after	  35	  days	  of	  culture.	  The	  reason	  for	  this	  was	  not	  apparent,	  but	  one	  confounding	  factor	  
may	  have	  been	  the	  clotting	  potential	  of	  the	  platelet	  lysate	  and	  need	  for	  repeated	  filtering	  in	  order	  to	  
remove	  aggregates.	  In	  addition,	  very	  few	  adherent	  cells	  could	  be	  observed	  on	  the	  culture	  flasks	  after	  
10	  days	  of	  culture.	  It	  is	  also	  noteworthy	  that	  this	  alternative	  method	  has	  not	  been	  adopted	  by	  other	  
groups	  to	  date.	  
	  
3.3.2	   Differences	  in	  colony	  formation	  	  
An	  average	  of	  2-­‐3	  colonies	  were	  obtained	   from	  50	  ml	  of	  blood,	  with	  a	   frequency	  of	  0.19±0.03/107	  
MNCs	  (median	  0.17;	  range	  0	  to	  0.57)	  and	  0.25±0.05/107	  MNCs	  (median	  0.19;	  range	  0	  to	  1.16)	  from	  
healthy	  controls	  and	  IPAH	  patients	  respectively.	  Colonies	  of	  ECFCs	  were	  successfully	  grown	  from	  88%	  
(22/25)	  of	  healthy	  volunteers	  and	  77%	  (23/30)	  of	  patients	  with	  IPAH	  (Figures	  3.3A-­‐B),	  the	  two	  groups	  
having	  a	  similar	  gender	  and	  age	  distribution	   (Table	  3.1).	  Colonies	  were	  successfully	  derived	   from	  2	  
HPAH	   patients,	   but	   these	   were	   not	   analysed	   further	   due	   to	   the	   small	   sample	   size	   (Table	   3.1).	  
Colonies	  were	   also	   successfully	   derived	   from	  83%	   (5/6)	   of	   the	  more	  elderly	   IPAH	  patients	   (Figures	  
3.3A-­‐B).	   No	   difference	   was	   apparent	   in	   the	   total	   number	   or	   frequency	   of	   colonies	   derived	   from	  
control	  subjects	  and	  patients	  with	   IPAH	  (Figure	  3.3A	  &	  B).	  Similarly,	  no	  significant	  differences	  were	  
observed	  when	  only	   the	   individuals	   that	  provided	   colonies	  were	   considered,	   although	   the	  number	  
and	   frequency	  of	   colonies	   tended	   to	  be	  greater	   for	   IPAH	  patients	   versus	   controls	   (Figures	  3.3C-­‐D).	  
Blood	   samples	   from	   the	   elderly	   IPAH	   patients	   provided	   a	   similar	   frequency	   of	   colonies	   when	  
compared	   with	   their	   younger	   counterparts	   (Figure	   3.3C-­‐D).	   The	   time	   when	   ECFC	   colonies	   first	  
appeared	  was	  similar	  in	  all	  three	  groups	  of	  subjects	  (Figure	  3.3E).	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The	   total	   number	   and	   frequency	   of	   colonies	   derived	   from	   healthy	   volunteers	   displayed	   an	   age-­‐
dependent	  decline,	  with	  Pearson’s	  correlation	  coefficient	  (r)	  of	  -­‐0.52	  (P	  =	  0.007,	  95%	  CI	  -­‐0.76	  to	  -­‐0.16)	  
and	  -­‐0.5	  (P	  =	  0.01,	  95%	  CI	  -­‐0.75	  to	  -­‐0.12)	  for	  colony	  number	  and	  frequency	  respectively	  (Figure	  3.4A	  
&	  C).	   In	  contrast,	   the	  number	  and	  frequency	  of	  colonies	  derived	  from	  IPAH	  patients	  tended	  to	  rise	  
with	   increasing	   age	   and	   did	   not	   decline	   in	   the	   more	   elderly	   patients	   (Figure	   3.4B	   &	   D).	   Using	  
multivariate	  ANOVA,	  there	  was	  a	  significant	  difference	  between	  the	  age-­‐dependent	  correlations	  for	  
ECFC	   colony	   number	   (P	   =	   0.02)	   and	   frequency	   (P	   =	   0.03)	   between	   the	   two	   groups.	   Following	  
continuous	   culture	  of	   ECFCs,	   it	  was	  also	  apparent	   that	   the	   cells	   that	   grew	  beyond	  passage	  8	  were	  
generally	  from	  a	  broad	  age-­‐range	  of	  IPAH	  patients	  (mean	  46	  yr,	  range	  20-­‐68	  yr)	  and	  a	  younger	  cohort	  
(mean	  27	   yr,	   range	  20-­‐35	   yr)	   of	   healthy	   volunteers	   (Figure	   3.4E).	  No	   colonies	  were	  obtained	   from	  
healthy	   volunteers	   >50	   yr	   of	   age	   whereas	   they	   were	   regularly	   derived	   from	   older	   IPAH	   patients	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Figure	   3.3.	   	   ECFC	   colonies	   derived	   from	  peripheral	   venous	  blood.	  Number	   (A)	   and	   frequency	  of	  
colonies	   (B)	  obtained	   from	  all	  healthy	  volunteers	   (n=25),	  gender-­‐	  and	  age-­‐matched	   IPAH	  patients	  
(n=30)	  and	  elderly	  (62-­‐82	  yr)	  IPAH	  patients	  (n=6).	  	  The	  number	  (C)	  and	  frequency	  of	  colonies	  (D)	   in	  
subjects	  that	  gave	  rise	  to	  ECFCs.	  (E)	  Time	  when	  the	  first	  colony	  was	  observed,	  following	  the	  initial	  





Figure	   3.4.	   Age-­‐related	   differences	   in	   ECFC	   colonies	   derived	   from	   healthy	   volunteers	   and	  
patients	  with	  IPAH.	   	  ECFC	  colony	  number	  (A-­‐B)	  and	  frequency	  (C-­‐D)	  versus	  the	  age	  of	  25	  healthy	  
volunteers	   (A	   &	   C)	   and	   30	   patients	   with	   IPAH	   (B	   &	   D).	   Statistics	   shown	   are	   from	   Pearson’s	  
correlation	  test.	  (E)	  The	  age	  distribution	  of	  9	  healthy	  volunteers	  and	  10	  IPAH	  patients,	  producing	  
ECFCs	   that	   grew	   beyond	   passage	   8.	   Data	   are	   presented	   as	   mean±SEM	   of	   ECFCs.	   N	   =	   9	   –	   10.	  
Statistic	  is	  from	  t-­‐test.	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3.3.3	   ECFC	  colony	  formation	  and	  the	  functional	  capacity	  of	  IPAH	  patients	  	  
Assessment	   of	   ECFC	   colony	   formation	   in	   the	   IPAH	   patient	   cohort	   indicated	   that	   the	   frequency	   of	  
colonies	  was	  not	  influenced	  by	  the	  patients’	  gender,	  duration	  of	  disease	  or	  treatment	  with	  therapies	  
approved	   for	   PAH	   (Figure	   3.5A-­‐F).	   There	   was	   also	   no	   significant	   association	   with	   baseline	  
haemodynamic	  parameters,	  although	  the	  frequency	  of	  colonies	  tended	  to	  be	  greater	  in	  patients	  with	  
higher	  baseline	  PVR	  and	  lower	  CI	  values	  (Figure	  3.6A-­‐D).	  The	  number	  (P	  =	  0.02)	  and	  frequency	  (P	  =	  
0.03)	  of	  ECFC	  colonies	  was	  however	  significantly	  greater	  in	  MNC	  cultures	  from	  IPAH	  patients	  in	  WHO	  
functional	  classes	  III	  &	  IV	  versus	  I	  &	  II	  (Figure	  3.6E	  &	  F).	  Patients	  in	  poorer	  functional	  classes	  III	  &	  IV,	  
at	   the	   time	   of	   blood	   collection,	   also	   exhibited	   significantly	   lower	   6MWDs	   (P	   =	   0.0005)	   when	  






Figure	  3.5.	  ECFC	  colony	  formation	  from	  patients	  with	  IPAH.	  Colony	  number	  according	  to	  gender	  of	  
healthy	  volunteer	  (n	  =	  25)	  (A)	  and	  IPAH	  patients	  (n	  =	  36)	  (B).	  Relationship	  of	  colony	  number	  with	  the	  
disease	  duration	  (C),	  and	  treatment	  with	  either	  endothelin	  receptor	  (ER)	  antagonists	  (D),	  prostanoids	  
(E)	   or	   phosphodiesterase	   type	   5	   (PDE5)	   inhibitors	   (F)	   within	   IPAH	   are	   also	   compared.	   Data	   are	  





Figure	  3.6.	  Relationship	  of	  ECFC	  colony	   formation	  and	  IPAH	  patient	  characteristics.	  ECFC	  colony	  
number	   according	   to	   mean	   pulmonary	   arterial	   pressure	   (mPAP)	   (A),	   6	   minute	   walk	   distance	  
(6MWD)	  (B),	  pulmonary	  vascular	  resistance	  (PVR)	  (C)	  and	  cardiac	  index	  (CI)	  (D)	  of	  IPAH	  patients	  (n	  
=	  36).	  ECFC	  colony	  number	  (E)	  and	  frequency	  (F)	  from	  IPAH	  patients	  in	  WHO	  functional	  classes	  I	  &	  
II	  (n	  =	  13)	  versus	  III	  &	  IV	  (n	  =	  23).	  6MWD	  concurrent	  with	  WHO	  functional	  class	  (G).	  	  Data	  in	  (E	  –	  G)	  
are	  presented	  as	  mean±SEM.	  Statistics	  shown	  are	  Pearson’s	  correlation	  test	  (A	  –	  D)	  and	  t-­‐tests	  (E	  –	  
G).	  Data	  for	  6MWD	  were	  obtained	  in	  the	  same	  day	  as	  the	  peripheral	  blood	  sample	  collection,	  while	  
the	  haemodynamic	  data	  used	  were	  from	  right-­‐to-­‐left	  heart	  catheterisation	  when	  the	  disease	  was	  
first	  diagnosed.	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3.3.4	   Characterisation	  and	  flow	  cytometric	  analysis	  of	  ECFCs	  	  
Phenotyping	  was	  generally	  conducted	  using	  ECFCs	  at	  passages	  2	  -­‐	  6.	  In	  addition	  to	  their	  morphology,	  
the	   endothelial-­‐like	   phenotype	   was	   verified	   by	   positive	   immunostaining	   for	   endothelial	   surface	  
proteins	   CD31	   and	   CD144,	   the	   presence	   of	   von	   Willebrand	   factor	   (vWF)	   in	   peri-­‐nuclear	   Weibal-­‐
Palade	  bodies	  and	  the	  ability	  of	  ECFCs	  to	  bind	  UEA-­‐1	  lectin	  (Figure	  3.7A	  -­‐	  D).	  Some	  immunostaining	  
for	  the	  progenitor	  marker	  CD34	  was	  also	  observed	  (Figure	  3.7E).	  There	  were	  no	  apparent	  differences	  
in	   the	  morphology	   or	   staining	   of	   ECFCs	   derived	   from	  healthy	   volunteers	   (healthy-­‐ECFCs)	   and	   IPAH	  
patients	  (IPAH-­‐ECFCs)	  and	  no	  immunostaining	  was	  observed	  when	  primary	  antisera	  were	  omitted	  or	  
cells	  were	  incubated	  with	  the	  microvascular	  ECs-­‐specific	  FITC-­‐conjugated	  Griffonia	  simplicifolia	  lectin	  
(Figure	  3.7F	  -­‐	  H).	  	  
ECFCs	   were	   also	   characterised	   by	   flow	   cytometry,	   with	   human	   pulmonary	   artery	   endothelial	   cells	  
(HPAECs)	   and	   human	   umbilical	   vein	   endothelia	   cells	   (HUVECs)	   being	   used	   as	   positive	   controls.	   All	  
three	  cell	  types	  were	  positive	  for	  the	  endothelial	  cells	  markers	  CD31	  and	  VEGFR2,	  but	  negative	  (<1%	  
positive)	  for	  the	  pan-­‐leukocyte	  marker	  CD45	  and	  immature	  cell	  marker	  CD133	  (Figure	  3.8	  &	  3.9).	  	  A	  
minority	  of	  ECFCs	  (14-­‐20%)	  were	  considered	  to	  be	  CD34-­‐positive	  and	  a	  variable	  proportion	  (~17%),	  
as	  well	  as	  some	  HPAECs	  and	  HUVECs,	  appeared	  to	  be	  positive	  for	  the	  monocytic	  marker	  CD14.	  More	  
than	  half	   of	   ECFCs,	  HPAECs	   and	  HUVECs	  were	   c-­‐kit	   positive	   and	  ~25%	  exhibited	  CXCR4	  expression	  
(Figure	  3.8	  &	  3.9).	  Overall,	  the	  ECFCs	  profile	  was	  very	  similar	  to	  that	  exhibited	  by	  mature	  endothelial	  
cells	  (HUVECs	  and	  HPAECs)	  in	  culture.	  The	  phenotype	  was	  however	  markedly	  different	  from	  that	  of	  
the	  mesenchymal-­‐like	   cells,	  which	  occasionally	   predominated	  when	  ECFC	   cultures	  were	   expanded.	  
More	  than	  50%	  of	  these	  cells	  expressed	  CD14	  and	  CD45,	  acting	  as	  a	  convenient	  positive	  control	  for	  
both	   proteins,	   whereas	   the	   proportion	   displaying	   either	   CD31	   or	   VEGFR2	   was	   reduced	   compared	  








Figure	  3.7.	  Immunostaining	  and	  lectin	  binding	  of	  ECFCs.	  Representative	  images	  of	  ECFCs,	  derived	  
from	   the	   peripheral	   blood	   of	   IPAH	   patients,	   showing	   fluorescence	   staining	   for	   the	   endothelial	  
markers	   CD31	   (A),	   CD144	   (B),	   von	   Willebrand	   factor	   (C)	   and	   UEA-­‐1	   lectin	   binding	   (D),	   and	  
immunostaining	   for	   the	   progenitor	   cell	   surface	   marker	   CD34	   (E).	   No	   staining	   observed	   when	  
primary	  antibodies	  were	  omitted	  and	  cells	   incubated	  with	  either	  FITC-­‐conjugated	  anti-­‐mouse	  (F)	  
or	   Alexa488-­‐conjugated	   anti-­‐rabbit	   secondary	   antibodies	   (G),	   or	   FITC-­‐conjugated	   Griffonia	  




Figure	   3.8.	   Flow	   cytometric	   analysis	   of	   ECFCs.	   Representative	   data	   showing	   flow	   cytometric	  
analysis	  of	  ECFCs	  from	  an	  IPAH	  patient	  at	  passage	  4.	  Cells	  were	  selected	  using	  a	  standard	  gating	  
for	   all	   ECFC	   populations,	   following	   forward	   scatter/side	   scatter	   analysis,	   and	   the	   proportion	   of	  
stained	  cells	  (blue	  line)	  determined	  after	  subtraction	  of	  the	  isotype	  control	  value	  (black	  line).	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Some	  variability	  was	  observed	  between	  different	  ECFC	  cultures	   in	  the	  expression	  of	  VEGFR2,	  CD14,	  
CD34	  and	  c-­‐kit,	  but	  this	  did	  not	  correlate	  with	  the	  number/frequency	  of	  the	  primary	  colonies	  (Figure	  
3.10A).	  On	  the	  other	  hand,	  the	  number/frequency	  of	  colonies	  showed	  a	  positive	  association	  with	  the	  
proportion	  of	  CXCR4+	  ECFCs	  (Figure	  3.10A).	  Further	  analysis	  of	  this	  relationship	  indicated	  that	  CXCR4+	  
expression	  correlated	  with	  number	  of	  ECFC	  colonies	  derived	  from	  healthy	  volunteers	   (r	  =	  0.56,	  P	  =	  
0.03,	  95%	  CI	  0.06	  to	  0.83)	  but	  not	   IPAH	  patients,	  although	  the	  CXCR4+	  expression	  did	  not	  correlate	  
with	  the	  age	  of	  the	  subjects	  (Figure	  3.10B).	  	  
Figure	   3.9.	   Flow	   cytometric	   analysis	   of	   ECFCs	   from	   IPAH	   patients	   and	   healthy	   volunteers.	   (A)	  
Proportion	  of	  cells	  (P3	  –	  P6)	  in	  separate	  ECFC	  populations,	  derived	  from	  healthy	  volunteers	  (n=10-­‐
16)	   and	   IPAH	   patients	   (n=13),	   showing	   expression	   of	   endothelial	   (CD31	   and	   VEGFR2),	  
hematopoietic/monocytic	   (CD14,	   CD45	   and	   CD133)	   and	   progenitor	   markers	   (CD34,	   c-­‐kit	   and	  
CXCR4).	  Human	  pulmonary	  artery	  endothelial	  cells	  (HPAECs)	  and	  human	  umbilical	  vein	  endothelia	  
cells	   (HUVECs)	   were	   included	   (n=2)	   as	   mature	   endothelial	   cell	   controls.	   Data	   are	   presented	   as	  
mean±SEM	  of	  each	  analysed	  ECFC	  sample.	   (B)	  Representative	  data	  showing	  distinct	  phenotyping	  
profile	   of	   a	   mesenchymal-­‐like	   cell	   population	   (P3),	   displaying	   expression	   of	  
























































































































































































































Figure	   3.10.	   Relationship	   between	   cell	   surface	   markers	   and	   ECFC	   frequency	   and	   number.	  
(A)	  Separate	  ECFCs	   from	  both	  control	  and	  IPAH	  subjects	  (n	  =	  23-­‐29;	  P3-­‐6)	  were	  assessed	  by	   flow	  
cytometry.	  Graphs	  show	  the	  association	  between	  the	  number/frequency	  of	  ECFC	  colonies	  and	  the	  
proportion	  of	  ECFCs	  exhibiting	  endothelial	  (VEGFR2),	  monocyte	  (CD14),	  progenitor	  (CD34	  and	  c-­‐kit)	  
and	  chemotactic	  (CXCR4)	  markers.	  (B)	  Positive	  correlation	  between	  number/frequency	  of	  colonies	  
and	  subsequent	  CXCR4	  expression	  in	  ECFCs	  from	  healthy	  volunteers	  (n	  =	  15)	  and	  IPAH	  patients	  (n	  =	  
13).	  Statistics	  are	  from	  Pearson’s	  correlation	  test.	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Assessment	  of	  surface	  marker	  expression	  over	  serial	  passages	  suggested	  that	  CD31	  expression	  was	  
stable,	   whereas	   the	   proportion	   of	   cells	   identified	   as	   VEGFR2-­‐positive	   tended	   to	   decline	   beyond	  
passages	   4-­‐6	   (Table	   3.2).	   Some	   variability	   was	   also	   observed	   in	   the	   proportion	   of	   cells	   displaying	  
CD14,	  CD34	  and	  CXCR4	  labelling	  between	  individual	  ECFC	  isolates	  and	  cultures	  at	  different	  passages.	  
In	  contrast,	  the	  majority	  (>99%)	  of	  cells,	  studied	  between	  passages	  2-­‐7,	  lacked	  both	  CD45	  and	  CD133	  
proteins	  (Table	  3.2).	  	  	  
	  
	  
	   Proportion	  of	  ECFCs	  exhibiting	  markers	  
Sample	  	   Passage	  	   Endothelial	  	   Hematopoietic/Monocytic	   Progenitor	  
	  	   	  	   CD31	   VEGFR2	   CD14	   CD45	   CD133	   CD34	   c-­‐kit	   CXCR4	  
Healthy	   2	   99.6	   95.7	   22.6	   0.1	   0.3	   0.9	   -­‐	   18.9	  
	  	   3	   99.8	   96.1	   34.8	   0.1	   0.2	   1.01	   -­‐	   19.9	  
	  	   4	   99.9	   95.9	   6.8	   0.5	   0.1	   2.8	   -­‐	   25.1	  
	  	   5	   99.6	   94.9	   31.7	   0.4	   3.5	   28.6	   -­‐	   72.0	  
	  	   6	   96.9	   76.5	   12.4	   0.0	   0.3	   0.0	   -­‐	   83.2	  
Healthy	   2	   99.3	   89.3	   14.0	   0.0	   0.0	   0.8	   -­‐	   36.8	  
	  	   3	   99.7	   91.9	   4.0	   0.2	   0.9	   0.1	   -­‐	   21.3	  
	  	   4	   99.2	   84.4	   36.5	   0.0	   0.2	   0.2	   -­‐	   49.4	  
Healthy	   2	   98.6	   90.7	   18.6	   0.9	   0.1	   39.5	   -­‐	   14.6	  
	  	   3	   99.3	   83.9	   5.6	   0.4	   0.1	   38.6	   -­‐	   45.6	  
IPAH	   4	   99.9	   92.1	   45.4	   0.0	   15.9	   6.2	   69.4	   24.2	  
	  	   5	   99.4	   94.4	   23.4	   0.0	   0.1	   1.9	   73.9	   4.0	  
	  	   6	   99.7	   87.5	   36.1	   0.2	   0.3	   0.2	   69.0	   10.9	  
	  	   7	   98.4	   73.9	   29.0	   0.1	   0.1	   0.5	   73.6	   7.5	  
Table	  3.2.	  	  Flow	  cytometric	  analysis	  of	  separate	  ECFC	  populations	  (derived	  from	  3	  healthy	  volunteers	  






3.3.5	   Proliferative	  capacity	  of	  ECFCs	  from	  IPAH	  patients	  and	  healthy	  volunteers	  	  
Colonies	  were	   serially	  expanded	   in	  T25,	  T75	  and	  T175	   flasks,	  producing	  more	   than	  107	   cells	  within	  
the	   first	   four	   passages.	   Variation	  was	   observed	   in	   the	   proliferative	   potential	   of	   ECFC	   populations,	  
with	   some	   reaching	   senescence	   at	   an	   early	   stage	   of	   expansion	  whereas	   others	   continued	   to	   grow	  
beyond	   14	   to	   17	   passages	   (~115	   days)	   in	   culture	   (Table	   3.3;	   Figure	   3.11A).	   Cells	   that	  were	   frozen	  
down	   during	   their	   early	   passages	   all	   recovered	   from	   cryopreservation	   and	   exhibited	   a	   similar	  
proliferative	  capacity	  to	  that	  observed	  before	  freezing	  (Figure	  3.11B).	  	  
After	   serially	   propagating	   each	   ECFC	   population	   for	   at	   least	   9	   passages,	   distinct	   cultures	   were	  
identified	  from	  9	  healthy	  volunteers	  and	  10	  IPAH	  patients	  that	  grew	  beyond	  passage	  8	  and	  exhibited	  
stable	  PDTs	  (Table	  3.3).	  These	  cell	  populations	  represented	  9/22	  (41%)	  of	  the	  healthy	  volunteers	  and	  
10/28	   (36%)	   of	   the	   IPAH	   patients	   that	   produced	   at	   least	   one	   colony.	   The	   PDT	   tended	   to	   increase	  
between	   the	   2nd/3rd	   and	   6th	   passage	   and	   generally	   increased	   markedly	   (PDT	   ≥3-­‐4	   days)	   prior	   to	  
senescence	  (Table	  3.3).	  	  Other	  than	  at	  the	  2nd	  passage,	  no	  significant	  difference	  was	  observed	  in	  the	  
PDT	  of	  ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients	  (Table	  3.3).	   	  Similarly,	   little	  difference	  was	  






Figure	   3.11.	   Proliferative	   potential	   of	   ECFCs.	   (A)	   Population	   doubling	   time	   (PDT)	   of	  
representative	   ECFC	   populations	   that	   displayed	   either	   early	   senescence	   (n=2)	   or	   grew	   beyond	  
eight	   passages	   (n=2)	   in	  continuous	  culture.	   Some	   isolates	  could	   potentially	  have	  grown	   further	  
than	  the	  last	  PDT	  estimation	  (≥).	   (B)	  PDT	  of	  ECFCs	  (n=3-­‐8)	  exhibiting	  no	  significant	  difference	  in	  
PDT	  before	  and	  after	  recovery	  from	  liquid	  nitrogen	  as	  assessed	  by	  two-­‐way	  ANOVA.	  Data	  points	  
are	  presented	  as	  mean±SEM.	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Sample	  
Population	  doubling	  time	  (days)	   Highest	  
passage	  No.	  P2	   P3	   P4	   P5	   P6	  
Healthy	  1	  
	   	  
2.09	   2.50	   2.14	   9	  
Healthy	  3	  
	   	  
3.60	   2.44	   3.05	   ≥9	  
Healthy	  4	  
	  
1.23	   4.12	   2.54	   2.96	   7	  
Healthy	  5	  
	  
1.10	   2.78	   2.53	   3.12	   ≥8	  
Healthy	  6	   0.96	   1.29	   2.42	   1.79	   1.28	   ≥10	  
Healthy	  7	   2.12	   4.36	   3.26	   S	   	   4	  










1.70	   2.93	   4.00	   1.96	   ≥11	  
Healthy	  13	  
	  
0.97	   0.96	   0.95	   1.13	   10	  
Healthy	  14	  
	  
3.27	   2.86	   2.50	   6.53	   7	  
Healthy	  15	  
	  
1.31	   1.67	   3.63	   ≥	   6	  
Healthy	  16	  
	  
1.48	   1.78	   1.79	   2.13	   9	  
Healthy	  19	  
	  
3.11	   3.11	   NA	   2.95	   6	  
Healthy	  20	   2.46	   1.80	   3.88	   1.75	   1.34	   ≥	  10	  
Healthy	  21	   1.39	   1.48	   2.10	   1.24	   3.28	   9	  
Healthy	  23	   2.07	   2.64	   4.67	   S	   	   	  
Healthy	  24	   2.32	   2.23	   S	   	   	   	  
Mean±SEM	   1.91±0.20	   2.14±0.25	   2.73±0.24	   2.31±0.26	   2.66±0.42	   	  
n	   7	   16	   17	   12	   12	   	  
	   IPAH	  1	  
	  
1.95	   1.12	   1.94	   1.69	   9	  
IPAH	  2	  
	  
1.14	   1.07	   2.08	   1.94	   ≥17	  
IPAH	  3	   	   1.39	   1.17	   1.89	   9.93	   10	  
IPAH	  4	   	   1.33	   2.84	   3.09	   4.03	   7	  
IPAH	  7	  
	  
1.73	   1.82	   1.92	   1.42	   ≥14	  
IPAH	  12	  
	  
4.34	   1.94	   5.97	   S	   5	  
IPAH	  15	  
	  





3.43	   S	  
	   	  
3	  
IPAH	  18	   1.19	   1.29	   0.87	   1.19	   1.16	   ≥10	  
IPAH	  19	   1.37	   1.79	   2.23	   2.20	   2.95	   9	  
IPAH	  21	   1.02	   1.27	   1.17	   2.12	   3.05	   11	  
IPAH	  22	   	   3.84	   1.94	   1.29	   2.77	   ≥10	  
IPAH	  29	   1.23	   1.02	   1.41	   1.55	   2.22	   ≥10	  
IPAH	  30	   1.20	   1.72	   3.21	   2.56	   7.77	   6	  
IPAH	  31	   	   1.32	   1.54	   1.62	   3.54	   ≥10	  
Mean±SEM	   1.20±0.06	   2.10±0.30	   2.02±0.32	   2.30±0.38	   2.96±0.57	   	  
N	   5	   15	   14	   13	   12	   	  
P-­‐value	  	   0.048*	   0.82	   0.12	   0.92	   0.54	   	  
	  
HUVEC	   0.95	   1.35	   0.95	   3.76	   1.69±0.31	   	  
N	   1	   1	   1	   1	   3	   	  
	  
Table	   3.3.	   Population	   doubling	   time	   (PDT)	   for	   ECFCs.	   PDTs	   between	   passages	   2-­‐6	   in	   ECFCs	   from	  
healthy	  controls	  (n=15)	  and	  IPAH	  patients	  (n=15).	  S,	  represents	  senescent	  cells;	  ≥,	  represents	  cells	  that	  
could	   potentially	   have	   grown	   further	   than	   the	   last	   recorded	   PDT.	   HUVEC,	   human	   umbilical	   vein	  
endothelial	   cell	   PDT	   data	   included	   for	   comparison.	   Average	   data	   presented	   as	  mean±SEM.	   Statistics	  





3.3.6	   Proliferative	  potentials	  of	  ECFCs	  measured	  by	  clonogenic	  growth	  assay	  	  
A	   key	   feature	   of	   ECFCs	   is	   their	   ability	   to	   grow	   under	   limiting	   dilutions	   and	   this	   also	   distinguishes	  
ECFCs	  from	  so-­‐called	  early	  outgrowth	  EPCs	  or	  haematopoietic	  cells.	  ECFCs	  were	  compared	  at	  passage	  
4	  from	  healthy	  volunteers	  (n=3)	  and	  IPAH	  patients	  (n=3)	  of	  similar	  age	  and	  gender.	  After	  plating	  at	  
limiting	   dilution	   (equivalent	   to	   one	   cell	   per	   well	   in	   a	   96-­‐well	   plate)	   the	   appearance	   and	   size	   of	  
colonies	  was	  assessed	  after	  14	  days,	  as	  previously	  described	  (Ingram	  et	  al.	  2004;	  International	  Patent	  
WO	  2005/078073	  A2).	  A	  similar	  proportion	  of	  wells	   (~	  37%)	   in	   the	  two	  groups	  contained	  cells	   that	  
had	  undergone	  at	   least	  one	  cell	  division	  and	  were	  distributed	  in	  clusters	  or	  colonies	  (Figure	  3.13B).	  
40-­‐60%	   contained	   clusters	   of	   2-­‐50	   cells	   and	   35-­‐60%	   colonies	   of	   51-­‐2000	   cells,	   the	   latter	   being	  
considered	   to	   represent	   ECFCs	   of	   low	   proliferative	   potential	   (LPP-­‐ECFC)	   (Coldwell	   et	   al.,	   2011).	   A	  
small	  percentage	  (5-­‐7%)	  showed	  more	  extensive	  proliferation,	  producing	  colonies	  that	  contained	  in	  
excess	  of	  2000	  cells/well,	  and	  are	  considered	  to	  represent	  ECFCs	  of	  high	  proliferative	  potential	  (HPP-­‐
ECFC)	  (Coldwell	  et	  al.,	  2011).	  No	  significant	  difference	  was	  observed	  between	  healthy	  volunteers	  and	  
IPAH	  patients	  in	  the	  relative	  proportions	  of	  either	  cell	  clusters	  or	  colonies	  (Figure	  3.13C).	  	  















Figure	   3.12.	   Population	  doubling	   time	   (PDT)	   for	  ECFCs	   that	  were	   serially	  propagated	   and	   grew	  
beyond	  eight	  passages.	  ECFCs	  from	  healthy	  volunteers	  (n=9)	  and	  IPAH	  patients	  (n=10),	  at	  passages	  





Figure	  3.13.	  Clonogenic	  and	  proliferative	  potential	  of	  ECFCs.	   (A)	  Representative	   images	  of	  cells	  
stained	  with	  Calcein-­‐AM,	  14	  days	  after	  plating	  at	  limiting	  dilution.	  Images	  show	  endothelial	  cluster	  
(2-­‐50	  cells/well)	  and	  colonies	  of	  low	  proliferative	  potential-­‐ECFCs	  (LPP-­‐ECFCs;	  51-­‐2000	  cells/well;	  
20x	   magnification)	   and	   high	   proliferative	   potential-­‐ECFCs	   (HPP-­‐ECFCs;	   >2000	   cells/well;	   10x	  
magnification).	   (B)	   Percentage	   of	   ECFCs	   from	   healthy	   volunteers	   (n=3)	   and	   IPAH	   patients	   (n=3)	  
having	  undergone	  at	   least	  one	  cell	  division	  after	  14	  days	  of	  culture.	  (C)	  Approximate	  number	  of	  
cell	  progeny	  derived	  from	  a	  single	  ECFC	  in	  each	  well,	  expressed	  as	  percentage	  of	  the	  divided	  cells.	  
Data	  are	  presented	  as	  mean±SEM.	  Statistics	  are	  from	  Mann-­‐Whitney	  test	  (B)	  and	  2-­‐way	  ANOVA	  
(C).	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3.4	   Discussion	  
In	   this	   chapter	   I	  describe	   the	   successful	   isolation,	   culture	  and	  characterisation	  of	  ECFCs	   from	  adult	  
peripheral	  blood	  and	  obtained	  the	  following	  key	  findings:	  
• ECFC	  colony	  formation	  declined	  with	  age	  in	  healthy	  volunteers,	  but	  not	  in	  IPAH	  patients.	  	  
• Colony	   formation	   correlated	  with	   the	  WHO	   functional	   class	   of	   IPAH	  patients,	   but	   not	  with	  
other	  clinical	  indices	  and	  prescribed	  treatments.	  	  
• ECFCs	  from	  IPAH	  patients	  and	  healthy	  volunteers	  exhibited	  a	  similar	  endothelial	  phenotype,	  
proliferative	  potential	  and	  clonogenic	  capacity.	  
	  
Using	  the	  protocol	  as	  described,	  I	  achieved	  a	  success	  rate	  of	  77-­‐88%	  in	  establishing	  at	  least	  one	  ECFC	  
colony	  per	  subject.	  This	  is	  greater	  than	  the	  54-­‐70%	  success	  rate	  reported	  by	  some	  groups	  (Asosingh	  
et	  al.,	  2008;	  Thill	  et	  al.,	  2008;	  Piaggio	  et	  al.,	  2009;	  Stroncek	  et	  al.,	  2009;	  Rosti	  et	  al.,	  2010;	  Teofili	  et	  
al.,	   2011)	   and	   comparable	   with	   that	   achieved	   by	   others	   (Thill	   et	   al.,	   2008;	  Martin-­‐Ramirez	   et	   al.,	  
2012).	  Variation	  in	  success	  rates	  may	  reflect	  technical	  differences	  in	  the	  protocols	  used.	  For	  example,	  
putting	  the	  blood	  sample	  on	  ice	  or	  in	  a	  refrigerator	  prior	  to	  MNC	  isolation	  and	  culture	  may	  have	  an	  
adverse	  effect	  on	  establishing	  ECFCs	  (Coldwell	  et	  al.,	  2011;	  Martin-­‐Ramirez	  et	  al.,	  2012).	  An	  average	  
of	   2-­‐3	   colonies	   were	   obtained	   from	   50	   ml	   of	   blood,	   with	   a	   median	   frequency	   of	   0.17/107	   MNCs	  
(range	   0	   to	   0.57)	   and	   0.19/107	   MNCs	   (range	   0	   to	   1.16)	   from	   healthy	   controls	   and	   IPAH	   patients	  
respectively.	  This	   is	   in	  agreement	  with	  the	  values	  reported	  for	  healthy	  volunteers	   in	  recent	  studies	  
(Piaggio	  et	  al.,	  2009;	  Rosti	  et	  al.,	  2010;	  Teofili	  et	  al.,	  2011)	  and	  confirms	  that	  circulating	  endothelial	  
progenitor	  cells	  are	  rare	  in	  human	  adult	  peripheral	  blood,	  with	  an	  estimated	  prevalence	  of	  one	  per	  
million	  nucleated	  cells	  (Ingram	  et	  al.,	  2004;	  Reinisch	  et	  al.,	  2009).	  	  	  
Once	   formed,	   some	   ECFC	   colonies	   did	   not	   survive	   the	   first	   passage	   or	   exhibited	   early	   senescence	  
between	  passages	  3	   to	  6,	   this	  being	  consistent	  with	   the	  experience	  of	  other	  groups	  using	  a	  similar	  
culture	  protocol	  (Otten	  et	  al.,	  2008;	  Stroncek	  et	  al.,	  2009).	  I	  therefore	  expanded	  all	  ECFC	  cultures	  for	  
at	   least	  8	  passages	  in	  order	  to	  identify	  isolates	  that	  were	  stable	  between	  passages	  3-­‐8	  and	  suitable	  
for	  functional	  and	  mechanistic	  studies.	  In	  fact,	  many	  cultures	  could	  be	  expanded	  beyond	  10	  passages	  
and	   some	   achieved	   14–17	   passages	   without	   showing	   signs	   of	   senescence	   or	   an	   increase	   in	   PDTs.	  
Cryopreservation	  is	  necessary	  in	  order	  to	  maintain	  a	  store	  of	  early	  passage	  cells.	  Importantly,	  there	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was	   no	   apparent	   difference	   in	   the	   proliferative	   capacity	   or	   PDTs	   of	   individual	   ECFC	   isolates	  when	  
compared	  before	  and	  after	  cryopreservation.	  
A	   number	   of	   factors	   influence	   the	   ability	   to	   establish	   cultures	   of	   ECFCs	   from	   peripheral	   blood.	   In	  
addition	  to	  the	  laboratory	  protocol,	  the	  source	  of	  the	  blood	  sample	  may	  affect	  the	  ability	  to	  derive	  
colonies	  and	  factors	  such	  as	  the	  donor’s	  age	  and	  disease	  status	  are	  likely	  to	  be	  important.	  Numerous	  
studies	   have	   for	   example	   demonstrated	   a	   negative	   correlation	   between	   the	   number	   of	   circulating	  
hematopoietic	  progenitor	  cells	  and	  increasing	  age	  (Thijssen	  et	  al.,	  2006;	  Hoetzer	  et	  al.,	  2007;	  Thum	  et	  
al.,	   2007;	   Umemura	   et	   al.,	   2008;	   Sun	   et	   al.,	   2009b)	   and	   others	   have	   pointed	   to	   an	   age-­‐related	  
functional	   impairment	   rather	   than	   a	   decline	   in	   number	   (Scheubel	   et	   al.,	   2003;	   Heiss	   et	   al.,	   2005).	  
Aging	  has	  also	  been	  associated	  with	  a	  pro-­‐apoptotic	  phenotype	  and	  reduced	  telomere	  length,	  which	  
may	   contribute	   to	   differences	   in	   the	   number	   and/or	   function	   of	   these	   cells	   (Kushner	   et	   al.,	   2009;	  
Kushner	   et	   al.,	   2011).	   Recently,	   it	   has	   been	   reported	   that	   older	   healthy	   rhesus	  monkey	   produces	  
lower	   frequency	   of	   ECFC	   colonies	   (Shelley	   et	   al.,	   2012)	   that	   supports	   the	   findings	   in	   this	   study	   in	  
human,	   demonstrating	   an	   age-­‐related	   reduction	   in	   the	   colony-­‐forming	   capacity	   of	   ECFCs	   from	  
healthy	  adults.	  This	  may	  also	  reflect	  an	  age-­‐related	  reduction	  in	  the	  number	  of	  circulating	  endothelial	  
progenitor	   cells,	   suggesting	   that	   larger	   volumes	   of	   blood	   (>50ml)	   might	   be	   required	   in	   order	   to	  
establish	  colonies	  from	  donors	  over	  50	  years	  of	  age.	  The	  average	  number	  (2.28	  colonies	  per	  50	  ml	  of	  
blood)	  and	  median	  frequency	  of	  colonies	  (0.17/107	  MNCs)	  obtained	  from	  healthy	  volunteers	  (median	  
age	   27	   years,	   range	   23-­‐57	   years)	   in	   this	   study	   is	   comparable	   with	   the	   values	   reported	   in	   other	  
investigations	  involving	  volunteers	  of	  a	  similar	  age	  (Ingram	  et	  al.,	  2004;	  Shepherd	  et	  al.,	  2006b;	  Yoder	  
et	  al.,	  2007;	  Thill	  et	  al.,	  2008).	  In	  keeping	  with	  my	  results,	  studies	  of	  older	  subjects	  with	  median	  ages	  
of	  67	  years	  (range	  42-­‐81	  years)	  and	  52	  years	  (range	  32-­‐68	  years)	  obtained	  markedly	  fewer	  colonies,	  
with	  median	  frequencies	  of	  0	  and	  0.05/107	  MNCs	  respectively	  (Massa	  et	  al.,	  2009;	  Rosti	  et	  al.,	  2010).	  
In	  addition,	  Xia	  and	  colleagues	  recently	  described	   impaired	  functions	  of	  ECFCs	  from	  elderly	  healthy	  
volunteers	   (mean	   age	   68.4±2.5	   years),	   displaying	   migration	   and	   adhesion	   activities	   that	   were	  
significantly	   lower	   than	   those	   from	  younger	   subjects	   (Xia	  et	  al.,	   2012b).	   It	   is	   therefore	  noteworthy	  
that	   I	   found	   that	   the	  ECFCs	   capable	  of	   long-­‐term	  culture,	  with	  expansion	  over	  at	   least	  8	  passages,	  
were	  only	   derived	   from	   the	   younger	   volunteers	  whereas	   they	  were	  obtained	   from	  a	  broader	   age-­‐
range	   of	   patients	  with	   IPAH.	   In	   fact,	   the	   frequency	   and	   growth	   of	   ECFCs	   is	   known	   to	   change	  with	  
gestational	  age	  (Baker	  et	  al.,	  2009;	  Borghesi	  et	  al.,	  2009)	  and	  a	  substantially	  higher	  frequency	  of	  ECFC	  
colonies	  has	  been	  obtained	   from	  umbilical	  cord	  blood	  versus	  adult	  peripheral	  blood	  (Ingram	  et	  al.,	  
2004;	   Ligi	   et	   al.,	   2011).	   Cells	   from	   cord	   blood	   also	   form	   colonies	   quicker,	   display	   a	   much	   higher	  
proliferative	  capacity	  and,	  unlike	  adult	  cells,	  have	  the	  ability	  to	  form	  secondary	  and	  tertiary	  colonies	  
in	  clonogenic	  assays	  (Ingram	  et	  al.,	  2004).	  Importantly,	  the	  enhanced	  growth	  characteristics	  of	  cord	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blood	  ECFCs,	  compared	  with	  adult	  ECFCs,	  were	  associated	  with	  relatively	  high	   levels	  of	   telomerase	  
activity	  (Ingram	  et	  al.,	  2004).	  In	  keeping	  with	  my	  results,	  this	  growing	  body	  of	  evidence	  indicates	  that	  
age	  has	  a	  negative	  impact	  on	  the	  frequency	  and	  proliferative	  capacity	  of	  ECFCs.	  While	  children	  with	  
IPAH	  may	  also	  produce	  more	  ECFC	  colonies	  than	  adult	  patients	  (Smadja	  et	  al.,	  2011b),	  I	  did	  not	  find	  
any	  correlation	  between	  the	  number/frequency	  of	  ECFC	  colonies	  and	  the	  age	  of	  the	  IPAH	  patients	  in	  
this	   study.	   I	   did	   not	   determine	   the	   telomerase	   activity	   of	   the	   cells,	   but	   observed	   that	   the	   average	  
time	  before	   the	  appearance	  of	  colonies,	   the	  rate	  of	  growth	  and	  clonogenic	  capacity	  of	  ECFCs	   from	  
IPAH	   patients	   was	   similar	   to	   that	   of	   cells	   derived	   from	   healthy	   volunteers.	   Duong	   and	   colleagues	  
recently	   reported	   the	   isolation	   and	   characterisation	   of	   ECFCs	   from	   the	   pulmonary	   artery	  
endothelium	  of	  patients	  with	  end-­‐stage	  PAH	  (Duong	  et	  al.,	  2011).	  They	  also	  observed	  no	  difference	  
in	  the	  number	  of	  ECFC	  colonies	  from	  PAH	  patients	  and	  control	  subjects.	  	  	  
Several	  studies	  have	  suggested	  that	  the	  number/frequency	  of	  ECFC	  colonies	  cultured	  from	  PBMNCs	  
is	  raised	  in	  a	  variety	  of	  inflammatory	  and	  vascular-­‐related	  disease	  states	  including	  acute	  myocardial	  
infarction	  (Massa	  et	  al.,	  2009;	  Meneveau	  et	  al.,	  2011),	  coronary	  artery	  disease	  (Guven	  et	  al.,	  2006)	  
and	   rheumatoid	   arthritis	   (Jodon	   de	   Villeroche	   et	   al.,	   2010)	  when	   compared	  with	   healthy	   controls,	  
while	  only	  a	  few	  studies	  have	  reported	  lower	  ECFC	  numbers	  and	  growth	  in	  disorder	  including	  chronic	  
kidney	  disease	  (Krenning	  et	  al.,	  2009)	  and	  type	  2	  diabetes	  mellitus	  (Ingram	  et	  al.,	  2008;	  Leicht	  et	  al.,	  
2011)	  (further	  discussed	  in	  section	  1.6.3).	  Although	  the	  number	  and	  frequency	  of	  ECFC	  colonies	  was	  
similar	  between	  healthy	  volunteers	  and	   IPAH	  patients,	   these	  were	  significantly	  greater	   in	   the	   IPAH	  
patients	  who	  were	  more	  severely	  functionally	  impaired	  (WHO	  functional	  classes	  III/IV	  versus	  I/II)	  and	  
also	   displayed	   lower	   exercise	   capacity	   (6MWD).	   Otherwise	   there	   was	   no	   correlation	   between	  
establishment	  of	  ECFCs	  in	  culture	  and	  baseline	  haemodynamic	  measurements	  or	  targeted	  therapies	  
for	  PAH.	  Interestingly,	  Smadja	  and	  colleagues	  have	  also	  found	  that	  the	  number	  of	  ECFC	  colonies	  was	  
not	  affected	  by	   treatment	  with	  endothelin	   receptor	  antagonists	   and/or	  PDE5	   inhibitors	   in	   children	  
with	   PAH,	   but	   was	   increased	   when	   subcutaneous	   treprostinil	   treatment	   was	   combined	   with	   the	  
other	  two	  therapies	  (Smadja	  et	  al.,	  2011b).	  I	  cannot	  exclude	  the	  possibility	  that	  a	  similar	  effect	  may	  
occur	   in	   adult	   IPAH	   patients	   as	   only	   two	   subjects	   in	   the	   present	   study	  were	   prescribed	   the	   same	  
combination	  of	  drugs	  (see	  Appendix	  2,	  Table	  A2.2).	  	  
The	  endothelial	   phenotype	  of	   ECFCs	  was	   verified	  by	   flow	   cytometry	   and	   immunocytochemistry	  on	  
cultures	  derived	  from	  up	  to	  16	  healthy	  volunteers	  and	  13	  patients	  with	  IPAH.	  Cells	  from	  both	  groups	  
exhibited	  a	  typical	  endothelial-­‐like	  phenotype,	  showing	  cobblestone	  morphology,	  staining	  positively	  
for	   the	   typical	   endothelial	   surface	   markers	   CD31	   (PECAM-­‐1),	   CD144	   (VE-­‐cadherin)	   and	   CD309	  
(VEGFR2),	  and	  displaying	  vWF-­‐immunoreactivity	   localised	   to	  endothelial	   cell-­‐specific	  Weibel-­‐Palade	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bodies.	  Varying	  amounts	  of	  CD34	   labelling	  was	  observed	   (average	  14.7	  –	  20.0%	  of	  ECFCs)	  whereas	  
≥99%	  of	  cells	  were	  negative	  for	  the	  immature	  marker	  CD133	  and	  haematopoietic	  marker	  CD45.	  This	  
is	   consistent	  with	   the	   view	   that	   ECFCs	   do	   not	   originate	   from	  CD133+	   cells	   or	  CD45+	   hematopoietic	  
precursors	  (Case	  et	  al.,	  2007;	  Timmermans	  et	  al.,	  2007;	  Mund	  et	  al.,	  2012).	  Importantly,	  the	  CD31+,	  
VEGFR2+,	   CD45-­‐,	   CD133-­‐	   phenotype	   of	   ECFCs	   in	   this	   study	   corresponds	   with	   that	   of	   other	  
investigations	  on	  ECFCs	  from	  adult	  peripheral	  and	  umbilical	  cord	  blood	  (Ingram	  et	  al.,	  2004;	  Ingram	  
et	  al.,	  2005;	  Yoon	  et	  al.,	  2005;	  Thill	  et	  al.,	  2008;	  Baker	  et	  al.,	  2009;	  Fujinaga	  et	  al.,	  2009;	  Stroncek	  et	  
al.,	  2009;	  van	  Beem	  et	  al.,	  2009;	  Ligi	  et	  al.,	  2011).	  	  
Despite	  the	  fact	   that	  ECFCs	   lacked	  the	  haematopoietic	  marker	  CD45,	   I	   found	  that	  a	  sub-­‐population	  
(~17%)	   of	   ECFCs	   and	   HPAECs	   and	   a	   minority	   of	   HUVECs	   were	   positive	   for	   the	   monocytic	   marker	  
CD14.	   In	  fact,	  examination	  of	  the	  representative	  flow	  cytometry	  plots	  published	   in	  other	  studies	  of	  
human	  ECFCs	  and	  mature	  ECs	  (Ingram	  et	  al.,	  2005;	  Thill	  et	  al.,	  2008;	  Stroncek	  et	  al.,	  2009)	  suggests	  
that	  this	  may	  not	  be	  an	  unusual	  phenomenon.	  However,	  the	  apparent	  expression	  of	  CD14	  on	  mature	  
ECs	   raises	  doubt	  about	   the	   specificity	  of	   the	  CD14	  antibodies	  and	   flow	  cytometry	  analysis.	  Cloning	  
cylinders	  were	  generally	  used	  to	  isolate	  individual	  ECFC	  colonies	  but	  I	  cannot	  exclude	  the	  possibility	  
that	  the	  cultures	  were	  contaminated	  by	  cells	  with	  a	  monocytic	  lineage,	  particularly	  as	  distinct	  CD14+	  
mesenchymal-­‐like	   cells	   were	   found	   to	   occasionally	   overrun	   some	   colonies	   (<4%)	   when	   they	   were	  
expanded.	  	  
Binding	  of	  the	  lectin	  UEA-­‐1	  is	  a	  typical	  characteristic	  of	  ECs	  and	  has	  been	  used	  to	  characterise	  ECFCs	  
in	  this	  as	  well	  as	  other	  studies	  (Yoder	  et	  al.,	  2007;	  Otten	  et	  al.,	  2008;	  Ligi	  et	  al.,	  2011).	  UEA-­‐1	  can	  bind	  
to	   ECs	   from	   proximal	   blood	   vessels	   (Conrad-­‐Lapostolle	   et	   al.,	   1996)	   as	   well	   as	   distal	   microvessels	  
(Gargett	  et	  al.,	  2000;	  Garrafa	  et	  al.,	  2006).	  Other	  lectins	  may	  distinguish	  between	  ECs	  from	  different	  
regions	   of	   the	   vascular	   bed	   and	   thereby	   provide	   further	   insight	   into	   the	   phenotype	   and	   possible	  
origins	   of	   circulating	   ECFCs.	   The	   lectin	   Griffonia	   simplicifolia	   is	   considered	   a	   specific	   marker	   of	  
microvascular	  ECs,	  including	  human	  pulmonary	  microvascular	  ECs	  (Comhair	  et	  al.,	  2012).	  I	  observed	  
no	  apparent	   immunostaining	  of	  ECFCs	  using	  this	   lectin,	  but	  the	  observation	   is	  uncertain	  due	  to	  the	  
lack	  of	  a	  positive	  control.	  	  Ideally,	  this	  should	  be	  examined	  together	  with	  other	  markers,	  such	  as	  the	  
macrovascular	   EC-­‐specific	  Helix	   Pomatia	   (Comhair	   et	   al.,	   2012)	   and	  microvascular	   EC	  marker	  CD36	  
(Swerlick	  et	  al.,	  1992),	  	  and	  staining	  of	  appropriate	  mature	  ECs	  as	  controls.	  	  	  
The	  EC	  surface	  marker	  CD31	  appeared	  to	  be	  stably	  expressed	  in	  >99%	  of	  cells	  when	  examined	  over	  2-­‐
5	   consecutive	   passages	   in	   a	   subgroup	   of	   ECFC	   cultures.	   The	   proportion	   of	   VEGFR2+	   ECFCs	   was	  
relatively	   high	   (>90%	   of	   cells)	   during	   earlier	   passages,	   but	   tended	   to	   decline	   (74-­‐84%	   of	   cells)	   at	  
higher	  passage.	  Another	  group	  has	  recently	  reported	  a	  similar	  observation,	  albeit	  with	  far	  fewer	  cells	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exhibiting	  VEGFR2	  expression	  (Wang	  et	  al.,	  2011).	  This	  may	  be	  significant	  as	  an	  association	  has	  been	  
found	  between	  VEGFR2	  expression	  and	  the	  number	  of	  colonies	  or	  ECFCs	  obtained	  in	  culture	  (Thill	  et	  
al.,	  2008).	  A	  decline	  in	  VEGFR2	  expression	  might	  also	  be	  accompanied	  by	  a	  reduction	  in	  cell	  survival	  
and	   the	   mitogenic	   effects	   of	   VEGF	   (Gerber	   et	   al.,	   1998).	   Nonetheless,	   there	   was	   no	   apparent	  
correlation	  between	  the	  number	  or	  frequency	  of	  ECFC	  colonies	  and	  the	  proportion	  of	  VEGFR2+	  cells	  
determined	  during	  the	  subsequent	  expansion	  of	  ECFCs	  in	  culture.	  The	  receptor	  tyrosine	  kinase	  c-­‐kit	  
was	   demonstrated	   on	   ≥50%	   of	   ECFCs.	   It	   is	   considered	   to	   be	   important	   in	   the	   recruitment	   of	  
progenitor	   cells	   from	   the	   bone	   marrow	   in	   to	   the	   circulation	   (Heissig	   et	   al.,	   2002)	   and	   is	   also	  
expressed	   by	   mature	   ECs,	   influencing	   for	   example	   the	   survival,	   migration	   and	   tube	   formation	   of	  
HUVECs	  in	  culture	  (Matsui	  et	  al.,	  2004).	  But	  in	  the	  present	  study	  no	  association	  was	  found	  between	  
the	  frequency	  of	  establishing	  ECFC	  colonies	  and	  proportion	  of	  c-­‐kit+	  ECFCs.	  	  
The	  proportion	  of	   ECFCs	  exhibiting	  CXCR4	  expression	   correlated	  with	   the	  number	  of	  primary	  ECFC	  
colonies	   from	   healthy	   volunteers,	   but	   not	   from	   IPAH	   patients.	   CXCR4	   expression	   modulates	   the	  
recruitment,	   migration	   and	   homing	   of	   progenitor	   cells	   to	   the	   injured	   endothelium	   via	   a	   stromal	  
derived	   factor-­‐1α	   	   (SDF-­‐1α,	  also	  known	  as	  CXCL12)	  gradient	   (Ceradini	  et	  al.,	  2004).	   Injection	  of	   the	  
CXCR4	   antagonist	   AMD3100	   induces	   a	   potent	   and	   rapid	   increase	   in	   the	   number	   of	   ECFC	   colonies	  
obtained	  from	  mice	  and	  healthy	  humans,	  reflecting	  the	  mobilisation	  of	  bone	  marrow	  cells	  (Shepherd	  
et	  al.,	  2006b;	  Pitchford	  et	  al.,	  2009).	  CXCR4	  is	  also	  important	  in	  regulating	  the	  function	  of	  ECFCs,	  as	  
inhibition	  with	  CXCR4-­‐small	  hairpin	  RNA	  (shRNA)	  or	  specific	  monoclonal	  antibodies	  cause	  a	  reduction	  
in	   SDF-­‐1α-­‐induced	   cell	   migration	   and	   adhesion,	   and	   attenuates	   reendothelisation	   by	   ECFCs	   in	   a	  
murine	  carotid	  artery	  injury	  model	  (Smadja	  et	  al.,	  2005;	  Xia	  et	  al.,	  2012a).	  Conversely,	  the	  induction	  
of	  CXCR4	  expression	   is	   accompanied	  by	  an	   increase	   in	   the	  proliferative	  and	  angiogenic	   capacity	  of	  
ECFCs	  (Smadja	  et	  al.,	  2010;	  Smadja	  et	  al.,	  2011a).	  The	  variation	  of	  CXCR4	  expression	   in	  ECFCs	  from	  
different	   cord	   blood	   samples	   also	   correlates	   with	   their	   migratory	   ability	   and	   neovascularisation	  
capacity	   in	   a	   hind	   limb	   ischemia	  model	   and	   lead	   to	   the	   suggestion	   that	   CXCR4	   expression	  may	  be	  
used	  as	   criteria	   to	   select	   ECFCs	  possessing	   superior	  proliferative	   and	   functional	   abilities	   (Oh	  et	   al.,	  
2010).	  It	  is	  tempting	  to	  speculate	  that	  CXCR4	  expression	  could	  be	  correlated	  to	  the	  impaired	  colony	  
forming	   ability	   in	   older	   healthy	   volunteers,	   but	   subjects’	   age	   did	   not	   correlate	   with	   the	   CXCR4	  
expression	  of	  the	  isolated	  ECFCs.	  CXCR4	  expression	  do	  not	  correlate	  with	  the	  ECFC	  colony	  formation	  
in	  IPAH	  patients,	  possibly	  indicate	  that	  ECFCs	  mobilise	  into	  the	  circulation	  irrespective	  of	  their	  CXCR4	  
expression	  in	  IPAH	  patients.	  However,	  CXCR4	  expression	  was	  not	  concurrently	  determined	  with	  the	  
functional	   analysis	   in	   this	   study,	   therefore	   it	   is	   not	   possible	   to	   determine	   the	   exact	   role	   of	   CXCR4	  
expression	  in	  the	  IPAH-­‐ECFCs.	  	  As	  antagonising	  CXCR4	  has	  attenuated	  disease	  progression	  in	  hypoxic	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model	  of	  PH	  (Young	  et	  al.,	  2009;	  Yu	  and	  Hales,	  2011),	  these	  provide	  scope	  for	  future	  investigation	  in	  
the	  role	  of	  CXCR4	  expression	  in	  ECFCs	  in	  the	  development	  of	  IPAH.	  	  
There	  was	   no	   apparent	   difference	   between	   the	   expression	   of	   endothelial	  markers	   by	   ECFCs	   from	  
healthy	  volunteers	  and	  IPAH	  patients	  or	  ECFCs	  and	  mature	  ECs.	  	  A	  number	  of	  studies	  have	  used	  flow	  
cytometry	   and	   immunocytochemistry	   and	   described	   the	   comparable	   characteristics	   of	   ECFCs	   from	  
healthy	  subjects	  and	  patients	  with	  various	  diseases	  (Avouac	  et	  al.,	  2008;	  Stroncek	  et	  al.,	  2009)	  as	  well	  
as	   their	   similarity	   to	   mature	   ECs,	   including	   those	   from	   the	   umbilical	   vein,	   aorta	   and	   dermal	  
microvasculature	  (Ingram	  et	  al.,	  2005;	  Avouac	  et	  al.,	  2008;	  Thill	  et	  al.,	  2008;	  Stroncek	  et	  al.,	  2009).	  A	  
study	   has	   also	   reported	   similarities	   in	   molecular	   markers	   between	   mature	   human	   (dermal	  
microvascular)	  ECs	  and	  ECFCs	   (Medina	  et	  al.,	  2010),	  but	  other	  studies	  have	  reported	  differences	   in	  
functional	  characteristics	  that	  distinguish	  ECFCs	  from	  mature	  ECs	  (as	  discussed	  in	  section	  1.5.4).	  	  
A	   number	   of	   studies	   have	   also	   described	   disease-­‐related	   differences	   in	   gene	   and/or	   protein	  
expression	  (Tan	  et	  al.,	  2010;	  Avouac	  et	  al.,	  2011)	  as	  well	  as	  the	  ability	  of	  ECFCs	  to	  proliferate,	  form	  
tubes	  and	  migrate	   in	   vitro	   (Krenning	  et	   al.,	   2009;	   Toshner	  et	   al.,	   2009;	   Tan	  et	   al.,	   2010;	   Ligi	   et	   al.,	  
2011;	   Starke	   et	   al.,	   2011),	   but	   few	   studies	   to	   date	   have	   examined	   ECFCs	   from	   patients	  with	   PAH.	  
Asosingh	  et	  al.	  derived	  similar	  numbers	  of	  ECFCs	   from	  the	  peripheral	  blood	  MNCs	  of	  patients	  with	  
IPAH	  (3	  out	  of	  5)	  and	  healthy	  controls	   (5	  out	  of	  7),	  but	  did	  not	  explore	  colony	  frequency	  and	  ECFC	  
function	  in	  vitro	  (Asosingh	  et	  al.,	  2008).	  In	  another	  study,	  Toshner	  and	  co-­‐workers	  provided	  evidence	  
of	  dysfunctional	  ECFCs	  cultured	   from	  three	  patients	  with	  known	  BMPR2	  mutations,	   the	  cells	  being	  
more	  proliferative	  and	  less	  able	  to	  form	  tubes	  in	  Matrigel	  than	  ECFCs	  derived	  from	  control	  subjects	  
(Toshner	   et	   al.,	   2009).	   In	   children	   with	   PH	   associated	   with	   congenital	   heart	   disease,	   ECFCs	   were	  
found	   to	   be	  more	   frequent	   in	   those	   with	   surgically	   reversible	   PAH	   than	   irreversible	   PAH	   or	   IPAH	  
(Smadja	  et	  al.,	  2011b).	  Finally,	   it	  has	  recently	  been	  shown	  that	  ECFCs	  are	  present	   in	  the	  pulmonary	  
artery	  endothelium	  as	  well	  as	  peripheral	  blood	  of	  PAH	  patients,	  with	  and	  without	  BMPR2	  mutation	  
and	  mosaic	   deletion	   of	   the	   X-­‐chromosome,	   and	   these	   cells	  may	   be	  more	   proliferative	   than	   those	  
derived	   from	  donor	   lung	   tissues	   (Duong	  et	   al.,	   2011).	   It	   is	   important	   to	   investigate	  whether	   ECFCs	  
derived	  from	  the	  peripheral	  blood	  of	   IPAH	  patients	  exhibit	  differences	   in	  endothelial	   functions	  that	  
can	   distinguish	   them	   from	   healthy	   volunteers,	   which	   could	   improve	   our	   understanding	   in	   the	  
endothelial	  dysfunctions	  underlying	  the	  pulmonary	  vascular	  remodelling	  in	  IPAH	  patients.	  
In	   the	  next	   chapter	   I	   determine	   the	   functional	   phenotype	   of	   ECFCs	   (as	   assessed	   by	   proliferation,	  
apoptosis,	   Matrigel	   tube	   formation,	   migration	   and	   barrier	   function)	   and	   explore	   possible	  
differences	  between	  cells	  derived	  from	  healthy	  volunteers	  and	  IPAH	  patients,	  using	  selected	  stable	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Chapter	  4	  -­‐	  Distinct	  phenotype	  of	  ECFCs	  from	  IPAH	  patient	  
	  
4.1	   Introduction	  
One	   of	   the	   histological	   hallmarks	   of	   end-­‐stage	   PAH	   is	   the	   focal	   proliferation	   of	   ECs	   in	   plexiform	  
lesions.	   It	   has	   been	   postulated	   that	   an	   initial	   apoptosis-­‐inducing	   insult	   gives	   rise	   to	   ECs	   that	   are	  
proliferative	   and	   resistant	   to	   apoptosis	   (Sakao	   et	   al.,	   2005)	   and,	   in	   the	   plexiform	   lesions	   of	   IPAH	  
patients,	   a	  monoclonal	   proliferation	  of	   cells	   (Lee	   et	   al.,	   1998).	   Vascular	   lesions	   in	   PAH	  also	   exhibit	  
inflammatory/immune	   cell	   infiltration	   and	   cells	   displaying	   progenitor	   cell	   markers	   such	   as	   CD133	  
(Majka	  et	  al.,	  2008;	  Toshner	  et	  al.,	  2009),	  but	  it	  is	  not	  known	  if	  the	  latter	  are	  derived	  from	  the	  tissue	  
or	   circulation.	  The	   isolation	  and	  culture	  of	  pulmonary	  ECs	   from	  explanted	   IPAH	   lungs	  has	   revealed	  
functional	   differences	   in	   several	   in	   vitro	   assays	   compared	   with	   control	   cells,	   including	   higher	  
proliferation	  and	  transwell	  migration	  and	  reduced	  sensitivity	  to	  apoptosis	  (Masri	  et	  al.,	  2007;	  Tu	  et	  
al.,	  2011;	  Tu	  et	  al.,	  2012).	  It	  is	  plausible	  that	  the	  dysfunctional	  characteristics	  of	  these	  pulmonary	  ECs	  
might	  also	  reflect	  the	  angioproliferative	  state	  of	  plexiform	  lesions.	  	  
Blood-­‐derived	  ECFCs	  from	  IPAH	  patients	  might	  manifest	  the	  dysfunctional	  characteristics	  of	  diseased	  
pulmonary	  ECs	  in	  vitro.	  In	  fact,	  functions	  of	  ECFCs	  have	  been	  examined	  in	  variety	  of	  vascular	  diseases	  
(Fernandez	  et	  al.,	  2005;	  Fernandez	  et	  al.,	  2007;	  Ingram	  et	  al.,	  2008;	  Thill	  et	  al.,	  2008;	  Fujinaga	  et	  al.,	  
2009;	   Tan	   et	   al.,	   2010;	   Ligi	   et	   al.,	   2011;	   Starke	   et	   al.,	   2011),	   but	   few	   studies	   have	   explored	   the	  
functional	   characteristics	   in	   PAH.	   Toshner	   and	   colleagues	   found	   that	   ECFCs	   from	   3	   patients	   with	  
BMPR2	  gene	  mutations	  proliferated	  significantly	  more	  over	   the	  course	  of	  7	  days	  than	  cells	  derived	  
from	  healthy	  controls	  (Toshner	  et	  al.,	  2009).	  It	  is	  doubtful	  however	  whether	  BMPR2	  mutations	  are	  a	  
prerequisite	  as	  studies	  on	  ECs	  derived	   form	  explanted	   lung	  tissues	   indicate	  that	   IPAH	  patients	  may	  
exhibit	   a	   proliferative	   EC	   phenotype	   irrespective	   of	  whether	   they	   carry	   a	   known	  BMPR2	  mutation	  
(Masri	  et	  al.,	  2007;	  Tu	  et	  al.,	  2011).	  This	  is	  also	  in	  keeping	  with	  the	  suggestion	  that	  hyperproliferative	  
ECFCs	  may	  reside	  in	  the	  pulmonary	  artery	  wall	  of	  patients	  with	  various	  forms	  of	  PAH	  (Duong	  et	  al.,	  
2011).	  
Therefore	  I	  hypothesised	  that	  blood-­‐derived	  ECFCs	  from	  IPAH	  patients	  are	  functionally	  distinct	  from	  
healthy	  volunteer	  cells	  and	  display	  characteristics	  similar	  to	  those	  reported	  for	  ECs	  cultured	  directly	  
from	  the	  diseased	  lung.	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The	  objectives	  of	  this	  chapter	  are:	  
• To	  confirm	  findings	  of	  Chapter	  3	  in	  regard	  to	  the	  proliferative	  capacity	  of	  ECFCs,	  as	  assessed	  
by	  direct	  cell	  counting	  and	  measurement	  of	  DNA	  synthesis.	  
• To	   investigate	   the	   functional	   differences	   between	   ECFCs	   from	   IPAH	   patients	   and	   healthy	  
volunteers.	   These	   include	   their	   angiogenic	   and	  migratory	   capacities,	   response	   to	  apoptosis	  
and	  barrier	  functions.	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4.2	   Methods	  
See	  Chapter	  2	  for	  detailed	  experimental	  materials	  and	  protocol.	  
All	   cell	   populations	   (passages	   4-­‐7)	   for	   functional	   assays	   were	   selected	   according	   to	   the	   following	  
criteria:	  
• Endothelial	  phenotype	  confirmed	  by	  flow	  cytometry	  
• Consistent	  population	  doubling	  times	  
• Continual	  growth	  beyond	  at	  least	  8	  passages	  
All	  data	  presented	  are	  representative	  of	  at	  least	  2	  repeated	  experiments.	  	  	  	  
	  
4.2.1	   Cell	  proliferation	  and	  DNA	  synthesis	  
Proliferation	  was	  assessed	  by	  viable	  cell	  counts	  and	  measuring	  DNA	  synthesis,	  as	  determined	  by	  the	  
BrdU	   incorporation	   assay.	   Cell	   counting	   was	   performed	   in	   triplicate,	   with	   ECFCs	   from	   healthy	  
volunteers	   (n=4)	   and	   IPAH	   patients	   (n=6)	   seeded	   in	   24-­‐well	   plates	   (7600	   cells/well)	   in	   EGM-­‐2	   and	  
20%	  FBS.	  The	  medium	  was	  changed	  every	  48h	  and	  trypsinised	  cells	  were	  counted	  on	  days	  4	  and	  7	  
with	  a	  haemocytometer.	  BrdU	  assay	  was	  performed	  with	  ECFCs	  from	  each	  groups	  (n=6–7)	  using	  the	  
optimised	  protocol	  as	  described	  in	  Chapter	  2.12.1.	  
	  
4.2.2	   Apoptosis	  assays	  	  
Caspase-­‐3/7	   activation/cleavage	   and	   subsequent	   cleavage	   of	   its	   substrate	   poly(ADP-­‐ribose)	  
polymerase	   (PARP)	  are	  hallmarks	  of	  apoptosis.	  Optimisation	  of	   the	  caspase-­‐3/7	  assay	   is	  detailed	   in	  
Chapter	   2.12.2.	   For	   the	   assessment	   of	   caspase	   3	   and	  PARP	   cleavage,	   protein	  was	   harvested	   in	   ice	  
cold	   RIPA	   buffer	   and	   equal	   amounts	   were	   (40	   μg/lane)	   separated	   by	   SDS-­‐PAGE,	   blotted	   onto	  
nitrocellulose	  membranes	  and	  probed	  using	  specific	  antibodies,	  as	  detailed	  in	  Chapter	  2.11.	  	  
Serum	   deprivation-­‐induced	   apoptosis	   was	   assessed	   in	   ECFCs	   from	   the	   healthy	   volunteers	   (n=7	   in	  
total)	  and	  IPAH	  patients	  (n=8	  in	  total)	  and	  HPAECs	  (measured	  in	  quadruplicate),	  following	  incubation	  
in	  serum-­‐free	  EBM-­‐2	  medium	  for	  24h	  and	  48h.	   	  The	  same	  treatments	  were	  also	  applied	   to	  cells	   in	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additional	   adjacent	   wells	   in	   clear-­‐bottomed	   96-­‐well	   plate	   to	   those	   used	   for	   determining	   caspase	  
activity	   and	   western	   blotting,	   enabling	   concurrent	   microscopic	   visualisation	   and	   the	   capture	   of	  
images	  showing	  of	  cell	  morphology.	  	  
	  
4.2.3	   Matrigel	  tube	  formation	  assay	  
Matrigel	   tube	   formation	   was	   examined	   using	   ECFCs	   from	   healthy	   volunteers	   (n=3-­‐5)	   and	   IPAH	  
patients	   (n=3-­‐6)	   and	   HPAECs	   (measured	   in	   triplicate).	   	   Tube	   formation	   was	   assessed	   in	   different	  
conditions,	   using	   either	   high	   concentration	   (HC)-­‐	   or	   growth	   factor	   reduced	   (GFR)-­‐basement	  
membrane	  matrix	  (Matrigel)	  and	  cells	  suspended	  in	  EBM-­‐2	  containing	  1%	  FBS	  or	  no	  serum.	  In	  some	  
experiments,	   cells	   were	   also	   serum-­‐deprived	   for	   24h	   before	   seeding	   on	   GFR-­‐Matrigel.	   Data	   is	  
presented	   as	   the	   average	   total	   tube	   length	   per	   field	   of	   view	   of	   values	   from	   2	   random	   fields	   in	  
triplicate	  wells.	  	  
	   	  
4.2.4	   Wound	  healing	  assay	  
A	  wound	   healing	   (scratch)	   assay	   was	   used	   to	   assess	   the	   planar	  migratory	   capacity	   of	   ECFCs	   from	  
healthy	  volunteers	   (n=3-­‐6)	  and	   IPAH	  patients	   (n=4-­‐6)	  and	  HPAECs	  (measured	   in	  triplicate).	  Wounds	  
were	  created	  in	  confluent	  monolayers	  of	  cells,	  with	  triplicate	  wells	  being	  used	  for	  each	  experimental	  
condition.	   Cells	   were	   incubated	   in	   either	   EBM-­‐2	   with	   1%	   FBS	   or	   EGM-­‐2	   (with	   endothelial	   growth	  
factors)	  containing	  20%	  FBS,	  and	  images	  were	  captured	  at	  baseline	  (0h),	  6h,	  18h	  and	  24h	  (EBM-­‐2	  and	  
1%	  FBS)	  or	  3h	  and	  21h	  (EGM-­‐2	  and	  20%	  FBS).	  Data	  is	  presented	  as	  a	  percentage	  of	  the	  area	  of	  the	  
wound	  recovered	  (closed)	  compared	  to	  baseline.	  	  
	  
4.2.5	   Assessment	  of	  endothelial	  barrier	  functions	  
Method	  for	  measuring	  gap	  junctional	  communication	  in	  ECFCs	  by	  FRAP	  is	  detailed	  in	  Chapter	  2.12.5.	  
Endothelial	   cell	   permeability	   measured	   by	   FITC-­‐dextran	   passage	   over	   endothelial	   monolayers	   is	  
detailed	  in	  Chapter	  2.12.6.	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4.3	   Results	  
4.3.1	   ECFCs	  from	  IPAH	  patients	  and	  healthy	  volunteers	  exhibit	  similar	  proliferation	  
As	   previously	   noted	   in	   Chapter	   3,	   ECFCs	   from	   IPAH	   patients	   grew	   at	   a	   comparable	   rate	   to	   cells	  
derived	  from	  healthy	  volunteers	  (Figure	  3.11	  and	  Table	  3.3).	  Similarly,	  no	  significant	  difference	  was	  
found	  between	  the	  two	  groups	  when	  ECFCs	  were	  counted	  after	  4	  and	  7	  days	  in	  culture	  (Figure	  4.1A).	  
The	  incorporation	  of	  BrdU	  varied	  between	  different	  ECFC	  populations,	  particularly	  when	  cultured	  in	  
EGM-­‐2	  and	  20%	  FBS,	  but	  again	  no	  significant	  difference	  was	   found	  between	  BrdU	   incorporation	   in	  
ECFCs	   from	   healthy	   volunteers	   and	   IPAH	   patients,	   and	   equivalent	   results	  were	   also	   obtained	  with	  
HPAECs	  (Figure	  4.1B).	  Comparison	  of	  DNA	  synthesis	  and	  cell	  counts	  in	  the	  same	  ECFC	  populations,	  3	  -­‐	  
4	  days	  after	  seeding,	  indicated	  that	  there	  was	  a	  significant	  association	  between	  the	  two	  parameters	  
(r	  =	  0.73,	  P	  =	  0.02,	  95%	  CI	  0.27	  to	  0.98;	  Figure	  4.1C),	  validating	  both	  BrdU	  assay	  and	  viable	  cell	  counts	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Figure	  4.1.	  ECFC	  proliferation	  and	  DNA	  synthesis.	  (A)	  Number	  of	  cells	  from	  healthy	  volunteers	  (n=4)	  
and	  IPAH	  patients	  (n=6),	  counted	  after	  4	  and	  7	  days	  in	  culture.	  (B)	  DNA	  synthesis	  measured	  by	  BrdU	  
incorporation	  (expressed	  as	  relative	  light	  units	  per	  second	  –	  RLU/s)	  in	  ECFCs	  from	  healthy	  volunteers	  
(n=6)	  and	  IPAH	  patients	  (n=7)	  and	  in	  HPAECs	  (n=3),	  following	  incubation	  in	  either	  EBM-­‐2	  and	  5%	  FBS	  
or	  EGM-­‐2	  and	  20%	  FBS	  for	  48h.	  ***,	  P	  <	  0.001,	  compared	  with	  cells	  cultured	  in	  EBM-­‐2	  and	  5%	  FBS.	  
Similar	  findings	  were	  observed	  in	  repeated	  experiments.	  (C)	  Correlation	  between	  BrdU	  incorporation	  
and	  cell	  number,	  determined	  3-­‐4	  days	  after	  the	  seeding	  of	  ECFCs	  from	  healthy	  volunteers	  (n=3)	  and	  
IPAH	  patients	  (n=4).	  Data	  presented	  as	  the	  mean±SEM	  of	  triplicate	  values	  from	  one	  sample.	  Statistics	  
in	  (A)	  and	  (B)	  are	  from	  Bonferroni	  post-­‐hoc	  analysis	  following	  two-­‐way	  repeated-­‐measures	  ANOVA.	  
Statistic	  shown	  in	  (C)	  are	  from	  Pearson’s	  correlation	  test.	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4.3.2	   ECFCs	  from	  IPAH	  patients	  are	  apoptosis-­‐resistant	  
Serum	  deprivation-­‐induced	  apoptosis	  was	  assessed	  by	  examining	  caspase-­‐3/7	  activity/cleavage	  and	  
PARP	  cleavage	  in	  distinct	  ECFC	  populations	  from	  a	  total	  of	  7	  healthy	  volunteers	  and	  8	  patients	  with	  
IPAH,	  as	  well	  as	   in	  HPAECs.	  Caspase	  3/7	  activity	   increased	  by	  24h	  and	  was	  significantly	  raised	  after	  
48h	  serum	  deprivation,	  compared	  with	  cells	  incubated	  in	  the	  control	  condition	  in	  the	  presence	  of	  2%	  
FBS	   (Figure	   4.2A-­‐B).	   Most	   importantly,	   ECFCs	   from	   IPAH	   patients	   exhibited	   a	   significantly	   smaller	  
increase	  (P	  <	  0.01)	  in	  caspase-­‐3/7	  activity	  when	  compared	  with	  either	  ECFCs	  from	  healthy	  volunteers	  
or	  HPAECs	  (Figure	  4.2A-­‐B).	  	  
The	  activity	  of	  the	  caspase-­‐3/7	  substrate	  declines	  once	  it	  is	  reconstituted	  and	  following	  storage	  for	  4	  
weeks	   at	   4°C	   the	   signal	   it	   provides	   is	   approximately	   75%	   of	   that	   obtained	   with	   fresh	   reagent.	  
Caspase-­‐3/7	  activity	  can	  therefore	  only	  be	  directly	  compared	  within	  each	  experiment,	  differences	  in	  
signal	   intensity	   between	   experiments	   (Figure	   4.2A-­‐B)	   reflecting	   variation	   in	   substrate	   activity.	  
Nevertheless,	   it	   is	   apparent	   that,	   in	   addition	   to	   displaying	   significantly	   less	   caspase-­‐3/7	   activity,	  
serum-­‐deprived	  ECFCs	  from	  IPAH	  patients	  also	  exhibit	  markedly	  less	  cleavage	  of	  caspase-­‐3	  and	  PARP	  
when	  compared	  with	  ECFCs	   from	  healthy	  volunteers	   (Figure	  4.2C).	   Interestingly,	   IPAH-­‐ECFCs	  under	  
basal	  conditions	  may	  also	  display	  less	  caspase-­‐3/7	  activity	  (Figure	  4.2A-­‐B)	  and	  cleavage	  of	  caspase-­‐3	  
or	  PARP	  than	  cells	  from	  healthy	  volunteers	  or	  HPAECs	  (Figure	  4.2C).	  In	  addition,	  adherent	  viable	  cells	  
were	  more	  frequently	  observed	  following	  serum-­‐deprivation	  of	  ECFCs	  from	  IPAH	  patients	  than	  ECFCs	  
from	  healthy	  volunteers	  or	  HPAECs	  (Figure	  4.3).	  Expression	  of	  the	  anti-­‐apoptotic	  modulators	  survivin	  
and	   apoptosis	   repressor	   with	   caspase	   recruitment	   domain	   (ARC)	   was	   assessed	   in	   ECFCs.	   No	  
significant	   differences	   were	   observed	   between	   control	   and	   IPAH	   cells	   under	   basal	   conditions.	  
However,	  serum	  deprivation	  for	  48h	  was	  associated	  with	  a	  marked	  reduction	  in	  survivin	  expression	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   B	  
Figure	  4.2.	  Serum	  deprivation-­‐induced	  apoptosis.	  (A)	  Caspase-­‐3/7	  activity	  in	  ECFCs	  (passage	  7)	  from	  
healthy	  volunteers	  (n=3)	  and	  IPAH	  patients	  (n=4),	  measured	  after	  24h	  and	  48h	  incubation	  in	  control	  
(EGM-­‐2	  with	  2%	  FBS)	  and	  serum-­‐deprived	  medium	  (EBM-­‐2	  with	  0%	  FBS).	  (B)	  Caspase-­‐3/7	  activity	  in	  
ECFCs	   (passage	   4),	   from	   a	   distinct	   set	   of	   healthy	   volunteers	   (n=4)	   and	   IPAH	   patients	   (n=4),	   and	  
HPAECs	  (triplicate)	  following	  serum-­‐deprivation	  for	  48h.	  Bars	  represent	  mean±SEM.	  Similar	  findings	  
observed	  in	  repeated	  experiments.	  Statistics	  shown	  from	  two-­‐way	   repeated	  measures	  ANOVA	  with	  
Bonferroni	  post-­‐hoc	  analysis.	  *,	  P	  <	  0.05,	  ***,	  P	  <	  0.001,	  versus	  their	  respected	  control	  condition.	  ##,	  
P	   <	   0.01,	   ###,	  P	   <	   0.001,	   comparison	  between	   indicated	   groups.	   (C)	   Representative	  western	   blots	  
showing	   the	   cleavage	   of	   poly(ADP-­‐ribose)	   polymerase	   (PARP;	   upper	   blot)	   and	   caspase-­‐3	   (middle	  
blots)	   following	  serum-­‐deprivation	   for	  48h	   in	  ECFCs	   from	  a	   total	  of	  3	  distinct	  healthy	  volunteers,	  3	  
IPAH	   patients	   and	   HPAECs.	   β-­‐actin	   (lower	   blots)	   was	   used	   to	   demonstrate	   equal	   protein	   loading.	  










Figure	   4.3.	   Effect	   of	   serum-­‐deprivation	   on	   ECFCs.	   Representative	   phase	   contrast	  
photomicrographs	  (4x	  magnification)	  showing	  cultures	  of	  ECFCs	  from	  distinct	  healthy	  volunteers	  
and	   IPAH	   patients	   and	   HPAECs.	   Decline	   in	   number	   of	   adherent	   viable	   cells,	   after	   serum-­‐
deprivation	  for	  48h,	  is	  less	  marked	  in	  ECFCs	  from	  IPAH	  patients	  versus	  those	  in	  healthy	  volunteers	  
and	  HPAECs.	  Control	  cells	  cultured	  in	  EGM-­‐2	  medium	  containing	  2%	  FBS.	  	  
Figure	  4.4.	  ECFCs	  survivin	  and	  ARC	  mRNA	  expression	  upon	  serum-­‐deprivation.	  qRT-­‐PCR	  analysis	  
of	   (A)	   survivin	   (n=7)	  and	   (B)	   apoptosis	   repressor	  with	  caspase	   recruitment	  domain	   (ARC)	  mRNA	  
expression	   (n=3)	   in	  ECFCs	   in	  both	  control	  (C)	  and	  serum-­‐deprived	  conditions	  (S)	  for	  48h.	  Data	   is	  
presented	   as	   mean±SEM	   expression,	   normalised	   to	   the	   expression	   of	   housekeeping	   reference	  
genes.	   Statistics	   shown	   from	   two-­‐way	   repeated	   measures	   ANOVA	   and	   Bonferroni	   post-­‐hoc	  
analysis.	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4.3.3	   Enhanced	  angiogenic	  capacity	  of	  ECFCs	  from	  IPAH	  patients	  
ECFCs	  from	  IPAH	  patients	  exhibited	  a	  greater	  angiogenic	  capacity	  compared	  with	  ECFCs	  derived	  from	  
healthy	  volunteers,	  this	  being	  apparent	  in	  each	  of	  the	  three	  conditions	  examined	  in	  the	  Matrigel	  tube	  
formation	  assay	  (Figure	  4.5A).	  The	  total	  tube	  length	  was	  significantly	  greater	  when	  IPAH-­‐ECFCs	  were	  
seeded	  on	  either	  HC-­‐Matrigel	  (in	  EBM-­‐2	  with	  1%	  FBS)	  or	  GFR-­‐Matrigel	  (in	  EBM-­‐2	  without	  serum)	  and	  
when	   the	   cells	   were	   subjected	   to	   24h	   serum-­‐deprivation	   prior	   to	   seeding	   (Figure	   4.5B-­‐C).	  
Interestingly,	   the	   tubes	  appeared	   thicker	  and	  more	   cellular	  on	  HC-­‐Matrigel	   (in	   the	  presence	  of	  1%	  
FBS)	   than	   under	   growth	   factor	   reduced	   and	   serum-­‐free	   conditions.	   HPAECs	   exhibited	   a	   superior	  
capacity	   to	   form	   tubular	   networks	   on	   Matrigel	   and,	   unlike	   ECFCs	   from	   IPAH	   patients,	   this	   was	  
significantly	   reduced	   following	   serum-­‐deprivation	   for	   24h	  prior	   to	   seeding	  on	  GFR-­‐Matrigel	   (Figure	  
4.5A	  &	   C).	   No	   significant	   difference	  was	   found	   in	   the	   expression	   of	   thrombospondin-­‐1	   (THBS1)	   in	  
ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients	  (Figure	  4.6),	  suggesting	  that	  this	  is	  probably	  not	  an	  



























































Figure	  4.5.	  Matrigel	  tube	  formation	  by	  ECFCs	  and	  HPAECs.	  (A)	  Representative	  images	  captured	  with	  
an	  inverted	  microscope,	  showing	  tube	  formation	  by	  ECFCs	  from	  healthy	  volunteers	  (top	  row),	  IPAH	  
patients	   (middle	   row)	   and	   HPAECs	   (bottom	   row).	   Cells	   were	   seeded	   either	   on	   high	   protein	  
concentration	   (HC)-­‐Matrigel	   (EBM-­‐2	   &	   1%	   FBS)	   or	   growth	   factor	   reduced	   (GFR)-­‐Matrigel	   in	   the	  
absence	  of	  serum	  (EBM-­‐2	  &	  0%	  FBS)	  and	  some	  were	  also	  serum-­‐deprived	  for	  24h	  before	  seeding	  on	  
GFR-­‐Matrigel.	   4x	   magnification.	   (B)	   Quantification	   of	   tube	   formation	   by	   ECFCs	   from	   healthy	  
volunteers	  (n=3)	  and	  IPAH	  patients	  (n=3),	  seeded	  on	  HC-­‐Matrigel	  in	  EBM-­‐2	  medium	  with	  1%	  FBS.	  (C)	  
Quantification	  of	   tube	   formation	  by	  ECFCs	   from	  healthy	  volunteers	   (n=5)	  and	   IPAH	  patients	   (n=6),	  
and	  HPAECs	  (n=3),	  seeded	  on	  GFR-­‐Matrigel	  in	  the	  absence	  of	  serum	  and	  -­‐/+	  24h	  serum-­‐deprivation	  
prior	   to	   seeding.	   Data	   presented	   as	   mean±SEM	   total	   tube	   length	   for	   each	   group	   of	   cell	   isolates,	  
using	  measurements	  from	   images	  of	  2	  random	  fields	   in	   triplicates	  wells,	  representative	  of	  at	   least	  
two	   experiments.	   Statistics	   obtained	   by	   T-­‐test	   (B)	   and	   two-­‐way	   repeated	   measures	   ANOVA	   with	  






4.3.4	   Impaired	  capacity	  in	  wound	  healing	  by	  ECFCs	  from	  IPAH	  patients	  
The	  migratory	  capacity	  of	  the	  ECFCs	  was	  assessed	  by	  wound	  healing	  assay.	  ECFCs	  from	  IPAH	  patients	  
consistently	   displayed	   a	   slower	   rate	   of	   wound	   recovery,	   when	   compared	   with	   healthy	   ECFCs	   and	  
HPAECs,	   and	   cultured	   either	   in	   EBM-­‐2	   with	   1%	   FBS	   or	   EGM-­‐2	   and	   20%	   FBS	   (Figure	   4.7).	   HPAECs	  
exhibited	  a	  superior	  rate	  of	  wound	  recovery,	  compared	  to	  both	  groups	  of	  ECFCs,	  when	  assessed	   in	  
EGM-­‐2	  and	  20%	  FBS	  (Figure	  4.7B).	  	  
	  


















Figure	  4.6.	  ECFCs	  Thrombospondin-­‐1	  mRNA	  expression.	  qRT-­‐PCR	  analysis	  of	  Thrombospondin-­‐1	  
(THBS1)	  mRNA	  expression	  in	  ECFCs	  from	  healthy	  volunteers	  (n	  =	  8)	  and	  IPAH	  patients	  (n	  =	  9).	  Data	  
is	   presented	   as	   mean±SEM	   expression	   after	   normalised	   by	   expression	   of	   the	   reference	   genes.	  





Figure	   4.7.	  Wound	   recovery	   analysis	   of	   ECFCs.	   (A)	  Representative	  microscopic	   images	  and	  area	  of	  
wound	  recovery	  (expressed	  as	  %	  of	  0h)	  by	  ECFCs	  from	  healthy	  volunteers	  (left	  panel;	  n=6)	  and	  IPAH	  
patients	  (middle	  panel;	  n=6)	  and	  HPAECs	  (right	  panel;	  n=3)	  after	  6h,	  18h	  and	  24h	  in	  EBM-­‐2	  with	  1%	  
FBS.	   4x	   magnification.	   (B)	   Representative	   images	   and	   area	   of	   wound	   recovery	   by	   healthy-­‐ECFCs	  
(n=3),	  IPAH-­‐ECFCs	  (n=4)	  HPAECs	  (n=3)	  after	  0h,	  3h	  and	  21h	  in	  EGM-­‐2	  containing	  20%	  FBS.	  Data	  points	  
represent	  the	  mean±SEM	  for	  distinct	  ECFC	  populations	  or	  triplicate	  values	  for	  HPAECs.	  Statistics	  from	  
two	  way	  ANOVA	  and	  Bonferroni	   post-­‐hoc	   test.	   P4	   –	   P5	   ECFCs	   and	  P7	  HPAECs	  were	   used	   in	   these	  
experiments.	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4.3.5	   ECFCs	  from	  IPAH	  patients	  display	  reduced	  barrier	  functions	  
FRAP	   analysis	  was	   performed	   to	   assess	   gap	   junctional	   communication	   in	   ECFCs	   (Figure	   4.8A).	   Gap	  
junctional	  communication	  was	  impaired	  in	  ECFCs	  from	  IPAH	  patients,	  displaying	  only	  about	  half	  the	  
fluorescence	   recovery	   rate	   of	   ECFCs	   from	  healthy	   volunteers	   (Figure	   4.8B).	   IPAH	   cells	   also	   formed	  
leaky	   monolayers	   that	   displayed	   4-­‐fold	   higher	   permeability,	   compared	   with	   cells	   from	   healthy	  
volunteers	  (Figure	  4.8C).	  	  
	  
Figure	   4.8.	   ECFCs	   from	   IPAH	   patients	   display	   impaired	   gap	   junctional	   communication	   and	  
increased	  permeability.	  (A)	  Representative	  images	  of	  fluorescent	  recovery	  after	  photobleaching	  
(FRAP)	  analysis.	  Confocal	  images	  show	  recovery	  of	  fluorescence	  in	  a	  laser-­‐bleached	  area	  (marked	  
with	   a	   square)	   in	   a	   monolayer	   of	   calcein-­‐labelled	   HPAECs.	   The	   coloured	   traces	   in	   the	  
corresponding	  graph	   show	  the	   kinetics	  of	   fluorescence	   recovery	   in	   three	   regions	  of	   interest	   as	  
indicated	  by	   the	  arrow.	  Scale	  bar	  =	  50µm.	   (B)	  FRAP	  data,	  expressed	  as	  a	  proportion	  of	  control,	  
showing	   the	   relative	   levels	   of	   gap	   junctional	   communication	   in	   cultures	   of	   ECFCs	   from	  healthy	  
volunteers	   (n=6)	   and	   IPAH	   patients	   (n=6).	   (C)	   Permeability	   of	   ECFC	   monolayers	   from	   healthy	  
volunteers	   (n=6)	   and	   IPAH	  patients	   (n=6),	   as	   assessed	  by	   the	   flux	   of	   FITC-­‐labelled	   dextran	   and	  
expressed	   as	   a	   proportion	   that	   observed	   in	   ECFCs	   from	  healthy	   volunteers.	  Data	   presented	   as	  
mean±SEM.	  Statistics	  was	  from	  t-­‐test.	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4.4	   Discussion	  
The	  main	  findings	  of	  this	  chapter	  are:	  
• ECFCs	  from	  IPAH	  patients	  and	  healthy	  volunteers	  have	  a	  similar	  proliferative	  potential.	  
• ECFCs	  from	  IPAH	  patients	  are	  resistant	  to	  serum	  deprivation-­‐induced	  apoptosis.	  
• ECFCs	  from	  IPAH	  patients	  possess	  a	  greater	  tube	  forming	  capacity	  than	  those	  from	  healthy	  
volunteers.	  
• ECFCs	   from	   IPAH	   patients	   display	   a	   lower	   migratory	   capacity	   than	   those	   from	   healthy	  
volunteers.	  
• ECFCs	   from	   IPAH	   patients	   also	   display	   impaired	   barrier	   function	   compared	   to	   ECFCs	   from	  
healthy	  volunteers.	  
	  
Endothelial	   dysfunction	   is	   considered	   to	   be	   critical	   factor	   in	   the	   initiation	   and	   progression	   of	   PAH	  
(Budhiraja	   et	   al.,	   2004)	   and	   endothelial	   damage	   is	   postulated	   to	   initiate	   pulmonary	   vascular	  
remodelling,	   contributing	   to	   intimal,	   medial	   and	   adventitial	   hypertrophy	   (Rabinovitch,	   2008).	   The	  
vascular	   remodelling	   includes	   the	   development	   of	   angioproliferative	   plexiform	   lesions,	  which	   have	  
recently	   been	   found	   to	   be	   a	   relatively	   common	   feature	   in	   the	   explanted	   lungs	   of	   IPAH	   patients	  
(Stacher	   et	   al.,	   2012).	   These	   lesions	   are	   found	   predominantly	   at	   sites	   immediately	   distal	   to	   the	  
bifurcation	  of	  pulmonary	  vessels	  and	  severely	  reduce	  the	  cross-­‐sectional	  area	  for	  blood	  flow	  (Cool	  et	  
al.,	  1999).	  ECs	  within	  plexiform	  lesions	  are	  known	  to	  be	  monoclonal	  in	  primary	  (idiopathic)	  PAH,	  with	  
distinct	   clones	   occurring	   in	   different	   regions	   of	   the	   same	   lung,	   but	   polyclonal	   in	   patients	   with	  
secondary	  (associated)	  forms	  of	  the	  disease	  (Lee	  et	  al.,	  1998).	  ECs	  within	  IPAH	  plexiform	  lesions	  have	  
also	  been	  found	  to	  display	  microsatellite	  instability	  within	  the	  MSH2,	  and	  microsatellite	  mutation	  and	  
reduced	  expressions	  of	  TGF-­‐βRII	  and	  pro-­‐apoptotic	  BAX	  genes	  (Yeager	  et	  al.,	  2001).	  Indeed,	  acquired	  
somatic	  mutations	  appear	   to	  occur	   relatively	   frequent	   in	   the	  PAECs	  of	  patients	  with	  PAH	  and	  may	  
predate	   the	   development	   of	   plexiform	   lesions	   (Aldred	   et	   al.,	   2010).	   These	   data	   suggest	   that	  
pulmonary	  ECs	  can	  acquire	  somatic	  mutations	  in	  genes	  regulating	  cell	  growth	  and	  apoptosis,	  which	  
may	   lead	   to	   a	   selective	   advantage	  and	  monoclonal	   expansion	  of	   individual	   cells.	   Furthermore,	   ECs	  
isolated	   from	   the	   pulmonary	   arteries	   of	   PAH	   patients	   are	   reported	   to	   be	   hyperproliferative	   and	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apoptosis-­‐resistant	   and	   display	   a	   predominantly	   glycolytic	   phenotype	   compared	  with	   control	   cells	  
(Masri	  et	  al.,	  2007;	  Xu	  et	  al.,	  2007;	  Tu	  et	  al.,	  2011;	  Tu	  et	  al.,	  2012).	  
The	  origin	  of	  circulating	  ECFCs	  in	  IPAH	  remains	  elusive,	  there	  being	  no	  markers	  that	  distinguish	  them	  
from	  mature	  ECs	  (Ingram	  et	  al.,	  2005).	  It	  was	  originally	  thought	  that	  while	  circulating	  endothelial	  cells	  
may	  be	  derived	  form	  the	  vessel	  wall,	  ECFCs	  or	  blood	  outgrowth	  endothelial	  cells	  arose	   from	  bone-­‐
marrow	   derived	   angioblasts	   (Lin	   et	   al.,	   2000).	   But	   subsequent	   studies	   identified	   ECFCs	   in	   a	  
‘vasculogenic	   zone’	   in	   blood	   vessels	   (Zengin	   et	   al.,	   2006)	   and	   the	   endothelium	  of	   various	   vascular	  
beds	  (Ingram	  et	  al.,	  2005;	  Alvarez	  et	  al.,	  2008;	  Yoder,	  2010).	   In	  fact,	   it	  has	  recently	  been	  suggested	  
that	  ECFCs	  occur	  relatively	  frequently	  in	  pulmonary	  arteries,	  comprising	  5-­‐30%	  of	  ECs	  cultured	  from	  
pulmonary	  arteries	  in	  explanted	  human	  lungs	  (Duong	  et	  al.,	  2011).	  It	  remains	  to	  be	  established	  if	  the	  
rare	  ECFCs	  present	   in	  the	  circulation	  are	  derived	  from	  the	  vascular	  endothelium	  (Yoder,	  2012),	  but	  
blood-­‐derived	  ECFCs	  from	  IPAH	  patients	  do	  appear	  to	  exhibit	  a	  disease-­‐related	  phenotype	  and	  have	  
at	  least	  some	  of	  the	  characteristics	  assigned	  to	  ECs	  in	  plexiform	  lesions	  and	  those	  cultured	  from	  the	  
explanted	  lung	  tissues	  of	  patients	  with	  end-­‐stage	  PAH.	  	  	  
Previous	   reports	   show	   that	   ECFCs	   isolated	   from	   patients	   with	   BMPR2	   gene	   mutations	   are	   more	  
proliferative	  (Toshner	  et	  al.,	  2009),	  while	  ECFCs	  and	  PAECs	  derived	  from	  explanted	  lung	  tissues	  from	  
IPAH	   patients	   also	   exhibit	   a	   hyperproliferative	   EC	   phenotype	   irrespective	   of	   whether	   they	   carry	   a	  
known	  BMPR2	  mutation	  (Masri	  et	  al.,	  2007;	  Duong	  et	  al.,	  2011;	  Tu	  et	  al.,	  2011).	  On	  the	  other	  hand,	  
Drake	   and	   colleagues	   recently	   demonstrated	   that	   PAECs	   isolated	   from	   explanted	   lungs	   of	   HPAH	  
patients	  (n=4)	  with	  heterozygous	  mutations	  of	  BMPR2	  or	  SMAD9	  proliferated	  faster	  in	  culture	  than	  
other	   forms	  of	  PAH	  (n=2)	  or	  controls	   (Drake	  et	  al.,	  2011).	   Interestingly,	   the	  rate	  of	  EC	  proliferation	  
appeared	   to	   correlate	   not	   only	   with	   the	   extent	   of	   BMPR2	   haploinsufficiency	   but	   also	   with	   an	  
impaired	   response	   to	   the	   ALK1-­‐selective	   agonist	   BMP9	   and	   reduction	   in	   the	   BMP9-­‐induced	  
production	  of	  the	  anti-­‐proliferative	  microRNAs	  miR-­‐21	  and	  miR-­‐27a.	  I	  cannot	  exclude	  the	  possibility	  
that	  at	  least	  some	  of	  the	  IPAH	  patients	  in	  the	  present	  study	  also	  possessed	  a	  mutation	  in	  the	  BMPR2	  
gene	  as	  they	  were	  not	  genotyped	  and	  BMPR2	  mutations	  have	  been	  found	  to	  occur	  in	  ~20%	  of	  IPAH	  
patients	  with	  no	  relevant	  family	  history	  of	  the	  disease	  (Thomson	  et	  al.	  2000).	  I	  found	  a	  wide	  range	  of	  
proliferative	   capacities	   among	   ECFCs,	   both	   from	  within	   and	   between	   different	   individuals,	   but	   no	  
significant	  difference	  overall	   in	  either	  cell	  number,	  PDT	  or	  the	  incorporation	  of	  BrdU	  by	  ECFCs	  from	  
IPAH	  patients	  and	  healthy	  volunteers.	  	  
ECFCs	  from	  IPAH	  patients	  possessed	  a	  number	  of	  other	  functional	  features	  that	  distinguished	  them	  
from	  control	  cells.	  In	  particular,	  I	  found	  that	  IPAH-­‐ECFCs	  were	  less	  sensitive	  to	  apoptosis	  induced	  by	  
serum	  deprivation,	  exhibiting	  significantly	  lower	  levels	  of	  caspase-­‐3/7	  activity	  as	  well	  as	  less	  cleavage	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in	   caspase-­‐3	   and	   its	   downstream	   target	   PARP	   compared	   to	   ECFCs	   from	   healthy	   volunteers	   and	  
HPAECs.	  This	  is	  consistent	  with	  the	  finding	  of	  decreased	  numbers	  of	  apoptotic	  (TUNEL	  positive)	  ECs	  
and	   strong	   immunostaining	   for	   the	   anti-­‐apoptotic	   factors	   BCL-­‐2	   and	   BCL-­‐xL	   in	   the	   endothelium	   of	  
distal	  pulmonary	  arteries	  of	  patients	  with	  IPAH	  (Tu	  et	  al.,	  2011).	  Pulmonary	  ECs	  isolated	  from	  lungs	  of	  
IPAH	   patients	   also	   displayed	   increased	   BCL-­‐2	   and	   BCL-­‐xL	   expression	   and	   a	   reduced	   sensitivity	   to	  
apoptosis	  induced	  by	  serum	  deprivation	  than	  ECs	  isolated	  from	  control	  lungs	  (Masri	  et	  al.,	  2007;	  Tu	  
et	  al.,	  2011).	  The	  anti-­‐apoptotic	  proteins	  survivin	  and	  apoptosis	  repressor	  with	  caspase	  recruitment	  
domain	   (ARC)	   have	   both	   been	   implicated	   in	   the	   pulmonary	   vascular	   remodelling	   of	   IPAH	   and	  
experimental	  PH,	  promoting	  PASMC	  survival	  and	  proliferation	  (McMurtry	  et	  al.,	  2005;	  Zaiman	  et	  al.,	  
2011).	  In	  this	  study,	  I	  found	  no	  difference	  in	  ARC	  mRNA	  expression	  between	  the	  two	  groups	  of	  ECFCs,	  
either	  at	  base	  level	  or	  upon	  apoptosis	  induction,	  indicating	  that	  ARC	  is	  probably	  more	  important	  as	  
an	  anti-­‐apoptotic	  factor	  in	  PASMCs	  than	  ECs	  (Zaiman	  et	  al.,	  2011).	  While	  survivin	  expression	  was	  also	  
similar	  in	  the	  two	  groups	  of	  ECFCs	  under	  basal	  conditions,	  the	  expression	  of	  this	  anti-­‐apoptotic	  factor	  
was	  selectively	  decreased	  upon	  serum	  deprivation	  in	  ECFCs	  from	  healthy	  volunteers	  but	  not	  in	  cells	  
derived	   from	   IPAH	   patients.	   Survivin	   is	   an	   important	   inhibitor	   of	   apoptosis,	   maintaining	   the	  
hyperpolarisation	  of	  the	  mitochondrial	  membrane	  or	  preventing	  caspase	  activation	  in	  response	  to	  an	  
apoptotic	   signal	   (McMurtry	   et	   al.,	   2005).	   In	   fact,	   the	   selection	   of	   apoptotic-­‐resistant	   human	  
pulmonary	  microvascular	  ECs	   in	  an	   in	   vitro	   artificial	   capillary	   (CELLMAX)	   system	   is	  accompanied	  by	  
expression	   of	   survivin	   (Sakao	   et	   al.,	   2005)	   and	   the	   autocrine	   anti-­‐apoptotic	   effect	   of	   VEGF	   is	  
dependent,	  at	  least	  in	  part,	  on	  increased	  survivin	  expression	  (Farahani	  et	  al.,	  2005).	  It	  is	  possible	  that	  
the	  reduction	  of	  survivin	  expression	  observed	  in	  control	  ECFCs	  following	  serum	  deprivation	  reflects	  
the	  normal	  cellular	  response	  to	  apoptotic	  stimuli,	  whereas	  ECFCs	  from	  IPAH	  patients	  maintain	  their	  
survivin	  expression	  in	  order	  to	  resist	  apoptosis.	  	  
Matrigel	   tube	   formation	   is	   traditionally	   used	   as	   an	   assay	   to	  measure	   the	   capacity	   of	   ECs	   to	   form	  
capillary-­‐like	   structures	   and	   is	   the	   preferred	   method	   for	   assessing	   angiogeneic	   capacity	   in	   vitro	  
(Arnaoutova	  and	  Kleinman,	  2010).	  Laminin	  is	  a	  major	  component	  of	  Matrigel	  and	  an	  important	  factor	  
stimulating	   the	   attachment,	   migration	   and	   differentiation	   of	   endothelial	   cells	   into	   capillary-­‐like	  
structures	   (Kubota	   et	   al.,	   1988).	   I	   have	   demonstrated	   that	   ECFCs	   from	   IPAH	   patients	   have	   an	  
enhanced	  capacity	  to	  form	  capillary-­‐like	  structures	  in	  the	  Matrigel	  assay	  under	  a	  variety	  of	  conditions,	  
involving	  both	   the	  manipulation	  of	   growth	   factors	   and	   serum	  content	  of	   the	   culture	  medium.	   The	  
apparent	   decline	   in	   tube	   formation	   after	   40h	   serum	   deprivation	   by	   both	   ECFCs	   from	   healthy	  
volunteers	   and	  HPAECs	  but	  not	   IPAH-­‐ECFCs,	  may	   also	   reflect	   the	   apoptosis-­‐resistant	  phenotype	  of	  
ECFCs	  from	  IPAH	  patients.	  Nonetheless,	   it	   is	  not	  known	  whether	  these	  cells	  also	  possess	  a	  superior	  
angiogenic	  capacity	  in	  vivo.	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Despite	   their	   superior	   capacity	   to	   form	   capillary-­‐like	   structures,	   ECFCs	   from	   IPAH	   patients	   were	  
consistently	   found	  to	  migrate	  slower	   in	  the	  wound	  healing	  assay	  compared	  with	  cells	   from	  healthy	  
volunteers.	  These	  observations	  may	  seem	  contradictory,	  but	  it	  has	  recently	  been	  shown	  that	  EC	  tube	  
formation	   in	   Matrigel	   is	   dependent	   more	   on	   the	   protrusion	   of	   filopodia,	   forming	   connections	  
between	   adjacent	   endothelial	   cells	   that	   subsequently	   coalesce	   and	   differentiate	   into	   a	   tubule	  
structure,	   than	   the	  proliferation	  or	  migration	  of	   cells	   (Logie	  et	  al.,	   2010).	   	   In	   fact,	   cell	  proliferation	  
and	  migration	   appear	   to	   play	   little	   role	   in	   the	   in	   vitro	   development	   of	   EC	   tube-­‐like	   structures	   and	  
cortisol-­‐mediated	  inhibition	  of	  tube	  formation	  was	  shown	  to	  occur	  without	  a	  measurable	  reduction	  
in	  either	  EC	  migration	  (transwell	  migration	  assay),	  proliferation	  (BrdU	  assay)	  or	  viability	  (assessed	  by	  
ATP	   production).	   Indeed,	   ECFCs	   from	   PAH	   patients	   with	   BMPR2	   mutations	   are	   reported	   to	   have	  
impaired	  Matrigel	   tube	   formation	   in	  vitro	  while	  exhibiting	  no	  difference	   in	   transwell	  migration	  and	  
enhanced	  proliferation	  compared	  to	  control	  cells	   (Toshner	  et	  al.,	  2009).	  The	  present	  results	  should	  
therefore	  serve	  to	  emphasise	  functional	  differences	  between	  ECFCs	  derived	  from	  IPAH	  patients	  and	  
healthy	  volunteers,	  rather	  than	  necessarily	  be	  extrapolated	  from	  one	  assay	  to	  another.	  Differences	  in	  
extracellular	  matrix	  (ECM)	  may	  also	  confound	  comparisons	  between	  the	  migration	  and	  tube	  forming	  
assays.	  Matrigel	   is	  mainly	  composed	  of	   laminin	  and	  collagen	  type	  IV,	  whereas	  I	  used	  gelatin-­‐coated	  
plasticware	   for	   the	   wound	   healing	   assay.	   Gelatin	   coating	   has	   also	   been	   used	   in	   other	   studies	   to	  
assess	  difference	  in	  the	  migration	  of	  ECFCs	  from	  patients	  or	  infants	  with	  vascular	  disorders	  (Ligi	  et	  al.,	  
2011;	  Starke	  et	  al.,	  2011).	  Growth	  factors	  and	  their	  receptors	  are	  known	  to	  co-­‐ordinate	  with	  the	  ECM	  
and	   ECM	   receptors	   (e.g.	   integrins)	   to	   regulate	   angiogenesis	   (Eliceiri,	   2001).	   While	   laminin	   and	  
collagen	  predominate	   in	   the	   ECM	  of	  mature	   vessels,	   fibronectin	   and	   its	   primary	   receptor	   (integrin	  
α5β1)	  are	  predominantly	  expressed	  in	  developing	  vessels	  and	  considered	  to	  be	  essential	  in	  vascular	  
physiology	  (Tian	  et	  al.,	  2012a).	  In	  fact,	  Matrigel	  does	  not	  contain	  fibronectin	  but	  recent	  data	  indicate	  
that	   the	   fibronectin/integrin	   α5β1	   pathway	   is	   intimately	   involved	   in	   the	   regulation	   of	   TGF-­‐β	  
superfamily	   signalling	   in	   ECs,	   affecting	   cell	   migration,	   apoptosis	   and	   capillary	   stability	   (Tian	   et	   al.,	  
2012a).	   Other	   studies	   have	   also	   revealed	   that	   ECFCs	   are	   capable	   of	   depositing	   collagen	   IV,	  
fibronectin,	   and	   laminin,	  whereas	  mature	   ECs	  only	   express	   these	   ECM	  proteins	   intracellularly,	   and	  
ECFC-­‐derived	  ECM	  is	  abrogated	  in	  response	  to	  the	  inhibition	  (SB431542)	  of	  TGF-­‐β	  signalling	  and	  actin	  
cytoskeleton	  disruption	  (Kusuma	  et	  al.,	  2012).	  	  
Thrombospondin-­‐1	  (THBS1)	  regulates	  the	  activation	  of	  TGF-­‐β	  and	  inhibits	  EC	  and	  SMC	  proliferation,	  
and	  loss-­‐of-­‐function	  mutations	  in	  the	  THBS1	  gene	  have	  been	  identified	  in	  heritable	  PAH	  (Maloney	  et	  
al.,	  2012).	  Examination	  of	  gene	  expression	  in	  laser	  microdissected	  regions	  of	  the	  explanted	  IPAH	  and	  
APAH	   lung	   also	   indicates	   that	   THBS1	   expression	   is	   lower	   in	   the	   plexiform	   lesions	   and	   adjacent	  
remodelled	  pulmonary	  vasculature,	  compared	  with	  arteries	  from	  control	  lung	  sections	  (Jonigk	  et	  al.,	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2011).	  Plexiform	  lesions	  were	  also	  reported	  to	  show	  up-­‐regulation	  of	  other	  “remodelling-­‐associated	  
genes”,	  such	  as	  HIF-­‐1α,	  VEGF-­‐α,	  VEGFR-­‐1/2	  and	  Tie-­‐2,	  and	  c-­‐kit	  expression,	  and	  decreased	  apoptosis	  
factor	   caspase	   9.	   I	   found	   no	   apparent	   difference	   between	   THBS1	  mRNA	  expression	   in	   ECFCs	   from	  
IPAH	   patients	   and	   healthy	   volunteers,	   although	   HIF-­‐1α	   protein	   levels	   were	   greater	   in	   ECFCs	   from	  
IPAH	  patients	  than	  control	  cells	  (see	  Chapter	  7).	  	  
One	  of	   the	  most	   important	   functions	  of	   the	  endothelium	   is	   to	  maintain	  a	   semi-­‐permeable	  barrier,	  
controlling	  the	  passage	  of	  blood-­‐borne	  factors,	  inflammatory	  cells	  and	  fluid	  between	  the	  blood	  and	  
tissue	  interstitial	  compartments.	  It	  is	  recognised	  that	  endothelial	  barrier	  disruption	  is	  likely	  to	  have	  a	  
critical	   role	   in	   the	   development	   of	   PAH	   (Budhiraja	   et	   al.,	   2004).	   The	   loss	   of	   endothelial	   integrity	  
enables	  the	  infiltration	  of	  inflammatory	  cells	  and	  activation	  of	  growth	  factor	  pathways	  and	  elastases	  
in	  the	  underlying	  media,	  leading	  to	  the	  PASMC	  proliferation	  and	  vascular	  remodelling	  (Morrell	  et	  al.,	  
2009).	  Furthermore,	  BMPR2	  expression	  has	  been	  linked	  to	  pulmonary	  endothelial	  integrity.	  HPAECs	  
with	  reduced	  BMPR2	  expression	  display	   increased	  permeability,	  cytokine	  production	  and	   leukocyte	  
recruitment,	   and	   the	   lungs	   of	  BMPR2	   deficient	  mice	   exhibit	   increased	  pulmonary	   vascular	   leakage	  
and	  leukocyte	  infiltration	   in	  vivo	  (Burton	  et	  al.,	  2011).	  In	  the	  present	  study	  I	  also	  found	  evidence	  of	  
disrupted	   barrier	   function,	   including	   impaired	   gap	   junctional	   communication	   and	   abnormal	  
endothelial	  permeability,	  in	  ECFCs	  from	  IPAH	  patients.	  	  
Finally,	   apart	   from	   Matrigel	   tube	   formation,	   no	   apparent	   differences	   were	   observed	   between	  
HPAECs	  and	  ECFCs	  from	  healthy	  volunteers.	  	  This	  is	  consistent	  with	  the	  endothelial	  lineage	  of	  ECFCs	  
and	  corresponds	  with	  the	  results	  of	  other	  studies	  indicating	  that	  ECFCs	  and	  HUVECs	  display	  a	  similar	  
sensitivity	   to	   apoptosis,	   migration,	   proliferation	   and	   tube	   forming	   capacity	   (Liu	   et	   al.,	   2005).	   It	   is	  
unclear	  why	  HPAECs	  displayed	  superior	  tube	  formation	  to	  ECFCs,	  but	   it	   is	  possible	  that	  this	  reflects	  
differences	  in	  sensitivity	  to	  serum	  depletion.	  HPAECs	  were	  routinely	  cultured	  in	  medium	  containing	  
2%	  FBS	  whereas	  the	  normal	  serum	  content	  for	  ECFC	  cultures	  was	  20%	  FBS.	  HPAECs	  might	  therefore	  
be	  more	   resilient	   than	  control	  ECFCs	   to	   the	  depletion	  of	  growth	   factors	  and	  serum	   in	   the	  Matrigel	  
assay.	  
There	  are	  a	  number	  of	  limitations	  to	  the	  studies	  in	  this	  chapter.	  Ideally,	  the	  patients	  providing	  blood	  
samples	  would	  have	  been	  genotyped	  for	  known	  mutations	  in	  BMPR2	  and	  for	  rare	  mutations	  in	  ALK1,	  
ENG	   (gene	   for	  endoglin),	  SMAD1	   and	  SMAD9	   (gene	   for	   Smad8).	   I	  would	  have	   liked	   to	  also	   include	  
ECFCs	  derived	   from	  patients	  with	  other	   forms	  of	   PAH,	   as	  well	   as	   types	  of	   PH	   that	   do	  not	   develop	  
plexiform	  lesions,	  and	  compare	  blood-­‐derived	  ECFCs	  with	  those	  directly	  derived	  from	  explanted	  lung	  
tissues.	   In	   addition,	   it	   would	   have	   been	   interesting	   to	   determine	   whether	   differences	   observed	  
between	  ECFCs	   in	  vitro	  were	  also	  apparent	   in	  vivo,	  using	  for	  example	  a	  Matrigel	  plug	  assay	  in	  mice,	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and	   if	   cells	   derived	   from	   IPAH	   patients	   exhibited	   the	   chromosomal	   abnormalities	   that	   have	   been	  
found	  in	  PAECs	  from	  PAH	  patients.	  
In	   this	   chapter,	   I	   have	   demonstrated	   that	   ECFCs	   from	   IPAH	   patients	   exhibit	   a	   distinct	   functional	  
phenotype,	  but	   the	  underlying	  molecular	  mechanisms	  are	  not	  clear.	  BMPs	  have	  been	  shown	  to	  be	  
critical	   in	   the	   differentiation,	   regulation	   and	   angiogenic	   capacity	   of	   ECFCs	   (Smadja	   et	   al.,	   2008).	   In	  
addition	  to	  mutations	  in	  the	  BMPR2	  gene,	  PAH	  can	  also	  arise	  from	  mutations	  in	  ALK1	  (Trembath	  et	  
al.,	   2001;	   Harrison	   et	   al.,	   2003),	   an	   endothelial-­‐selective	   receptor	   that	   responds	   to	   the	   circulating	  
quiescent	  factor	  BMP9	  (David	  et	  al.,	  2007a;	  Scharpfenecker	  et	  al.,	  2007).	  Given	  the	  important	  roles	  
that	   BMP	   and	   TGF-­‐β	   signalling	   play	   in	   the	   pathogenesis	   of	   IPAH	   and	   regulation	   of	   EC	   functions	  
(Morrell,	  2010),	  I	  will	  focus	  on	  exploring	  the	  possible	  dysfunction	  of	  these	  pathways	  in	  ECFCs.	  	  
In	   Chapter	   5,	   I	   will	   investigate	   if	   members	   of	   the	   TGF-­‐β	   receptor	   superfamily	   are	   differentially	  
expressed	  in	  ECFCs	  from	  IPAH	  patients	  and	  healthy	  volunteers	  and	  determine	  whether	  downstream	  
BMP	  and	  TGF-­‐β	  signalling	  pathways	  are	  affected.	  
In	  Chapter	  6,	   I	  will	   investigate	  whether	  differences	   in	  BMP	  and	  TGF-­‐β	  signalling	  contribute	  to	  the	  

















Expression	  and	  signalling	  
of	  the	  transforming	  growth	  
factor-­‐β	  (TGF-­‐β)	  receptor	  
superfamily	  in	  ECFCs	  
	  
	   	  
	  156	  
Chapter	   5	   –	   Expression	   and	   signalling	   of	   the	   transforming	   growth	  
factor-­‐β	  (TGF-­‐β)	  receptor	  superfamily	  in	  ECFCs	  
	  
5.1	   Introduction	  
Abnormalities	   in	   TGF-­‐β/BMP	   signalling	  pathways	   are	   associated	  with	  PAH.	  As	  discussed	   in	  Chapter	  
1.2.8,	  BMPR2	  mutations	  have	  been	  identified	  in	  most	  cases	  of	  HPAH	  and	  10	  –	  40%	  of	  IPAH	  patients.	  
The	   dysregulation	   of	   TGF-­‐β	   signalling	   may	   differ	   however	   in	   IPAH	   patients	   without	   mutations	   of	  
genes	  encoding	  BMP	  receptors	  and	  canonical	   signalling	  molecules,	  as	  differences	   in	   the	  expression	  
pattern	   of	   the	   TGF-­‐β/BMP	   superfamily	   have	   been	   found	   that	   could	   differentiate	   these	   groups	   of	  
patients	  (Geraci	  et	  al.,	  2001).	   Indeed,	  as	  discussed	  in	  Chapter	  1.7.5,	  dysregulation	  of	  both	  BMP	  and	  
TGF-­‐β	   signalling	   pathways	   has	   been	   reported	   in	   IPAH	   patients	   and	   pre-­‐clinical	   models	   of	   PH.	  
Nevertheless,	  the	  role	  of	  TGF-­‐β	  signalling	  in	  regulating	  pulmonary	  EC	  function	  and	  the	  pathogenesis	  
of	  the	  disease	  is	  still	  unclear.	  The	  pulmonary	  endothelium	  of	  IPAH	  patients	  displays	  several	  changes	  
in	  gene	  expression	  and	  activation,	  which	  persist	   in	  vitro	  and	  are	  associated	  by	  the	  dysregulation	  of	  
endothelial	   functions	   (Xu	   et	   al.,	   2004;	   Dewachter	   et	   al.,	   2006;	  Masri	   et	   al.,	   2007;	   Xu	   et	   al.,	   2007;	  
Fijalkowska	  et	  al.,	  2010).	  The	  expression	  of	  TGF-­‐β	  receptors	  has	  been	  poorly	  assessed	  in	  ECs	  isolated	  
from	   the	   explanted	   lungs	   of	   IPAH	   patients,	   possibly	   reflecting	   the	   limited	   nature	   of	   this	   resource.	  	  
ECFCs	  represent	  a	  readily	  accessible	  autologous	  patient	  cell	  type	  of	  endothelial	  lineage,	  which	  can	  be	  
obtained	  throughout	  the	  course	  of	  the	  disease	  and	  may	  provide	  further	  insights	  in	  the	  dysregulation	  
of	  TGF-­‐β	  receptors	  and	  signalling	  in	  the	  pathogenesis	  of	  IPAH.	  
In	  this	  chapter	  I	  will	  use	  PCR	  and	  Western	  blotting	  techniques	  to	  conduct	  a	  comprehensive	  analysis	  
of	   members	   of	   the	   TGF-­‐β	   receptor	   superfamily	   in	   ECFCs	   derived	   from	   IPAH	   patients	   and	   healthy	  
volunteers.	   Possible	   dysregulation	   of	   endothelial	   TGF-­‐β	   signalling	   will	   be	   determined	   both	   by	  
examining	   expression	   of	   ALK1,	   ALK5	   and	   TGF-­‐βRII	   receptors	   and	   the	   accessory	  membrane	   protein	  
endoglin,	   and	   assessing	   TGF-­‐β1-­‐induced	   activation	   of	   Smad2/3	   (Goumans	   et	   al.,	   2002).	   BMP9	   and	  
BMP10	   are	   specific	   agonists	   for	   ALK1,	   which	   is	   almost	   exclusively	   expressed	   by	   ECs	   and	   forms	   a	  
receptor	  complex	  with	  BMPR2	  and	  other	  type	  2	  receptors,	  ActRIIA	  and	  ActRIIB	  (David	  et	  al.,	  2007a;	  
Townson	  et	  al.,	  2012).	  In	  addition	  to	  the	  expression	  of	  these	  receptors,	  signalling	  will	  be	  assessed	  by	  
stimulating	   the	   cells	   with	   BMP9	   and	   determining	   the	   activation	   of	   the	   downstream	   targets	  
pSmad1/5/8	   and	   ID	   gene	   expression.	   Further	   details	   on	   receptor	   combination	   and	   their	   specific	  
agonists	  can	  be	  found	  in	  Figure	  1.5	  in	  Chapter	  1.7.	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The	  main	  objectives	  of	  this	  chapter	  are	  to:	  
• Determine	  mRNA	  expression	  of	  members	  of	   the	  TGF-­‐β	   receptor	   superfamily	   in	  ECFCs	   from	  
IPAH	  patients	  and	  healthy	  volunteers,	  using	  semi-­‐quantitative	  PCR	  and	  qPCR.	  
• Confirm	  differences	  in	  mRNA	  expression	  at	  the	  protein	  level,	  using	  Western	  blotting.	  
• Investigate	  dysregulation	  of	  ALK5/TGF-­‐βRII	  signalling	  by	  assessing	  TGF-­‐β1-­‐stimulated	  Smad2	  
phosphorylation	  in	  ECFCs.	  
• Investigate	   dysregulation	   of	   ALK1/BMPR2	   signalling	   by	   assessing	   BMP9-­‐stimulated	  
Smad1/5/8	  phosphorylation	  and	  ID	  gene	  expression.	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5.2	   Methods	  
See	  Chapter	  2	  for	  detailed	  experimental	  materials	  and	  protocols.	  
	  
5.2.1	   Expression	  of	  TGF-­‐β	  receptor	  superfamily	  	  
Expression	  of	  members	  of	   the	  TGF-­‐β	   receptor	   superfamily	  was	  examined	   in	  ECFC	  populations	  with	  
the	  capacity	  to	  grow	  beyond	  passage	  8.	  This	  included	  expression	  of	  both	  TGF-­‐β	  type	  1	  (ALK1,	  ALK2,	  
ALK3,	   ALK4,	   ALK5,	   ALK6)	   and	   type	   2	   receptors	   (ActRIIA,	   ActRIIB,	   BMPR2,	   TGF-­‐βRII),	   the	   accessory	  
membrane	  protein	  endoglin	  (CD105)	  and	  a	  related	  protein	  caveolin-­‐1.	  Cells	  were	  seeded	  (5000/cm2	  
in	  EGM-­‐2	  containing	  20%	  FBS)	  in	  10-­‐cm	  petri	  dishes	  and	  grown	  to	  confluency,	  prior	  to	  the	  extraction	  
of	   mRNA	   or	   protein.	   In	   parallel	   studies,	   ECFCs	   were	   cultured	   to	   sub-­‐confluency	   (typically	   ~70%	  
confluent)	   in	   normal	   culture	   medium,	   or	   confluent	   cells	   serum-­‐deprived	   for	   13-­‐18	   h	   in	   EBM-­‐2	  
containing	   0.1%	   FBS	   before	   assessing	   receptor	   expression.	   RNA	  was	   extracted	   from	   cultured	   cells	  
using	   either	   Trizol	   (Sigma)	   or	   RNeasy	   kits	   (QIAGEN)	   and	   proteins	   extracted	   in	   RIPA	   buffer,	   as	  
described	   in	   Chapter	   2.	   The	   expression	   level	   of	   selected	   receptors	   was	   also	   compared	   in	   surgical	  
samples	  of	  lung	  tissue	  from	  IPAH	  patients	  and	  lobectomy	  controls,	  as	  described	  below.	  	  
	  
5.2.2	   BMP	  and	  TGF-­‐β	  signalling	  	  
Potential	  differences	  between	  the	  canonical	  BMP	  and	  TGF-­‐β	  signalling	  pathways,	  in	  ECFCs	  from	  IPAH	  
patients	   and	   healthy	   volunteers,	   were	   determined	   by	   examining	   the	   effects	   of	   (1)	   TGF-­‐β1	   on	  
Smad2/3	   activation	   (phosphorylation	   –	   pSmad2/3),	   and	   (2)	   BMP9	   (an	   ALK1-­‐selective	   ligand)	   on	  
Smad1/5/8	  activation	  (phosphorylation	  –	  pSmad1/5/8)	  and	  downstream	  transcription	  of	  ID	  genes.	  As	  
junctional	  clustering	  between	  confluent	  ECs	  is	  critical	  for	  optimal	  TGF-­‐β	  signalling	  (Rudini	  et	  al.,	  2008),	  
all	   ECFCs	   were	   seeded	   (5000/cm2)	   in	   gelatin-­‐coated	   6-­‐cm	   dish	   and	   cultured	   to	   confluence	   before	  
proceeding	   to	   the	   following	   signalling	   experiments.	   For	  Western	   blot	   analysis	   of	   TGF-­‐β	   signalling,	  
ECFCs	   were	   serum-­‐deprived	   for	   12	   h	   in	   EBM-­‐2	   with	   0.1%	   FBS,	   before	   stimulation	   with	  	  
TGF-­‐β1	  (0.001	  –	  2.5	  ng/ml)	  for	  1h.	  	  Following	  SDS-­‐PAGE	  separation,	  membranes	  were	  probed	  first	  for	  
pSmad2	  and	  then	  re-­‐probed	  for	  Smad2,	  the	   latter	  typically	  being	  detected	  within	  a	   few	  seconds	  of	  
exposure	  to	  autoradiography	  film.	  The	  optimal	  ligand	  concentration	  and	  duration	  of	  stimulation	  was	  
established	   before	   comparing	   Smad	   phosphorylation	   in	   ECFCs	   from	   healthy	   volunteers	   and	   IPAH	  
patients.	   The	   specificity	   of	   TGF-­‐β1-­‐induced	   pSmad2	  was	   also	   established	   using	   the	  ALK5	   inhibitors	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SD208	   and	   SB431542.	   Cells	   were	   treated	   with	   0–15	   µM	   SD208	   or	   SB431542,	   30	   min	   before	  
stimulation	   by	   TGF-­‐β1.	   For	   Western	   blot	   analysis	   of	   BMP	   signalling,	   ECFCs	   were	   seeded	   at	   5000	  
cells/cm2	   in	   6-­‐cm	   dishes	   and	   grown	   to	   full	   confluency	   (typically	   4	   days).	   Cells	   were	   then	   serum-­‐
deprived	   for	  12	  h	   in	  EBM-­‐2	  with	  0.1%	  FBS,	  and	   stimulated	  with	  0.01–10	  ng/ml	  of	  BMP9	   for	  1	  h	   in	  
fresh	   serum-­‐deprived	   medium.	   Equal	   amounts	   of	   protein	   were	   probed	   in	   separate	   gels	   for	  
pSmad1/5/8	   and	   total	   Smad1	   protein	   expression,	   the	   latter	   typically	   being	   demonstrated	   after	   30	  
min	  exposure	  to	  radiography	  film.	  The	  specificity	  of	  BMP9-­‐induced	  pSmad1/5/8	  was	  also	  established	  
using	   the	  ALK1	   inhibitors	  ALK1-­‐Fc	  chimera	   (ALK1-­‐Fc).	  BMP9-­‐containing	  medium	  were	   reconstituted	  
with	  0–10	  µg/ml	  ALK1-­‐Fc,	  or	  cells	  treated	  with	  15	  µM	  SD208,	  30	  min	  before	  stimulation	  by	  BMP9.	  All	  
blots	   were	   reprobed	   for	   β-­‐actin	   to	   act	   as	   loading	   control.	   Further	   details	   of	   the	  Western	   blotting	  
methods	  and	  antibodies	  used	  are	  provided	  in	  Chapter	  2.11	  and	  Table	  2.5.	  
The	   downstream	   effects	   of	   BMP9	   stimulation	   on	   the	   transcription	   of	   ID	   genes	   was	   examined	   in	  
confluent	   ECFCs,	   following	   serum-­‐deprivation	   (EBM-­‐2	   and	   0.1%	   FBS)	   for	   16h	   and	   stimulation	  with	  
0.01–10	  ng/ml	  BMP9	  (in	  fresh	  EBM-­‐2	  and	  0.1%	  FBS)	  for	  2,	  4,	  and	  8h.	  RNA	  was	  extracted	  using	  Trizol	  
(Invitrogen)	  as	  this	  provided	  a	  higher	  concentration	  of	  RNA	  from	  a	  smaller	  culture	  surface	  area	  when	  
compared	  with	  extraction	  by	  RNeasy	  kit.	   	   ID1,	   ID2	  and	   ID3	  mRNA	  expression	  was	   first	  analysed	  by	  
semi-­‐quantitative	  RT-­‐PCR	  and	  then	  validated	  in	  separate	  experiments	  using	  qRT-­‐PCR,	  as	  described	  in	  
Chapter	  2.	  
	  
5.2.3	   Lung	  tissue	  samples	  
Lung	   tissue	   samples	   were	   previously	   obtained	   with	   the	   informed	   consent	   of	   patients	   and	   the	  
approval	   of	   the	   Brompton,	   Harefield	   &	  NHLI	   and	   Hammersmith	   and	  Queen	   Charlotte’s	   &	   Chelsea	  
Hospitals	  Research	  Ethics	  Committees	  (Ref	  No.	  01-­‐210	  and	  2001/6003).	  Fresh	  surgical	  specimens	  of	  
explanted	  lung	  tissue	  were	  collected,	  either	  at	  transplantation	  or	  at	  lobectomy/pneumonectomy	  for	  
carcinoma	   of	   the	   bronchus,	   snap	   frozen	   within	   4	   hours	   of	   surgery	   and	   stored	   at	   -­‐80°C.	   RNA	   was	  
extracted	  from	  comparable	  frozen	  samples	  of	  peripheral	  lung	  tissue	  (200-­‐500mg	  each)	  from	  patients	  





5.2.4	   Reagents	  
Details	  on	  the	  reagents	  used	  were	  described	  in	  Chapter	  2.14.	  	  
Where	  receptor	  inhibitors	  (e.g.	  SB	  431542	  and	  SD208)	  were	  used,	  cells	  were	  treated	  with	  inhibitors	  
or	   DMSO	   solution	   (vehicle)	   30	   min	   in	   prior	   to	   treatments	   with	   TGF-­‐β1.	   ALK1	   binding	   sites	   were	  
blocked	  by	  incubating	  treating	  medium	  with	  recombinant	  human	  ALK1	  antibodies	  for	  30	  min	  in	  prior	  
to	  treatment.	  	  
	  
5.2.5	   Data	  presentation	  
Western	   blotting	   and	   RT-­‐PCR	   data	   are	   presented	   as	  mean±SEM.	   Data	   from	   semi-­‐quantitative	   PCR	  
analysis	   are	  presented	   as	   a	   ratio	   relative	   to	   the	   reference	   gene	   β2-­‐microglobulin.	  Data	   from	  qPCR	  
analysis	   are	   presented	   as	   ratio	   following	   normalisation	   to	   PPIA	   and	   α-­‐tubulin	   expression,	   as	  
described	   in	   Chapter	   2.10.2.	  Data	   of	   protein	   expression	   from	  Western	  blotting	   are	   presented	   as	   a	  
ratio	  relative	  to	  β-­‐actin.	  Levels	  of	  pSmad1/5/8	  were	  assessed	  following	  normalisation	  against	  Smad1	  
and	   β-­‐actin,	   enabling	   cross-­‐comparison	   between	   different	   blots.	   pSmad2	   levels	   were	   assessed	  
following	   normalisation	   against	   Smad2	   in	   the	   same	   blot.	   All	   Smad	   phosphorylation	   and	   ID	   gene	  
expression	  data	  are	  presented	  as	  fold	  changes	  against	  vehicle	  controls.	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5.3	   Results	  
5.3.1	   Differential	  expression	  of	  the	  TGF-­‐β	  receptor	  superfamily	  in	  ECFCs	  from	  IPAH	  patients	  
The	   integrity	  of	  RNA	  extracted	  from	  ECFCs	  was	  confirmed	  by	  demonstrating	  two	  clear	  28S	  and	  18S	  
ribosomal	  bands	  (Figure	  5.1A).	  The	  expression	  of	  the	  TGF-­‐β	  receptor	  superfamily	  was	  examined	  with	  
semi-­‐quantitative	   RT-­‐PCR,	   using	   optimal	   PCR	   conditions	   to	   ensure	   amplified	   products	  were	  within	  
their	  linear	  phase	  of	  amplification	  and	  was	  not	  over-­‐saturated.	  	  
Semi-­‐quantitative	  RT-­‐PCR	  examination	  of	  mRNA	  expression	  showed	  that	  ECFCs	  expressed	  the	  TGF-­‐β	  
type	   1	   receptors	   ALK1,	   ALK2,	   ALK3,	   ALK4,	   ALK5,	   and	   ALK6,	   and	   type	   2	   receptors	   ActRIIA,	   ActRIIB,	  
BMPR2,	  and	  TGF-­‐βRII,	  as	  well	  as	  the	  accessory	  membrane	  protein	  endoglin	  (CD105)	  and	  caveolin-­‐1	  
(Figures	  5.1	  &	  5.2).	  Except	   for	  ALK3	  and	  ALK6	   transcripts,	  which	  were	  generally	   in	   low	  abundance,	  
expression	   of	   the	   various	   receptors	   was	   demonstrated	   in	   all	   ECFC	   populations	   examined	   and	   in	  
HPAECs.	  As	  expected,	  human	  PASMCs	  exhibited	  relatively	  high	  levels	  of	  ALK5	  and	  lacked	  expression	  
of	   the	  endothelial	   specific	  ALK1	  receptor	   (Figure	  5.1).	   Interestingly,	   the	   relative	  expression	  of	  ALK5	  
and	  ActRIIA	  receptors	  was	  significantly	  lower	  in	  ECFCs	  from	  IPAH	  patients,	  when	  compared	  with	  cells	  






Figure	  5.1.	   Expression	  of	   the	  TGF-­‐β	   receptor	   superfamily	   in	  ECFCs,	  HPAECs	   and	  HPASMCs.	   (A)	  
RNA	   integrity	   in	   two	   ECFC	   extracts,	   as	   demonstrated	   by	   distinct	   18S	   and	   28S	   rRNA	   bands	  
following	   GelRed-­‐stained	   agarose	   gel	   electrophoresis.	   (B)	   Expression	  of	   TGF-­‐β	   type	   1	   receptors	  
ALK1,	  ALK2,	  ALK3,	  ALK4,	  ALK5,	  and	  ALK6;	  type	  2	  receptors	  ActRIIA,	  ActRIIB,	  BMPR2,	  and	  TGF-­‐βRII;	  
endoglin;	   caveolin-­‐1	   and	  β2-­‐microglobulin	   (β2M)	  mRNA	   in	  ECFCs	   from	  healthy	  volunteers	   (n=9)	  
and	   IPAH	   patients	   (n=7).	   HPAECs	   were	   included	   as	   a	   mature	   endothelial	   cell	   control,	   while	  
HPASMCs	  were	   used	   as	   negative	   control	   for	   ALK1	   expression.	  mRNA	   transcripts	  were	   reverse-­‐
transcribed	   into	   cDNA	   and	   subjected	   to	   PCR	   amplification	   before	   being	   separated	   by	   GelRed-­‐





Figure	  5.2.	  Semi-­‐quantitative	  analysis	  of	  TGF-­‐β	  receptor	  superfamily	  mRNA	  expression	  in	  ECFCs.	  
The	   intensity	  of	   the	  bands	   in	  Figure	  5.1	  was	  measured	  using	   ImageJ	  and	  normalised	  against	   the	  
reference	  gene	  β2-­‐microglobulin	  for	  each	  cell	  population.	  Relative	  expression	  of	  (A)	  TGF-­‐β	  type	  1	  
receptors	  ALK1,	  ALK2,	  ALK3,	  ALK4,	  ALK5,	  and	  ALK6;	  (B)	  type	  2	  receptors	  ActRIIA,	  ActRIIB,	  BMPR2,	  
and	  TGFβRII;	  (C)	  endoglin	  and	  caveolin-­‐1	  in	  ECFCs	  from	  healthy	  volunteers	  (n=9)	  and	  patients	  with	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In	  subsequent	  studies,	  quantitative	  RT-­‐PCR	  was	  used	  to	  examine	  the	  expression	  of	  ALK5	  and	  ActRIIA,	  
as	  well	   as	   four	  other	  genes	   (ALK1,	  endoglin,	  BMPR2,	  TGF-­‐βRII)	   implicated	   in	   regulating	  endothelial	  
function	   and	   the	   pathophysiology	   of	   PAH.	   Following	   culture	   in	   complete	   EGM-­‐2	  medium	  and	   20%	  
FBS,	   the	  expression	   levels	  of	  ALK5,	  ActRIIA	  and	  endoglin	  were	  all	   found	  to	  be	  significantly	   lower	   in	  
confluent	  ECFCs	  from	  IPAH	  patients	  versus	  healthy	  volunteers.	  Interestingly,	  the	  levels	  of	  ALK5,	  TGF-­‐
βRII	  and	  endoglin	  expression	  were	  also	  greater	  in	  ECFCs	  from	  healthy	  controls	  than	  HPAECs	  (Figure	  
5.3A).	  In	  ECFCs	  that	  were	  serum-­‐deprived	  in	  EBM-­‐2	  and	  0.1%	  FBS	  for	  up	  to	  18h,	  ALK5	  expression	  was	  
again	   significantly	   lower	   in	   cells	   derived	   from	   IPAH	   patients	   compared	   with	   healthy	   volunteers	  
(Figure	  5.3A-­‐B).	  Decreased	  ALK5	  expression	  was	  also	  confirmed	  in	  ECFCs	  cultured	  in	  EGM-­‐2	  with	  2%	  
FBS	   for	   48	   h	   (Figure	   5.3C).	   In	   addition	   to	   ECFCs,	   lower	   ALK5	  mRNA	   levels	   were	   observed	   in	   lung	  
tissues	   from	   end-­‐stage	   IPAH	   patients	   versus	   control	   lobectomy	   samples	   (Figure	   5.4).	   BMPR2	  
expression	  was	  also	   lower	   in	   lung	  homogenates	   from	  IPAH	  patients	  compared	  with	  control	   tissues,	  
whereas	  no	  significant	  difference	  was	  found	  in	  ALK1	  or	  endoglin	  expression	  (Figure	  5.4).	  










ç 	  Figure	  5.3.	  Relative	  expression	  of	  ALK1,	  ALK5,	  ActRIIA,	  BMPR2,	  TGFBRII	  and	  endoglin	  in	  ECFCs	  
and	  HPAECs.	  Quantitative	  RT-­‐PCR	  analysis	  of	  mRNA	  expression	   in	  confluent	  ECFCs	   from	  healthy	  
volunteers	   (n=9)	   and	   IPAH	  patients	   (n=9)	   and	  HPAECs	   (n=3).	   	   (A)	   ECFCs	   cultured	   in	   EGM-­‐2	  with	  
20%	  FBS	  and	  HAPECs	  in	  EGM-­‐2	  with	  2%	  FBS.	  (B)	  ECFCs	  serum-­‐deprived	  in	  EBM-­‐2	  and	  0.1%	  FBS	  for	  
18	   h	   prior	   to	   RNA	   extraction.	   (C)	   Decreased	   ALK5	   expression	   is	   confirmed	   in	   ECFCs	   cultured	   in	  
EGM-­‐2	  with	  2%	  FBS	  for	  48	  h.	  Data	  are	  presented	  as	  mean±SEM.	  Statistics	  obtained	  following	  (A)	  
one-­‐way	  ANOVA	  and	  Bonferroni	   post-­‐hoc	  analysis	  and	   (B-­‐C)	   t-­‐test	   or	  Mann-­‐Whitney	   test	  where	  
appropriate.	  The	  data	  presented	  is	  representative	  of	  at	  least	  2	  independent	  experiments.	  
	  
Figure	   5.4.	   Relative	   expression	   of	   (A)	   ALK1,	   (B)	   ALK5,	   (C)	   BMPR2	   and	   (D)	   endoglin	   mRNA	   in	  
human	  peripheral	   lung.	  Surgical	  samples	  obtained	  at	  lobectomy	  (n=7)	  and	  transplantation	  (IPAH,	  
n=12).	  Data	  are	  presented	  as	  mean±SEM.	  Statistics	  obtained	  from	  Mann-­‐Whitney	  test.	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5.3.2	   ALK5	  protein	  expression	  and	  Smad2	  signalling	  in	  ECFCs	  
Confluent	  ECFCs	  from	  IPAH	  patients	  exhibited	  lower	  (~40%	  less)	  ALK5	  protein	  levels	  compared	  with	  
ECFCs	   from	   healthy	   volunteers	   (Figure	   5.5A).	   This	   difference	   was	   not	   apparent	   however	   in	   an	  
additional	  experiment,	  which	  compared	  ALK5	  protein	  expression	  in	  sub-­‐confluent	  cultures	  of	  ECFCs	  





To	  explore	  whether	   intracellular	   signalling	  was	  affected	   in	  ECFCs	  exhibiting	   reduced	  ALK5	   receptor	  
expression,	   the	   effect	   of	   TGF-­‐β1	   (an	   ALK5	   agonist)	   on	   downstream	   Smad2	   phosphorylation	   was	  
examined.	  Firstly,	   the	   selective	  effect	  of	  TGF-­‐β1	  on	  Smad	  activation	  was	  assessed	  by	  examining	   its	  
ability	  to	  stimulate	  pSmad2	  but	  not	  pSmad1/5/8	  in	  ECFCs	  (Figure	  5.6A-­‐B).	  	  
Figure	   5.5.	   ALK5	   protein	   expression	   in	   confluent	   and	   sub-­‐confluent	   ECFCs.	   Representative	  
Western	  blots	  and	  quantitative	  assessment	  of	  ALK5	  protein	  expression	  in	  (A)	  confluent	  ECFCs	  from	  
healthy	   volunteers	   (n=8)	   and	   IPAH	   patients	   (n=9)	   and	   (B)	   sub-­‐confluent	   ECFCs	   from	   healthy	  







It	  was	  apparent	  that	  1–10	  ng/ml	  TGF-­‐β1	  over	  saturated	  the	  activation	  of	  pSmad2,	  hence	  ECFCs	  were	  
examined	   using	   a	   wider	   range	   of	   TGF-­‐β1	   concentrations	   (0.001-­‐2.5	   ng/ml).	   TGF-­‐β1	   induced	   a	  
concentration-­‐	  and	   time-­‐dependent	   stimulation	  of	  pSmad2,	  while	  having	  no	  effect	  on	   total	   Smad2	  
protein	   levels	   (Figure	   5.7A-­‐B).	   These	   initial	   experiments	   indicated	   that	   TGF-­‐β1	   had	   a	   biphasic	  
influence	   on	   confluent	   ECFCs,	   pSmad2	   levels	   rising	   to	   a	  maximum	   1	   h	   after	   stimulation	  with	   0.05	  
ng/ml	  TGF-­‐β1	  and	  declining	  in	  the	  presence	  of	  increasing	  concentrations	  of	  TGF-­‐β1.	  The	  stimulation	  
of	   pSmad2	   was	   attenuated	   with	   the	   addition	   of	   the	   selective	   ALK5	   inhibitor	   SD208	   in	   a	  
concentration-­‐dependent	  manner,	  and	  was	  abolished	  in	  the	  presence	  of	  15	  µM	  SD208	  (Figure	  5.7C).	  
The	   addition	   of	   SB431542,	   another	   ALK5	   inhibitor,	   also	   abolished	   pSmad2	   in	   TGF-­‐β1	   stimulated	  
ECFCs	  (Figure	  5.7D).	  	  
Figure	   5.6.	   TGF-­‐β1-­‐stimulated	   phosphorylation	   of	   Smad1/5/8	   (pSmad1/5/8)	   and	   Smad2	  
(pSmad2).	  Representative	  Western	  blots	  from	  ECFCs	  from	  a	  healthy	  volunteers	  and	  a	  patient	  with	  
IPAH,	  showing	  expression	  of	  (A)	  pSmad1/5/8	  and	  total	  Smad1,	  and	  (B)	  pSmad2	  and	  total	  Smad2	  
after	   serum-­‐deprived	   (12	   h	   in	   0.1%	   FBS)	   and	   treated	   with	   TGF-­‐β1	   (1–10	   ng/ml)	   for	   1	   h,	   with	  






Stimulation	   with	   0.005,	   0.05	   and	   0.5	   ng/ml	   TGF-­‐β1	   for	   1	   h	   induced	   similar	   levels	   of	   Smad2	  
phosphorylation	  in	  ECFCs	  from	  IPAH	  patients	  and	  healthy	  volunteers	  (Figure	  5.8A-­‐C).	  HPASMC	  were	  
used	  as	  a	  control	  (Figure	  5.8B)	  as	  they	  exhibit	  high	  ALK5	  expression	  and	  low	  ALK1	  expression	  (Seki	  et	  
al.,	   2006)	   and	   can	  be	  efficiently	   stimulated	  by	   TGF-­‐β1	   (Upton	  et	   al.,	   2009).	  A	  differential	   response	  
was	   observed	   however	  when	   ECFCs	  were	   stimulated	  with	   1.0	   ng/ml	   TGF-­‐β1,	   pSmad2	   levels	   being	  
lower	  in	  cells	  from	  IPAH	  patients	  compared	  with	  those	  derived	  from	  healthy	  volunteers	  (Figure	  5.8D-­‐
E).	  	  
Figure	  5.7.	  TGF-­‐β1-­‐stimulated	  phosphorylation	  of	  Smad2	  (pSmad2).	  Representative	  Western	  blots	  
showing	   expression	   of	   pSmad2	   and	   total	   Smad2	   in	   serum-­‐deprived	   ECFCs.	   (A)	   pSmad2	   and	   total	  
Smad2	   in	   the	   presence	   of	   vehicle	   alone	   (0)	   or	   increasing	   concentrations	   of	   TGF-­‐β1	   (0.001	   –	   2.5	  
ng/ml)	  for	  1	  h.	  (B)	  pSmad2	  and	  Smad2	  expression	  in	  ECFCs	  after	  stimulation	  with	  0.05	  ng/ml	  TGF-­‐β1	  
for	   various	   times	   (0	   –	   120	   min).	   (C-­‐D)	   TGF-­‐β1	   (0.05	   ng/ml	   for	   1	   h)	   stimulated	   pSmad2	   in	   the	  
presence	  of	  the	  ALK5	  inhibitors	  SD208	  and	  SB431542	   (1	  –	  15	  µM).	  Treatment	  with	  SD208	  (SD,	  15	  
µM)	  was	  used	  as	  control	  (D).	  All	  blots	  were	  reprobed	  for	  β-­‐actin	  to	  ensure	  equal	  protein	  loadings.	  
Results	  shown	  are	  representative	  of	  at	   least	  1	  healthy-­‐ECFC	  sample,	  and	  similar	  effective	  range	  of	  




Figure	  5.8.	  TGF-­‐β1-­‐stimualated	  phosphorylation	  of	  Smad2	  in	  ECFCs	  from	  healthy	  volunteers	  and	  
IPAH	   patients.	  Confluent	  ECFCs	  were	   serum-­‐deprived	   in	   0.1%	   FBS	   for	  12h	  before	  being	   treated	  
with	   TGF-­‐β1	   or	   vehicle	   alone	   (0)	   for	   1	   h.	   (A-­‐C)	   Representative	  Western	   blots	   and	   quantitative	  
assessment	   of	   pSmad2	   in	   ECFCs	   from	   IPAH	   patients	   (n=6)	   and	   healthy	   volunteers	   (n=6),	   with	  
HPASMCs	  used	  here	  as	  controls.	  Blots	  were	  reprobed	  for	  β-­‐actin	  to	  ensure	  equal	  protein	  loadings.	  
(D)	  Representative	  Western	  blots	  of	  pSmad2	  and	  Smad2	  in	  two	  healthy	  (H20	  and	  H21)	  and	  IPAH-­‐
derived	  ECFC	  populations	  (IPAH1	  and	  IPAH29)	  after	  treatment	  with	  vehicle	  (0)	  or	  1	  ng/ml	  TGF-­‐β1	  
for	  1	  h.	  (E)	  Quantitative	  assessment	  of	  pSmad2,	  following	  treatment	  with	  1	  ng/ml	  TGF-­‐β1,	  in	  ECFCs	  
from	  IPAH	  patients	  (n=6)	  and	  healthy	  volunteers	  (n=6).	  Data	  presented	  as	  fold	  changes	  compared	  
with	  vehicle	  controls.	  Bars	  represent	  mean±SEM.	  Statistics	  obtained	  from	  two-­‐way	  ANOVA,	  with	  
Bonferroni	  post-­‐hoc	  analysis.	  *,	  P	  <	  0.05;	  **,	  P	  <	  0.01,	  compared	  with	  vehicle	  controls.	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5.3.3	   BMPR2	  protein	  expression	  and	  Smad1/5/8	  signalling	  in	  ECFCs	  
Previous	  studies	  have	  indicated	  that	  pulmonary	  BMPR2	  expression	  is	  affected	  in	  patients	  with	  IPAH,	  
with	  a	  reduction	  in	  BMPR2	  protein	  rather	  than	  mRNA	  levels	  being	  observed	  in	  diseased	  lung	  tissues	  
and	   isolated	  pulmonary	  vascular	  cells	   (Atkinson	  et	  al.,	  2002;	  Dewachter	  et	  al.,	  2009;	  Alastalo	  et	  al.,	  
2011).	  I	  therefore	  used	  Western	  blotting	  and	  a	  widely	  employed	  antibody	  against	  human	  BMPR2	  to	  
compare	   BMPR2	  protein	   levels	   in	   ECFCs.	   Three	   distinct	  molecular	  weight	   bands	  were	   identified	   in	  
proteins	   extracted	   from	   confluent	   ECFCs	   and	  HPAECs,	   corresponding	   to	   ~110,	   ~130	   and	   ~150	   kDa	  
(Figure	  5.9A,	  5.10A	  and	  5.11F),	  and	  the	   intensity	  of	  all	   three	  bands	  decreased	  upon	  knockdown	  by	  
siRNA	   targeting	   BMPR2	   (Figure	   5.11F).	   The	   intensity	   of	   the	   three	   BMPR2	  molecular	   weight	   bands	  
showed	  marked	  variation	  between	  different	  ECFC	  populations	  and	  no	  significant	  difference	  between	  
the	  two	  groups	  of	  ECFCs,	  this	  being	  reproducible	  in	  several	  different	  experiments	  as	  well	  as	   in	  cells	  
that	  had	  been	  deprived	  of	  serum	  prior	  to	  the	  extraction	  of	  proteins	  (Figure	  5.9B-­‐E	  &	  5.10B-­‐E).	  Human	  
BMPR2	  transcripts	  are	  alternatively	  spliced	  to	  produce	  at	   least	   two	  primary	  transcripts	  and	  BMPR2	  
protein	  isoforms	  (Liu	  et	  al.,	  1995;	  Rosenzweig	  et	  al.,	  1995),	  the	  ratio	  between	  the	  two	  having	  recently	  
been	  used	  to	  distinguish	  BMPR2	  mutant	  PAH	  patients	  from	  unaffected	  carriers	  (Cogan	  et	  al.,	  2012).	  I	  
therefore	  compared	  the	  ratio	  of	  the	  bottom	  band	  versus	  the	  top	  two	  bands	  and	  found	  that	  this	  was	  
significantly	  lower	  in	  confluent	  ECFCs	  from	  IPAH	  patients	  cultured	  compared	  with	  cells	  from	  healthy	  








Figure	  5.9.	  BMPR2	  protein	  expression	  in	  confluent	  ECFCs	  cultured	   in	   the	  presence	  of	  20%	  FBS.	  	  
(A)	  Representative	  Western	  blots	   showing	  varying	  expression	  of	  BMPR2	  molecular	  weight	  bands	  
in	  two	  distinct	  groups	  of	  confluent	  ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients	  (n=8	  in	  each	  
group).	  Confluent	  HPASMCs	  extract	  was	  used	  as	  control.	  §	  indicates	  the	  same	  ECFC	  sample	  run	  on	  
both	  gels	  for	  comparison.	  Graphs	  display	  the	  quantitative	  assessment	  of	  the	  relative	   intensity	  of	  
the	  (B)	  top	  band,	  (C)	  middle	  band,	  (D)	  bottom	  band,	  and	  (E)	  the	  total	  intensity	  of	  all	  three	  bands	  of	  
the	  detected	  BMPR2	  expression.	  (F)	  The	  relative	  intensity	  of	  the	  bottom	  band	  versus	  the	  top	  two	  
bands.	   Bars	   represent	   mean±SEM.	   Data	   are	   representative	   of	   2	   independent	   experiments.	  






Figure	   5.10.	   BMPR2	   protein	   expression	   in	   confluent	   ECFCs	   following	   serum-­‐deprivation.	  	  
(A)	  Representative	  Western	  blots	  showing	  varying	  expression	  of	  BMPR2	  molecular	  weight	  bands	  
in	  confluent	  ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients	  (n=6-­‐7),	  harvested	  after	  13	  h	  serum	  
deprivation	  in	  0.1%	  FBS.	  Graphs	  display	  the	  quantitative	  assessment	  of	  the	  relative	  intensity	  of	  the	  
(B)	  top	  band,	  (C)	  middle	  band,	  (D)	  bottom	  band,	  and	  (E)	  the	  total	  intensity	  of	  all	  three	  bands	  of	  the	  
detected	   BMPR2	   expression.	   (F)	   The	   relative	   intensity	   of	   the	   bottom	   band	   versus	   the	   top	   two	  
bands	   were	   analysed.	   Bars	   represent	   mean±SEM.	   Data	   are	   representative	   of	   2	   independent	  
experiments.	  Statistics	  shown	  was	  from	  t-­‐test.	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In	   contrast	   to	   confluent	   ECFCs,	   two	  molecular	   weight	   bands	   (~110	   and	   ~150	   kDa)	   dominated	   the	  
Western	  blots	  of	   sub-­‐confluent	  cells	  and	  HPAECs	   (Figure	  5.11A),	  but	  no	  significant	  difference	  were	  
observed	  between	  the	  two	  groups	  of	  ECFCs	  (Figure	  5.11B-­‐E).	  Two	  similar	  protein	  bands	  were	  found	  
in	  extracts	  of	  confluent	  HPASMCs	  (Figure	  5.9A),	  whereas	  two	  distinct	  BMPR2	  isoforms	  appeared	  to	  
predominate	  in	  HPAECs	  (~110	  kDa)	  and	  HepG2	  cells	  (~150	  kDa)	  respectively	  (Figure	  5.11F).	  
	  
	  
Figure	  5.11.	  BMPR2	  protein	  expression	  in	  sub-­‐confluent	  ECFCs	  cultured	  in	  the	  presence	  of	  20%	  
FBS.	   (A)	   Representative	  Western	   blots	   showing	   varying	   expression	   of	   BMPR2	  molecular	  weight	  
bands	   in	   two	  distinct	   groups	  of	   sub-­‐confluent	   ECFCs	   from	  healthy	   volunteers	   and	   IPAH	  patients	  
(n=6-­‐7).	   A	   sub-­‐confluent	   HPAEC	   extract	   was	   used	   as	   control.	   Graphs	   display	   the	   quantitative	  
assessment	  of	   the	   relative	   intensity	  of	   the	   (B)	   top	  band,	   (C)	  bottom	  band,	   (D)	   total	   intensity	  for	  
both	   bands	   and	   (E)	   the	   ratio	   of	   the	   bottom	   versus	   the	   top	   band.	   Bars	   represent	   mean±SEM.	  
Statistics	  shown	  was	  from	  t-­‐test.	   (F)	  BMPR2	  expression	  is	  reduced	  in	  ECFCs	  following	  transfection	  
with	   siRNA	   targeting	   BMPR2	   (siBMPR2)	   compared	   to	   transfection	   with	   scrambled	   controls	  
(Scram).	  Two	  distinct	  BMPR2	  isoforms	  predominated	  in	  confluent	  HPAECs	  and	  HepG2	  cells.	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Given	   the	   finding	   that	  BMPR2	   forms	  complexes	  with	   the	   type	   I	   receptor	  ALK1	  on	  endothelial	   cells,	  
selectively	  mediating	  the	  effects	  of	  BMP9	  (David	  et	  al.,	  2007a;	  Scharpfenecker	  et	  al.,	  2007),	  I	  sought	  
to	  explore	  whether	  the	  downstream	  signalling	  effects	  of	  BMP9	  differed	  in	  ECFCs	  derived	  from	  IPAH	  
patients	  and	  healthy	  volunteers.	  Initial	  experiments	  were	  conducted	  to	  determine	  the	  concentration-­‐
dependent	   effects	   of	   BMP9	   on	   Smad1/5/8	   phosphorylation,	   with	   pSmad1/5/8	   levels	   reaching	   a	  
plateau	   after	   1h	   treatment	   with	   1-­‐10.0	   ng/ml	   BMP9	   (Figure	   5.12A).	   The	   addition	   of	   the	   ALK1-­‐Fc	  
chimera	   (1-­‐10	   µg/ml)	   inhibited	   BMP9-­‐induced	   pSmad1/5/8	   in	   a	   concentration-­‐dependent	  manner,	  
whereas	   the	   ALK5	   inhibitor	   SD208	   had	   no	   effect	   (Figure	   5.12B),	   confirming	   the	   specific	   affinity	   of	  
BMP9	   for	  ALK1.	  No	   significant	   difference	  was	   found	  between	  BMP9-­‐induced	  pSmad1/5/8	   levels	   in	  
ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients	  (Figure	  5.12C-­‐D).	  
The	   downstream	   effect	   of	   BMP9	   stimulation	   on	   the	   transcription	   of	   ID	   genes	  was	   also	   examined.	  	  
Serum-­‐deprived	  ECFCs	  exhibited	  a	  concentration-­‐dependent	  increase	  in	  ID1,	  ID2	  and	  ID3	  expression	  
after	  2-­‐4h	  treatment	  with	  0.01-­‐10.0	  ng/ml	  BMP9,	  although	  the	  response	  appeared	  to	  be	  attenuated	  
by	   8h	   (Figure	   5.13A).	   Subsequent	   studies,	   using	   qPCR	   techniques,	   showed	   that	   both	   ID1	   and	   ID2	  
expression	  was	  induced	  in	  ECFCs	  derived	  from	  IPAH	  patients	  and	  healthy	  volunteers	  (Figure	  5.13B-­‐C).	  
No	   significant	   difference	   in	   BMP9-­‐induced	   ID1	   and	   ID2	   expression	   was	   found	   between	   the	   two	  
groups,	  although	  after	  4h	  the	  ECFCs	  from	  IPAH	  patients	  treated	  with	  0.1	  &	  1	  ng/ml	  BMP9	  tended	  to	  
show	  lower	  ID2	  expression	  (P	  	  =	  0.09	  &	  P	  =	  0.08	  respectively)	  when	  compared	  with	  cells	  from	  healthy	  





Figure	   5.12.	   BMP9-­‐stimulated	   Smad1/5/8	   phosphorylation	   (pSmad1/5/8).	   ECFCs	   were	   serum-­‐
deprived	  for	  12	  h	  in	  0.1%	  FBS	  before	  being	  treated	  with	  various	  concentration	  of	  BMP9	  (0.01	  –	  10	  
ng/ml)	  or	  vehicles	  for	  1	  h.	  (A-­‐B)	  Representative	  western	  blots	  showing	  stimulation	  of	  pSmad1/5/8	  
by	  BMP9	  in	  serum-­‐deprived	  ECFCs	  from	  healthy	  volunteers	  and	  inhibition	  in	  the	  presence	  of	  ALK1-­‐
Fc	   chimera	   (1	   –	   10	   µg/ml).	   (C-­‐D)	   Representative	   western	   blots	   and	   quantitative	   assessment	   of	  
BMP9-­‐stimulated	  pSmad1/5/8	  in	  ECFCs	  from	  healthy	  volunteers	  (n=6)	  and	  IPAH	  patients	  (n=5).	  All	  
blots	   were	   reprobed	   for	   β-­‐actin	   to	   ensure	   equal	   loading.	   Data	   presented	   as	   fold	   increases	   of	  
pSmad1/5/8	  against	   vehicle	  controls.	  Bars	   represent	  mean±SEM.	  Statistics	   shown	   from	  two-­‐way	  
ANOVA,	   with	   Bonferroni	   post-­‐hoc	   analysis.	   *,	   P	   <	   0.05;	   **,	   P	   <	   0.01;	   versus	   respective	   vehicle	  




Figure	   5.13.	  BMP9-­‐stimulated	   ID	  gene	   expression	   in	   ECFCs.	   ECFC	  were	  serum-­‐deprived	   for	  16h	  
(EBM-­‐2	   with	   0.1%	   FBS)	   before	   being	   treated	   with	   various	   concentrations	   of	   BMP9	   (0.01	   –	   10	  
ng/ml)	  or	  vehicle	  (0)	  for	  2	  h,	  4	  h	  and	  8	  h.	  (A)	  Representative	  agarose	  gel	  images	  of	  PCR	  amplified	  
ID1,	   ID2	   and	   ID3	   transcripts.	   β2-­‐microglobulin	   (β2M)	  was	   included	  as	   a	   reference	  housekeeping	  
gene.	  	  (B-­‐C)	  Quantitative	  PCR	  analysis	  of	  ID1	  and	  ID2	  expression	  in	  ECFCs	  from	  healthy	  volunteers	  
(n	  =	  7)	  and	  IPAH	  patients	  (n	  =	  5	  –	  6)	  after	  treatment	  with	  BMP9	  for	  2	  h	  and	  4	  h.	  Data	  presented	  as	  
fold	  change	  compared	  to	  vehicle	  controls.	  Statistics	  shown	  from	  two-­‐way	  ANOVA	  and	  Bonferroni	  
post-­‐hoc	  analysis.	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5.4	   Discussion	  
The	  main	  findings	  in	  this	  chapter	  are:	  
• ALK5	  expression	  is	  reduced	  at	  both	  the	  mRNA	  and	  protein	  level	  in	  ECFCs	  from	  IPAH	  patients.	  
• ECFCs	  from	  IPAH	  patients	  display	  an	  impaired	  response	  to	  1ng/ml	  TGF-­‐β1-­‐stimulated	  Smad2	  
phosphorylation.	  	  
• BMP9	  stimulation	  of	  BMPR2/ALK1	  induced	  similar	  downstream	  activation	  (phosphorylation)	  
of	  Smad1/5/8	  in	  ECFCs	  from	  IPAH	  patients	  and	  healthy	  volunteers.	  
• There	  is	  marked	  heterogeneity	  in	  the	  expression	  of	  BMPR2	  protein	  isoforms	  among	  ECFCs.	  	  
	  
In	   this	   chapter	   I	   have	   analysed	  members	   of	   the	   TGF-­‐β	   receptor	   superfamily	   that	   are	   implicated	   in	  
PAH	   (Richter	   et	   al.,	   2004).	   Throughout	   these	   studies,	   I	   found	   reduced	   ALK5,	   ActRIIA	   and	   endoglin	  
mRNA	  expression	  levels	  in	  ECFCs	  from	  IPAH	  patients.	  In	  particular,	  ALK5	  expression	  was	  consistently	  
reduced	   in	   confluent	   ECFCs	   from	   IPAH	  patients,	   both	   in	   the	   presence	   of	   serum	   and	   under	   serum-­‐
deprived	  conditions,	  although	  no	  difference	  was	  apparent	   in	  sub-­‐confluent	  cultures	  of	  cells.	  This	   is	  
perhaps	  not	  surprising	  as	  TGF-­‐β/ALK/Smad	  signalling	   in	  ECs	   is	  known	  to	  be	  context	  dependent	  and	  
may	  vary	  according	  to	  cell	  confluence	  and	  the	  organisation	  of	  intercellular	  junctional	  proteins	  such	  as	  
VE-­‐cadherin	  (Rudini	  et	  al.,	  2008).	  Interestingly,	   lung	  tissues	  from	  IPAH	  patients	  also	  displayed	  lower	  
levels	   of	   ALK5	   mRNA	   expression,	   compared	   with	   control	   lobectomy	   tissues.	   Furthermore,	   other	  
groups	  have	  described	  a	  decrease	  in	  ALK5	  protein	  expression	  in	  the	  lungs	  of	  IPAH	  patients,	  notably	  
localised	   to	  ECs	   in	   the	  core	  of	  plexiform	   lesions	   (Richter	  et	  al.,	  2004;	  Gore	  et	  al.,	  2010).	   In	  keeping	  
with	  lower	  ALK5	  expression,	  TGF-­‐β1-­‐induced	  Smad2	  phosphorylation	  was	  also	  reduced	  in	  ECFCs	  from	  
IPAH	  patients.	  The	  impaired	  response	  was	  apparent	  following	  stimulation	  with	  1ng/ml	  TGF-­‐β1,	  rather	  
than	  at	   lower	   concentrations	   (0.005-­‐0.5	  ng/ml).	   This	   suggests	   that	   the	   second	  part	  of	   the	  biphasic	  
response	   to	   TGF-­‐β1	   may	   be	   selectively	   affected	   in	   IPAH	   cells	   and	   indicates	   the	   need	   to	   further	  
compare	   the	  effects	  of	   TGF-­‐β1	  at	   physiological	   concentrations;	   the	  normal	   venous	   level	   of	   TGF-­‐β1	  
has	  been	  reported	  to	  be	  2.6-­‐12.5	  ng/ml	  or	  1.0-­‐4.7	  ng/ml	  (Selimovic	  et	  al.,	  2009;	  Evrard	  et	  al.,	  2012).	  
Nevertheless,	   it	   remains	   to	   be	   established	   whether	   a	   30-­‐40%	   reduction	   in	   ALK5	   expression	   alone	  
leads	   to	   the	   observed	   reduction	   in	   Smad2	   phosphorylation	   or	   if	   the	   altered	   expression	   of	   other	  
receptors	  is	  also	  required.	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A	   substantial	   body	   of	   evidence	   indicates	   that	   TGF-­‐β	   signalling	   has	   an	   important	   role	   in	   the	  
pathogenesis	  of	  PAH	  and,	  despite	  differences	  between	  studies,	  it	  is	  generally	  considered	  that	  there	  is	  
dysregulation	   of	   TGF-­‐β	   signalling	   in	   the	   lungs	   and	   vascular	   cells	   of	   patients	   with	   IPAH.	   Earlier	  
immunohistochemical	  studies	  indicated	  that	  endothelial	  BMPR2	  expression	  was	  reduced	  in	  the	  lungs	  
of	  PAH	  patient	  irrespective	  of	  whether	  BMPR2	  mutations	  were	  present,	  while	  the	  levels	  of	  TGF-­‐βRII	  
appeared	   to	   be	   similar	   to	   that	   of	   controls	   (Atkinson	   et	   al.,	   2002).	   In	   contrast	   to	   the	   high	   level	   of	  
expression	   and	   potential	   TGF-­‐β	   signalling	   in	   endothelial	   cells	   of	   pulmonary	   arteries,	   Richter	   and	  
colleagues	   found	   a	   marked	   reduction	   of	   TGF-­‐β	   receptors	   and	   signalling	   proteins	   (ALK5,	   TGF-­‐βRII,	  
pSmad1/5/8	  and	  pSmad2/3)	  in	  the	  core	  ECs	  of	  plexiform	  lesions	  in	  patients	  with	  IPAH,	  regardless	  of	  
their	  BMPR2	  mutation	  status	   (Richter	  et	  al.,	  2004).	  Decreased	  pulmonary	  ALK5	  expression	  has	  also	  
been	   reported	   in	   the	   lungs	   of	   IPAH	   patients,	   which	   was	   accompanied	   by	   increases	   in	   TGF-­‐β	  
production	  and	  endoglin	  and	  ALK1	  protein	  levels	  (Gore	  et	  al.,	  2010).	  In	  addition,	  a	  reduction	  in	  TGF-­‐β	  
signalling	   proteins	   expression	   has	   been	   found	   in	   the	   lungs	   and	   PASMCs	   of	  MCT-­‐treated	   rats	   with	  
severe	  PH	  (Zakrzewicz	  et	  al.,	  2007),	  although	  most	  studies	  have	  described	  increased	  TGF-­‐β	  signalling	  
in	  the	  MCT	  model	  and	  attenuation	  of	  PH	  in	  animals	  treated	  with	  ALK5	  inhibitors	  (Zaiman	  et	  al.,	  2008;	  
Long	  et	  al.,	  2009;	  Thomas	  et	  al.,	  2009).	  The	  reduction	  of	  BMP	  signalling	  in	  the	  MCT	  model	  of	  PH	  may	  
also	   contribute	   to	  a	  gain	   in	  TGF-­‐β	   signalling	   (Long	  et	  al.,	   2009).	  At	   the	   cellular	   level,	   PASMCs	   from	  
patients	   with	   IPAH	   exhibit	   a	   heightened	   sensitivity	   to	   TGF-­‐β1	   in	   vitro,	   the	   abnormal	   proliferative	  
effect	  being	  abolished	  by	  pre-­‐incubation	  with	  an	  ALK5	  inhibitor	  (Morrell	  et	  al.,	  2001;	  Thomas	  et	  al.,	  
2009).	   It	   is	   uncertain	   how	   TGF-­‐β	   signalling	   may	   be	   affected	   in	   ECs	   from	   IPAH	   patients,	   but	   the	  
response	  could	  differ	  from	  that	  of	  PASMCs	  and	  may	  vary	  between	  cells	  from	  different	  regions	  of	  the	  
pulmonary	   arterial	   tree	   (Lu,	   2008;	   Lu	   et	   al.,	   2009).	   PAECs	   harbouring	   BMPR2	   mutations	   can	   also	  
produce	   more	   TGF-­‐β1	   than	   control	   cells,	   with	   conditioned	   medium	   causing	   an	   ALK5-­‐dependent	  
proliferation	  of	  PASMCs	  (Yang	  et	  al.,	  2011),	   indicating	  the	  therapeutic	  effects	  of	  ALK5	   inhibitions	   in	  
the	  MCT	  models	  of	  PH	  could	  be	  due	  to	  the	  effects	  on	  PASMCs.	  In	  the	  present	  study,	  I	  postulated	  that	  
decreased	   ALK5	   expression	   and	   impaired	   TGF-­‐β/Smad2	   signalling	   might	   contribute	   to	   the	  
dysfunctional	  (apoptosis-­‐resistant	  and	  angiogenic)	  phenotype	  displayed	  by	  ECFCs	  from	  IPAH	  patients,	  
similar	  to	  those	  observed	  in	  ECs	  within	  plexiform	  lesions.	  
Immunohistochemical	   studies	   have	   described	   decreased	   endothelial	   BMPR2	   protein	   expression	   in	  
sections	   of	   lung	   and	   isolated	   pulmonary	   microvascular	   ECs	   from	   IPAH	   patients	   without	   BMPR2	  
mutations	   (Atkinson	  et	  al.,	  2002;	  Alastalo	  et	  al.,	  2011).	  Others	  have	   found	  no	  difference	   in	  BMPR2	  
protein	   levels	   in	   lung	   tissues	   and	   isolated	   ECs	   from	   controls	   and	   IPAH	   patients,	   using	   Western	  
blotting	  to	  identify	  single	  bands	  of	  90	  kDa	  and	  75	  kDa	  respectively	  (Du	  et	  al.,	  2003;	  Dewachter	  et	  al.,	  
2009).	  Another	   recent	   study	   also	   indicated	   that	   the	  mRNA	  expression	  of	  BMPR2	   in	   ECs	  within	   the	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plexiform	   lesions	   of	   IPAH	   lungs	   was	   similar	   compared	   to	   controls	   (Jonigk	   et	   al.,	   2011).	   Overall,	   I	  
observed	  no	  difference	   in	  BMPR2	  mRNA	  or	  protein	  expression	  between	  ECFCs	   from	   IPAH	  patients	  
and	  healthy	  controls,	  despite	  having	  analysed	  cells	   that	  were	  cultured	   in	  a	  variety	  of	  conditions.	   In	  
fact,	   there	   was	   considerable	   heterogeneity	   in	   the	   BMPR2	   isoforms	   expressed	   by	   different	   ECFC	  
populations.	  Three	  molecular	  isoforms	  were	  expressed	  by	  confluent	  ECFCs	  (~110	  kDa,	  ~130	  kDa	  and	  
~150	   kDa)	   and	   two	   bands	   (~110	   kDa	   and	   ~150	   kDa)	   predominated	   in	   sub-­‐confluent	   ECFCs,	   the	  
intensity	   of	   all	   three	   bands	   being	   significantly	   reduced	   following	   BMPR2	   siRNA	   knockdown.	  
Interestingly,	  three	  bands	  of	  BMPR2	  protein	  expression	  were	  also	  seen	  in	  human	  aortic	  ECs	  (Shao	  et	  
al.,	   2009).	   Cultures	  of	  HPAECs	   also	  produced	   two	  bands	   (~110	   kDa	  and	  ~150	   kDa),	  with	   the	   lower	  
molecular	   isoform	   predominating.	   This	   is	   consistent	   with	   published	   reports	   of	   BMPR2	   protein	  
expression	   in	   HPAECs	   and	   HPMVECs	   that	   used	   the	   same	   source	   of	   BMPR2	   antibody	   (from	   BD	  
Transduction),	   with	   the	  majority	   demonstrating	   either	   single	   or	   double	   bands	   in	   the	   110-­‐150	   kDa	  
range	  (de	  Jesus	  Perez	  et	  al.,	  2009;	  Upton	  et	  al.,	  2009;	  Alastalo	  et	  al.,	  2011;	  Burton	  et	  al.,	  2011;	  Drake	  
et	  al.,	  2011;	  Gangopahyay	  et	  al.,	  2011;	  Park	  et	  al.,	  2012;	  Star	  et	  al.,	  2012).	  Two	  similar	  bands	  were	  
also	  detected	  in	  confluent	  human	  PASMCs	  in	  this	  study	  and	  others	  (Upton	  et	  al.,	  2008)	  and	  in	  HeLa	  
cells	  (Durrington	  et	  al.,	  2010),	  whereas	  HepG2	  exhibited	  a	  single	  ~150	  kDa	  isoform.	  Taken	  together,	  
these	  data	  suggest	  that	  the	  processing	  of	  BMPR2	  isoforms	  may	  be	  influenced	  by	  cell-­‐cell	  contact	  in	  
ECFCs	  and	  can	  vary	  between	  different	  cell	  types.	  	  
The	  BMPR2	  gene	  contains	  19	  exons	  and,	  out	  of	  6	  alternatively	  spliced	  potential	  variants,	  two	  primary	  
transcripts	   and	   BMPR2	   protein	   isoforms	   have	   been	   identified	   (Liu	   et	   al.,	   1995;	   Rosenzweig	   et	   al.,	  
1995)	   that	   occur	   in	  most	   normal	   and	  HPAH	  patient	   tissues	   (Cogan	   et	   al.,	   2012).	   These	   comprise	   a	  
‘long’	   13-­‐exon	   isoform	   A	   (NCBI	   ref:	   NM_001204)	   and	   a	   ‘short’	   12-­‐exon	   isoform	   B	   (NCBI	   ref:	  
HSU25110)	   in	  which	   exon	   12	   is	   spliced	  out.	   The	   latter	   sequence	   encodes	  most	   of	   the	   intracellular	  
cytoplasmic	  tail	  of	  the	  receptor,	  which	  is	  important	  for	  interactions	  between	  BMPR2	  and	  β-­‐actin,	  and	  
mutations	  that	  lack	  exon	  12	  are	  thought	  to	  cause	  HPAH	  through	  a	  dominant	  negative	  effect	  (Cogan	  
et	   al.,	   2012).	   Interestingly,	   lung	   and	   placental	   tissues	   were	   found	   to	   have	   the	   highest	   levels	   of	  
expression	   of	   both	   isoforms	   of	   the	   receptor	   and,	   in	   cultured	   lymphocytes,	   HPAH	   patients	   with	  
BMPR2	   mutation	   exhibited	   a	   higher	   B/A	   isoform	   ratio	   than	   healthy/unaffected	   BMPR2	  mutation	  
carriers	   (Cogan	   et	   al.,	   2012).	   Importantly,	   this	   difference	   in	   ratio	   also	   had	   a	  measurable	   effect	   on	  
BMP	   signalling,	   cells	   with	   a	   high	   B/A	   ratio	   dephosphorylating	   phospho-­‐cofilin	   less	   efficiently	   than	  
those	   from	   non-­‐affected	   carriers	   with	   a	   lower	   B/A	   ratio.	   It	   is	   unclear	   whether	   isoforms	   A	   and	   B	  
correspond	   with	   the	   two	   protein	   bands	   that	   were	   found	   to	   predominate	   in	   ECFCs	   and	   PAECs	   by	  
Western	  blotting,	  the	   lower	  molecular	  weight	  band	  (~110	  kDa)	  being	   larger	  than	  that	  predicted	  for	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isoform	  B.	  Nevertheless,	  I	  consistently	  found	  the	  ratio	  of	  the	  bottom	  band	  intensity	  over	  the	  top	  two	  
bands	  was	  lower	  in	  confluent	  ECFCs	  from	  IPAH	  patients,	  compared	  with	  control	  cells.	  
Endoglin	  mRNA	  expression	  was	  found	  to	  be	  lower	  in	  confluent	  ECFCs	  from	  IPAH	  patients,	  cultured	  in	  
the	  presence	  of	  20%	  FBS,	  although	  this	  was	  not	  consistently	  observed	  in	  other	  conditions.	  Endoglin	  
expression	   is	  upregulated	  by	  TGF-­‐β	  and	  BMP9	   in	  bovine	  aortic	  ECs	  and	  HPAECs	   (Scharpfenecker	  et	  
al.,	  2007;	  Upton	  et	  al.,	  2009),	  TGF-­‐β-­‐stimulated	  endoglin	  expression	  being	  mediated	  through	  Smad3	  
(Sanchez-­‐Elsner	   et	   al.,	   2002)	   and	   the	   effect	   of	   BMP9	   via	   ALK1,	   BMPR2	   and	   Smad4	   (Upton	   et	   al.,	  
2009).	   It	   is	   conceivable	   that	   reduced	   endoglin	   expression	   in	   ECFCs	   from	   IPAH	   patients	   reflects	  
impaired	   stimulation	  of	   the	  endoglin	   transcription	  promoter	  by	  TGF-­‐β/Smad2/3	   signalling,	   but	   this	  
would	  require	  further	  investigation	  to	  establish.	  	  
BMP9	   is	   a	   potent	   ALK1	   agonist	   in	   various	   types	   of	   endothelial	   cells,	   which	   typically	   induces	  
downstream	  signalling	  via	  pSmad1/5/8	  and	  ID	  gene	  expression	  (David	  et	  al.,	  2007a;	  Scharpfenecker	  
et	  al.,	  2007;	  Upton	  et	  al.,	  2009).	   I	  have	  shown	  that	  BMP9	  also	  stimulates	  pSmad1/5/8	  and	   induces	  
ID1	  and	  ID2	  gene	  expression	  in	  ECFCs,	  the	  responses	  being	  similar	  in	  cells	  derived	  from	  IPAH	  patients	  
and	  healthy	  volunteers.	  This	  is	  consistent	  with	  the	  recent	  analysis	  of	  BMP9-­‐induced	  ID1	  expression	  in	  
PAECs	   isolated	   from	   HPAH,	   IPAH	   and	   APAH	   patients,	   demonstrating	   that	   the	   response	   was	  
unchanged	   in	   IPAH	   and	   APAH	   patients	   and	   only	   affected	   in	   cells	   isolated	   from	   HPAH	   cases	   with	  
BMPR2	  or	  SMAD9	  mutations	  (Drake	  et	  al.,	  2011).	  In	  addition,	  Toshner	  and	  co-­‐workers	  have	  reported	  
that	   ECFCs	   from	   HPAH	   patients	   with	   BMPR2	   mutations	   exhibited	   impaired	   BMP9/pSmad1/5	  
signalling	  and	  induction	  of	  downstream	  ID1	  gene	  expression	  (Toshner	  et	  al.,	  2011).	  These	  differences	  
in	  activation	  of	  BMP	  canonical	  signalling	  suggest	  possible	  variation	   in	  the	  molecular	  mechanisms	  of	  
ECFC	   dysfunction	   between	   HPAH	   patients	   with	   BMPR2	   mutations	   and	   IPAH	   patients.	   Conversely,	  
another	   recent	   study	   indicated	   that	   the	  expression	  of	   genes-­‐associated	  with	   remodelling	   (e.g.	  HIF-­‐
1α,	   TGF-­‐β1,	  VEGF-­‐α,	  VEGFR-­‐1/2,	  Ang-­‐1,	   Tie-­‐2	   and	   THBS1)	   did	   not	   differ	   between	  plexiform	   lesions	  
from	  a	  patient	  with	  BMPR2	  mutation	  and	  others	  with	  idiopathic	  or	  associated	  forms	  of	  PAH	  (Jonigk	  
et	  al.,	  2011).	  However,	  TGF-­‐β/BMP	  signalling	  can	  also	  occur	  via	  Smad-­‐independent	   (non-­‐canonical)	  
pathways,	   including	  activation	  of	  Rho	  GTPases	  and	  the	  MAP	  kinases	  p38,	  ERK	  and	  JNK,	  and	   involve	  
cross-­‐talk	   with	   other	   pathways	   (Zhang,	   2009;	   Akhurst	   and	   Hata,	   2012)	   as	   well	   as	   alterations	   in	  
microRNA	   processing	   (Drake	   et	   al.,	   2011).	   I	   cannot	   exclude	   possible	   dysregulation	   of	   these	  
alternative	  Smad-­‐independent	  pathways	  in	  ECFCs	  from	  IPAH	  patients,	  especially	  as	  the	  expression	  of	  
other	  receptors	  and	  accessory	  proteins	  (e.g.	  ActRIIA	  and	  endoglin)	  may	  also	  be	  affected.	  
In	  the	  present	  study,	  ECFCs	  exhibited	  most	  members	  of	  TGF-­‐β	  receptor	  superfamily,	  except	  for	  ALK3	  
and	  ALK6,	  which	  were	  generally	  expressed	  only	  at	  low	  level.	  Previously,	  Upton	  and	  colleagues	  found	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that	  ALK3	  and	  ALK6	  were	  also	  expressed	  at	  a	  low	  level	  in	  HPAECs	  and	  linked	  this	  to	  poor	  binding	  and	  
stimulation	   by	   the	   selective	   ligands	   BMP2	   and	   BMP4	   (Upton	   et	   al.,	   2008;	   Upton	   et	   al.,	   2009).	  
However,	   BMP2/4	   proteins	   are	   reported	   to	   be	   selectively	   expressed	   in	   ECFCs	   and	   involved	   in	  
regulating	  their	  proliferation,	  migration,	  and	  tube	  formation	  (Smadja	  et	  al.,	  2008).	  The	  efficiency	  of	  
BMP9	  in	  stimulating	  pSmad1/5/8	  and	  ID	  gene	  expression	  in	  ECFCs	  is	  comparable	  to	  that	  described	  in	  
HPAECs	  (Upton	  et	  al.,	  2009),	   these	  studies	  having	  been	  performed	  under	  very	  similar	  experimental	  
conditions.	   This	   is	   perhaps	   not	   surprising	   as	   we	   and	   others	   (Evrard	   et	   al.,	   2012)	   have	   found	  
comparable	  levels	  of	  ALK1	  and	  BMPR2	  expression	  in	  ECFCs	  and	  HPAECs.	  	  
There	  are	  a	  number	  of	  limitations	  to	  the	  studies	  in	  this	  chapter.	  I	  was	  unable	  to	  explore	  further	  the	  
differential	   effect	   of	   TGF-­‐β1	   stimulation	   (at	   higher	   concentration)	   on	   pSmad2/3	   or	   the	   impact	   of	  
intercellular	   contact	   and	   other	   regulatory	  mechanisms	   on	   the	   expression	   of	   BMPR2	   isoforms	   and	  
downstream	  signalling	  in	  ECFCs.	  I	  did	  not	  consider	  possible	  differences	  in	  the	  expression	  of	  accessory	  
proteins	   such	   as	   Smurf	   and	   SARA	   or	   explore	   potential	   differences	   in	   other	   non-­‐canonical	  	  
TGF-­‐β/BMP/Smad	  signalling	  pathways	  in	  ECFCs.	  In	  ECs,	  TGF-­‐β1	  can	  signal	  via	  both	  ALK5-­‐Smad2/3	  and	  
ALK1-­‐Smad1/5/8,	  with	  possible	  cross-­‐talk	  between	  the	  two,	  and	  stimulation	  of	  these	  pathways	  can	  
have	  quite	  distinct	  effects	  on	  EC	  quiescence,	  proliferation,	  migration	  and	  tube	  formation	  (Goumans	  
et	  al.,	  2002;	  Goumans	  et	  al.,	  2003).	  Given	  the	  necessary	  additional	  time,	  I	  would	  have	  examined	  the	  
effect	  of	  knocking	  down	  the	  expression	  of	  ALK5	  and	  ALK1	  receptors,	  as	  well	  as	  BMPR2,	   in	  order	  to	  
gain	  further	  insight	  into	  the	  contribution	  and	  interaction	  of	  the	  two	  pathways	  in	  ECFCs.	  Despite	  these	  
limitations,	  I	  have	  demonstrated	  impaired	  ALK5	  expression	  and	  TGF-­‐β	  signalling	  in	  ECFCs	  from	  IPAH	  
patients.	   This	   might	   contribute	   to	   endothelial	   dysfunction,	   possibly	   shifting	   the	   balance	   towards	  
activation	  of	   the	  alternative	  endothelial	   TGF-­‐β/ALK1	  pathway	  as	  described	   in	   ECs	   (Goumans	  et	   al.,	  
2002),	  and	  contribute	   to	   the	  phenotypic	  differences	   found	  between	  ECFCs	   from	   IPAH	  patients	  and	  
healthy	  controls.	  
In	   chapter	   6	   I	   will	   investigate	   the	   role	   of	   ALK1	   and	   ALK5	   receptor	   signalling	   in	   regulating	   ECFC	  
functions,	   using	   selective	   TGF-­‐β/BMP	   stimulation	  and	  pharmacological	   inhibition	   to	   examine	   the	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Chapter	  6	  –	  TGF-­‐β	  receptor	  signalling	  and	  phenotypic	  differences	  in	  
ECFCs	  from	  IPAH	  patients	  
	  
6.1	   Introduction	  
In	  Chapter	  5,	   I	  demonstrated	   reduced	  expression	  of	   the	  TGF-­‐β	   type	  1	   receptor	  ALK5	  and	   impaired	  
TGF-­‐β1	   activation	   of	   Smad2	   in	   ECFCs	   from	   IPAH	   patients.	   Due	   to	   the	   importance	   of	   the	   TGF-­‐β	  
receptor	   superfamily	   in	   the	   regulation	   of	   the	   endothelium,	   it	   is	   possible	   that	   deficiencies	   in	   the	  
ALK5/Smad2	  pathway	  might	  contribute	  to	  a	  dysfunctional	  ECFC	  phenotype.	  In	  order	  to	  establish	  this	  
link,	   it	   is	  necessary	  to	  understand	  the	  role	  of	  the	  endothelial	  ALK1	  and	  ALK5	  signalling	  pathways	   in	  
regulating	  cell	  function,	  but	  few	  studies	  have	  examined	  the	  effects	  of	  TGF-­‐β/BMP	  signalling	  in	  ECFCs.	  
An	   early	   investigation	   of	   ECFCs	   from	   patients	   with	   hereditary	   hemorrhagic	   telangiectasia	   (HHT),	  
caused	  by	  mutations	   in	  ENG	   (HHT1)	  or	  ALK1	   (HHT2),	   revealed	  deficiencies	   in	  both	  ALK5-­‐	  and	  ALK1-­‐
dependent	   signalling	   that	   were	   associated	   with	   a	   disorganised	   cytoskeleton	   and	   disruption	   of	  
proliferation,	  migration	  and	  angiogenesis	  (inability	  to	  form	  a	  tubular-­‐like	  network)	  in	  vitro	  (Fernandez	  
et	   al.,	   2005;	   Fernandez	   et	   al.,	   2007).	   BMP2	   and	   BMP4	   have	   been	   shown	   to	   induce	   proliferation,	  
migration	   and	   angiogenesis	   of	   ECFCs	   obtained	   from	   umbilical	   cord	   blood	   (Smadja	   et	   al.,	   2008).	   A	  
subsequent	  study	  found	  that	  ECFCs	  derived	  from	  the	  peripheral	  blood	  of	  HPAH	  patients	  with	  BMPR2	  
gene	  mutations	  were	  more	  proliferative	  and	  less	  angiogenic	   in	  vitro	  than	  cells	  derived	  from	  healthy	  
controls	  (Toshner	  et	  al.,	  2009).	  More	  recently,	  TGF-­‐β1	  has	  been	  found	  to	  promote	  the	  migration	  of	  
ECFCs	  in	  vitro	  as	  well	  as	  their	  angiogenic	  capacity	  in	  vivo	  (Evrard	  et	  al.,	  2012).	  	  
Endothelin-­‐1	   (ET-­‐1)	   is	  a	  potent	  endothelium-­‐derived	  vasoconstrictor	  and	  SMC	  mitogen	  (Hassoun	  et	  
al.,	  1992)	  and	  increased	  ET-­‐1	  levels	  are	  implicated	  in	  the	  pathogenesis	  of	  PAH	  (Stewart	  et	  al.,	  1991;	  
Giaid	   et	   al.,	   1993).	   The	   endothelium	   is	   postulated	   to	   be	   the	  main	   source	   of	   increased	   ET-­‐1	   in	   the	  
circulation	  and	  lung	  tissues	  in	  PAH	  (Langleben	  et	  al.,	  2006).	  It	   is	  known	  that	  TGF-­‐β1	  stimulates	  ET-­‐1	  
synthesis	   in	  ECs	  from	  several	  vascular	  origins	  (Kurihara	  et	  al.,	  1989;	  Rodriguez-­‐Pascual	  et	  al.,	  2004),	  
including	  human	  PMVECs	  (Star	  et	  al.,	  2009).	  More	  recent	  studies	  have	  shown	  that	  BMP9	  and	  BMP7	  
regulate	   ET-­‐1	   production,	   acting	   via	   several	   pathways	   to	   induce	   the	   release	   of	   ET-­‐1	   from	   human	  
PMVECs	  (Star	  et	  al.,	  2009;	  Star	  et	  al.,	  2010;	  Star	  et	  al.,	  2012).	  Studies	  on	  human	  PAECs	  also	  indicate	  
that	  BMP9-­‐stimulated	  ET-­‐1	  production	  may	  have	  a	  role	  in	  angiogenesis,	  ALK1	  or	  BMPR2	  knockdown	  
attenuating	  this	  while	  also	   increasing	  ET-­‐1	  expression	  and	  release	  (Park	  et	  al.,	  2012).	   In	  addition	  to	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investigating	  potential	   deficiencies	   in	   TGF-­‐β/BMP	   signalling	   I	   therefore	  also	   sought	   to	  examine	   the	  
regulation	  of	  ET-­‐1	  production	  by	  ECFCs.	  
The	  objectives	  of	  this	  chapter	  are	  to:	  
• Determine	   the	   contribution	   of	   ALK1	   and	   ALK5	   signalling	   in	   the	   survival	   of	   serum-­‐deprived	  
ECFCs,	   using	   protein	   ligands	   (BMP4,	   BMP9,	   TGF-­‐β1)	   and	   selective	   inhibitors	   for	   these	  
receptors.	  	  
	  
• Investigate	  the	  role	  of	  ALK1	  and	  ALK5	  signalling	  in	  regulating	  the	  proliferation,	  migration	  and	  
tube	  forming	  capacity	  of	  ECFCs	  in	  vitro.	  
	  
• Compare	   the	   production	   of	   ET-­‐1	   by	   ECFCs	   from	   IPAH	   patients	   and	   healthy	   controls	   and	  
examine	  the	  role	  of	  ALK1	  and	  ALK5	  signalling	  in	  regulating	  ET-­‐1	  release.	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6.2	   Methods	  
See	  Chapter	  2	  for	  detailed	  experimental	  materials	  and	  protocol.	  
	  
6.2.1	   Apoptosis	  assay	  
Serum	   deprivation-­‐induced	   apoptosis	   was	   assessed	   by	   determining	   caspase-­‐3/7	   activity.	  	  
Optimisation	  of	  apoptosis	  assay	  is	  detailed	  in	  Chapter	  2.12.2.	  Sub-­‐confluent	  ECFCs	  and	  HPAECs	  were	  
examined	   48h,	   64h	   and	   72h	   after	   culture	   in	   EBM-­‐2	  medium	   containing	   2%	   FBS	   (control)	   or	   under	  
serum	  deprived	  conditions	  (apoptosis	  stimulus),	  either	  in	  the	  absence	  of	  serum	  or	  presence	  of	  0.5%	  
FBS.	  Cells	  were	  treated	  with	  either	  10	  ng/ml	  BMP4,	  10	  ng/ml	  BMP9	  or	  0.01-­‐50	  ng/ml	  TGF-­‐β1	  and,	  in	  
some	  experiments,	  were	  also	  co-­‐treated	  with	  the	  ALK5	  inhibitors	  SD208	  (15	  µM)	  and	  SB431542	  (15	  
µM),	  the	  ALK1	  inhibitor	  ALK1-­‐Fc	  (2.5	  or	  10	  µg/ml)	  or	  vehicle	  alone.	  	  	  
	  
6.2.2	   BrdU	  incorporation	  assay	  
Optimisation	  of	  BrdU	  assay	  is	  detailed	  in	  Chapter	  2.12.1.	  Sub-­‐confluent	  cultures	  of	  ECFCs	  or	  HPAECs	  
were	  seeded	  (3000	  cells/well	  in	  EBM-­‐2	  containing	  5%	  FBS)	  in	  black-­‐walled	  optical-­‐bottomed	  96-­‐well	  
plates	  and	   incubated	  for	  18	  h	  before	  being	  serum-­‐deprived	  for	  6h.	  Cells	  were	  then	   incubated	  for	  a	  
total	  of	  48h	  in	  EBM-­‐2	  medium	  (containing	  5%	  FBS)	  and	  treated	  (in	  triplicate)	  with	  either	  vehicle,	  10	  
ng/ml	  BMP4,	  10	  ng/ml	  BMP9	  or	  0.1-­‐10	  ng/ml	  TGF-­‐β1,	  both	   in	  the	  absence	  and	  presence	  of	  15	  μM	  
SD208,	   15	   µM	   SB431542,	   or	   10	   µg/ml	   ALK1-­‐Fc.	   DNA	   synthesis	   was	   assessed	   by	   measuring	   BrdU	  
incorporation	  and	  the	  luminescence	  signal	  was	  not	  saturated	  under	  these	  conditions	  (Chapter	  2.12.1;	  
Figure	  2.6).	  	  
	  
6.2.3	   Matrigel	  tube	  formation	  assay	  
The	   effects	   of	   BMP4,	   BMP9	   and	   TGF-­‐β1	   on	   ECFC	   and	  HPAEC	   tube	   formation	  were	   assessed	   using	  
GFR-­‐Matrigel	   and	   EBM-­‐2	   medium	   without	   serum.	   Sub-­‐confluent	   (~70%)	   ECFCs	   or	   HPAECs	   were	  
trypsinised	  and	  resuspended	  in	  medium	  containing	  either	  10	  ng/ml	  BMP4,	  10	  ng/ml	  BMP9	  or	  0.1-­‐10	  
ng/ml	  TGF-­‐β1,	  both	   in	   the	  absence	  and	  presence	  of	  15	  µM	  SD208,	  15	  µM	  SB431542	  and	  10	  µg/ml	  
ALK1-­‐Fc.	  Control	  experiments	   included	   the	  addition	  of	   the	  VEGFR2	   inhibitor	  SU1498	   (10	  µM).	  Cells	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were	  seeded	  onto	  GFR-­‐Matrigel	   (7000	  cells/well	   in	  a	  96-­‐wells	  plate)	  and	   incubated	   in	  a	  humidified	  
atmosphere	  at	  37°C	  for	  16h,	  before	  being	  fixed	  with	  4%	  formaldehyde.	  Measurements	  of	  total	  tube	  
length	   are	   presented	   as	   total	   tube	   lengths,	   each	   data	   point	   being	   the	   mean	   of	   triplicate	   values	  
derived	  from	  images	  of	  2	  random	  fields	  per	  well.	  	  
	  
6.2.4	   Wound	  healing	  assay	  
Confluent	  ECFCs	  and	  HPAECs,	  cultured	  in	  EBM-­‐2	  and	  1%	  FBS	  on	  gelatin-­‐coated	  24-­‐wells	  plates,	  were	  
treated	  with	  either	  15	  µM	  SD208,	  15µM	  SB	  431542	  or	  vehicle	  for	  30	  min	  before	  creating	  the	  wound.	  
Afterwards,	   10	  ng/ml	  BMP4,	   10	  ng/ml	  BMP9	  or	   0.1-­‐10	  ng/ml	   TGF-­‐β1	  was	   added.	   Some	   cells	  were	  
treated	  with	   the	   VEGFR2	   inhibitor	   SU1498	   (10	   μM)	   as	   negative	   control.	   Images	  were	   captured	   at	  
baseline	  (0	  h),	  18	  h	  and	  24	  h	  and	  data	  presented	  as	  a	  percentage	  of	  the	  area	  of	  the	  wound	  recovered	  
(closed)	  compared	  to	  baseline.	  
	  
6.2.5	   Measurement	  of	  endothelin-­‐1	  (ET-­‐1)	  release	  
Sub-­‐confluent	  cells	  were	  resuspended	  in	  EGM-­‐2	  containing	  20%	  FBS	  and	  seeded	  at	  40,000	  cells	  per	  
well	   (equivalent	   to	   7000	   cells/well	   in	   a	   96-­‐wells	   plate)	   on	   gelatin-­‐coated	   24-­‐well	   plates.	   Following	  
overnight	  incubation,	  cells	  were	  washed	  twice	  with	  warm	  sterile	  PBS	  and	  incubated	  (200	  μl/well)	  in	  
either	  EGM-­‐2	  with	  2%	  FBS	  (control),	  EBM-­‐2	  with	  0.5%	  FBS	  or	  EBM-­‐2	  with	  no	  serum.	  Cells	  were	  also	  
treated	  with	   vehicle	  or	  10	  ng/ml	  BMP9	  or	  15	  μM	  SD208.	  Conditioned	  medium	  was	   collected	  after	  
24h	  and	  stored	  frozen	  at	  -­‐80°C	  until	  used.	  Cells	  were	  washed	  with	  PBS	  and	  protein	  harvested	  in	  RIPA	  
buffer	   for	   protein	   measurement.	   ET-­‐1	   levels	   were	   assayed	   with	   a	   commercial	   ELISA	   kit	   (Human	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6.3	   Results	  
	  
6.3.1	   BMP4	  and	  BMP9	  attenuate	  apoptosis	  in	  ECFCs	  from	  healthy	  volunteers	  and	  in	  HPAECs	  
The	  effects	  of	  BMP4	  and	  BMP9	  on	  serum	  deprivation-­‐induced	  apoptosis	  were	  examined	  in	  ECFCs	  and	  
HPAECs.	  As	  demonstrated	  in	  Chapter	  4,	  ECFCs	  from	  IPAH	  patients	  were	  again	  found	  to	  be	  protected	  
from	   serum	   deprivation-­‐induced	   apoptosis,	   exhibiting	   significantly	   less	   caspase-­‐3/7	   activity	  
compared	   to	   ECFCs	   from	  healthy	   volunteers	   and	  HPAECs	   (Figure	  6.1A-­‐B,	   Figure	  6.2A-­‐B).	   BMP4	   (10	  
ng/ml)	   induced	  a	  small,	  but	  nonetheless	   significant	   reduction	   in	  caspase-­‐3/7	  activity	   in	  ECFCs	   from	  
healthy	  volunteers	  and	  in	  HPAECs,	  whereas	  no	  difference	  was	  apparent	  in	  ECFCs	  from	  IPAH	  patients	  
(Figure	  6.1A	  and	  C-­‐D).	  BMP9	   (10	  ng/ml)	  exhibited	  a	  more	  marked	   inhibitory	  effect	  on	  apoptosis	   in	  
ECFCs	   from	   healthy	   volunteers	   and	   HPAECs,	   both	   cell	   types	   displaying	   a	   homogeneous	   (~50%)	  
reduction	   in	   caspase-­‐3/7	   activity	   (Figure	   6.1B	   and	   E).	   When	   considered	   together,	   BMP9	   had	   no	  
overall	   effect	   on	   caspase-­‐3/7	   activity	   in	   ECFCs	   from	   all	   the	   IPAH	   patients	   studied.	   The	   effect	   was	  
heterogeneous	   however,	   with	   cells	   from	   four	   out	   of	   the	   seven	   patients	   examined	   displaying	   an	  
inhibitory	  response	  whereas	  an	  equivocal	  or	  positive	  effect	  was	  observed	  in	  the	  other	  three	  (Patient	  





































































































Figure	  6.1.	  Effects	  of	  BMP4	  and	  BMP9	  on	  serum	  deprivation-­‐induced	  apoptosis.	  Serum-­‐starved	  
(0%	  FBS)	  ECFCs	  and	  HPAECs	  were	  incubated	  for	  48	  h	  in	  the	  presence	  of	  vehicle	  (control),	  BMP4	  (10	  
ng/ml)	  or	  BMP9	  (10	  ng/ml).	  (A-­‐B)	  Caspase-­‐3/7	  activity	  (expressed	  as	  RLU/s)	  in	  ECFCs	  derived	  from	  
healthy	  volunteers	  (n=6-­‐7)	  and	  IPAH	  patients	  (n=7)	  and	  HPAECs	  (n=3).	  Bars	  represent	  mean±SEM.	  
(C-­‐D)	  The	  effect	  of	  BMP4	  on	  caspase-­‐3/7	  activity	  in	  ECFCs	  from	  individual	  healthy	  volunteers	  and	  
IPAH	  patients.	   (E-­‐F)	   The	  effect	  of	  BMP9	  on	  caspase-­‐3/7	  activity	   in	  ECFCs	   from	   individual	  healthy	  
volunteers	  and	  IPAH	  patients.	  Statistics	  obtained	  from	  Bonferroni	  post-­‐hoc	  analysis	  following	  two-­‐
way	   repeated	  measures	  ANOVA	   (A-­‐B)	   or	  paired	   t-­‐test	   (C-­‐F).	  ***,	  P	   <	  0.001	   (caspase-­‐3/7	   activity	  
significantly	  lower	  in	  ECFCs	  from	  IPAH	  patients	  compared	  with	  other	  cell	  types).	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6.3.2	   BMP9	  attenuates	  apoptosis	  through	  ALK1	  receptor	  signalling	  
In	   agreement	   with	   previous	   experiments,	   BMP9	   had	   a	   significant	   inhibitory	   effect	   on	   serum	  
deprivation-­‐induced	  apoptosis	  in	  ECFCs	  from	  healthy	  volunteers	  and	  HPAECs,	  but	  not	  in	  ECFCs	  from	  
IPAH	  patients	  (Figure	  6.2A-­‐B).	  Interestingly,	  the	  impaired	  response	  to	  BMP9	  was	  most	  evident	  in	  cells	  
from	   the	   same	   subset	   of	   IPAH	   patients	   (Patient	   code:	   IPAH	   18,	   IPAH	   19	   and	   IPAH	   31)	   that	   were	  
distinguished	   above	   in	   section	   6.3.1	   (Figure	   6.2B).	   The	   inhibitory	   effect	   of	   BMP9	   on	   caspase-­‐3/7	  
activity,	  both	   in	  ECFCs	   from	  healthy	  volunteers	  and	  HPAECs,	  was	  unaffected	  by	   the	  addition	  of	  2.5	  
µg/ml	  ALK1-­‐Fc	  but	  abolished	  in	  the	  presence	  of	  a	  higher	  concentration	  (10	  µg/ml)	  of	  ALK1-­‐Fc	  (Figures	  
6.2A-­‐B	   and	  6.3).	   In	   contrast,	   the	   addition	  of	   15	  µM	  SD208	   (a	   concentration	   that	   effectively	   blocks	  
ALK5	  signalling,	  see	  Figure	  5.7	  in	  Chapter	  5)	  had	  no	  apparent	  effect	  on	  the	  responses	  of	  these	  cells	  to	  







































































Figure	  6.2.	  BMP9	  attenuates	  apoptosis	  through	  ALK1	  receptor	  signalling.	  (A)	  Caspase-­‐3/7	  activity	  
(expressed	  as	  RLU/s)	   in	  ECFCs	   from	  healthy	  volunteers	  and	   IPAH	  patients	  and	  HPAECs	   (n=3	   in	  all	  
groups),	  measured	  48h	  after	  culture	  in	  EBM-­‐2	  medium	  containing	  either	  2%	  FBS	  +	  EGM-­‐2	  growth	  
factors	  (control)	  or	  no	  serum,	  together	  with	  10	  ng/ml	  BMP9,	  2.5	  µg/ml	  ALK1-­‐Fc	  chimera	  and	  15µM	  
SD208	   or	   a	   combination	   of	   these	   compounds.	   (B)	   Caspase-­‐3/7	   activity	   in	   ECFCs	   from	   healthy	  
volunteers	  (n=4)	  and	  IPAH	  patients	  (n=4)	  and	  HPAECs	  (n=3),	  measured	  48h	  after	  culture	  in	  EBM-­‐2	  
medium	  containing	  either	  2%	  FBS	  +	  EGM-­‐2	  growth	  factors	  (control)	  or	  no	  serum,	  in	  the	  presence	  of	  
10	  ng/ml	  BMP9	  or	  BMP9	  together	  with	  either	  10	  µg/ml	  ALK1-­‐Fc	  chimera	  or	  15µM	  SD208.	  Data	  are	  
presented	  as	  mean±SEM.	  Statistics	  obtained	  from	  Bonferroni	  post-­‐hoc	  analysis	  following	  two-­‐way	  
repeated	  measures	  ANOVA;	  *,	  P	  <	  0.05,	  **,	  P	  <	  0.01,	  ***,	  P	  <	  0.001,	  compares	  to	  2%	  FBS	  within	  the	  
































	   	   	  





































	   	   	  
Figure	  6.3.	   	  Protective	  effect	  of	  BMP9	   is	  mediated	  through	  ALK1	  receptor.	  Representative	  phase-­‐
contrast	  photomicrographs	  of	  data	   in	  Figure	   6.2B,	   showing	  ECFCs	  and	  HPAECs	  cultured	   for	  48h	   in	  
EGM-­‐2	  (control)	  or	  serum-­‐free	  EBM-­‐2	  medium	  in	  the	  presence	  of	  BMP9	  (10	  ng/ml),	  both	  alone	  and	  
in	  combination	  with	  either	  10	  µg/ml	  ALK1-­‐Fc	  or	  15	  µM	  SD208.	  10x	  magnification.	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6.3.3	   Effect	  of	  exogenous	  TGF-­‐β1	  on	  apoptosis	  
Initial	  experiments	  indicated	  that	  the	  addition	  of	  TGF-­‐β1	  (0.01-­‐10	  ng/ml)	  had	  relatively	  little	  effect	  on	  
serum	  deprivation-­‐induced	  apoptosis	  in	  ECFCs,	  and	  a	  moderate	  pro-­‐apoptotic	  effect	  in	  HPAECs	  at	  the	  
highest	   concentration	   (Figure	   6.4A).	  When	   examined	   again	   in	   a	   larger	   cohort	   of	   cells,	   TGF-­‐β1	   (10	  
ng/ml)	   appeared	   to	   selectively	   enhance	   caspase-­‐3/7	   activity	   in	   ECFCs	   from	   IPAH	   patients	   and	  
HPAECs,	  but	  not	  in	  ECFCs	  from	  healthy	  volunteers	  (Figure	  6.4B).	  However,	  this	  was	  not	  reproduced	  
when	  the	  experiment	  was	  repeated	  in	  the	  presence	  of	  both	  10	  and	  50	  ng/ml	  TGF-­‐β1	  (Figure	  6.4C).	  



































































































































Figure	   6.4.	   Effect	   of	   TGF-­‐β1	   on	   serum	   deprivation-­‐induced	   apoptosis.	   (A)	   Caspase-­‐3/7	   activity	  
(expressed	  as	  RLU/s)	  in	  ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients	  and	  HPAECs	  (n=3	  in	  all	  
groups)	  after	  48h	  in	  EBM-­‐2	  with	  2%	  FBS	  (control)	  or	  no	  serum,	  together	  with	  0-­‐10	  ng/ml	  TGF-­‐β1.	  
(B)	   Caspase-­‐3/7	   activity	   in	   ECFCs	   from	   healthy	   volunteers	   (n=7)	   and	   IPAH	   patients	   (n=7)	   and	  
HPAECs	  (n=3)	  after	  48h	  in	  EBM-­‐2	  with	  2%	  FBS	  (control)	  or	  no	  serum,	  together	  with	  10	  ng/ml	  TGF-­‐
β1.	  (C)	  Caspase-­‐3/7	  activity	   in	  ECFCs	  from	  healthy	  volunteers	  (n=4)	  and	  IPAH	  patients	  (n=4)	  and	  
HPAECs	  (n=3)	  after	  48h	  in	  EBM-­‐2	  with	  2%	  FBS	  (control)	  or	  no	  serum,	  together	  with	  either	  10	  or	  50	  
ng/ml	   TGF-­‐β1.	   Data	   are	   presented	   as	   mean±SEM.	   Statistics	   derived	   from	   Bonferroni	   post-­‐hoc	  
analysis	  following	  one-­‐way	  repeated	  measures	  ANOVA;	  *,	  P	  <	  0.05,	  **,	  P	  <	  0.01,	  ***,	  P	  <	  0.001,	  
compared	  with	  control	  (C).	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6.3.4	   ALK5	  inhibition	  attenuates	  apoptosis	  in	  ECFCs	  from	  IPAH	  patients	  
During	   the	   course	   of	   my	   studies	   it	   became	   apparent	   that	   ECFCs	   from	   IPAH	   patients	   were	   less	  
sensitive	   to	   the	   apoptotic	   effect	   of	   serum-­‐deprivation,	   when	   compared	   with	   ECFCs	   from	   healthy	  
volunteers	  and	  HPAECs	   (see	  Chapter	  4).	  Moreover,	   I	   fortuitously	   found	   that,	   in	   the	  presence	  of	  an	  
ALK5	   inhibitor,	   these	   cells	   were	   also	   able	   to	   survive	   for	   prolonged	   periods	   (at	   least	   11	   days)	   in	  
continuous	   culture	   without	   a	   change	   in	   medium	   (EBM-­‐2	   and	   1%	   FBS;	   Figure	   6.5).	   Further	  
experiments	   were	   therefore	   conducted	   to	   explore	   the	   effects	   of	   ALK5	   inhibition	   on	   caspase-­‐3/7	  
activity	  in	  ECFCs	  cultured	  either	  in	  serum-­‐free	  medium	  for	  48h	  or	  in	  the	  presence	  of	  low	  level	  serum	  
(0.5%	  FBS)	   for	  72h.	  Taking	   the	   results	   as	  a	  whole,	  ALK5	   inhibitors	  had	  a	   tendency	  but	   insignificant	  
effect	  in	  ECFCs	  from	  healthy	  volunteers	  and	  HPAECs,	  but	  reduced	  caspase-­‐3/7	  activity	  by	  up	  to	  ~50%	  
in	   ECFCs	   from	   IPAH	   patients.	   This	   effect	   was	   most	   marked	   under	   less	   severe	   serum-­‐deprivation	  





Figure	   6.5.	   Protective	   effect	   of	   ALK5	   inhibition	   in	   ECFCs	   from	   IPAH	   patients.	   Representative	  
phase-­‐contrast	   photomicrographs	   of	   ECFCs	   from	   healthy	   volunteers	   and	   IPAH	   patients	   and	  
HPAECs,	  11	  days	  after	  continuous	  culture	  in	  EBM-­‐2	  and	  1%	  FBS	  supplemented	  with	  either	  10	  ng/ml	  
BMP9,	   10	   ng/ml	   TGF-­‐β1	   or	   15	   µM	   SD208	   and	   TGF-­‐β1	   in	   combination	   with	   SD208.	   10x	  






	   	  
Figure	  6.6.	  ALK5	  inhibitors	  attenuate	  serum	  deprivation-­‐induced	  apoptosis.	  Caspase-­‐3/7	  activity	  
(expressed	  as	  a	  ratio	  of	  control)	  in	  ECFCs	  from	  healthy	  volunteers	  (n=4),	  IPAH	  patients	  (n=4),	  and	  
HPAECs	  (n	  =	  3-­‐6)	  incubated	  in	  (A)	  serum-­‐free	  conditions	  (EBM-­‐2	  without	  FBS)	  for	  48h	  or	  (B)	  serum-­‐
deprived	  medium	  (EBM-­‐2	  and	  0.5%	  FBS)	   for	  72h.	  Cells	  were	  incubated	  in	  the	  presence	  of	  either	  
vehicle	  (control),	  15	  µM	  SD208	  or	  15	  µM	  SB431542.	  Data	  are	  presented	  as	  mean±SEM.	  Statistics	  
derived	   from	  Bonferroni	  post-­‐hoc	  analysis	   following	  one-­‐way	   repeated	  measures	  ANOVA,	   *,	  P	  <	  
0.05,	  **,	  P	  <	  0.01,	  compared	  with	  serum	  free	  (A)	  or	  0.5%	  FBS	  (B).	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6.3.5	   Differential	  effects	  of	  ALK1	  and	  ALK5	  signalling	  on	  caspase-­‐3/7	  activity	  
In	   the	  presence	  of	   low	   concentrations	   of	   serum	   (0.5%	   FBS),	   apoptosis	   is	   induced	   in	   all	   ECFCs,	   and	  
moderately	   increased	   in	   HPAECs	   (Figure	   6.7A-­‐C).	   Prolonged	   incubation	   (up	   to	   64h)	  with	   ALK5	   and	  
ALK1	  inhibitors	  had	  opposing	  effects	  on	  caspase-­‐3/7	  activity.	  In	  fact,	  the	  ALK5	  inhibitor	  SB431542	  (15	  
µM)	  had	  a	  significant	  negative	  effect,	  reducing	  caspase-­‐3/7	  activity	  significantly	  by	  about	  1.8-­‐fold	  in	  
ECFCs	   from	   healthy	   volunteers,	   2.8-­‐fold	   in	   ECFCs	   from	   IPAH	   patients	   and	   2.6-­‐fold	   in	   HPAECs	   after	  	  
64	  h	   incubation	   (Figure	  6.7A-­‐C	  &	  Figure	  6.8A),	  which	  effect	   is	  somehow	  more	  prominent	   than	  that	  
observed	   in	   healthy-­‐ECFCs	   after	   longer	   incubation	   for	   72	   h	   (Figure	   6.6B).	   In	   contrast,	   the	   ALK1-­‐Fc	  
chimera	   (10	   µg/ml)	   was	   found	   to	   exacerbate	   apoptosis	   and	   significantly	   increased	   caspase-­‐3/7	  
activity	  more	  than	  1.6-­‐fold	  in	  all	  three	  cell	  types.	  When	  added	  together,	  the	  respective	  effects	  of	  the	  
ALK5	  and	  ALK1	  inhibitors	  were	  negated	  in	  ECFCs	  from	  IPAH	  patients	  and	  HPAECs	  whereas	  the	  effect	  
of	  ALK1	  inhibition	  still	  predominated	  in	  ECFCs	  from	  healthy	  volunteers	  (Figure	  6.7A-­‐C	  &	  Figure	  6.8A).	  
The	   addition	   of	   TGF-­‐β1	   (at	   10	   and	   50	   ng/ml)	   had	   a	   modest	   but	   insignificant	   positive	   effect	   on	  
caspase-­‐3/7	  activity	  in	  all	  the	  three	  cell	  types	  and	  was	  attenuated	  in	  the	  presence	  of	  SB431542,	  this	  
effect	   being	   most	   prominent	   in	   IPAH-­‐ECFCs	   co-­‐treated	   with	   50	   ng/ml	   TGF-­‐β1	   (Figure	   6.7B).	   In	  
contrast,	  caspase-­‐3/7	  activity	  was	  either	  unaffected	  or	  enhanced	  when	  TGF-­‐β1	  was	  combined	  with	  
the	  ALK1-­‐Fc	  chimera	  (Figure	  6.7A-­‐C).	  Taken	  altogether,	  these	  results	  suggest	  an	  antagonism	  between	  
ALK5	   and	   ALK1	   signalling,	   reflecting	   the	   respective	   activation	   and	   inhibition	   of	   apoptosis	   through	  
ALK5	   and	  ALK1	   receptors.	   In	   keeping	  with	   this	   proposal,	   ALK5	   inhibition	   appeared	   to	   enhance	   the	  
longer-­‐term	  survival	  of	  ECFCs	  from	  IPAH	  patients.	  The	  addition	  of	  SB431542	  was	  associated	  with	  the	  
presence	  of	  more	  adherent	  ‘viable’	  cells	  after	  7	  days	  (168	  h)	  of	  continuous	  culture	  in	  serum-­‐deprived	  
conditions	   compared	   to	   culture	   in	   the	   control	   medium	   (2%	   FBS	   in	   EGM-­‐2),	   and	   this	   effect	   was	  



































































































































































































































































































Figure	  6.7.	  Differential	  effects	  of	  ALK1	  and	  ALK5	  signalling	  on	  caspase-­‐3/7	  activity.	  	  Caspase	  3/7	  
activity	   (expressed	   as	   RLU/s)	   in	  ECFCs	   from	   (A)	  healthy	  volunteers	   (n=4),	   (B)	   IPAH	  patients	   (n=4)	  
and	  (C)	  HPAECs	  (n=3),	  64h	  after	  incubation	  in	  EBM-­‐2	  medium	  containing	  either	  2.0%	  FBS	  and	  EGM-­‐
2	  growth	  factors	  (control)	  or	  0.5%	  FBS.	  Serum-­‐deprived	  cells	  were	   treated	  with	  TGF-­‐β1	   (10	  or	  50	  
ng/ml),	  SB431542	  (15	  µM)	  and	  ALK1-­‐Fc	  (10	  µg/ml)	  as	  well	  as	  a	  combination	  of	  these	  compounds.	  
Data	  are	  presented	  as	  mean±SEM.	  Statistics	  obtained	  from	  Bonferroni	  post-­‐hoc	  analysis	  following	  
one-­‐way	  repeated	  measures	  ANOVA.	  *,	  P	  <	  0.05,	  **,	  P	  <	  0.01,	  ***,	  P	  <	  0.001,	  compared	  with	  C;	  #,	  P	  




























































































	   	  


























































	   	  
	  
Figure	   6.8.	   Differential	   effects	   of	   ALK1	   and	   ALK5	   inhibtion	   on	   caspase-­‐3/7	   activity.	  	  
Representative	  phase-­‐contrast	  photomicrographs	  showing:	  (A)	  the	  differential	  effects	  of	  TGF-­‐
β1	  (10	  or	  50	  ng/ml),	  SB431542	  (15	  µM)	  and	  ALK1-­‐Fc	  (10	  µg/ml)	  on	  the	  number	  of	  adherent,	  
viable-­‐looking	   ECFCs	   from	   a	   healthy	   volunteer	   and	   IPAH	   patient,	   64h	   after	   incubation	   in	  
serum-­‐deprived	   (0.5%	   FBS)	   EBM-­‐2	  medium;	   (B)	   the	   differential	   effect	   of	   SB431542	   and	   co-­‐
treatment	  with	   ALK1-­‐Fc	   or	   TGF-­‐β1	   (50	   ng/ml)	   on	   the	   ECFCs	   from	   the	   same	   subjects	   as	   (A),	  
168h	  after	  incubation	  in	  serum-­‐deprived	  (0.5%	  FBS)	  EBM-­‐2	  medium.	  Control	  medium	  is	  EGM-­‐
2.	  10x	  magnification	  in	  all	  images.	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6.3.6	   	  Effects	  of	  BMP4,	  BMP9	  and	  TGF-­‐β1	  on	  DNA	  synthesis	  
The	   incorporation	   of	   BrdU	   again	   varied	   between	   different	   ECFC	   populations,	   but	   no	   significant	  
difference	   was	   found	   between	   BrdU	   incorporation	   in	   ECFCs	   from	   healthy	   volunteers	   and	   IPAH	  
patients	  (Figure	  6.9A-­‐D).	  Treatment	  with	  either	  BMP4	  or	  BMP9	  (10	  ng/ml)	  had	  no	  apparent	  effect	  on	  
the	  synthesis	  of	  DNA	  in	  ECFCs	  from	  IPAH	  patients	  (Figure	  6.9A).	  BMP4	  enhanced	  BrdU	  incorporation	  
in	  both	  ECFCs	  from	  healthy	  volunteers	  and	  HPAECs,	  while	  BMP9	  selectively	  inhibited	  DNA	  synthesis	  
in	   HPAECS	   (Figure	   6.9A).	   ECFCs	   from	   IPAH	   patients	   also	   appeared	   to	   be	   unresponsive	   to	   TGF-­‐β1	  
stimulation,	   whereas	   ECFCs	   from	   healthy	   volunteers	   and	   HPAECs	   exhibited	   a	   concentration-­‐
dependent	   increase	   in	   BrdU	   incorporation	   (Figure	   6.9B).	   Treatment	   of	   cells	  with	   an	  ALK5	   inhibitor	  
(SD208	   or	   SB431542)	   tended	   to	   promote	  DNA	   synthesis	  when	   added	   alone	   in	   both	   healthy-­‐ECFCs	  
and	  HPAECs	   (Figure	   6.9C-­‐D),	   and	   in	  HPAECs,	   ALK5	   inhibitor	   further	   enhanced	   the	   effect	   of	   TGF-­‐β1	  
stimulation	   (Figure	   6.9C-­‐D).	   ALK1	   inhibition	   using	   10	   µg/ml	   ALK1-­‐Fc	   had	   tended	   to	   lower	   BrdU	  
incorporation	  of	  ECFCs	  in	  healthy-­‐ECFCs,	  and	  this	  was	  not	  rescued	  by	  the	  addition	  of	  TGF-­‐β1	  (Figure	  
6.9E),	   while	   no	   effects	   could	   be	   observed	   in	   IPAH-­‐ECFCs	   (Figure	   6.9F).	   In	   contrast,	   ALK1-­‐Fc	  
significantly	   increased	   BrdU	   incorporation	   in	   HPAECs	   (Figure	   6.9G),	   suggesting	   there	   might	   be	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Figure	   6.9.	   Effects	   of	   BMP4,	   BMP9	   and	   TGF-­‐β1	   on	   DNA	   synthesis.	  BrdU	   incorporation	   in	  ECFCs	  
from	  healthy	  volunteers	  (n	  =	  4-­‐6),	  IPAH-­‐ECFCs	  (n	  =	  4-­‐7)	  and	  HPAECs	  (n	  =	  3-­‐4)	  cultured	  in	  EBM-­‐2	  and	  
5%	  FBS	  with	  vehicle	  controls	  or	  A)	  BMP4	  and	  BMP9,	  (B)	  TGF-­‐β1	  (0.1	  –	  10	  ng/ml),	  (C-­‐D)	  TGF-­‐β1	  (10	  
ng/ml)	  alone	  or	  co-­‐treated	  with	  ALK5	   inhibitor	  SD208	   (15	  µM.	  BrdU	  incorporation	   in	  response	   to	  
treaetmnet	  with	  ALK1-­‐Fc	   (10	   ng/ml),	   TGF-­‐β1	   (10	  ng/ml),	   or	   both	   together	   in	   (E)	   healthy	   control	  
ECFCs,	  (F)	  ECFCs	  from	  IPAH	  patients	  and	  (G)	  HPAECs.	  Data	  presented	  as	  mean±SEM.	  Statistics	  from	  
Bonferroni	   post-­‐hoc	   analysis	   following	   either	   two-­‐way	   repeated	  measures	  ANOVA	   (A-­‐D)	   or	   one-­‐
way	  repeated	  measures	  ANOVA	  (E-­‐G).	  *,	  P	  <	  0.05,	  **,	  P	  <	  0.01,	  ***,	  P	  <	  0.001,	  compared	  with	  C;	  #,	  
P	  <	  0.05,	  ##,	  P	  <	  0.01,	  ###,	  P	  <	  0.001,	  comparisons	  as	  indicated.	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6.3.7	   	  Effects	  of	  BMP4,	  BMP9	  and	  TGF-­‐β1	  on	  Matrigel	  tube	  formation	  
ECFCs	   from	   IPAH	  patients	   again	  displayed	   increased	   level	   of	  Matrigel	   tube	   formation	   compared	   to	  
ECFCs	   from	   healthy	   volunteers	   (Figure	   6.10A-­‐B).	   Tube	   formation	   was	   attenuated,	   albeit	   non-­‐
significantly,	   in	   the	  presence	  of	  BMP4	   (10	  ng/ml)	  and	  significantly	   inhibited	  by	  BMP9	   (10	  ng/ml)	   in	  
ECFCs	   from	  healthy	   volunteers	   and	   IPAH	   patients	   and	  HPAECs	   (Figure	   6.10A-­‐C).	   Additional	   studies	  
indicated	   that	   TGF-­‐β1	   had	   little	   or	   no	   effect	   on	   tube	   formation	   by	   ECFCs	   and	   induced	   a	  
concentration-­‐dependent	  increase	  in	  the	  tube	  formation	  of	  HPAECs,	  these	  cells	  also	  being	  sensitive	  
to	  TGF-­‐β1	  at	  low	  concentration	  (0.01	  ng/ml)	  (Figure	  6.11A).	  The	  addition	  of	  the	  ALK5	  inhibitor	  SD208	  
(15	  µM)	  had	  a	  negative	  effect,	   inhibiting	   tube	   formation	   in	  all	   three	  groups	  of	   cells	   (Figure	  6.11A).	  
The	  VEGFR2	  inhibitor	  SU1498	  also	  exerted	  a	  significant	   inhibitory	  effect	  on	  tube	  formation	  by	  both	  




Figure	  6.10.	  Effects	  of	  BMP4	  and	  BMP9	  on	  Matrigel	  tube	  formation.	  Total	  tube	  length	  formed	  on	  
growth	  factor	  reduced	  Matrigel	  in	  response	  to	  EBM-­‐2	  with	  vehicle	  (control)	  or	  (A)	  BMP4	  (10	  ng/ml)	  
by	   ECFCs	   from	  healthy	   volunteers	   (n=4)	   and	   IPAH	  patients	   (n=3);	   	   (B)	   BMP9	   (10	  ng/ml)	   by	   ECFCs	  
from	  healthy	  volunteers	  (n=7)	  and	  IPAH	  patients	  (n=6);	  (C)	  BMP4	  (10	  ng/ml)	  or	  BMP9	  (10	  ng/ml)	  by	  
HPAECs	  (n=3).	  Representative	  phase-­‐contrast	  photomicrographs	  of	  tube	  formation	  by	  each	  sample	  
groups	  are	  shown	  to	  demonstrate	  the	  effects	  of	  each	  condition.	  Data	  are	  presented	  as	  mean±SEM.	  
Statistics	  obtained	   from	  Bonferroni	  post-­‐hoc	  analysis	   following	  either	   two-­‐way	   repeated	  measures	  






Figure	   6.11.	   Effects	   of	   TGF-­‐β1	   and	   VEGFR2	   inhibitor	   on	   Matrigel	   tube	   formation.	   Total	   tube	  
length,	  formed	  on	  growth	  factor	  reduced	  Matrigel,	   in	  response	  to	  EBM-­‐2	  with	  vehicle	  (0,	  control)	  
and	   (A)	   TGF-­‐β1	   (0.01–10	   ng/ml)	   or	   ALK5	   inhibitor	   SD208	   (SD;	   15	   µM)	   by	   ECFCs	   from	   healthy	  
volunteers	  (n=5),	  IPAH	  patients	  (n=5)	  and	  HPAECs	  (n=4)	  or	  (B)	  VEGFR2	  inhibitor	  SU1498	  (10	  µM)	  by	  
ECFCs	  from	  healthy	  volunteers	  (n=6),	  IPAH	  patients	  (n=6)	  and	  HPAECs	  (n=3).	  Representative	  phase-­‐
contrast	   photomicrographs	  of	   each	   corresponding	  numbered	   condition	   in	   the	  bar	  chart	   in	   (A)	  or	  
effects	  of	  SU1498	  in	  (B)	  are	  displayed.	  Data	  are	  presented	  as	  mean±SEM.	  Statistics	  obtained	  from	  
Bonferroni	   post-­‐hoc	   analysis	   following	   one-­‐way	   repeated	  measures	   ANOVA.	   *,	   P	  <	  0.05,	   **,	  P	   <	  
0.01,	  versus	  control;	  ###,	  P	  <	  0.001,	  compared	  with	  control.	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6.3.8	   	  Effects	  of	  BMP4,	  BMP9	  and	  TGF-­‐β1	  on	  cell	  migration	  in	  wound	  healing	  assay	  
ECFCs	  from	  IPAH	  patients	  exhibited	  an	   impaired	  capacity	  to	  recover	  and	  repopulate	  the	  area	  made	  
by	  a	  wound	  (scratch),	  when	  compared	  with	  ECFCs	  derived	  from	  healthy	  volunteers	  (Chapter	  4.3.4).	  
This	  difference	  was	  reproduced	  in	  the	  current	  experiments	  (Figure	  6.12A-­‐C).	  The	  addition	  of	  BMP4	  or	  
TGF-­‐β1	  had	   little	   influence	  on	  wound	  recovery	   in	  ECFCs	  from	  healthy	  volunteers	  and	   IPAH	  patients	  
(Figure	  6.12A-­‐C),	  while	  BMP9	  appeared	  to	  selectively	  reduce	  migration	   in	   IPAH	  cells	   (Figure	  6.12A).	  
ALK5	   inhibition	  was	  accompanied	  by	  a	  reduction	   in	  the	  rate	  of	  wound	  recovery,	  both	   in	  ECFCs	  and	  
HPAECs,	  with	  SD208	  tending	  to	  be	  more	  effective	  than	  SB431542	  (Figure	  6.12B),	  and	  co-­‐treatment	  of	  
cells	  with	  SD208	  and	  TGF-­‐β1	  had	  a	  similar	  inhibitory	  effect	  to	  SD208	  alone	  (Figure	  6.12C).	  As	  in	  the	  
tube	  formation	  assay	  above,	  the	  VEGFR2	  inhibitor	  SU1498	  had	  a	  negative	  effect	  on	  the	  migration	  of	  




Figure	  6.12.	  Effects	  of	  BMP4,	  BMP9	  and	  TGF-­‐β1	  on	  cell	  migration	   in	  wound	   (scratch)	  assay.	   (A)	  
Area	   recovered	   by	   ECFCs	   from	   healthy	   volunteers	   (n=6)	   and	   IPAH	   patients	   (n=7)	   after	   18	   h	  
treatment	   with	   vehicle	   (control),	   BMP4	   (10	   ng/ml)	   or	   BMP9	   (10	   ng/ml).	   (B)	   Area	   recovered	   by	  
ECFCs	   from	   healthy	   volunteers	   (n=5),	   IPAH	  patients	   (n=7)	   and	  HPAECs	   (n=3)	   in	   response	   to	   pre-­‐
treatment	  with	   the	  ALK5	   inhibitors	   SD208	   (15	  µM)	  or	   SB431542	   (15	  µM).	   (C)	   Area	   recovered	  by	  
ECFCs	  from	  healthy	  volunteers	  (n=6),	   IPAH	  patients	  (n=7)	  and	  HPAECs	   (n=6)	  after	  18	  h	  treatment	  
with	  TGF-­‐β1	  (10	  ng/ml),	  SD208	  (15	  µM)	  or	  a	  combination	  of	  the	  two,	  and	  in	  cells	  pre-­‐treated	  with	  
the	   VEGFR2	   inhibitor	   SU1498	   (10	   µM).	   Data	   are	   presented	   as	   mean±SEM.	   Statistics	   from	  
Bonferroni	   post-­‐hoc	   analysis	   following	   two-­‐way	   repeated	  measures	   ANOVA.	   *,	   P	  <	  0.05,	   **,	  P	  <	  
0.01,	  ***,	  P	  <	  0.001,	  compared	  to	  vehicle	  controls	  in	  each	  group.	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6.3.9	   	  Endothelin-­‐1	  release	  in	  ECFCs	  and	  HPAECs	  
One	  of	  the	  hallmarks	  of	  IPAH	  is	  raised	  circulating	  levels	  of	  ET-­‐1	  (Stewart	  et	  al.,	  1991;	  Langleben	  et	  al.,	  
2006),	   with	   ECs	   in	   the	   remodelled	   pulmonary	   vasculature	   being	   considered	   a	   likely	   source	   of	  
production	   (Giaid	   et	   al.,	   1993).	   I	   compared	   ET-­‐1	   levels	   in	   the	   conditioned	  medium	   of	   ECFCs	   from	  
healthy	  volunteer	  and	  IPAH	  patients	  and	  found	  no	  difference,	  although	  both	  groups	  of	  cells	  produced	  
more	   ET-­‐1	   than	   HPAECs	   after	   24h	   in	   either	  medium	  with	   no	   serum	   or	   EGM-­‐2	   containing	   2%	   FBS	  
(Figure	  6.13A-­‐C).	  ET-­‐1	  has	  been	  reported	  to	  act	  as	  a	  pro-­‐survival	  factor	  in	  ECs	  (Dong	  et	  al.,	  2005)	  and	  
BMP9	   stimulates	   ET-­‐1	   release	   from	   human	   pulmonary	  microvascular	   ECs	   and	   HPAECs	   (Star	   et	   al.,	  
2010;	  Park	  et	  al.,	  2012).	  I	  therefore	  sought	  to	  investigate	  whether	  the	  pro-­‐survival	  effect	  of	  BMP9	  on	  
ECFCs	  might	  also	  be	  linked	  to	  ET-­‐1	  release.	  Cells	  were	  seeded	  in	  24-­‐well	  plates,	  at	  the	  same	  density	  
used	  for	  the	  caspase	  3/7	  assay,	  and	  treated	  with	  10	  ng/ml	  BMP9	  in	  serum-­‐free	  EBM-­‐2	  medium.	  This	  
concentration	   of	   BMP9	   is	   within	   the	   normal	   range	   (9-­‐41	   pmol/ml	   or	   2-­‐12	   ng/ml)	   reported	   for	  
circulating	   BMP9	   (David	   et	   al.,	   2008).	   Treatment	  with	   BMP9	   significantly	   increased	   ET-­‐1	   release	   in	  
both	  ECFCs	  from	  healthy	  volunteers	  and	  HPAECs,	  but	  not	  in	  ECFCs	  from	  IPAH	  patients	  (Figure	  6.13D–
F).	  However,	  the	  latter	  response	  was	  heterogeneous	  and	  two	  cell	  populations	  (IPAH	  18	  and	  IPAH	  31)	  
showed	  a	  negative	  effect	  (Figure	  6.13E),	  these	  corresponding	  with	  two	  of	  the	  three	  ECFC	  lines	  that	  
also	   did	   not	   respond	   to	   BMP9	   in	   the	   apoptosis	   assay	   (Figure	   6.1F).	   The	   protein	   content	   of	   ECFC	  
cultures	  was	  not	  affected	  following	  changes	  in	  either	  the	  serum	  content	  of	  the	  medium	  or	  treatment	  
with	  BMP9	  for	  24h	  (Figure	  6.14),	  suggesting	  that	  differences	  in	  ET-­‐1	  levels	  did	  not	  reflect	  variation	  in	  
cell	  number.	  Although	  the	  protein	  level	  was	  lower	  in	  BMP9-­‐treated	  HPAECs,	  the	  production	  of	  ET-­‐1	  






















































































































Figure	  6.13.	  Endothelin-­‐1	  production	  by	  ECFCs	  and	  PAECs.	  Endothelin-­‐1	  (ET-­‐1)	  levels,	  measured	  by	  
ELISA,	   in	   conditioned	  medium	   collected	   after	   24h.	   The	   upper	   panel	   shows	   ET-­‐1	   release	   by	   cells	  
incubated	  in	  (A)	  EBM-­‐2	  with	  no	  serum,	  (B)	  EBM-­‐2	  with	  0.5%	  FBS	  and	  (C)	  EGM-­‐2	  with	  2%	  FBS.	  The	  
lower	  panel	  shows	  ET-­‐1	  release	  by	  ECFCs	  from	  (D)	  healthy	  volunteers	  and	  (E)	  IPAH	  patients	  and	  (F)	  
HPAECs,	  cultured	  in	  EBM-­‐2	  medium	  with	  no	  serum	  and	  in	  the	  presence	  of	  BMP9	  (10	  ng/ml)	  for	  24	  
h.	  (G)	  The	  incremental	  change	  in	  ET-­‐1	  release	  upon	  treatment	  with	  BMP9	  (10	  ng/ml),	  relative	  to	  the	  
vehicle	  control,	  for	  each	  ECFC	  population.	  Data	  are	  presented	  as	  mean±SEM	  (A-­‐C,	  F,	  G).	  Statistics	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Figure	   6.14.	   Protein	   levels	   in	  cell	   cultures	  used	   for	   ET-­‐1	  measurements.	   (A-­‐F)	  Cell	  protein	   levels	  
were	  measured	   after	   removal	   of	   the	   24	   h	   conditioned	  medium	   (see	   Figure	   6.13).	   (G)	   Total	   ET-­‐1	  
release	   by	   HPAECs	   after	   normalisation	   for	   the	   content	   of	   each	   well.	   Data	   are	   presented	   as	  
mean±SEM.	  Statistics	  from	  Bonferroni	  post-­‐hoc	  test	  following	  one-­‐way	  ANOVA	  (A-­‐C)	  or	  t-­‐test	  (D-­‐G).	  
	  
	  213	  
TGF-­‐β1	   is	   a	   known	   stimulator	   of	   ET-­‐1	   release	   from	   HMVECs	   and	   HPAECs	   (Star	   et	   al.,	   2009).	  
Interestingly,	  the	  ALK5	  inhibitor	  SD208	  had	  dramatic	  effect,	  abolishing	  ET-­‐1	  release	  in	  all	  cells	  while	  
having	  no	  significant	  effect	  on	  cell	  protein	  level	  (Figure	  6.15),	  indicating	  that	  ALK5	  receptors	  and	  TGF-­‐
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D E F 
Figure	  6.15.	  Effect	  of	  ALK5	  inhibition	  ET-­‐1	  release	  by	  ECFCs	  and	  HPAECs.	  ET-­‐1	  production	  by	  ECFCs,	  
derived	  from	   (A)	  healthy	  volunteers	  (n	  =	  7)	  and	  (B)	   IPAH	  patients	  (n	  =	  6),	  and	  (C)	  HPAECs	   (n	  =	  4).	  
Conditioned	  medium	   collected	   24h	   after	   incubation	   in	   EBM-­‐2	  with	   0.5%	   FBS	   (control)	   and	   in	   the	  
presence	  of	  15	  µM	  SD208.	  (D-­‐F)	  Proteins	  levels	  were	  also	  measured	  in	  each	  of	  the	  three	  groups	  of	  
cells.	  Data	  are	  presented	  as	  mean±SEM	  (D-­‐F).	  Statistics	  from	  t-­‐test.	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6.4	   Discussion	  
The	  main	  findings	  in	  this	  chapter	  are:	  
• ECFCs	   from	   healthy	   volunteers	   and	   HPAECs	   exhibited	   comparable	   functional	   responses	   to	  
BMP4,	  BMP9,	  TGF-­‐β1	  and	  selective	  ALK1	  or	  ALK5	  inhibitors.	  
• ECFCs	  from	  IPAH	  patients	  were	  generally	  less	  responsive	  than	  the	  other	  two	  groups	  of	  cells	  
to	  stimulation	  by	  BMP4,	  BMP9	  and	  TGF-­‐β1.	  
• 	  ALK1	   and	   ALK5	   receptor	   signalling	   exerted	   opposing	   effects	   on	   apoptosis	   (caspase-­‐3/7	  
activation)	  induced	  by	  serum-­‐deprivation.	  	  
• An	   imbalance	   in	  ALK1	  and	  ALK5	  signalling	  might	  contribute	  to	  the	  apoptosis-­‐resistance	  and	  
slower	  migration	  of	  ECFCs	  from	  IPAH	  patients.	  
• Equivalent	   amounts	   of	   ET-­‐1	   were	   produced	   by	   ECFCs	   from	   IPAH	   patients	   and	   healthy	  
volunteers	  and	  its	  release	  was	  markedly	  sensitive	  to	  ALK5	  inhibition.	  	  
	  
Regulation	  of	  apoptosis	  by	  TGF-­‐β/BMP	  signalling	  	  
Normal	  BMP	  signalling	   is	   important	  for	  the	  survival	  of	  HPAECs	  and	  disruption	  of	  BMPR2	  expression	  
promotes	  serum	  deprivation-­‐induced	  apoptosis	  (Teichert-­‐Kuliszewska	  et	  al.,	  2006;	  de	  Jesus	  Perez	  et	  
al.,	  2009;	  Yang	  et	  al.,	  2011).	  I	  explored	  signalling	  through	  BMPR2	  by	  stimulating	  cells	  with	  BMP4	  and	  
BMP9.	   The	   addition	   of	   BMP4	   reduced	   the	   apoptotic	   response	   in	   HPAECs	   and	   ECFCs	   from	   healthy	  
volunteers,	  similar	  to	  that	  reported	  by	  others	  (Southwood	  et	  al.,	  2008),	  but	  the	  effect	  was	  relatively	  
modest.	  This	  may	  reflect	  the	  longer	  exposure	  to	  serum	  deprivation	  (48	  h),	  compared	  to	  other	  studies	  
(24	   h)	   with	   BMP4	   (Southwood	   et	   al.,	   2008)	   and	   the	   structurally	   related	   ligand	   BMP2	   (Teichert-­‐
Kuliszewska	  et	  al.,	  2006;	  de	  Jesus	  Perez	  et	  al.,	  2009).	  The	  endothelial	  ALK1/BMPR2	  receptor	  complex	  
is	  selectively	  stimulated	  by	  BMP9	  (Upton	  et	  al.,	  2009)	  and	  the	  addition	  of	  BMP9	   induced	  a	  marked	  
reduction	   in	  caspase-­‐3/7	  activation	   in	  HPAECs	  and	  ECFCs	   from	  healthy	  volunteers	  but	  not	   in	  ECFCs	  
from	   IPAH	   patients.	   Interestingly,	   only	   3	   out	   of	   the	   7	   IPAH	   cell	   lines	   tested	   failed	   to	   display	   an	  
inhibitory	  response	  to	  BMP9,	  suggesting	  that	  cohort	  of	  ECFCs	  from	  IPAH	  patients	  was	  heterogeneous.	  
Further	  evidence	  of	  the	   importance	  of	  ALK1	  activation	   in	  modulating	  EC	  survival	   is	  provided	  by	  the	  
pro-­‐apoptotic	  effect	  that	  the	  ALK1	  inhibitor	  ALK1-­‐Fc	  had	  induced	  on	  all	  three	  groups	  of	  cells.	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TGF-­‐β1	  is	  typically	  considered	  to	  be	  pro-­‐apoptotic	  agent	  in	  ECs,	  although	  the	  underlying	  mechanism	  
is	  not	   fully	   clear.	  Most	   studies	  have	  described	  pro-­‐apoptotic	  effects	  of	  TGF-­‐β1	   in	  ECs	  derived	   from	  
the	  umbilical	  vein,	  aorta	  and	  microvasculature	  of	  various	  species	  (Tsukada	  et	  al.,	  1995;	  Ferrari	  et	  al.,	  
2006;	   Lu	  et	  al.,	   2009;	  Tian	  et	  al.,	   2012a).	  But	  other	   studies	   found	   that	  TGF-­‐β1	  was	  also	   capable	  of	  
promoting	  survival	  in	  bovine	  PAECs	  and	  mouse	  capillary	  ECs	  (Vinals	  and	  Pouyssegur,	  2001;	  Lu,	  2008).	  
These	   disparate	   responses	   have	   been	   attributed	   to	   endothelial	   heterogeneity	   in	   the	   vasculature,	  
with	  TGF-­‐β1	  exerting	  pro-­‐	  and	  anti-­‐apoptotic	  effects	  (through	  the	  ALK5	  receptor)	  in	  ECs	  derived	  from	  
proximal	   and	   distal	   regions	   of	   the	   bovine	   pulmonary	   artery	   bed	   respectively	   (Lu,	   2008;	   Lu	   et	   al.,	  
2009).	   I	   found	   that	   two	   different	   pharmacological	   inhibitors	   of	   ALK5	   (SD208	   and	   SB431542)	   also	  
attenuated	  serum	  deprivation-­‐induced	  apoptosis	  in	  all	  three	  cell	  types,	  and	  selectively	  promoted	  the	  
longer-­‐term	   survival	   of	   ECFCs	   from	   IPAH	   patients	   (beyond	   3	   –	   11	   days).	   This	   suggests	   that	   ALK5	  
signalling	  is	  an	  important	  determinant	  of	  apoptosis/survival	  and,	  at	  least	  in	  longer-­‐term	  culture,	  may	  
differ	   in	   IPAH.	   Further	   studies	   are	   required	   to	   explore	   the	   autocrine/paracrine	   activation	   of	   ALK5	  
signalling	  during	  serum-­‐deprived	  conditions	  and	  the	  potential	  contribution	  of	  serum	  as	  a	  source	  of	  
BMP9	   and	   TGF-­‐β1	   in	   the	   culture	   experiments.	   It	   is	   recognised	   that	   the	   effects	   of	   TGF-­‐β	   signalling	  
through	  ALK1	  and	  ALK5	  receptors	  are	  both	  cell	  type	  and	  context	  dependent.	  Studies	  with	  ECFCs	  from	  
normal	   subjects	   have	   shown	   for	   example	   that	   incubation	   with	   growth	   factor-­‐free,	   low	   serum	  
medium	   containing	   high	   glucose	   and	   glycated	   albumin	   induces	   ALK5	   expression	   and	   TGF-­‐β1	  
production	   without	   affecting	   ALK1	   or	   endoglin	   protein	   levels	   (Wang	   and	   Hirschberg,	   2009).	   The	  
‘diabetic	   milieu’	   induced	   ECFC	   proliferation	   as	   well	   as	   caspase-­‐3	   activity	   and	   the	   effects	   were	  
respectively	  enhanced	  and	  attenuated	  by	  the	  ALK5	  inhibitor	  SB431542.	  	  
Despite	  using	  a	  wide	  concentration	  range	  (0.01-­‐50	  ng/ml),	  the	  pro-­‐apoptotic	  effects	  of	  TGF-­‐β1	  were	  
not	  prominent	  in	  ECFCs.	  However,	  TGF-­‐β1	  has	  been	  shown	  to	  induce	  survival	  as	  well	  as	  apoptotsis	  in	  
ECs,	  by	  shifting	  VEGF	  signalling	  between	  different	  p38	  MAPK	  isoforms	  (Ferrari	  et	  al.,	  2009;	  Ferrari	  et	  
al.,	  2012).	  This	  results	  in	  the	  transient	  induction	  of	  apoptosis,	  within	  6-­‐12	  h	  of	  stimulation,	  followed	  
by	  a	  long	  period	  when	  the	  cells	  are	  refractory	  to	  the	  pro-­‐apoptotic	  effects	  of	  TGF-­‐β1.	  So	  it	  is	  possible	  
that	  the	  apoptotic	  effect	  of	  TGF-­‐β1	  in	  ECFCs	  had	  waned	  after	  48-­‐64	  h	  incubation	  and	  the	  results	  were	  
confounded	  by	   its	  dual	  activity.	  Conversely,	   sustained	  ALK5	  activation	  may	   impair	   the	  permeability	  
and	  contact	  of	  ECs	  and	  lead	  to	  apoptosis	  over	  a	  longer	  time	  course	  (42	  h)	  (Antonov	  et	  al.,	  2012).	  	  
Nevertheless,	  when	  considered	  together,	  the	  present	  data	  support	  the	  concept	  that	  ALK1	  and	  ALK5	  
signalling	   have	   opposing	   actions	   on	   EC	   apoptosis:	   activation	   of	   ALK1	   being	   pro-­‐survival	   (anti-­‐
apoptotic)	   and	   activation	   of	   ALK5	   pro-­‐apoptotic	   (see	   Figure	   6.16A).	   It	   is	   unclear	   if	   the	   reduced	  
expression	   of	   ALK5	   and	   impaired	   ALK5/Smad2	   activation	   contributed	   to	   the	   apoptosis-­‐resistant	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phenotype	  of	  ECFCs	   from	  IPAH	  patients,	  but	  ALK5	   inhibition	   in	  serum-­‐deprived	  healthy-­‐ECFCs	  have	  
attenuated	   the	   apoptosis	   down	   to	   similar	   level	   as	   those	   observed	   in	   serum-­‐deprived	   IPAH-­‐ECFCs	  
without	   treatment,	  while	  co-­‐treatment	  of	  ALK1	   inhibition	  and	  TGF-­‐β1	   in	   IPAH-­‐ECFCs	  has	  raised	  the	  
apoptosis	   level	   close	   to	   those	   displayed	   by	   serum-­‐deprived	   healthy-­‐ECFCs	   (Figure	   6.7A	   &	   B).	   It	   is	  
conceivable	   to	   suggest	   that	   normal	   TGF-­‐β	   signalling	   allows	   ECFCs	   to	   undergo	  normal	   programmed	  
cell	   death,	   whereas	   dysregulated	   TGF-­‐β	   signalling	   in	   ECFCs	   from	   IPAH	   patients	   could	   lead	   to	   the	  
impaired	   sensitivity	   of	   these	   cells	   to	   apoptosis	   (Figure	   6.16A-­‐B).	   This	  might	   play	   an	   important	   role	  
especially	  in	  the	  formation	  of	  apoptosis-­‐resistant	  ECs	  lining	  the	  plexiform	  lesions	  in	  IPAH	  lungs	  where	  
ALK5	  and	  pSmad2	  expression	  are	  both	  significantly	  reduced	  (Richter	  et	  al.,	  2004).	  Ideally,	  I	  would	  like	  
to	   have	   confirmed	   the	   differential	   effects	   of	   ALK1	   and	   ALK5	   signalling	   using	   another	   apoptotic	  
stimulus,	  such	  as	  the	  treatment	  of	  ECs	  with	  the	  combination	  of	  TNF-­‐α	  and	  cycloheximide	  (Sakao	  et	  al.,	  
2005),	   and	   explored	   the	   effect	   of	   manipulating	   ALK5	   expression	   on	   the	   apoptosis	   of	   ECFCs	   from	  
healthy	   volunteers.	   Additional	   experiments	   might	   also	   benefit	   from	   the	   use	   of	   luiferase	   reporter	  
gene	  constructs	  that	  are	  responsive	  to	  ALK1	  (e.g.	  BRE-­‐lux)	  and	  ALK5	  (e.g.	  CAGA-­‐lux)	  activation	  (Shao	  
et	   al.,	   2009).	   Interestingly,	   caspase-­‐3/7	   activation	   was	   modulated	   by	   selective	   ALK1	   and	   ALK5	  
inhibitors	   on	   their	   own,	   indicating	   signalling	   through	   these	   receptors	   in	   the	   absence	  of	   exogenous	  
ligands.	   Whether	   the	   receptors	   are	   constitutively	   active,	   stimulated	   by	   endogenously	   produced	  
















Figure	   6.16.	   ALK1	   and	   ALK5	   regulations	   of	   apoptosis	   in	   ECFCs.	   (A)	   TGF-­‐β	   signalling	   regulation	  of	  
ECFCs	   apoptosis	   rely	   on	   the	   balance	   of	   the	   ALK1	   and	   ALK5	   signalling.	   ALK5	   activation	   promotes	  
apoptosis,	  while	  ALK1	  activation	  paradoxically	  inhibits	  apoptosis	  and	  promotes	  survival	  of	  ECFCs.	  In	  
healthy-­‐ECFCs	   with	   normal	   ALK5	   expression,	   TGF-­‐β1	   preferentially	   activates	   ALK5	   while	   BMP9	  
activates	  ALK1	   to	  provide	  a	   fine-­‐tuned	  balance	   that	  allows	  ECFCs	   to	  undergo	  normal	  programmed	  
cell	  death.	   (B)	   In	   IPAH-­‐ECFCs,	  ALK5	  expression	   is	   significantly	   lower.	   This	  could	  significantly	   impair	  
ALK5	   signalling,	   shifting	   the	   balance	   of	   functional	   regulation	   to	   ALK1,	   resulting	   in	   substantial	  
resistance	  to	  apoptosis	  in	  these	  cells	  that	  could	  be	  important	  in	  the	  pulmonary	  vascular	  remodelling	  
in	  IPAH.	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Regulation	  of	  proliferation,	  migration	  and	  angiogenesis	  by	  TGF-­‐β/BMP	  signalling	  
Exploring	   the	   role	  of	  ALK1	  and	  ALK5	   signalling	   in	  other	  ECFC	   functions	  may	  provide	   further	   insight	  
into	   the	   significance	   of	   impaired	   ALK5	   expression/signalling	   in	   the	   disease-­‐related	   phenotype	   of	  
ECFCs	   from	   IPAH	   patients.	   Some	   understanding	   of	   the	   importance	   of	   these	   receptors	   and	   their	  
interaction	  has	  been	  provided	  by	  studies	  of	  ECFCs	  isolated	  from	  HHT	  patients	  with	  endoglin	  (HHT1)	  
and	  ALK1	   (HHT2)	  mutations	   (Fernandez	  et	   al.,	   2005).	  Notably,	   reduced	  expression	  of	   endoglin	   and	  
ALK5	   occurred	   in	   both	   types	   of	   mutation	   and	   was	   accompanied	   by	   impaired	   ALK5	   signalling	   and	  
Matrigel	   tube	   formation.	   Furthermore,	   it	   was	   proposed	   that	   the	   down	   regulation	   of	   ALK5	  
expression/signalling	   represents	   an	   adaptive	   response	   that	   aims	   to	  maintain	   the	   balance	   between	  
endothelial	   TGF-­‐β/ALK1	   and	   TGF-­‐β/ALK5	   signalling	   (Fernandez	   et	   al.,	   2005).	   ECFCs	   derived	   from	  
HPAH	  patients	  with	  BMPR2	  mutations	  have	  also	  been	  found	  to	  exhibit	  increased	  proliferation	  as	  well	  
as	  reduced	  tube	  formation	  in	  vitro	  (Toshner	  et	  al.,	  2009).	  These	  observations	  suggest	  that	  disruption	  
of	  key	  components	  in	  the	  BMPR2/ALK1/endoglin	  receptor	  complex	  may	  affect	  the	  ALK5	  pathway	  and	  
functions	  of	  ECFCs	  in	  culture.	  	  
In	   accordance	   with	   previous	   findings	   (Smadja	   et	   al.,	   2008),	   BMP4	   had	   a	   positive	   effect	   on	  
proliferation	  (DNA	  synthesis)	  in	  ECFCs	  from	  healthy	  controls.	  However,	  the	  effects	  of	  BMP9	  and	  TGF-­‐
β1	  on	  DNA	  synthesis	  were	  inconclusive	  and	  ECFCs	  from	  IPAH	  patients	  appeared	  unresponsive	  to	  all	  
three	   proteins	   under	   the	   same	   experimental	   conditions.	   The	   results	   with	   HPAECs	   were	   more	  
informative;	   BMP9	   causing	   a	   marked	   reduction	   in	   DNA	   synthesis	   while	   TGF-­‐β1	   had	   the	   opposite	  
effect	  and	  this	  was	  further	  enhanced	  in	  the	  presence	  of	  an	  ALK5	  inhibitor.	  While	  most	  studies	  to	  date	  
have	  also	   shown	   that	  ALK1	   signalling	   inhibits	  EC	  proliferation	   (Lamouille	  et	  al.,	   2002;	  Koleva	  et	  al.,	  
2006;	   David	   et	   al.,	   2007a;	   Shao	   et	   al.,	   2009;	   Upton	   et	   al.,	   2009)	   several	   have	   reported	   that	   ALK5	  
signalling	  has	  this	  effect	  as	  well	  (Goumans	  et	  al.,	  2002;	  Castanares	  et	  al.,	  2007;	  Froese	  et	  al.,	  2011).	  
This	  serves	  to	  underline	  the	  complexity	  of	  TGF-­‐β	  receptor	  signalling	  in	  the	  endothelium	  and	  the	  need	  
for	   further	   work	   to	   dissect	   the	   role	   of	   ALK1	   and	   ALK5	   pathways	   in	   regulating	   the	   proliferation	   of	  
mature	  ECs	  as	  well	  as	  ECFCs.	  	  
BMP9/ALK1	   signalling	   has	   consistently	   been	   shown	   to	   inhibit	   EC	  migration	   (Lamouille	   et	   al.,	   2002;	  
David	  et	  al.,	  2007a;	  David	  et	  al.,	  2007b;	  Scharpfenecker	  et	  al.,	  2007;	  Lee	  et	  al.,	  2009;	  Park	  et	  al.,	  2012).	  
In	  this	  study,	  BMP9	  inhibited	  the	  migration	  of	  ECFCs,	  significantly	  in	  cells	  derived	  form	  IPAH	  patients.	  
ALK5	   inhibition	   also	   attenuated	   the	   migration	   of	   ECFCs.	   This	   is	   in	   agreement	   with	   other	   studies	  
describing	  the	  opposing	  effects	  of	  ALK1	  and	  ALK5	  signalling	  on	  the	  migratory	  capacity	  of	  ECs	  (Shao	  et	  
al.,	   2009;	   Tian	   et	   al.,	   2012a).	   Dysregulation	   of	   ALK5	   in	   ECFCs	   from	   IPAH	   patients	  might	   therefore	  
contribute	  to	  their	  impaired	  migration	  phenotype.	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In	  contrast	   to	   the	  marked	   inhibitory	  effect	  of	  BMP9	  on	  Matrigel	   tube	   formation,	  TGF-­‐β1	  exerted	  a	  
modest	   positive	   effect	   on	   ECFCs	   from	  healthy	   volunteers	   and	   stimulated	   angiogenesis	   by	  HPAECs.	  
The	  observations	  are	  consistent	  with	  the	  opposing	  angiogenic	  effects	  of	  TGF-­‐β1	  and	  BMP9	  in	  other	  
EC	   studies	   (Shao	   et	   al.,	   2009;	   Ferrari	   et	   al.,	   2012),	   but	   are	   limited	   by	   the	   absence	   of	   experiments	  
using	   selective	   ALK1	   and	   ALK5	   receptor	   blockade.	   While	   BMP9-­‐stimulation	   of	   ALK1	   has	   been	  
described	   to	   inhibit	   EC	   proliferation	   and	   angiogenesis	   (David	   et	   al.,	   2007a;	   Scharpfenecker	   et	   al.,	  
2007;	   Lee	   et	   al.,	   2009;	   Shao	   et	   al.,	   2009),	   some	   studies	   have	   reported	   that	   angiogenesis	   was	  
promoted	  by	  BMP9	  in	  vitro	  (Park	  et	  al.,	  2012)	  and	  in	  vivo	  (Suzuki	  et	  al.,	  2010).	  A	  possible	  explanation	  
is	   that	   the	   distinct	   effects	   of	   BMP9	   are	   concentration-­‐dependent	   and	   the	   BMP9/ALK1	   pathway	   is	  
essential	   for	   endothelial	   sprouting	   (van	  Meeteren	   et	   al.,	   2012).	   Thus	   ALK1	   has	   been	   considered	   a	  
potential	   target	   in	  anti-­‐angiogenesis	  therapy,	  with	  clinical	  phase	   I	  studies	  being	  conducted	  to	  block	  
ALK1	  signalling	  using	  ALK1-­‐Fc	  chimera	  (ClinicalTrials.gov	  Identifier	  NCT00996957)	  and	  an	  anti-­‐human	  
ALK1	  antibody	  (ClinicalTrials.gov	  Identifier	  NCT00557856).	  	  
	  
Regulation	  of	  ET-­‐1	  release	  by	  TGF-­‐β/BMP	  signalling	  
One	  of	  the	  hallmarks	  of	  IPAH	  is	  raised	  circulating	  levels	  of	  ET-­‐1	  (Stewart	  et	  al.,	  1991;	  Langleben	  et	  al.,	  
2006),	   with	   ECs	   in	   the	   remodelled	   pulmonary	   vasculature	   being	   considered	   a	   likely	   source	   of	  
production	   (Giaid	   et	   al.,	   1993).	   Serum-­‐deprived	   pulmonary	   ECs	   from	   IPAH	   patients	   release	   higher	  
level	  of	  ET-­‐1	  compared	  to	  the	  controls	  (Eddahibi	  et	  al.,	  2006).	  However,	  the	  results	  presented	  here	  
demonstrate	   that	   basal	   ET-­‐1	   production	   by	   ECFCs	   from	   IPAH	   patients	   and	   healthy	   volunteers	   is	  
comparable	   in	   serum-­‐deprived	   condition	   as	   well	   as	   cultured	   in	   various	   levels	   of	   FBS.	   A	   few	  
discrepancies	  might	   explain	   these	   disparate	   findings.	   Firstly,	   it	   is	   not	   known	  whether	   the	   isolated	  
pulmonary	   ECs	   in	   the	   earlier	   study	   also	   constitute	   a	   large	   proportion	   of	   ECs	   from	   the	   remodelled	  
plexiform	  lesions.	  Secondly,	  it	  is	  unclear	  whether	  ECs	  from	  these	  lesions	  also	  release	  excessive	  levels	  
of	   ET-­‐1	   in	   IPAH	   lungs,	   as	  dysfunctional	   ECFCs	  might	   specifically	   contribute	   to	   the	  plexiform	   lesions	  
rather	  than	  exist	  as	  ECs	  elsewhere	  in	  the	  pulmonary	  circulation.	  In	  fact,	   increased	  ET-­‐1	  levels	  might	  
not	  be	  exclusively	  contributed	  by	  the	  dysregulated	  pulmonary	  endothelium,	  as	  other	  pulmonary	  cells	  
such	  as	  PASMCs	   (Wort	  et	   al.,	   2001)	  and	   lung	   fibroblasts	   (Shi-­‐Wen	  et	  al.,	   2004)	  are	  also	   capable	  of	  
producing	  considerable	  amount	  of	  ET-­‐1.	  
ET-­‐1	  is	  reported	  to	  be	  a	  survival	  factor	  for	  ECs	  (Dong	  et	  al.,	  2005)	  and	  it	  would	  be	  interesting	  to	  know	  
whether	   the	   anti-­‐apoptotic	   effects	   of	   BMP9	   are	   dependent	   on	   the	   paracrine/autocrine	   action	   of	  	  
ET-­‐1.	  As	  expected	   from	  recent	  studies	  on	  ECs	  by	  other	  groups	   (Star	  et	  al.,	  2010;	  Park	  et	  al.,	  2012),	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BMP9	   induced	  a	   significant	   increase	   in	  ET-­‐1	   release	   from	  healthy	  ECFCs	  and	  HPAECs.	  But	   I	  did	  not	  
have	   time	   to	  explore	   the	  contribution	  of	  ET-­‐1	   to	   the	  downstream	  effects	  of	  BMP9/ALK1	  signalling,	  
using	  either	  inhibitors	  or	  mature	  ET-­‐1	  cleavage	  or	  selective	  ETA/ETB	  receptor	  antagonists.	  	  In	  contrast	  
to	   ECFCs	   from	   healthy	   controls,	   those	   derived	   from	   IPAH	   patients	   displayed	   a	   heterogeneous	  
response	  to	  BMP9	  stimulation,	  with	  no	  significant	  change	  overall.	  It	  is	  notable	  that	  three	  of	  the	  ECFC	  
lines	   derived	   from	   IPAH	   patients	   did	   not	   exhibit	   either	   BMP9-­‐induced	   ET-­‐1	   secretion	   or	   BMP9-­‐
induced	   inhibition	   of	   apoptosis.	   Future	   studies	  might	   explore	  whether	   ALK1,	   the	   type	   II	   receptors	  
BMPR2,	  ActRIIA,	  and	  ActRIIB	  or	  ALK1	  co-­‐receptor	  endoglin	  are	  selectively	  affected	  in	  these	  cells.	  	  	  	  
ET-­‐1	   is	   also	   a	   target	   gene	   for	   the	   action	   of	   TGF-­‐β1,	   which	   stimulates	   endothelial	   expression	   and	  
release	  of	  ET-­‐1	  through	  activation	  of	  the	  ALK5/Smad3	  pathway	  (Castanares	  et	  al.,	  2007).	  In	  addition,	  
ET-­‐1	  was	   shown	   to	  mediate	   some	  of	   the	   anti-­‐migratory	   and	  anti-­‐proliferative	   actions	  of	   TGF-­‐β1	   in	  
cultured	  ECs	   (Castanares	  et	   al.,	   2007).	   I	   did	  not	  directly	  demonstrate	   the	  effect	  of	   TGF-­‐β1	  on	  ET-­‐1	  
production,	   but	   did	   establish	   that	   basal	   ET-­‐1	   release	   from	   both	   ECFCs	   and	   HPAECs	   was	   almost	  
abolished	   in	   the	   presence	   of	   the	   ALK5	   inhibitor	   SD208.	   It	   would	   seem	   doubtful	   if	   this	   general	  
inhibitory	  effect	  on	  ET-­‐1	  production	  contributes	  to	  the	  apparently	  selective	  effect	  of	  ALK5	  inhibitors,	  
attenuating	   serum-­‐deprivation	   induced	   apoptosis	   in	   ECFCs	   from	   IPAH	   patients	   versus	   healthy	  
controls.	  A	  diagrammatic	  summary	  of	  TGF-­‐β/BMP	  signalling	   in	   the	  regulation	  of	  ECFC	  proliferation,	  








Limitations	  and	  conclusions	  
There	   are	   a	   number	   of	   limitations	   to	   the	   studies	   in	   this	   chapter,	   several	   of	   which	   have	   been	  
highlighted	  above.	  In	  particular,	  I	  sought	  to	  expose	  potential	  differences	  at	  the	  receptor	  level	  and	  did	  
Figure	   6.17.	   TGF-­‐β	   and	   BMP	   signalling	   in	   functional	   regulations	   of	   ECFCs.	   (A)	   Hypothetical	  
mechanism	   showing	   the	   regulation	   of	   proliferation	   by	   ALK1	   and	   ALK5	   activation	   based	   on	   the	  
literature	   and	   data	   collected	   in	   this	   study.	   (B)	   TGF-­‐β1-­‐activated	   ALK5	   signalling	   promotes	   tube	  
formation	  and	  migration,	  while	  BMP9-­‐activated	  ALK1	  signalling	  paradoxically	  inhibits	  both	  of	  these	  
functions.	  (C)	  Both	  ALK5	  and	  BMP9-­‐activated	  ALK1	  signalling	  induces	  ET-­‐1	  secretion	  from	  ECFCs.	  Full	  
arrow	  represents	  confirmed	  observations,	  while	  dashed	  arrow	  shows	  mechanism	  that	  has	  not	  been	  
completely	  validated	  in	  this	  and	  other	  studies.	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not	   consider	   downstream	   Smad-­‐dependent	   and	   -­‐independent	   intracellular	   pathways.	   I	   used	   only	  
pharmacological	   tools	   whereas	   molecular	   interventions,	   designed	   to	   manipulate	   expression	   of	  
specific	   genes	   and	   introduce	   reporter	   constructs,	   may	   have	   been	   more	   informative.	   The	  
concentrations	   of	   proteins/reagents	   used	  were	   determined	   by	   their	   ability	   to	   acutely	   affect	   Smad	  
phosphorylation,	   as	   shown	   in	  Chapter	   5,	   and	   the	   results	   of	   published	   studies,	   and	   I	  may	  not	   have	  
adequately	  considered	  the	  biphasic	  and	  time-­‐dependent	  nature	  of	  the	  functional	  effects.	  I	  used	  two	  
ALK5	   inhibitors,	  with	  SB431542	  being	  considered	  one	  of	  most	  specific	  and	  effective	  ALK5	   inhibitors	  
commonly	   available,	   but	   cannot	   exclude	   possible	   inhibitory	   effects	   on	   other	   receptors	   (e.g.	   ALK4,	  
ALK7)	   (Vogt	  et	  al.,	  2011).	  ALK1	  has	  a	  very	  discriminating	   ligand	  binding	  profile,	  binding	  both	  BMP9	  
and	   BMP10	   with	   high	   affinity	   and	   these	   ligands	   are	   considered	   to	   signal	   exclusively	   via	   the	   ALK1	  
receptor	  in	  ECs	  (David	  et	  al.,	  2007a;	  Scharpfenecker	  et	  al.,	  2007;	  Upton	  et	  al.,	  2009).	  I	  used	  BMP9	  to	  
explore	  ALK1	  mediated	  responses	   in	  ECFCs,	  but	   it	  has	  recently	  been	  shown	  that	  BMP9	  and	  BMP10	  
differ	   in	   their	   interactions	   with	   ALK1	   and	   the	   type	   II	   receptors	   BMPR2,	   ActRIIA	   and	   ActRIIB,	   the	  
relative	  affinity	  of	  BMP9	  being	  ActRIIB	  >	  BMPR2	  >>	  ActRIIA	  whereas	  BMP10	  exhibited	  a	  similar	  high	  
affinity	   for	  all	   three	  receptors	   (Townson	  et	  al.,	  2012).	  Future	  studies	  may	  need	  to	  use	  both	   ligands	  
and	   selective	   knockdowns	   or	  mutants	   in	   order	   to	   explore	   which	   type	   II	   receptors	   are	   involved	   in	  
complexes	  mediating	  effects	  in	  ECFCs	  and	  ECs.	  Although	  there	  was	  no	  difference	  in	  ET-­‐1	  production	  
between	   the	   two	   groups	   of	   ECFCs,	   this	   observation	   could	   be	   limited	   by	   the	   controlled	   cell	  
environment	  used	  in	  this	  study.	  As	  alterations	  in	  shear	  stress	  and	  levels	  of	  angiotensin	  II,	  NO,	  growth	  
factors	   and	   inflammatory	   cytokines	   can	  modulate	   the	   release	   of	   ET-­‐1	   (Kuchan	   and	   Frangos,	   1993;	  
Marasciulo	  et	  al.,	  2006),	   it	   is	   important	   in	  future	  to	  analyse	  the	  ability	  of	  ET-­‐1	  release	  by	  the	  ECFCs	  
under	  more	   physiological	   conditions	   to	   determine	   whether	   alterations	   in	   those	   parameters	   could	  
contribute	  to	  the	  excessive	  endothelial	  production	  of	  ET-­‐1	  in	  IPAH	  patients.	  
In	  conclusion,	  ALK1	  and	  ALK5	  signalling	  pathways	  exert	  distinct	  effects	  on	  ECFC	  apoptosis,	  migration	  
and	   tube	   formation.	   ECFCs	   from	   healthy	   volunteers	   and	   HPAECs	   exhibited	   comparable	   functional	  
responses	  when	  treated	  with	  BMP4,	  BMP9,	  TGF-­‐β1	  and	  selective	  ALK1	  or	  ALK5	  inhibitors.	  ECFCs	  from	  
IPAH	   patients	   were	   generally	   found	   to	   be	   less	   reactive	   and	   displayed	   heterogeneity	   in	   specific	  
responses	  to	  BMP9	  stimulation.	  An	  imbalance	  in	  ALK1	  and	  ALK5	  signalling	  may	  be	  significant	   in	  the	  
apoptosis-­‐resistance	  and	  slower	  migration	  of	  ECFCs	  from	  IPAH	  patients,	  but	  the	  contribution	  of	  these	  
pathways	  in	  the	  enhanced	  tube	  forming	  capacity	  of	  these	  cells	  seems	  less	  likely.	  Equivalent	  amounts	  
of	  ET-­‐1	  were	  produced	  by	  ECFCs,	  with	  no	  difference	  being	   found	  between	  cells	  derived	   from	   IPAH	  
patients	   and	   healthy	   volunteers.	   In	   the	   next	   chapter	   I	   will	   use	   ECFCs	   to	   examine	   two	   other	  
targets/pathways	   implicated	   in	   the	   pathogenesis	   of	   PAH:	   chloride	   intracellular	   channel	   4	   and	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7.1	   Introduction	  
To	  further	  demonstrate	  that	  ECFCs	  represent	  an	  effective	  cellular	  model	  for	  investigating	  endothelial	  
dysfunction	  in	  IPAH,	  I	  have	  used	  these	  cells	  to	  examine	  two	  novel	  targets/pathways	  implicated	  in	  the	  
pathogenesis	  of	  PAH:	  chloride	  intracellular	  channel	  4	  and	  asymmetric	  dimethylarginine.	  
Chloride	   intracellular	   channel	   4	   (CLIC4)	   belongs	   to	   a	   family	   of	   six	   highly	   conserved	   redox-­‐sensitive	  
proteins	  (CLIC1-­‐6)	  that	  are	  homologous	  to	  glutathione	  transferases	  (Littler	  et	  al.,	  2010).	  Expression	  of	  
CLIC4	   is	   affected	   by	   reactive	   oxygen	   species,	   DNA	   damage	   and	   cytokines	   such	   as	   tumour	   necrosis	  
factor-­‐α	  (TNF-­‐α)	  and	  TGF-­‐β	  (Suh	  et	  al.,	  2007;	  Yao	  et	  al.,	  2009a).	  	  Studies	  on	  the	  systemic	  vasculature	  
in	  vitro	  and	  in	  vivo	  have	  shown	  that,	  unlike	  other	  CLIC	  proteins,	  CLIC4	  is	  required	  for	  endothelial	  cell	  
network	  formation	  and	  morphogenesis	  (Chalothorn	  et	  al.,	  2009;	  Tung	  et	  al.,	  2009;	  Littler	  et	  al.,	  2010).	  
Knock	  out	  of	  the	  murine	  CLIC4	  gene	  also	  results	  in	  reduced	  collateral	  vessel	  formation	   in	  vivo	  and	  a	  
reduction	   in	   the	   ischemia-­‐induced	   expression	   of	   hypoxia	   inducible	   factor-­‐1α	   (HIF-­‐1α)	   and	  
downstream	   targets	   such	   as	   vascular	   endothelial	   growth	   factor	   (VEGF)	   and	   angiopoietin-­‐2	  
(Chalothorn	   et	   al.,	   2009).	   Furthermore,	   CLIC4	   contributes	   to	   several	   signalling	   pathways	   that	   have	  
been	  implicated	  in	  the	  pathogenesis	  of	  PAH,	   including	  Rho,	  VEGF,	  BMP,	  TGF-­‐β	  and	  TNF-­‐α	  signalling	  
(Suh	  et	  al.,	  2005;	  Shukla	  et	  al.,	  2009;	  Spiekerkoetter	  et	  al.,	  2009).	  
The	  level	  of	  CLIC4	  expression	  is	  greater	  in	  the	  explanted	  lungs	  of	  patients	  with	  PAH,	  compared	  with	  
control	   lung	  tissues	  (Abdul-­‐Salam	  et	  al.,	  2010).	   In	  the	  PAH	  lung,	  CLIC4	  is	   localised	  predominantly	  to	  
the	  endothelium	  and	  is	  prominent	  in	  occlusive	  and	  plexiform	  lesions,	  which	  are	  characterised	  by	  the	  
proliferation	   of	   apoptotic-­‐resistant	   endothelial	   cells	   and	   considered	   to	   reflect	   disorganised	  
angiogenesis	  (Tuder	  and	  Voelkel,	  2002).	  Pulmonary	  CLIC4	  levels	  are	  also	  raised	  in	  rat	  models	  of	  PH,	  
where	  CLIC4	  is	  also	  localised	  predominantly	  to	  the	  vascular	  endothelium	  (Abdul	  Salam	  et	  al.,	  2012).	  
Furthermore,	  CLIC4	  expression	  promoted	  the	  stabilisation	  of	  HIF-­‐1α	  (Abdul	  Salam	  et	  al.,	  2012),	  and	  
this	  in	  turn	  has	  been	  associated	  with	  increased	  tube	  formation	  by	  HPAECs	  (Yamakawa	  et	  al.,	  2003).	  I	  
therefore	   sought	   to	   determine	   whether	   ECFCs	   from	   IPAH	   patients	   also	   exhibited	   increased	  
expression	  of	  CLIC4	  and	  explore	  the	  impact	  this	  may	  have	  on	  their	  tube	  forming	  capacity.	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Asymmetric	   dimethylarginine	   (ADMA)	   is	   an	   endogenous	   inhibitor	   of	   nitric	   oxide	   (NO)	   production,	  
inhibiting	  all	  three	  isoforms	  of	  NO	  synthase,	  and	  is	  a	  cardiovascular	  risk	  factor	  (Vallance	  and	  Leiper,	  
2004).	  While	   reduced	  NO	  signalling	   in	  PAH	   is	  well	   described	   (Budhiraja	  et	   al.,	   2004)	  and	   increased	  
plasma	  and	   tissue	   levels	   of	  ADMA	  are	   evident	   in	   patients	  with	   IPAH	   (Pullamsetti	   et	   al.,	   2005),	   the	  
mechanisms	  leading	  to	  impaired	  endothelial	  function	  in	  IPAH	  are	  not	  fully	  understood.	  	  
The	  lung	  has	  a	  critical	  role	  in	  determining	  circulating	  levels	  of	  ADMA	  (Bulau	  et	  al.,	  2007)	  and	  two	  key	  
enzymes,	  dimethylarginine	  dimethylaminohydrolase	  I	  and	  II	  (DDAHI	  and	  DDAHII),	  are	  responsible	  for	  
ADMA	  metabolism	  (Leiper	  et	  al.,	  2007).	  DDAHI	  heterozygous	  knockout	  mice	  have	  high	  plasma	  ADMA	  
levels	  compared	  to	  controls	  and	  show	  remodelling	  of	  small	  pulmonary	  arteries,	  increased	  pulmonary	  
vascular	   permeability	   and	   right	   ventricular	   pressure	   (Leiper	   et	   al.,	   2007;	   Wojciak-­‐Stothard	   et	   al.,	  
2009).	  Increased	  ADMA	  levels	  have	  also	  been	  associated	  with	  reduced	  DDAH	  expression	  and	  activity	  
in	  lung	  tissues	  and	  pulmonary	  endothelium	  of	  patients	  with	  IPAH	  and	  established	  animal	  models	  of	  
PH	  (Millatt	  et	  al.,	  2003;	  Pullamsetti	  et	  al.,	  2005).	  
ADMA	   has	   been	   shown	   to	   induce	   pulmonary	   endothelial	   leakage	   and	   inhibit	   VEGF-­‐induced	  
angiogenesis	  in	  vitro,	  these	  effects	  being	  prevented	  by	  over	  expression	  of	  DDAHI	  (Fiedler	  et	  al.,	  2009;	  
Wojciak-­‐Stothard	   et	   al.,	   2009).	   Gap	   junctions	   connect	   the	   cytoplasm	   of	   adjacent	   cells	   and	   allow	  
exchange	  of	  small	  signalling	  molecules	  such	  as	  cyclic	  nucleotides,	  Ca2+,	  adenosine	  triphosphate	  (ATP)	  
and	   inositol	   1,4,5-­‐trisphosphate	   between	   cells.	   They	   are	   formed	   by	   two	   hemi-­‐channels,	   each	  
composed	  of	  six	  connexin	  subunits,	  and	  in	  the	  vascular	  system,	  the	  core	  proteins	  of	  these	  channels	  
are	  connexins	  (Cx)	  37,	  40	  and	  43	  (van	  Kempen	  and	  Jongsma,	  1999).	  Deletion	  of	  these	  connexin	  genes	  
causes	   severe	   cardiovascular	   abnormalities	   (Reaume	   et	   al.,	   1995;	   Liao	   et	   al.,	   2001;	   Simon	   and	  
McWhorter,	   2002;	   de	  Wit	   et	   al.,	   2003).	   NO	   signalling	   and	   gap	   junctional	   communication	   are	   also	  
essential	   for	   normal	   vascular	   function	   (Looft-­‐Wilson	   et	   al.,	   2012).	   My	   colleagues	   have	   recently	  
demonstrated	   that	   Cx43	   has	   a	   role	   in	   mediating	   the	   effects	   of	   ADMA	   on	   HPAECs,	   where	   ADMA	  
disrupts	   endothelial	   barrier	   function	   and	   angiogenesis	   by	   inhibiting	   the	   expression	   and	  membrane	  
localisation	  of	  Cx43	   (Tsang	  et	   al.,	   2011).	   I	   therefore	   sought	   to	  explore	  whether	  ADMA	  metabolism	  
and	  Cx43	  expression	  are	  affected	  in	  ECFCs	  from	  IPAH	  patients,	  and	  explore	  the	   impact	  these	  might	  
have	  on	  their	  permeability	  and	  tube	  forming	  abilities.	  	  
I	  hypothesised	  that	  CLIC4	  expression	  is	  increased	  in	  ECFCs	  from	  IPAH	  patients	  and	  contributes	  to	  the	  
dysregulation	  of	  tube	  formation	  by	  these	  cells.	  I	  also	  postulated	  that	  ECFCs	  from	  IPAH	  patients	  would	  
produce	  more	  ADMA	  and	  exhibit	  corresponding	  differences	  in	  DDAHI	  and	  Cx43	  expression	  compared	  
to	  control	  cells.	  Finally,	  disruption	  of	  Cx43	  expression	  might	  contribute	  to	  the	   impaired	  endothelial	  
barrier	  function	  exhibited	  by	  ECFCs	  from	  IPAH	  patients.	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The	  objectives	  of	  this	  chapter	  are:	  
• Investigate	   the	  expression	  of	  CLIC4	  and	  HIF-­‐1α	   in	  ECFCs	   from	  healthy	   volunteers	   and	   IPAH	  
patients.	  
• Examine	   the	   role	   of	   CLIC4	   in	   the	   excessive	   tube	   formation	   exhibited	   by	   ECFCs	   from	   IPAH	  
patients.	  
• Determine	  the	  effects	  of	  BMPR2	  knockdown	  on	  CLIC4	  expression	  in	  ECFCs.	  
• Investigate	  ADMA	  production	  and	  the	  expression	  of	  connexins,	  DDAHI	  and	  DDAHII	  by	  ECFCs	  
from	  healthy	  volunteers	  and	  IPAH	  patients.	  
• Examine	  the	  effects	  of	  manipulating	  Cx43	  and	  DDAHI	  expression	  on	  endothelial	  permeability	  
and	  in	  vitro	  tube	  formation	  in	  ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients.	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7.2	   Methods	  
See	  Chapter	  2	  for	  detailed	  experimental	  materials	  and	  protocols	  for	  cell	  culture,	  Matrigel	  tube	  assay,	  
Western	  blotting,	  adenoviral	  transfection,	  siRNA	  transfection	  and	  permeability	  assessment.	  	  
	  
7.2.1	   Declaration	  of	  responsibilities	  
Data	   from	   the	   CLIC4	   experiments	   (Figures	   7.1,	   7.2	   and	   7.5)	   were	   collected	   and	   analysed	   in	  
collaboration	  with	  Dr	  Vahitha	  Abdul-­‐Salam.	  Data	   in	   Figure	  7.3	   and	  data	   from	   the	   connexin	  43	  and	  
DDAHI	   experiments	   (Figures	   7.6-­‐7.9)	   were	   collected	   and	   analysed	   in	   collaboration	   with	   Dr	   Hilda	  
Tsang.	  The	  measurement	  of	  ADMA	  (Figure	  7.6C)	  was	  performed	  by	  Lucio	  Iannone.	  Other	  data	  were	  
produced	  and	  analysed	  by	  myself.	  	  
	  
7.2.2	   Protein	  expression	  
Cells	  were	  seeded	   (5000/cm2	   in	  EGM-­‐2	  medium	  containing	  20%	  FBS)	   in	  10	  cm	  gelatin-­‐coated	  petri	  
dishes,	  grown	  to	   full	   confluency	  and	  extracted	   in	   ice-­‐cold	  RIPA	  buffer.	  Expression	  of	  CLIC4,	  HIF-­‐1α,	  
Cx37,	   Cx40,	   Cx43,	   DDAHI	   and	   DDAHII	   proteins	   was	   assessed	   by	   Western	   blotting.	   Protocols	   and	  
antibody	  characteristics	  are	  detailed	  in	  Chapter	  2.11	  and	  Table	  2.5	  respectively.	  	  
	  
7.2.3	   Manipulation	  of	  gene	  expression	  and	  activity	  in	  cultured	  cells	  
Manipulation	  of	  CLIC4	  	  
Over	   expression	   of	   CLIC4,	   predominantly	   cytoplasmic,	   was	   induced	   by	   adenoviral	   (AdCLIC4)	   gene	  
transfer	  (Suh	  et	  al.,	  2004).	  AdCLIC4	  was	  heme	  agglutinin	  (HA)-­‐	  and	  myc-­‐tagged	  and	  expressed	  under	  
tetracycline	   control,	   allowing	   precise	   regulation	   of	   CLIC4	   expression	   and	   localization.	   Cells	   were	  
infected	  with	  adenoviruses	  at	  a	  multiplicity	  of	  infection	  (MOI)	  of	  100	  and	  left	  for	  24	  h	  prior	  to	  further	  
treatment	   or	   analysis.	   Cells	   infected	   with	   AdGFP	   or	   AdCLIC4	   without	   AdTet-­‐off	   were	   treated	   as	  
adenoviral	  controls.	  	  
Inhibition	  of	  CLIC4	  expression	  was	  achieved	  with	  adenoviral	  gene	  transfer	  of	  CLIC4	  small	  hairpin	  RNA	  
(shRNA)	   (pEQU6-­‐Clic4-­‐shRNA-­‐GFP;	   5’-­‐GCCGTAATGTTGAACAGAATT-­‐3’,	   Welgen	   Inc.).	   pEQU6-­‐
controlshRNA-­‐GFP	  (5’-­‐CAACAAGATGAAGAGCACC-­‐3’)	  was	  used	  as	  control	  and	  shRNA	  constructs	  were	  
transfected	  24	  h	  before	  CLIC4	  adenoviral	  gene	  transfer	  of	  AdCLIC4	  (i.e.	  total	  expression	  time	  48	  h).	  
The	  effects	  of	  CLIC4	  gene	  silencing	  were	  verified	  by	  Western	  blotting.	  Inhibition	  of	  CLIC4	  activity	  was	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also	   achieved	   by	   treatment	   with	   the	   non-­‐selective	   CLIC	   inhibitor	   5-­‐nitro-­‐2-­‐(3-­‐phenylpropylamino)-­‐
benzoate	  (NPPB)	  (Sigma-­‐Aldrich,	  catalogue	  No.	  N4779).	  
	  
Knockdown	  of	  BMPR2	  and	  ALK5	  	  
Knockdown	  of	  BMPR2	  and	  ALK5	  expression	  in	  ECFCs	  and	  HPAECs	  was	  performed	  using	  siRNA	  specific	  
for	   ALK5	   (catalogue	   No.	   SI00301903;	   Qiagen,	   Crawley,	   UK),	   BMPR2	   (catalogue	   No.	   VHS41350;	  
Invitrogen,	   Paisley,	  UK)	   or	   a	   scrambled	   sequence	   of	   similar	  GC	   content	   (catalogue	  No.	   12935-­‐200;	  
Invitrogen).	  The	  efficiency	  of	  the	  knockdown	  was	  determined	  by	  measuring	  protein	  and	  mRNA	  levels	  
in	  cell	  extracts,	  using	  Western	  blotting	  and	  RT-­‐PCR	  respectively.	  
	  
Manipulation	  of	  Cx43	  and	  DDAHI	  
To	  modulate	  Cx43	  and	  DDAHI	  expression,	  AdGFP	   (Wojciak-­‐Stothard	  and	  Ridley,	  2003),	  AdCx43-­‐GFP	  
and	   AdDDAHI-­‐GFP	   (all	   from	   Welgen	   Inc,	   Worcester,	   MA)	   were	   generated	   using	   Ad5	   ΔE1ΔE3	  
backbone	   vector.	   The	   cDNA	   of	   wildtype	   Cx43	   (a	   kind	   gift	   from	   Professor	   David	   Becker,	   University	  
College	  London)	  (Becker	  et	  al.,	  2001)	  was	  cloned	  into	  KpnI	  and	  XbaI	  restriction	  sites	  of	  pAdTrackCMV	  
vector.	  The	  recombinant	  adenoviruses	  were	  constructed	  using	  the	  Ad-­‐Easy-­‐1	  system	  as	  described	  in	  
Chapter	  2.13.2.	  The	  titre	  of	  Ad-­‐GFP	  was	  1	  x	  1011	  pfu/ml,	  and	  AdCx43-­‐GFP	  was	  8.5	  x	  1010.	  Adenoviral	  
transient	  infections	  of	  cells	  using	  MOI	  of	  100	  lead	  to	  a	  maximal	  rate	  of	  infection	  efficiency	  (~90	  –	  95%)	  
without	  obvious	  cytopathic	  effects.	  Manipulation	  of	  Cx43	  and	  DDAH1	  expression	  was	  confirmed	  by	  
Western	  blotting	  for	  both	  proteins.	  Activation	  of	  Cx43	  gap	  junction	  was	  achieved	  by	  treatment	  with	  
rotigaptide	  (100	  nM)	  (a	  kind	  gift	  from	  Dr	  Ninian	  Lang,	  University	  of	  Edinburgh),	  whereas	  inhibition	  of	  
Cx43	   gap	   junction	   and	   DDAHI	   was	   achieved	   by	   treatment	   with	   Gap26	   (VCYDKSFPISHVR,	   200	   µM,	  
Peptide	   Protein	   Research	   Ltd)	   and	   L-­‐257	   (a	   kind	   gift	   from	   Dr	   James	   Leiper,	  MRC	   Clinical	   Sciences	  
Centre,	  Imperial	  College	  London)	  respectively.	  	  
	  
7.2.4	   Matrigel	  tube	  formation	  assay	  
Cells	   were	   plated	   on	   gelatin-­‐coated	   6-­‐well	   plates	   at	   a	   density	   of	   1	   x	   105	   cells/well,	   incubated	  
overnight,	   and	   either	   left	   untreated,	   infected	   with	   recombinant	   adenoviruses	   to	   induce	   over	  
expression	   of	   GFP,	   DDAHI	   and	   Cx43	   or	   inhibition	   of	   CLIC4	   expression.	   Two	   hours	   after	   infection,	  
adenovirus	  was	  removed	  and	  cells	  were	  incubated	  with	  fresh	  medium	  for	  a	  further	  24h	  before	  being	  
trypsinised	   and	   reseeded	   for	   the	   Matrigel	   assay	   (HC-­‐Matrigel	   was	   used	   in	   the	   CLIC4	   experiment,	  
while	  GFR-­‐Matrigel	  was	  used	  in	  the	  DDAHI/Cx43	  experiment)	  together	  with	  relevant	  treatments	  for	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24	  h.	  Changes	   in	  total	  endothelial	   tube	   length	  were	  expressed	  as	  a	  proportion	  of	   the	  control,	  each	  
data	   point	   representing	   the	  mean	   of	   triplicate	   values	   derived	   from	   images	   of	   2	   random	   fields	   per	  
well.	  	  
	  
7.2.5	   In	  vitro	  assessment	  of	  endothelial	  cell	  permeability	  
Cells	   were	   plated	   in	   Transwell-­‐Clear	   chambers	   (1µm	   pore	   size,	   12mm	   diameter;	   Costar	   Corning,	  
Costar)	  at	  a	  cell	  density	  of	  1	  x	  104	  cells/well	  and	  grown	  to	  confluency.	  The	  cells	  were	  left	  untreated	  or	  
infected	  with	  recombinant	  adenoviruses	  to	  induce	  over	  expression	  of	  GFP,	  DDAHI	  or	  Cx43.	  2	  h	  post-­‐
infection,	  adenovirus	  was	   removed	  and	  cells	  were	   incubated	  with	   fresh	  medium	  for	  a	   further	  24	  h	  
before	  adding	  FITC-­‐dextran	  for	  assessment	  of	  endothelial	  permeability.	  	  
	  
7.2.6	   ADMA	  measurement	  
Levels	  of	  ADMA	  in	  conditioned	  medium	  were	  quantified	  by	  high-­‐performance	  liquid	  chromatography	  
(HPLC)	  as	  previously	  described	  (Leiper	  et	  al.,	  2007).	  Briefly,	  ECFCs	  were	  seeded	  on	  24-­‐well	  plate	  and	  
grown	   to	   confluence	   in	   EGM-­‐2	   and	   20%	   FBS.	   The	   medium	   was	   replaced	   with	   fresh	   medium	  
(containing	  5%	  FBS)	   and	   incubated	   for	   a	   further	   48h.	   The	   conditioned	  medium	  was	   centrifuged	   to	  
remove	   cell	   debris	   and	   100	   µl	   used	   for	   ADMA	   measurement.	   2,3,3,4,4,5,5-­‐D7-­‐asymmetric	  
dimethylarginine	  (D7-­‐ADMA	  ,	  5	  μmol/L)	  was	  added	  to	  each	  sample	  as	  an	  internal	  standard.	  Methanol	  
protein	   precipitation	   was	   performed	   followed	   by	   desiccation	   in	   a	   vacuum	   centrifuge,	   and	   the	  
resultant	   pellets	   were	   re-­‐suspended	   in	   mobile	   phase	   (0.1%	   formic	   acid	   in	   ultra-­‐pure	   water).	   The	  
ADMA	  concentration	  was	  determined	  by	  HPLC	  with	  an	  ASI-­‐100	  auto	  sampler	  (model	  P680,	  gradient	  
pump	  model	  RF-­‐2000).	  Protein	  precipitation	  efficiency	  was	  estimated	  from	  the	  concentration	  of	  D7-­‐
ADMA	  and	  the	  ADMA	  concentration	  corrected	  accordingly.	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7.3	   Results	  
7.3.1	   CLIC4	  and	  HIF-­‐1α	  protein	  expression	  is	  increased	  in	  ECFCs	  from	  IPAH	  patients	  
ECFCs	  from	  IPAH	  patients	  displayed	  significantly	  higher	  levels	  of	  CLIC4	  and	  HIF-­‐1α	  protein	  expression,	  










Figure	   7.1.	   CLIC4	   and	   HIF-­‐1α	   expression	   in	   ECFCs.	   Quantitative	   assessment	   and	   representative	  
Western	  blots	  showing	  (A)	  CLIC4	  and	  (B)	  HIF-­‐1α	  expression	  in	  ECFCs	  from	  healthy	  volunteers	  (n=5)	  
and	  IPAH	  patients	  (n=5).	  	  Statistics	  obtained	  from	  t-­‐test.	  	  
	  
	  231	  
7.3.2	   Increased	  CLIC4	  expression	  in	  IPAH-­‐ECFCs	  mediates	  increased	  tube	  formation	  
Manipulation	  of	  CLIC4	  expression	  by	  AdCLIC4	  and	  CLIC4	  shRNA	  were	  confirmed	  by	  Western	  blotting	  
(Figure	  7.2A).	  Hypoxia	   induced	  a	  3.2-­‐fold	   increase	   in	  Matrigel	  tube	  formation	  in	  HPAECs,	  compared	  
with	   normoxic	   controls	   (Figure	   7.2B-­‐C).	   Overexpression	   of	   CLIC4	   significantly	   increased	   tube	  
formation	   (2.0-­‐fold	   in	   normoxia	   and	   5.8-­‐fold	   in	   hypoxia)	   compared	   to	   adenoviral	   controls	   (Figure	  
7.2B-­‐C).	   Treatment	   with	   CLIC4	   shRNA	   inhibited	   the	   stimulatory	   effects	   of	   hypoxia	   and	   CLIC4	  
overexpression	  (in	  both	  normoxic	  and	  hypoxic	  conditions),	  while	  the	  chloride	  channel	  inhibitor	  NPPB	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Figure	   7.2.	   CLIC4	   modulates	   in	   vitro	  Matrigel	   tube	   formation	   by	   HPAECs.	   (A)	   Representative	  
Western	   blots	   showing	   the	   over	   expression	   of	   CLIC4	   following	   transfection	   with	   AdCLIC4	   and	  
inhibition	  of	  CLIC4	  expression	  by	  CLIC4	  shRNA.	   (B)	  Representative	   images	  showing	  the	  effects	  on	  
HPAEC	   tube	   formation	   following	   exposure	   to	   hypoxia,	   overexpression	   of	   CLIC4	   and	   inhibition	   of	  
CLIC4	   expression.	   (C)	   Changes	   in	   total	  endothelial	   tube	   length	   (expressed	   as	   a	   proportion	   of	   the	  
control)	  following	  over	  expression	  of	  CLIC4,	  inhibition	  of	  CLIC4	  by	  CLIC4	  shRNA	  or	  the	  CLIC	  inhibitor	  
NPBB	   (25	   µmol/L)	   and	   exposure	   to	   hypoxia	   for	   24	   h.	   Each	   bar	   represents	   mean±SEM	   (n=5).	  
Statistics	   from	   two-­‐way	   ANOVA	   and	   Bonferroni	   post-­‐hoc	   analysis.	   *,	   P	   <0.05;	   **,	   P	   <0.01,	  
compared	  with	  normoxic	  Ad	  control;	  ##,	  P	  <0.01,	  compared	  with	  hypoxic	  Ad	  control.	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In	   keeping	   with	   the	   proposed	   pro-­‐angiogenic	   role	   of	   CLIC4,	   the	   enhanced	   Matrigel	   tube	   forming	  
capacity	   of	   ECFCs	   from	   IPAH	   patients	  was	   attenuated	   following	   the	   inhibition	   of	   CLIC4	   expression	  
with	   CLIC4	   shRNA.	   CLIC4	   protein	   levels	   were	   reduced	   to	   the	   level	   found	   in	   ECFCs	   derived	   from	  




Figure	   7.3.	   Inhibition	  of	   CLIC4	   expression	   in	   ECFCs	   and	  effects	   on	   tube	   formation.	  CLIC4	  protein	  
expression	   was	   selectively	   attenuated	   by	   adenoviral	   mediated	   expression	   of	   CLIC4	   shRNA	   (CSh),	  
with	   scramble	   shRNA	   (Ssh)	   and	   untreated	   (UT)	   samples	   being	   used	   as	   controls.	  	  
(A)	   Representative	   Western	   blots	   and	   quantitative	   demonstration	   of	   CLIC4	   expression.	  	  
(B)	   Representative	   phase-­‐contrast	   photomicrographs	   and	   quantitative	   demonstration	   of	  	  
Matrigel	  tube	  formation	  by	  ECFCs	  from	  healthy	  volunteers	  (n=3-­‐4)	  and	  IPAH	  patients	  (n=3-­‐4).	  Each	  
bar	   represents	   mean±SEM.	   Statistics	   obtained	   from	   two-­‐way	   ANOVA	   with	   Bonferroni	   post-­‐tests.	  	  	  
*,	  P	  <	  0.05;	  **,	  P	  <	  0.01,	  compared	  with	  untreated	  controls.	  ##,	  P	  <	  0.01,	  compared	  with	  untreated	  
ECFCs	  from	  IPAH	  patients.	  	  
	  
	  233	  
7.3.3	   CLIC4	  expression	  is	  not	  affected	  by	  BMPR2	  knockdown	  
BMPR2	  siRNA	  was	  used	  to	  inhibit	  expression	  of	  the	  receptor	  in	  both	  ECFCs	  from	  healthy	  volunteers	  
and	  HPAECs,	  BMPR2	  mRNA	  and	  protein	  levels	  being	  reduced	  by	  ~80%	  compared	  to	  controls	  (Figures	  
7.4	  &	  7.5).	  Despite	  this	  marked	  reduction	   in	  BMPR2	  expression,	  no	  significant	  change	  was	  found	  in	  
CLIC4	  mRNA	  or	  protein	  expression	  in	  either	  cell	  type	  (Figures	  7.4	  &	  7.5).	  	  
	  
	  
Figure	  7.4.	  Effect	  of	  BMPR2	  knockdown	  on	  CLIC4	  expression	   in	  ECFCs	   from	  healthy	  volunteers.	  
Cells	   were	   subjected	   to	   transfection	   with	   scrambled	   siRNA	   as	   controls	   or	   BMPR2	   siRNA	   and	  
expression	  of	  BMPR2	  and	  CLIC4	  analysed	  2	  days	   later.	   (A)	  Representative	  Western	  blots	   showing	  
BMPR2	  and	  CLIC4	  protein	  expression,	  with	  densitometric	  analysis	  normalised	  to	  the	  β-­‐actin	  loading	  
control.	  (B)	  Representative	  images	  of	  RT-­‐PCR	  anaylsis	  showing	  BMPR2	  and	  CLIC4	  mRNA	  expression.	  
Transfection	   of	   ALK5	   siRNA	   served	   as	   an	   additional	   negative	   control,	   not	   targeting	   BMPR2	  
expression.	  β2	  microglobulin	  (β2M)	  served	  as	  a	  reference	  gene.	  (C)	  Quantitative	  RT-­‐PCR	  analysis	  of	  
(C)	   BMPR2	   and	   (D)	   CLIC4	  mRNA	   expression	   normalised	   to	   PPIA	   and	   α-­‐tubulin	   (n=3-­‐4).	   Each	   bar	  








	   	  
Figure	   7.5.	   Effect	   of	   BMPR2	   knockdown	   on	   CLIC4	   expression	   in	   HPAECs.	   (A)	   Representative	  
Western	  blot	  images	  showing	  BMPR2	  and	  CLIC4	  expression	  in	  HPAECs	  at	  2	  days	  post-­‐transfection.	  
Scrambled	   siRNA	   served	   as	   a	   control	   for	   BMPR2	   siRNA	   and	   β-­‐actin	   acted	   as	   a	   loading	   control.	  
Densitometric	  analysis	  of	  (B)	  BMPR2	  and	  (C)	  CLIC4	  protein	  expression	  normalised	  to	  β-­‐actin	  (n=3).	  
Each	  bar	  represents	  mean±SEM.	  	  Statistics	  obtained	  from	  t-­‐test.	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7.3.4	   ECFCs	   from	   IPAH	   patients	   have	   lower	   DDAHI	   and	   Cx43	   protein	   expression	   and	   greater	  
	   ADMA	  production	  
ECFCs	  from	  IPAH	  patients	  exhibited	  significantly	  lower	  levels	  (≥50%	  less)	  of	  Cx43	  and	  DDAHI	  proteins	  
compared	   to	   ECFCs	   from	   healthy	   volunteers	   (Figure	   7.6A-­‐B).	   In	   contrast,	   there	   was	   no	   significant	  
difference	  in	  the	  expression	  of	  Cx40	  between	  the	  two	  groups	  of	  cells.	  The	  expression	  of	  DDAHII	  and	  
Cx37	   was	   also	   probed,	   but	   neither	   protein	   was	   detectable.	   ECFCs	   from	   IPAH	   patients	   produced	  
significantly	  more	  ADMA	  (2-­‐folds)	  compared	  to	  ECFCs	  from	  healthy	  volunteers	  (Figure	  7.6C).	  
	  
Figure	   7.6.	   Expression	   of	   Cx43	   and	   DDAHI	   proteins	   and	   production	   of	   ADMA	   by	   ECFCs.	  	  
(A)	   Representative	  Western	   blots	   showing	   Cx43,	   Cx40	   and	   DDAHI	   levels	   in	   ECFCs	   from	   healthy	  
volunteers	   and	   IPAH	  patients.	  Numbers	  on	   the	   left	   indicate	  molecular	  weight	   (kDa).	   β-­‐actin	  was	  
used	  to	  demonstrate	  equal	  protein	   loading.	  (B)	  Quantitative	  analysis	  of	  Cx43	  and	  DDAHI	  protein	  
expression,	  showing	  the	  optical	  densities	  (OD)	  of	  the	  respective	  bands	  expressed	  as	  a	  proportion	  
of	   control	   values.	   (C)	   ADMA	   production	  measured	   in	   conditioned	  medium	   from	   ECFCs	   cultures.	  
Each	  bar	  represents	  mean±SEM	  (n=6).	  	  Statistics	  obtained	  from	  t-­‐test.	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7.3.5	   DDAHI	  and	  Cx43	  overexpression	  reduces	  endothelial	  permeability	  
ECFCs	   from	   IPAH	   patients	  were	   found	   to	   form	   leaky	  monolayers	   that	   exhibited	   higher	   endothelial	  
permeability	   than	  cells	   from	  healthy	  volunteers	   (Figure	  4.8	   in	  Chapter	  4).	  Here,	  over	  expression	  of	  
DDAHI	  or	  Cx43	  expression	  partially	  improved	  endothelial	  barrier	  function,	  reducing	  the	  levels	  of	  FITC-­‐

















































































Figure	  7.7.	  Overexpression	  of	  DDAH1	  and	  Cx43	  reduces	  endothelial	  permeability.	  Permeability	  of	  
ECFC	  monolayers	   (assessed	   by	   the	   flux	   of	   FITC-­‐labelled	   dextran),	   expressed	   as	   a	   proportion	   that	  
observed	   in	   cells	   from	   healthy	   volunteers	   (n=6).	  Measurements	   obtained	   after	   transfection	  with	  
adenoviral	  control	  or	  adenoviral	  over	  expression	  of	  DDAH1	  (Ad	  DDAH)	  or	  Cx43	  (Ad	  Cx43).	  Each	  bar	  
represents	  mean±SEM.	   Statistics	   derived	   from	   two-­‐way	  ANOVA,	   followed	  by	  Bonferroni	   post-­‐hoc	  
analysis.	  ***,	  P	  <	  0.001,	  compared	  with	  healthy-­‐ECFCs	  in	  control	  condition.	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7.3.6	   DDAHI	   and	   Cx43	   overexpression	   has	   no	   effect	   on	   tube	   formation	   by	   ECFCs	   from	   IPAH	  
	   patients	  
Connexins	  are	  important	  regulators	  of	  endothelial	  angiogenic	  responses	  (Gartner	  et	  al.,	  2012).	  ADMA	  
inhibited	  endothelial	   tube	   formation	   in	  HPAECs	   and	   this	  was	  prevented	  by	  DDAHI	  over	   expression	  
(Figure	  7.8),	  consistent	  with	  previously	  published	  data	   (Fiedler	  et	  al.,	  2009).	  Treatment	  with	  DDAHI	  
inhibitor	  L-­‐257	  or	  Cx43	  junctional	  blocker	  Gap26	  also	  attenuated	  tube	  formation	  whereas	  treatment	  
with	   Cx43	   junctional	   activator	   rotigaptide	   and	   Cx43	   overexpression	   promoted	   tube	   formation	   and	  




Figure	   7.8.	   ADMA,	   DDAHI	   and	   Cx43	   regulate	   Matrigel	   tube	   formation	   in	   HPAECs.	  	  
(A)	  Tube	  formation	  in	  HPAECs	  treated	  with	  ADMA	  (100	  µM),	  DDAHI	   inhibitor	  L-­‐257	  (1	  µM),	  Cx43	  
gap	   junction	   blocker	   Gap26	   (200	   µM),	   Cx43	   gap	   junction	   activator	   rotigaptide	   (100	   nM)	   or	  
overexpression	  of	   Cx43	  or	   DDAHI.	   Each	  bar	   represents	  mean±SEM	   relative	   to	   control.	   Statistics	  
derived	   from	   one-­‐way	   ANOVA	   and	   Bonferroni	   post	   hoc	   analysis.	   *,	   P<0.05;	   **,	   P<0.01;	   ***,	  
P<0.001,	   comparisons	   with	   untreated	   controls;	   ∆,	   P<0.05;	   ∆∆∆,	   P<0.001,	   comparisons	   between	  
ADMA	  +	  treatement	  and	  ADMA	  controls;	  	  N=	  3.	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When	  assessing	  tube	  formation	  in	  ECFCs,	  ECFCs	  from	  IPAH	  patients	  were	  again	  found	  to	  display	  an	  
increased	   angiogenic	   capacity,	   as	   demonstrated	   by	   enhanced	  Matrigel	   tube	   formation,	   compared	  
with	  cells	  from	  healthy	  volunteers	  (Figure	  7.9).	  However,	   in	  contrast	  to	  normal	  HPAECs	  (Figure	  7.8)	  
and	  ECFCs	  from	  healthy	  controls,	  over	  expression	  of	  Cx43	  or	  DDAHI	  did	  not	  promote	  tube	  formation	  








Figure	  7.9.	  Matrigel	  tube	  formation	  by	  ECFCs	  and	  the	  effects	  of	  Cx43	  and	  DDAHI	  over	  expression.	  
Quantitative	  analysis	  showing	  the	  effects	  of	  over	  expression	  of	  Cx43	  or	  DDAHI	  on	  tube	  formation	  by	  
ECFCs	   from	   healthy	   volunteers	   (control;	   n=3)	   and	   IPAH	   patients	   (n=4).	   Each	   bar	   represents	  
mean±SEM	   relative	   to	   healthy	   control	   ECFCs.	   Statistics	   derived	   from	   one-­‐way	   ANOVA	   and	  




7.4	   Discussion	  
CLIC4	  and	  endothelial	  dysfunction	  in	  ECFCs	  from	  IPAH	  patients	  
The	  main	  findings	  in	  the	  CLIC4	  experiments	  are:	  
• ECFCs	  from	  IPAH	  patients	  exhibit	  increased	  CLIC4	  expression	  and	  HIF-­‐1α	  stabilisation.	  
• Increased	  CLIC4	  expression	  contributes	  to	  the	  enhanced	  tube	  formation	  exhibited	  by	  ECFCs	  
from	  IPAH	  patients.	  
• Inhibition	  of	  BMPR2	  expression	  does	  not	  significantly	  affect	  CLIC4	  expression	  in	  ECFCs.	  
	  
We	  have	  recently	  described	  the	  critical	   role	  of	  CLIC4	   in	   regulating	  several	   functions	  of	  HPAECs	  and	  
suggested	  that	  CLIC4	  could	  be	  important	  in	  the	  development	  of	  experimental	  PH	  (Abdul	  Salam	  et	  al.,	  
2012).	  CLIC4	  expression	  was	  found	  to	  be	  increased	  in	  the	  lungs	  of	  rats	  with	  chronic	  hypoxia-­‐	  or	  MCT-­‐
induced	   PH,	   and	   localised	   predominantly	   to	   the	   endothelium	   in	   the	   remodelled	   pulmonary	  
vasculature.	  Despite	  being	  expressed	  in	  abundance	  in	  various	  mammalian	  endothelial	  cells	  and	  blood	  
vessels,	  including	  those	  in	  the	  kidney	  (Bohman	  et	  al.,	  2005),	  CLIC4	  levels	  were	  reduced	  in	  renal	  and	  
myocardial	   tissues	   of	   chronically	   hypoxic	   animals	   (unpublished	   data,	   Abdul	   Salam	   2012).	   These	  
observations	  suggest	  an	  organ-­‐specific	  response	  to	  hypoxia,	  with	  CLIC4	  expression	  having	  a	  distinct	  
role	  in	  the	  development	  of	  hypoxia-­‐induced	  PH.	  	  
In	   keeping	   with	   the	   observation	   that	   raised	   CLIC4	   expression	   was	   predominantly	   localised	   to	   the	  
pulmonary	  endothelium	  in	  IPAH	  lungs	  (Abdul-­‐Salam	  et	  al.,	  2010),	  CLIC4	  expression	  was	  also	  found	  to	  
be	   raised	   in	   ECFCs	   derived	   from	   IPAH	   patients.	   HIF-­‐1α	   expression	   had	   previously	   been	   identified	  
within	  endothelial	  plexiform	  lesions	  (Tuder	  et	  al.,	  2001),	  in	  isolated	  PASMCs	  (Bonnet	  et	  al.,	  2006)	  and	  
pulmonary	   ECs	   from	   IPAH	   patients	   (Fijalkowska	   et	   al.,	   2010),	   suggesting	   that	   HIF-­‐dependent	  
signalling	  may	  contribute	   to	   the	  pulmonary	  angioproliferative	   remodelling	   in	   IPAH.	  Recently,	  CLIC4	  
overexpression	   was	   found	   to	   promote	   the	   stabilisation	   and	   nuclear	   translocation	   of	   HIF-­‐1α	   and	  
increased	  production	  of	  VEGF	  in	  HPAECs,	  these	  effects	  being	  abrogated	  by	  inhibition	  of	  endogenous	  
CLIC4	  (Abdul	  Salam	  et	  al.,	  2012).	  We	  have	  now	  also	  demonstrated	   increased	  HIF-­‐1α	  stabilisation	   in	  
ECFCs	   from	   IPAH	   patients	   and	   shown	   that	   the	   reduction	   of	   CLIC4	   expression	   in	   ECFCs	   from	   IPAH	  
patients	   (to	   the	   levels	   found	   in	   ECFCs	   from	   healthy	   volunteers)	   abolishes	   their	   enhanced	   tube	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forming	   capacity.	   Taken	   together,	   these	   observations	   suggest	   that	   CLIC4	   is	   an	   important	   factor	  
contributing	  to	  the	  disease-­‐related	  phenotype	  of	  ECFCs	  from	  IPAH	  patients.	  
As	  heterozygous	  germline	  BMPR2	  mutations	  contribute	   to	  HPAH	   (Machado	  et	  al.,	  2009)	  and	  down	  
regulation	  of	  BMP	  signalling	  has	  been	  implicated	  in	  the	  development	  of	  experimental	  PH	  (Morty	  et	  
al.,	  2007;	  Long	  et	  al.,	  2009),	  we	  examined	  whether	  differences	  in	  BMPR2	  expression	  might	  influence	  
CLIC4	  protein	   levels.	  Despite	   the	  marked	   suppression	  of	  BMPR2	  mRNA	  and	  protein	  expression,	  no	  
significant	   changes	  were	   found	   in	   CLIC4	   protein	   and	  mRNA	   levels	   in	   either	  HPAECs	   or	   ECFCs	   from	  
healthy	  volunteers.	  This	   is	  consistent	  with	  the	  results	  of	  an	  earlier	  study	  on	  the	  regulation	  of	  CLIC4	  
mRNA	  expression	  in	  isolated	  smooth	  muscle	  cells	  (Spiekerkoetter	  et	  al.,	  2009)	  and	  suggests	  that	  the	  
enhanced	   expression	   of	   CLIC4	   found	   in	   endothelial	   cells	   from	   IPAH	   patients	   (Abdul-­‐Salam	   et	   al.,	  
2010)	   and	   lungs	   from	   rats	   with	   pulmonary	   hypertension	   is	   not	   a	   direct	   manifestation	   of	   altered	  
BMPR2	  expression.	  It	  is	  however	  unclear	  whether	  TGF-­‐β	  signalling	  affects	  CLIC4	  expression	  in	  ECFCs,	  
as	  TGF-­‐β1	  has	  been	  shown	  to	  increase	  CLIC4	  expression	  in	  primary	  keratinocyte	  (Shukla	  et	  al.,	  2009).	  
	  
Role	  of	  ADMA,	  DDAHI	  and	  Cx43	  and	  endothelial	  dysfunction	  in	  ECFCs	  from	  IPAH	  patients	  
The	  main	  findings	  in	  the	  ADMA/DDAHI/Cx43	  experiments	  are:	  	  
• ECFCs	  from	  IPAH	  patients	  exhibit	  reduced	  DDAHI	  and	  Cx43	  expression	  compared	  with	  ECFCs	  
from	  healthy	  volunteers.	  
• ECFCs	  from	  IPAH	  patients	  also	  produce	  more	  ADMA	  than	  ECFCs	  from	  healthy	  volunteers.	  
• Increasing	   the	   expression	   of	   DDAHI	   and	   Cx43	   attenuates	   the	   excessive	   endothelial	  
permeability	  and	  the	  enhanced	  tube	  forming	  capacity	  of	  ECFCs	  from	  IPAH	  patients.	  
	  
ADMA	  was	  recently	   found	  to	   inhibit	   the	  expression	  and	  membrane	   localisation	  of	  Cx43	   in	  HPAECs,	  
while	  Cx37	  and	  Cx40	  were	  unaffected	  (Tsang	  et	  al.,	  2011).	  ADMA	  also	  disrupted	  the	  barrier	  functions	  
of	  HPAECs,	   decreasing	   gap	   junctional	   communication	   and	   increasing	   endothelial	   permeability,	   and	  
this	  was	  prevented	  by	  Cx43	  or	  DDAHI	  overexpression.	  DDAHI	  was	  the	  predominant	  isoform	  of	  DDAH	  
found	  in	  HPAECs	  and	  the	  manipulation	  of	  DDAHI	  expression	  did	  not	  induce	  a	  compensatory	  change	  
in	  DDAHII	  expression	  (Tsang	  et	  al.,	  2011).	  Indeed,	  similar	  observations	  have	  recently	  been	  described	  
in	  mice	  (Hu	  et	  al.,	  2011).	  The	  expression	  of	  DDAHI	  and	  Cx43	  proteins	  was	  significantly	  reduced	  and	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production	   of	   ADMA	   increased	   in	   ECFCs	   derived	   from	   IPAH	   patients.	   It	   is	   conceivable	   that	   the	  
increased	  production	  of	  ADMA	  reflects	  decreased	  DDAHI	  expression	  but	  unclear	  whether	  circulating	  
ECFCs	  and/or	  cells	   residing	   locally	   in	   the	  pulmonary	  vasculature	   (Alvarez	  et	  al.,	  2008;	  Duong	  et	  al.,	  
2011)	  contribute	  to	  the	  circulating	  levels	  of	  ADMA,	  which	  are	  raised	  in	  IPAH	  patients	  (Pullamsetti	  et	  
al.,	   2005).	   Increased	   ADMA	   release	   might	   also	   lead	   to	   a	   reduction	   in	   Cx43	   expression	   and	   the	  
disruption	   of	   barrier	   function	   observed	   in	   ECFCs	   from	   IPAH	   patients.	   Indeed,	   increasing	   the	  
expression	  of	  DDAHI	  or	  Cx43	  partially	  attenuated	  the	  excessive	  endothelial	  permeability	  displayed	  by	  
these	  cells	  (Figure	  7.7).	  
In	  fact,	  connexin	  expression	  is	  frequently	  disrupted	  in	  response	  to	  lung	  disease	  (Johnson	  and	  Koval,	  
2009).	  ADMA-­‐induced	  impairment	  of	  endothelial	  barrier	  function	  was	  associated	  with	  a	  reduction	  of	  
Cx43	  expression	   and	   activation,	  which	   is	   reminiscent	   of	   the	   actions	  of	   other	   barrier-­‐compromising	  
factors	  such	  as	  bioactive	  lipids,	  ET-­‐1	  and	  thrombin	  (Hill	  et	  al.,	  1994;	  Spinella	  et	  al.,	  2003;	  D'Hondt	  et	  
al.,	   2007).	   Intercellular	   junctions	   between	   endothelial	   cells	   maintain	   vascular	   permeability	   and	  
integrity.	  Gap	  junctions	  are	  located	  in	  close	  proximity	  to	  the	  tight	  and	  adherens	  junctions	  that	  form	  
the	   endothelial	   barrier	   (Derangeon	   et	   al.,	   2009).	   The	   interaction	  of	   Cx43	  with	   submembrane	   actin	  
cytoskeleton	   helps	   coordinate	   formation	   of	   protein	   scaffolds	   containing	   proteins	   such	   as	   the	   tight	  
junction	  protein-­‐1	  (ZO-­‐1),	  cadherins,	  and	  integrins	  and	  therefore	  is	  important	  for	  the	  formation	  and	  
maintenance	  of	   intercellular	  contacts	   (Giepmans,	  2004;	  Nagasawa	  et	  al.,	  2006;	  Kojima	  et	  al.,	  2007;	  
Vitale	   et	   al.,	   2009).	   Another	   possibility	   is	   that	   Cx43	   hemichannels	   enhance	   barrier	   function	   by	  
promoting	   release/transfer	   of	   barrier-­‐protective	   signalling	   molecules	   such	   as	   ATP	   (Gunduz	   et	   al.,	  
2003),	  nicotinamide	  adenine	  dinucleotide	  (NAD+)	  (Umapathy	  et	  al.,	  2010),	  or	  prostaglandin	  (Birukova	  
et	  al.,	  2007)	  or	  by	  helping	  to	  normalise	  intracellular	  calcium	  levels	  (Parthasarathi	  et	  al.,	  2006;	  Li	  et	  al.,	  
2010).	  
In	  addition	  to	  effects	  on	  inter-­‐cellular	  communication	  and	  barrier	  function,	  the	  pharmacological	  and	  
genetic	  manipulation	  of	  DDAH	  and	  CX43	  activity/expression	  also	  enhanced	  angiogenic	  responses	   in	  
HPAECs.	   Cx43	   augments	   several	   processes	   important	   in	   angiogenesis,	   such	   as	   cell-­‐cell	   adhesion	  
(Giepmans,	  2004;	  Vitale	  et	  al.,	  2009),	  cell	  migration	  (Behrens	  et	  al.,	  2010)	  and	  expression	  of	  genes	  in	  
VEGF-­‐	  and	  TGF-­‐β-­‐signaling	  pathways	   (Walker	  et	  al.,	  2005).	  Nonetheless,	   in	  contrast	   to	  HPAECs	  and	  
ECFCs	   from	  healthy	   volunteers,	   ECFCs	   from	   IPAH	  patients	   showed	  an	  elevated	  angiogenic	   capacity	  
and	  apparent	  resistance	  to	  the	  effect	  of	  overexpressing	  DDAHI	  or	  Cx43.	  It	  is	  possible	  that	  other	  NO-­‐
independent	   pro-­‐angiogenic	   factors	   might	   be	   involved.	   For	   example,	   basic	   FGF,	   a	   growth	   factor	  
implicated	   in	   the	   pathogenesis	   of	   PAH,	   can	   act	   in	   an	  NO-­‐independent	  manner	   and	   synergise	  with	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VEGF	   in	   inducing	   endothelial	   permeability	   and	   angiogenesis	   (Arcot	   et	   al.,	   1995;	   Tille	   et	   al.,	   2001;	  






	   	  
Figure	   7.10.	   Schematic	   diagram	   of	   the	   proposed	   role	   of	   ADMA/DDAH	   in	   the	   regulation	   of	  
HPAECs	  and	  ECFCs	   functions.	  ADMA	  inhibits	  Cx43	  expression	  and	  gap	  junctional	  communication,	  
which	   destabilises	   inter-­‐cellular	   junctions,	   contributing	   to	   the	   breakdown	   of	   endothelial	   barrier	  
function	  and	  inhibition	  of	  angiogenesis	  in	  HPAECs	  and	  ECFCs	  from	  healthy	  volunteers.	  The	  DDAHI	  
inhibitor,	   L-­‐257	  and	  Cx43	   inhibitor,	  Gap26	  mimic	   the	   effects	  of	  ADMA,	  while	  over	   expression	  of	  
DDAHI,	  Cx43	  or	  treatment	  with	  rotigaptide,	  have	  a	  protective	  effect.	  In	  ECFCs	  from	  IPAH	  patients,	  
decreased	  DDAHI	  expression	  might	  lead	  to	  reduced	  ADMA	  metabolism,	  which	  leads	  to	  increased	  
ADMA	  release	  and	  inhibition	  of	  Cx43	  expression.	  Loss	  of	  Cx43	  could	   lead	  to	  the	  impaired	  barrier	  
function	  (increased	  permeability)	  in	  the	  IPAH	  cells.	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Conclusion	  and	  future	  perspective	  
The	   findings	   in	   this	   chapter	   indicate	   that	   increased	   tube	   forming	  capacity	  exhibited	  by	  ECFCs	   from	  
IPAH	  patients	  is	  mediated	  by	  excessive	  CLIC4	  expression.	  Decreased	  DDAHI	  and	  Cx43	  expression	  may	  
also	  contribute	  to	  the	  disrupted	  barrier	  functions	  of	  ECFCs	  from	  IPAH	  patients.	  It	  will	  be	  of	  interest	  to	  
see	  whether	  these	  cells	  produce	  more	  VEGF	  than	  ECFCs	  from	  healthy	  controls	  and	  if	  this	  is	  mediated	  
through	  CLIC4	  and	  the	  HIF-­‐1α	  stabilisation.	  This	  is	  of	  particular	  relevance	  to	  PAH	  as	  circulating	  VEGF	  
levels	   are	   raised	   in	   IPAH	   patients	   (Selimovic	   et	   al.,	   2009;	   Kumpers	   et	   al.,	   2010).	   It	   would	   also	   be	  
interesting	   to	   explore	   whether	   the	   altered	   expression	   of	   these	   proteins	   affects	   the	   other	  
dysfunctional	   phenotypic	   characteristics	   of	   ECFCs	   from	   IPAH	   patients.	   In	   this	   regard,	   we	   recently	  
reported	  that	  CLIC4	  over	  expression	  increases	  the	  endothelial	  permeability	  of	  HPAECs	  (Abdul	  Salam	  
et	  al.,	  2012).	  In	  fact,	  VEGF	  has	  also	  been	  shown	  to	  increase	  endothelial	  permeability	  by	  inducing	  VE-­‐
cadherin	   destabilisation	   (Gavard,	   2009),	   providing	   a	   hypothetical	   mechanism	   for	   CLIC4-­‐induced	  
changes	  in	  the	  barrier	  functions	  of	  ECFCs.	  Manipulation	  of	  CLIC4	  expression	  has	  however	  been	  found	  
to	  have	  no	  effect	  on	  the	  wound	  recovery	  rate	  of	  endothelial	  cells	  (Tung	  et	  al.,	  2009),	  whereas	  Cx43	  
has	   been	   shown	   to	   mediate	   migration	   of	   HeLa	   cells	   and	   mouse	   embryonic	   EPCs	   (Behrens	   et	   al.,	  
2010).	  Therefore,	  it	  will	  be	  worthwhile	  to	  investigate	  the	  role	  of	  DDAHI/ADMA/Cx43	  pathway	  in	  the	  
impaired	  migration	  of	  ECFCs	  from	  IPAH	  patients.	  	  
In	   summary,	   this	   chapter	   has	   demonstrated	   that	   blood-­‐derived	   ECFCs	   can	   be	   used	   to	   investigate	  
novel	   aspects	   of	   signalling	   dysregulation	   that	   might	   contribute	   to	   the	   pathogenic	   dysfunction	   of	  
endothelial	   cells	   in	   IPAH	  patients.	   The	  data	   also	   provides	   a	   proof	   of	   concept	   indicating	   that	   ECFCs	  













Chapter	  8	  –	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  future	  work	  	  
	  
The	  studies	   in	  this	  thesis	  aimed	  to	  establish	   if	  ECFCs	  are	  a	  credible	  endothelial	  cell	  model	  for	   IPAH.	  
The	   investigations	   commenced	   with	   the	   finding	   of	   an	   altered	   colony-­‐forming	   capacity	   in	   IPAH	  
patients.	   Specifically,	   the	   cells	   lacked	   the	   age-­‐dependent	   decline	   in	   colony	   formation	   that	   was	  
observed	  in	  healthy	  individuals.	  The	  frequency	  of	  colonies	  was	  also	  associated	  with	  clinical	  features	  
and	  disease	  severity	  in	  IPAH	  patients.	  In	  vitro	  expansion	  of	  the	  colonies	  gave	  rise	  to	  cells	  with	  typical	  
endothelial	  progenitor	  cell	  characteristics	  (Yoder	  et	  al.,	  2007);	  namely	  cobblestone-­‐like	  morphology,	  
expression	  of	  endothelial	  markers,	   lack	  of	  hematopoetic/monocytic	  markers,	   in	  vitro	  Matrigel	   tube	  
formation	   and	   clonogenic	   growth.	   Importantly,	   ECFCs	   derived	   from	   IPAH	   patients	   exhibited	  
apoptosis-­‐resistance,	   enhanced	   angiogenic	   capacity,	   impaired	   migration	   and	   disrupted	   barrier	  
function.	  BMPR2	  expression	  has	  been	  found	  to	  be	  impaired	  in	  PAH	  patients	  and	  animal	  models,	  but	  
did	  not	  appear	  to	  differ	  between	  ECFCs	  from	  patients	  and	  healthy	  subjects.	  Among	  the	  other	  TGF-­‐β	  
receptors	   analysed,	   expression	   of	   ALK5	   was	   reduced	   in	   IPAH	   cells	   and	   may	   be	   associated	   with	  
impaired	   TGF-­‐β1/ALK5/Smad2/3	   signalling.	   The	   ALK1	   and	   ALK5	   signalling	   pathways	   had	   opposing	  
effects	  on	  ECFC	  survival,	  tube	  formation	  and	  migration	  and	  lower	  ALK5	  expression	  might	  contribute	  
to	   distinct	   effects	   on	   apoptosis	   and	   migration	   in	   ECFCs	   from	   IPAH	   patients.	   Differences	   in	   CLIC4,	  	  
HIF-­‐1α,	  DDAHI	  and	  Cx43	  expression	  and	  ADMA	  production	  were	  also	  found	  that	  mediated,	  at	  least	  in	  
part,	   the	   dysregulation	   of	   tube	   formation	   and	   endothelial	   permeability	   in	   cells	   derived	   from	   IPAH	  
patients.	   Collectively,	   these	   findings	   provide	   support	   for	   the	   contention	   that	   blood-­‐derived	   ECFCs	  
represent	   a	   suitable	   surrogate	   endothelial	   cell	   model	   to	   investigate	   the	   pathogenic	   mechanisms	  
underlying	  endothelial	  dysfunction	  in	  IPAH.	  	  
	  
Phenotypic	  differences	  between	  ECFCs	  from	  IPAH	  patients	  and	  healthy	  volunteers	  
The	   discovery	   of	   an	   age-­‐dependent	   decline	   of	   ECFC	   colony	   formation	   in	   healthy	   individuals	   is	  
supported	  by	  a	  recent	  report	  describing	  similar	  findings	  found	  in	  the	  rhesus	  monkey	  (Shelley	  et	  al.,	  
2012).	  It	  is	  interesting	  that	  the	  older	  IPAH	  patients	  (over	  62	  years)	  did	  not	  follow	  this	  trend	  and	  the	  
underlying	   mechanism	   needs	   to	   be	   clarified.	   Further	   investigation	   would	   be	   to	   compare	   the	  
telomerase	   activity	   of	   these	   cells	   as	   this	   is	   thought	   to	   correlate	   with	   the	   greater	   number/colony	  
forming	  capacity	  of	  ECFCs	  in	  cord	  blood	  compared	  with	  adult	  peripheral	  blood	  (Ingram	  et	  al.,	  2004).	  
Determining	  the	  origin	  of	  circulating	  ECFCs	  may	  also	  help	  to	  understand	  their	  potential	  contribution	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to	   endothelial	   repair	   and	   pulmonary	   vascular	   remodelling	   in	   IPAH.	   Endothelial	   cells	   isolated	   from	  
both	   human	   pulmonary	   arteries	   (Duong	   et	   al.,	   2011)	   and	   the	   rat	   pulmonary	   microvasculature	  
(Alvarez	  et	  al.,	  2008)	  have	  been	  shown	  to	  contain	  ECFCs,	   indicating	  that	  these	  cells	  reside	  locally	   in	  	  
walls	  of	  pulmonary	  vessels	  as	  well	  as	  in	  bone	  marrow.	  Studies	  exploring	  the	  microvascular	  (Griffonia	  
simplicifolia	   lectin	   binding	   and	   CD36	   positive)	   and	   macrovascular	   (Helix	   Pomatia	   lectin	   binding)	  
endothelial	  phenotype	  (Swerlick	  et	  al.,	  1992;	  Comhair	  et	  al.,	  2012)	  of	  ECFCs	  may	  provide	  additional	  
insight	   into	   their	   vascular	   origin	   and	   potential	   contribution	   to	   plexiform	   lesions,	   the	   latter	  
representing	   a	   monoclonal	   proliferation	   (Lee	   et	   al.,	   1998)	   of	   macro-­‐	   rather	   than	   micro-­‐vascular	  
endothelial	  cells	  (Comhair	  et	  al.,	  2012).	  Further	  experiments	  with	  ECFCs	  derived	  from	  both	  explanted	  
lung	  tissues	  and	  contemporary	  peripheral	  blood	  samples,	  involving	  the	  rigorous	  use	  of	  the	  single	  cell	  
clonogenic	   assay	   (replating	   cells	   from	   the	   primary	   colony	   to	   produce	   secondary	   and	   tertiary	  
colonies),	  may	  help	  to	  determine	  whether	  the	  source	  of	  ECFCs	  influences	  observed	  differences	  in	  the	  
frequency	  and	  proliferation	  of	  ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients.	  	  	  
To	   establish	   ECFCs	   as	   an	   effective	   endothelial	   cell	   model	   for	   IPAH,	   a	   clear	   understanding	   of	   their	  
functional	   phenotype	   is	   required.	   I	   have	   shown	   that	   ECFCs	   from	   IPAH	   patients	   exhibit	   several	  
characteristics	   (most	   notably	   resistance	   to	   apoptosis)	   that	   are	   reminiscent	   of	   ECs	   in	   the	   diseased	  
pulmonary	  vasculature	  of	   IPAH	  patients,	  studied	  both	   in	  situ	  and	  as	  cultured	  cells	   in	  vitro	  (Masri	  et	  
al.,	   2007;	  Tu	  et	  al.,	   2011).	   I	   also	  observed	   that	  ECFCs	   from	   IPAH	  patients	  were	  more	  angiogenic	   in	  
vitro	  but	  it	  will	  be	  important	  to	  determine	  whether	  this	  can	  be	  replicated	  in	  vivo,	  using	  for	  example	  
cellularised	   gel	   implants	   or	  Matrigel	   plugs	   in	   nude	  mice	   (Melero-­‐Martin	   et	   al.,	   2007;	   Yoder	   et	   al.,	  
2007).	   It	   is	   unclear	   how	   the	   results	   of	   the	   cell	  migration	   (wound	   healing)	   and	   proliferation	   assays	  
relate	  to	  the	  potential	  contribution	  of	  ECFCs	  in	  the	  pathogenesis	  of	  IPAH,	  but	  impaired	  migration	  or	  
proliferation	   could	   be	   deleterious	   to	   endothelial	   repair	   and	   vascular	   homeostasis.	   It	   also	   is	  
interesting	   to	  note	   that	  patients	  with	  HHT,	  who	  harbour	  mutations	  of	  endoglin	  or	  ALK1,	  have	  also	  
been	   found	  to	  give	   rise	   to	  ECFCs	   that	  display	   impaired	  migratory	  and	  proliferative	  capacity	   in	  vitro	  
(Fernandez	  et	  al.,	  2007).	  	  
	  
Dysregulated	  TGF-­‐β	  signalling	  contributes	  to	  the	  functional	  phenotype	  of	  ECFCs	  from	  IPAH	  patients	  
ECFCs	  from	  IPAH	  patients	  displayed	  differences	  in	  ALK5	  expression	  and	  the	  canonical	  TGF-­‐β1/Smad2	  
signalling	   pathway,	   when	   compared	   with	   cells	   isolated	   from	   healthy	   volunteers.	   Studies	   into	   the	  
regulation	  of	  endothelial	   cell	   functions	  by	  TGF-­‐β	  signalling	  have	  been	  complicated	  by	   the	  opposing	  
responses	  this	  can	  induce,	  due	  to	  biphasic	  concentration-­‐dependent	  effects	  and	  the	  distinct	  effects	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of	  activating	  ALK1/TGF-­‐β	  and	  ALK5/TGF-­‐β	  receptor	  pathways.	  Indeed,	  differing	  results	  have	  also	  been	  
found	   using	   the	   same	   model/cell	   type,	   as	   shown	   for	   example	   by	   studies	   into	   the	   mechanism	   by	  
which	  endoglin	  regulates	  endothelial	  cell	  growth.	  Earlier	  studies	  reported	  pro-­‐proliferative	  and	  pro-­‐
migratory	   responses	   elicited	   by	   endoglin	   in	   mouse	   embryonic	   ECs,	   whereas	   others	   found	   that	  
endoglin	  inhibited	  proliferation	  and	  migration;	  these	  disparate	  findings	  probably	  reflect	  signalling	  via	  
Smad-­‐independent	   as	  well	   as	   Smad-­‐dependent	   pathways	   (Lebrin	   et	   al.,	   2004;	   Pece-­‐Barbara	   et	   al.,	  
2005;	  Ray	  et	  al.,	  2010;	  Pan	  et	  al.,	  2012).	  In	  the	  present	  study,	  one	  of	  the	  most	  consistent	  findings	  was	  
the	  resistance	  to	  apoptosis	  in	  serum-­‐deprived	  ECFCs	  from	  IPAH	  patients	  and	  the	  opposing	  effects	  of	  
ALK1	  and	  ALK5	  signalling,	  apoptosis	   (caspase-­‐3/7	  activity)	  being	  attenuated	  by	  ALK1	  activation	  and	  
ALK5	   inhibition.	  Nevertheless,	   the	  mechanisms	  controlling	   these	  effects	  and	   the	  significance	  of	   the	  
depletion	   in	   ALK5,	   endoglin	   and	   ActRIIA	   expression	   in	   IPAH-­‐derived	   cells	   have	   not	   been	   fully	  
explored.	   Increasing	   evidence	   demonstrates	   that	   stimulation	   of	   TGF-­‐β	   and	   BMP	   signalling	   can	  
activate	   intracellular	  non-­‐Smad	  pathways	   that	   regulate	  a	   range	  of	   cellular	   functions	   (Zhang,	  2009).	  
These	   include	   the	  MAP	   kinase	   pathways	   (p38,	   ERK,	   JNK),	   Rho	   GTPase	   and	   phosphatidylinositol-­‐3-­‐
kinase/AKT	  pathways.	  In	  endothelial	  cells,	  the	  activation	  of	  p38	  MAPK	  by	  BMP9	  and	  TGF-­‐β1	  has	  been	  
shown	  to	  mediate	  ET-­‐1	  synthesis,	  tube	  formation,	  migration	  and	  apoptosis	  (Ferrari	  et	  al.,	  2009;	  Park	  
et	   al.,	   2012),	  whereas	   ALK1/endoglin-­‐mediated	   ERK	   and	   JNK	   signalling	   promoted	   proliferation	   and	  
migration	   (David	   et	   al.,	   2007b;	   Pan	   et	   al.,	   2012).	   In	   fact,	   interactions	   between	   these	   signalling	  
pathways	  can	  have	  unexpected	  effects	  on	  endothelial	  cell	  apoptosis	  and	  involve	  different	  isoforms	  of	  
p38	  MAPK	  (Ferrari	  et	  al.,	  2012).	  I	  only	  considered	  Smad	  signalling	  in	  this	  study	  and	  the	  examination	  
of	  non-­‐Smad	  pathways	  may	  provide	  further	  insight	  into	  the	  dysfunctional	  phenotype	  of	  ECFCs	  from	  
IPAH	  patients.	  	  
Disparate	  findings	  in	  functional	  phenotypes	  and	  canonical	  BMP9	  signalling	  activation	  between	  ECFCs	  
from	   IPAH	   patients	   in	   this	   study	   and	   HPAH	   patients	   with	   BMPR2	   mutations	   by	   others	   suggests	  
possible	   variation	   in	   the	  molecular	  mechanisms	   of	   ECFC	   dysfunction	   between	  HPAH	   patients	  with	  
BMPR2	   mutations	   and	   IPAH	   patients	   (Toshner	   et	   al.,	   2009;	   Toshner	   et	   al.,	   2011).	   Furthermore,	  
Yeager	  and	  co-­‐workers	  identified	  TGF-­‐βRII	  and	  Bax	  microsatellite	  instabilities	  in	  the	  endothelial	  cells	  
of	  plexiform	  lesions	  in	  IPAH	  lungs,	  while	  the	  same	  group	  and	  others	  failed	  to	  identify	  these	  mutations	  
in	  the	  plexiform	  lesions	  of	  APAH	  and	  HPAH	  lungs	  (Yeager	  et	  al.,	  2001;	  Yeager	  et	  al.,	  2002;	  Machado	  et	  
al.,	  2005).	  Identifying	  these	  mutations	  in	  ECFCs	  from	  IPAH	  patients	  would	  provide	  a	  more	  direct	  link	  
between	  the	  monoclonal	  proliferation	  in	  vitro	  (ECFC	  colony	  formation)	  and	  in	  vivo	  (plexiform	  lesions)	  
and	  add	  weight	   to	   the	  suggestion	   that	  ECFCs	  have	  a	   role	   in	   the	  pathogenesis	  of	   IPAH.	  Thus,	  ECFCs	  
might	  provide	  an	  accessible	  cell	  source	  to	  investigate	  the	  formation	  of	  plexiform	  lesions	  in	  the	  lungs	  
of	   IPAH	   patients.	   Unfortunately,	   only	   two	   ECFC	   samples	  were	   derived	   from	  HPAH	   patients	   in	   this	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study	  and	   the	  BMPR2	  mutation	  status	  of	   the	   IPAH	  patients	  was	  not	  available.	  Given	   the	  necessary	  
time	  and	  facilities	  I	  would	  have	  liked	  to	  investigate	  the	  receptor	  signalling	  and	  functional	  properties	  
of	  ECFCs	  from	  well	  phenotyped	  and	  genotyped	  patients,	  with	  and	  without	  known	  BMPR2,	  ALK1	  and	  
SMAD	  mutations	  associated	  with	  PAH.	  	  
	  
Novel	  therapeutic	  perspectives	  
It	  has	  been	  suggested	  that	  the	  inhibition	  of	  the	  ALK5	  receptor	  could	  have	  therapeutic	  benefit	  as	  the	  
receptor	   is	   thought	   to	   mediate	   abnormal	   proliferation	   of	   VSMCs	   from	   patients	   with	   HPAH,	   and	  
increased	  ALK5/TGF-­‐β	  signalling	  is	  considered	  to	  promote	  the	  proliferation	  and	  migration	  of	  PASMCs	  
in	   experimental	   models	   of	   PH	   (Zaiman	   et	   al.,	   2008;	   Long	   et	   al.,	   2009;	   Thomas	   et	   al.,	   2009).	  
Nonetheless,	   we	   need	   to	   more	   fully	   understand	   the	   potential	   significance	   of	   impaired	   ALK5	  
expression	   and	   regulation	   of	   apoptosis	   in	   the	   pulmonary	   endothelium	   before	   undertaking	   more	  
general	   targeting	  of	  ALK5	  expression	   in	   the	  pulmonary	  vascular	   system.	   In	   fact,	  other	  groups	  have	  
observed	  that	  ALK1	  (not	  ALK5)	  expression	   is	  affected	   in	  the	   lungs	  and	  PASMCs	  of	  MCT-­‐treated	  rats	  
(Zakrzewicz	   et	   al.,	   2007)	   and	   selective	   down	   regulation	   of	   ALK5	   may	   offer	   growth	   advantages	   to	  
abnormal	  pulmonary	  endothelial	  cells	  (Richter	  et	  al.,	  2004).	  The	  coordinated	  activity	  of	  both	  type	  1	  
receptors	  is	  necessary	  for	  the	  normal	  regulation	  of	  VEGF	  in	  endothelial	  cells	  (Shao	  et	  al.,	  2009)	  and	  
the	  inhibition	  of	  ALK5	  and	  Smad2	  activation	  has	  been	  found	  to	  enhance	  the	  angiogenic	  function	  and	  
survival	  of	  endothelial	   cells	   (Froese	  et	  al.,	  2011).	  Further	   studies	  are	  also	  warranted	   in	  view	  of	   the	  
intricate	   interaction	  between	  ALK1	   and	  ALK5	   signalling	   in	   regulating	   endothelial	   functions	   and	  our	  
current	  understanding	  of	  the	  role	  of	  endothelial	  cell	  apoptosis	  in	  the	  initiation	  versus	  progression	  of	  
pulmonary	  vascular	  remodelling	  and	  formation	  of	  plexiform	  lesions	  (Sakao	  et	  al.,	  2005).	  The	  present	  
results	   indicate	   that	   ALK5	   inhibition	   protects	   ECFCs	   and	   PAECs	   from	   apoptosis	   whereas	   ALK1	  
inhibition	  had	  the	  opposite	  effect	  and	  reversed	  the	  apoptosis-­‐resistant	  property	  of	  ECFCs	  from	  IPAH	  
patients.	  It	  would	  be	  interesting	  to	  see	  what	  effect	  selective	  ALK1	  and	  ALK5	  inhibition	  might	  have	  on	  
the	   early	   versus	   late	   stages	   of	   pulmonary	   vascular	   remodelling	   in	   animal	  model	  where	   angiogenic	  
(plexiform-­‐like)	  lesions	  are	  also	  manifested	  (Abe	  et	  al.,	  2010).	  	  
Excessive	   CLIC4	   and	   impaired	   DDAHI	   and	   Cx43	   expression	   were	   identified	   in	   ECFCs	   from	   IPAH	  
patients,	   suggesting	   novel	   therapeutic	   strategies	   that	   target	   these	   proteins.	   The	   general	   CLIC	  
inhibitor	  NPPB	  was	   found	   to	  attenuate	  hypoxia-­‐induced	  angiogenesis	   (tube	   formation	   in	  vitro)	  and	  
endothelial	   permeability	   in	  HPAECs	   (Abdul	   Salam	  et	   al.,	   2012).	   To	   date	   there	   is	   no	   selective	   CLIC4	  
inhibitor	   available	   to	   explore	   the	   functional	   significance	   of	   reducing	   CLIC4	   expression	   in	   PH,	   but	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preliminary	  results	  with	  CLIC4	  knockout	  mice	  suggest	  that	  they	  may	  be	  protected	  from	  the	  effects	  of	  
hypoxia	  on	  cardiovascular	   remodelling.	   In	   contrast,	   rotigaptide	   is	  a	  Cx43-­‐specific	  activator	   that	  has	  
been	   found	   to	   reverse	   the	   detrimental	   effects	   of	   ADMA	   on	   HPAEC	   functions	   (Tsang	   et	   al.,	   2011).	  
Rotigaptide	   is	   a	   stable	  anti-­‐arrhythmic	  peptide	   that	   increases	  phosphorylation	  of	   Ser-­‐368	   in	   the	  C-­‐
terminus	   of	   Cx43,	   rapidly	   improves	   Cx43	   membrane	   targeting	   and	   enhances	   intercellular	   gap-­‐
junctional	  conduction	  (Dhein	  et	  al.,	  2010).	  Studies	  over-­‐expressing	  different	  connexins	   in	  HeLa	  cells	  
have	  shown	  that	  rotigaptide	  specifically	  affects	  Cx43	  and	  Cx45	  but	  not	  other	  connexins	  present	  in	  the	  
vascular	   system	   (Dhein	   et	   al.,	   2010).	   The	   effect	   of	   rotigaptide	   on	   hypoxia-­‐induced	   pulmonary	  
vasoconstriction	  remains	  to	  be	  established	  but	  it	  is	  reported	  to	  have	  no	  effect	  on	  vascular	  tone	  in	  the	  
forearm	  of	  healthy	  subjects,	  either	  in	  the	  presence	  or	  absence	  of	  the	  nitric	  oxide	  synthase	  inhibitor	  L-­‐
NMMA	  (Lang	  et	  al.,	  2008),	  and	  to	  have	  a	  protective	  effect	  against	  endothelial	  ischaemia	  reperfusion	  
injury	  (unpublished	  data,	  Dr	  Ninian	  Lang,	  University	  of	  Edinburgh,	  2012).	  This	  suggests	  that	  impaired	  
Cx43	  expression/function	  may	  contribute	  to	  endothelial	  dysfunction	  in	  conditions	  of	  oxidative	  stress	  
(Pullamsetti	  et	  al.,	  2011)	  and	   testing	  drugs	   such	  as	   rotigaptide	  on	  ECFCs	  might	   reduce	   the	  need	   to	  
use	   animal	   models	   of	   PH.	   Indeed,	   potential	   therapeutic	   targeting	   of	   the	   DDAH/Cx43	   pathway	   in	  
patients	   with	   PAH	   will	   require	   careful	   consideration	   as	   increased	   Cx43	   expression	  may	   affect	   the	  
phenotype	  and	  proliferation	  of	  smooth	  muscle	  cells	  and	  enhance	  neointimal	  formation	  in	  a	  systemic	  
model	  of	  arterial	  injury	  (Song	  et	  al.,	  2009).	  Furthermore,	  DDAH/NO	  signalling	  has	  been	  implicated	  in	  
pulmonary	  fibrosis	  and	  conditions	  associated	  with	  inflammation	  and	  increased	  inducible	  NOS	  activity	  
(Pullamsetti	   et	   al.,	   2011).	   ECFCs	   from	   IPAH	   patients	   and	   healthy	   controls	   may	   represent	   a	   useful	  
means	  of	  testing	  drugs	  such	  as	  rotigaptide	  and	  could	  reduce	  the	  need	  for	  using	  animal	  models	  of	  PH.	  
	  
Limitations	  
There	  are	  a	  number	  of	   limitations	  to	  these	  studies.	  Firstly,	  the	  sample	  size	  was	  relatively	  small	  and	  
there	  was	  a	  lack	  of	  usable	  ECFC	  populations	  (one	  out	  of	  ten)	  from	  patients	  in	  WHO	  functional	  class	  I	  
and	  II.	  The	  results	  of	  the	  functional	  studies	  may	  therefore	  be	  more	  applicable	  to	  patients	  with	  severe	  
functional	  impairment	  and	  the	  latter	  stages	  of	  the	  disease	  than	  the	  mechanisms	  initiating	  endothelial	  
dysfunction	   in	   IPAH.	  Microarray	   analysis	   of	   gene	   and	  microRNA	   expression	   in	   ECFCs	   from	   all	   four	  
WHO	  functional	  classes	  may	  provide	  more	  information	  on	  the	  factors	  implicated	  in	  disease	  initiation	  
and	  progression.	  
Second,	   the	   ECFCs	   were	   studied	   in	   isolation	   and	   reproducing	   the	   in	   vivo	   environment	   requires	   a	  
multi-­‐cellular	   system.	   Blood-­‐derived	   smooth	   muscle	   progenitor	   cells	   (SMPCs)	   could	   provide	   an	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analogous	  non-­‐invasive	  approach	  to	  obtain	  patient-­‐specific	  smooth	  muscle	  cells	  (Simper	  et	  al.,	  2002).	  
The	  initial	  steps	  of	  culturing	  SMPCs	  are	  very	  similar	  to	  those	  required	  for	  ECFCs,	  indicating	  that	  both	  
cell	  types	  could	  be	  derived	  from	  the	  same	  blood	  sample.	  SMPCs	  are	  also	  reported	  to	  express	  smooth	  
muscle	   cell	  markers	   and	   display	   a	   typical	   	   “hill-­‐and-­‐valley”	   smooth	  muscle	   cell	  morphology	   that	   is	  
readily	   distinguished	   from	   the	   cobblestone	   appearance	   of	   ECFCs	   (Wang	   et	   al.,	   2012).	   Co-­‐culturing	  
both	  cell	  types	  from	  the	  same	  patient	  could	  recreate	  a	  more	  credible	  in	  vitro	  model	  and	  enhance	  our	  
understanding	   of	   the	   paracrine	   relationship	   between	   them.	   Furthermore,	   no	   reprogramming	   is	  
required.	   Epigenetic	   changes	   are	   thought	   to	   have	   a	   role	   in	   the	   development	   of	   PAH	   (Zhao	   et	   al.,	  
2012)	   and	   the	   reprogramming	   involved	   in	   the	  production	  of	   induced	  pluripotent	   stem	  cells	   (IPScs)	  
might	  affect	  their	  cellular	  functions	  through	  methylation	  and	  acetylation	  events	  (Saha	  and	  Jaenisch,	  
2009).	  	  Furthermore,	  if	  induced	  vascular	  progenitor	  cells	  (iVPCs)	  are	  required,	  which	  can	  differentiate	  
into	  vascular	   smooth	  muscle	  and	  endothelial	   cells,	   then	  ECFCs	  may	   represent	  a	  useful	   starting	   cell	  
type.	   Unlike	   fibroblasts,	   they	   may	   require	   only	   partial	   reprogramming	   and	   retain	   the	   ‘epigenetic	  
memory’	  of	  their	  endothelial	  lineage	  (Yin	  et	  al.,	  2012).	  
Third,	   ECFCs	   were	   cultured	   and	   analysed	   under	   static	   conditions	   that	   were	   devoid	   of	   the	   in	   vivo	  
milieu.	   In	   particular,	   they	   were	   not	   subjected	   to	   the	   shear	   stress	   present	   within	   the	   pulmonary	  
circulation	  of	  PAH	  patients	  (Voelkel	  and	  Tuder,	  1995),	  yet	  endothelial	  cell	  functions	  are	  known	  to	  be	  
influenced	  by	  shear	  stress	  (Ando	  and	  Yamamoto,	  2011).	  The	  CELLMAX	  artificial	  capillary	  system	  could	  
be	  used	   to	   recreate	   a	  pulsatile	   flow	  environment	   and	   could	  be	  used	   to	  observe	   the	  differences	   in	  
functional	  responses	  between	  ECFCs	  from	  healthy	  volunteers	  and	  IPAH	  patients	  (Sakao	  et	  al.,	  2005).	  	  
Fourth,	   the	   concentration-­‐dependent	   effects	   of	   agonists	   such	   as	   BMP4	   and	   BMP9	   were	   not	   fully	  
explored	  in	  this	  study.	  The	  concentrations	  used	  were	  based	  on	  published	  reports	  investigating	  effects	  
on	  endothelial	  cells.	  But	  BMP9	  can	  activate	  both	  pSmad1/5/8	  and	  pSmad2	  in	  HPAECs,	  depending	  on	  
the	  concentration	  used	  (Upton	  et	  al.,	  2009),	  and	  might	  have	  biphasic	  effects	  on	  ECFCs	  that	  serve	  to	  







Novelty	  and	  value	  
The	  value	  of	  this	  study	   is	  that	   it	  represents	  the	  first	  concerted	  attempt	  to	  demonstrate	  that	  blood-­‐
derived	   ECFCs	   are	   an	   effective	   endothelial	   cell	   model	   in	   IPAH.	   These	   cells	   exhibited	   significant	  
differences	   in	   several	   pathways	   that	   are	   considered	   to	   be	   fundamental	   to	   the	   initiation	   and	  
progression	   of	   the	   disease.	   As	   such,	   they	   provide	   a	   valuable	   surrogate	   source	   of	   patient	   specific	  
endothelial-­‐like	  cells	   that	  may	  be	  used	  to	  test	  potential	  drugs,	   identify	  novel	   therapeutic	  strategies	  
and	   increase	   our	   understanding	   of	   mechanisms	   that	   underlie	   IPAH.	   This	   approach	   could	   be	  
particularly	   powerful	   when	   combined	   with	   the	   genotyping	   and	   deep	   phenotyping	   of	   patients,	  
contributing	   to	   the	   sub-­‐classification	   of	   IPAH	   as	   a	   disease	   category	   and	   the	   development	   of	  
personalised	  medicine.	  As	  ECFCs	  have	  an	  established	  endothelial	   lineage	  they	  may	  also	  represent	  a	  
useful	  cell	   type	  for	  the	  development	  of	   IPS	  cells.	  On	  the	  other	  hand,	  the	  demonstration	  that	  ECFCs	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Appendix	  1	  –	  Healthy	  volunteers	  demographics	   	  






Healthy	  1	   F	   27	   1	   0.100	   9	  
Healthy	  2	   F	   38	   1	   0.063	   0	  
Healthy	  3	   M	   27	   2	   0.171	   ≥9	  
Healthy	  4	   M	   26	   1	   0.056	   7	  
Healthy	  5	   F	   29	   1	   0.062	   ≥8	  
Healthy	  6	   F	   27	   4	   0.340	   ≥10	  
Healthy	  7	   M	   23	   3	   0.286	   4	  
Healthy	  8	   M	   24	   5	   0.362	   4	  
Healthy	  9	   M	   23	   7	   0.574	   4	  
Healthy	  10	   M	   25	   3	   0.288	   0	  
Healthy	  11	   F	   27	   0	   0.000	   -­‐	  
Healthy	  12	   F	   33	   1	   0.059	   ≥11	  
Healthy	  13	   F	   28	   1	   0.053	   10	  
Healthy	  14	   F	   28	   3	   0.300	   7	  
Healthy	  15	   F	   25	   2	   0.185	   6	  
Healthy	  16	   F	   24	   6	   0.405	   9	  
Healthy	  17	   F	   46	   1	   0.087	   0	  
Healthy	  18	   F	   57	   0	   0.000	   -­‐	  
Healthy	  19	   F	   43	   2	   0.215	   6	  
Healthy	  20	   F	   23	   6	   0.383	   ≥10	  
Healthy	  21	   F	   24	   2	   0.157	   9	  
Healthy	  22	   M	   30	   1	   0.104	   2	  
Healthy	  23	   F	   23	   2	   0.200	   4	  
Healthy	  24	   F	   46	   2	   0.228	   3	  
Healthy	  25	   F	   54	   0	   0.000	   -­‐	  
	   	   	   	   	   	  







Appendix	  2	  –	  PAH	  patients	  demographics	   	  
Sample	  
Code	  











IPAH	  1	   F	   62	   1.1	  IPAH	   61	   3	   1	   0.090	   9	  
IPAH	  2	   F	   56	   1.1	  IPAH	   21	   3	   2	   0.200	   ≥17	  
IPAH	  3	   M	   65	   1.1	  IPAH	   17	   3	   1	   0.104	   10	  
IPAH	  4	   M	   28	   1.1	  IPAH	   80	   1	   2	   0.176	   7	  
IPAH	  5	   M	   35	   1.1	  IPAH	   0.5	   2	   0	   0.000	   -­‐	  
IPAH	  6	   M	   75	   1.1	  IPAH	   55	   3	   0	   0.000	   -­‐	  
IPAH	  7	   F	   67	   1.1	  IPAH	   0.1	   3	   7	   0.330	   ≥14	  
IPAH	  8	   F	   27	   1.1	  IPAH	   34	   4	   2	   0.170	   0	  
IPAH	  9	   M	   37	   1.1	  IPAH	   48	   2	   0	   0.000	   -­‐	  
IPAH	  10	   F	   54	   1.1	  IPAH	   58	   1	   6	   0.450	   0	  
IPAH	  11	   M	   49	   1.1	  IPAH	   51	   3	   12	   1.160	   2	  
IPAH	  12	   F	   46	   1.1	  IPAH	   79	   3	   8	   0.480	   6	  
IPAH	  13	   M	   82	   1.1	  IPAH	   16	   3	   2	   0.240	   0	  
IPAH	  14	   M	   38	   1.1	  IPAH	   53	   3	   9	   0.450	   3	  
IPAH	  15	   M	   72	   1.1	  IPAH	   25	   3	   6	   0.940	   4	  
IPAH	  16	   F	   49	   1.1	  IPAH	   73	   2	   2	   0.250	   3	  
IPAH	  17	   M	   47	   1.1	  IPAH	   21	   1	   1	   0.110	   0	  
IPAH	  18	   F	   44	   1.1	  IPAH	   13	   3	   3	   0.325	   ≥10	  
IPAH	  19	   F	   24	   1.1	  IPAH	   9	   4	   4	   0.270	   9	  
IPAH	  20	   M	   51	   1.1	  IPAH	   16	   4	   0	   0.000	   -­‐	  
IPAH	  21	   F	   42	   1.1	  IPAH	   12	   2	   3	   0.260	   11	  
IPAH	  22	   F	   37	   1.1	  IPAH	   46	   3	   7	   0.610	   ≥10	  
IPAH	  23	   F	   35	   1.1	  IPAH	   90	   3	   2	   0.170	   1	  
IPAH	  24	   F	   37	   1.1	  IPAH	   122	   2	   0	   0.000	   -­‐	  
IPAH	  25	   F	   47	   1.1	  IPAH	   91	   2	   0	   0.000	   -­‐	  
IPAH	  26	   M	   44	   1.1	  IPAH	   19	   3	   1	   0.115	   0	  
IPAH	  27	   M	   44	   1.1	  IPAH	   17	   2	   1	   0.130	   2	  
IPAH	  28	   F	   27	   1.1	  IPAH	   18	   2	   2	   0.230	   1	  
IPAH	  29	   F	   39	   1.1	  IPAH	   48	   3	   6	   0.600	   ≥10	  
IPAH	  30	   M	   46	   1.1	  IPAH	   14	   3	   9	   0.500	   6	  
IPAH	  31	   F	   27	   1.1	  IPAH	   60	   4	   1	   0.130	   ≥10	  
IPAH	  32	   F	   33	   1.1	  IPAH	   25	   3	   2	   0.168	   0	  
IPAH	  33	   F	   22	   1.1	  IPAH	   57	   2	   0	   0.000	   -­‐	  
IPAH	  34	   F	   28	   1.1	  IPAH	   48	   3	   0	   0.000	   -­‐	  
IPAH	  35	   M	   29	   1.1	  IPAH	   88	   2	   2	   0.225	   MSC-­‐like	  
IPAH	  36	   M	   45	   1.1	  IPAH	   79	   3	   4	   0.296	   7	  
	   	   	   	   	   	   	   	   	  
HPAH	  1	   F	   37	   1.2.1	  HPAH	   0.2	   4	   8	   0.696	   ≥8	  
HPAH	  2	   F	   35	   1.2.1	  HPAH	   73	   2	   10	   1.000	   ≥9	  
Table	  A2.1.	  Demographics	  and	  colony	  formation	  of	  PAH	  patients.	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Table	  A2.2	   	  
Sample	  
Code	  















IPAH	  1	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (50	  mg	  tds),	  
Warfarin	   39	   NA	   NA	   210	  
IPAH	  2	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (25	  mg	  tds)	  
Warfarin	   70	   1545	   NA	   418	  
IPAH	  3	   Bosentan	  (125	  mg	  bd)	   Warfarin	   66	   800	   2.25	   285	  
IPAH	  4	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (25	  mg	  tds),	  
Treprostinil	  (75	  ng/kg/min)	  
Warfarin	   46	   764	   1.58	   570	  
IPAH	  5	   Nifedipine	  (10	  mg	  bd)	   Atorvastati
n	  (10	  mg	  
qd)	  
50	   364	   3.7	   567	  





n	  (8	  mg	  qd)	  
36	   270	   3.86	   420	  
IPAH	  7	   Naïve	   	   68	   905	   1.96	   396	  
IPAH	  8	   Sildenafil	  (50	  mg	  tds),	  
Ambrisentan	  (5	  mg	  qd)	  
Warfarin	   72	   1448	   1.9	   471	  
IPAH	  9	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (25	  mg	  tds)	  
Warfarin,	  
Simvastatin	  
(80	  mg	  qd)	  
60	   644	   2.67	   555	  
IPAH	  10	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (50	  mg	  tds),	  
Treprostinil	  (3	  ng/kg/min)	  
Warfarin	   72	   1730	   1.72	   457	  
IPAH	  11	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (50	  mg	  tds)	  
Warfarin,	  
Simvastatin	  
(80	  mg	  qd)	  
42	   865	   1.25	   339	  
IPAH	  12	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (50	  mg	  tds)	  
Warfarin,	  
Simvastatin	  
(40	  mg	  qd)	  
57	   696	   2.34	   336	  
IPAH	  13	   Sildenafil	  (12.5	  mg	  tds)	   Warfarin	   50	   675	   2.82	   120	  
IPAH	  14	   Sildenafil	  (25	  mg	  tds)	   	   49	   427	   3.5	   525	  
IPAH	  15	   Bosentan	  (125	  mg	  bd)	   Warfarin	   49	   NA	   NA	   264	  
IPAH	  16	   Sildenafil	  (25	  mg	  tds)	   Warfarin	   NA	   NA	   NA	   468	  
IPAH	  17	   Nifedipine	  (80	  mg	  bd)	   	   50	   516	   2.95	   540	  
IPAH	  18	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (25	  mg	  tds)	  
Warfarin	   67	   1169	   2.17	   330	  
IPAH	  19	   Treprostinil	  (25	  ng/kg/min),	  
Sildenafil	  (20mg	  tds)	  
Warfarin	   56	   872	   2.26	   120	  
IPAH	  20	   Bosentan	  (125	  mg	  tds),	  
Sildenafil	  (50	  mg	  tds)	  
Warfarin	   73	   1352	   1.5	   NA	  
IPAH	  21	   Nifedipine	  (40	  mg	  bd),	  
Sildenafil	  (20	  mg	  tds)	  
	   50	   802	   2.66	   438	  
IPAH	  22	   Bosentan	  (125mg	  bd),	  
Sildenafil	  (75mg	  tds)	  







Table	  A2.2	  (continued)	  
Sample	  
Code	  















IPAH	  23	   Sildenafil	  (25	  mg	  tds),	  
Treprostinil	  (42.5	  ng/kg/min)	  
Warfarin	   51	   573	   2.3	   NA	  
IPAH	  24	   Treprostinil	  (0.046	  mL	  per	  hr),	  
Sildenafil	  (25	  mg	  tds)	  
Warfarin	   53	   NA	   NA	   396	  
IPAH	  25	   Bosentan	  (125	  mg	  bd)	   Warfarin	   43	   NA	   NA	   450	  
IPAH	  26	   Sildenafil	  (50	  mg	  tds),	  Ferrous	  
Sulphate	  (200mg	  bd)	  
Warfarin	   79	   1248	   1.98	   258	  
IPAH	  27	   Sildenafil	  (50	  mg	  tds)	   Warfarin	   59	   682	   2.47	   495	  
IPAH	  28	   Treprostinil	  (41	  ng/kg/min)	   Warfarin	   56	   906	   2.13	   456	  
IPAH	  29	   Sildenafil	  (25	  mg	  tds)	  +	  
Treprostinil	  (45	  ng/kg/min)	  
Warfarin	   71	   NA	   NA	   368	  
IPAH	  30	   Sildenafil	  (25	  mg	  tds)	   Warfarin	   51	   1252	   2.12	   480	  
IPAH	  31	   Bosentan	  (125	  mg	  bd,	  
Treprostinil	  (110	  ng/kg/min)	  
Warfarin	   66	   1472	   1.59	   300	  
IPAH	  32	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (25	  mg	  tds)	  
Warfarin	   52	   472	   4.1	   325	  
IPAH	  33	   Ambrisentan	  (5	  mg	  qd),	  
Sildenafil	  (25	  mg	  tds)	  
Warfarin	   NA	   NA	   NA	   345	  
IPAH	  34	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (50	  mg	  tds)	  
Warfarin	   57	   664	   3.15	   330	  
IPAH	  35	   Sildenafil	  (50	  mg	  tds),	  
Treprostinil	  (42.5ng/kg/min)	  
Warfarin	   39	   NA	   NA	   322	  
IPAH	  36	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (75mg	  tds),	  
Nebulised	  Iloprost	  (5	  µg	  
x5/day)	  
Warfarin	   NA	   NA	   NA	   120	  
	   	   	   	   	   	   	  
HPAH	  1	   Naïve	   	   79	   2510	   1.15	   NA	  
HPAH	  2	   Bosentan	  (125	  mg	  bd),	  
Sildenafil	  (20mg	  tds)	  
	   NA	   NA	   NA	   NA	  
	   	   	   	   	   	   	  
Table	  A2.2.	  PAH	  patients	  treatments	  and	  clinical	  characteristicss	  of	  36	  IPAH	  patients	  and	  2	  HPAH	  
patients.	   6MWD,	   6	   minutes	   walk	   distance;	   CI,	   cardiac	   index;	   mPAP,	   mean	   pulmonary	   arterial	  
pressure;	  PVR,	  pulmonary	  vascular	  resistance.	  
